Studies to allow the consistent fabrication of many units of engineered tissue. by Christopher, M.
STUDIES TO ALLOW THE CONSISTENT FABRICATION OF MANY UNITS OF 
ENGINEERED TISSUE
A thesis submitted to the University of London as part of the requirements for the
degree of Doctor of Philosophy
Christopher Mason FRCS
2005
Department of Biochemical Engineering 
University College London 
Roberts Building 
Torrington Place 
London WC1E7JE
UMI Number: U591673
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
Dissertation Publishing
UMI U591673
Published by ProQuest LLC 2013. Copyright in the Dissertation held by the Author.
Microform Edition © ProQuest LLC.
All rights reserved. This work is protected against 
unauthorized copying under Title 17, United States Code.
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106-1346
ABSTRACT
Tissue engineering is the regeneration of tissues through the use of cells with the aid of scaffolds. 
Such in vitro fabrication of tissues is beginning to become an option for the management of 
patients who have irreversible failure of an organ. There are many technical challenges to 
overcome before 'off-the-shelf' tissues that represent the translation of scientific discoveries 
into routine treatments for millions of patients becomes a reality. To meet this demand, the 
products must be manufactured reproducibly and in large numbers employing current good 
tissue practice (cGTP). This thesis takes a whole bioprocess approach and includes:
Bioreactor design
A new and novel methodology is described which potentially allows any tubular organ to 
be fabricated using an easily scalable liquid based technique suited to automated mass- 
production. It is novel in that it employs a single multitasking chamber which functions as both 
a "dynamic former" to create a precise tubular cell/polymer construct and then acts as the 
core of the bioreactor in which to grow the tissue.
Optical coherence tomography (OCT]
OCT is an advanced non-invasive high-resolution clinical imaging technique. This thesis 
describes both its initial application to the engineering of tissue as a means of imaging 
a construct within its individual bioreactor and also the use of Doppler enhanced OCT to 
qualitatively and quantitatively image the flow of culture medium through the construct.
Polymer scaffold
Typically, tissue engineers construct a scaffold and then seed it with cells. This has inherent 
difficulties including the achievement of homogeneous seeding densities. An alternative is 
described whereby cells and liquid polymer are mixed prior to scaffold formation.
Stem cells
Because of the novel approach to construct fabrication, rat smooth muscle cells were used for 
"range-finding" experiments. Later experiments deployed human adult mesenchymal stem 
cells (MSCs) which were shown to network within the tubular constructs.
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1.0 Overview
Regenerative medicine is an emerging multi-disciplinary field demanding the integration of 
life sciences, engineering and clinical medicine, which is likely to have a major impact on a 
number of fields including patient therapies, drug discovery and development, diagnostics 
and biosensors.
Currently multiple approaches exist for the treatment of tissue or organ failure or loss, 
e.g. diabetic patients can be treated by dietary advice, tablets, injections or pancreas 
transplantation. None of these options however cures the patient, they just manage the disease
i.e. attempt to reduce its symptoms or progression. However to achieve a true cure, the patient 
would need to regenerate the lost tissue or organ - revivification of the particular body part. 
The capacity to regenerate whilst common in "simpler" animals and human fetuses, is very 
much reduced in the adult human and is largely replaced with only the capacity to repair. 
Repair is generally a faster process but results in permanently scarred tissues and organs with 
decreased or absent function.
Regenerative medicine proposes three main approaches to restore human tissues and 
organs. Whilst small molecule pharmaceutical compounds may still have a role to play e.g. 
controlling stem cell differentiation (Ding et al, 2003 and Wu et al, 2004), the initial and 
simplest approach to regenerative medicine is to employ genes or proteins as therapies e.g. 
gene therapy for the cure of severe combined immunodeficiency disease (SCID) (Gasper 
et al, 2003) and recombinant granulocyte colony stimulating factor (G-CSF - Neupogen, 
Amgen, Thousand Oaks, CA, USA) to accelerate the production, maturation and activation 
of neutrophils following chemotherapy (Hubei and Engert, 2003). If this initial approach 
fails or is inappropriate then two further options need to be considered; cell therapies and 
tissue engineering. Cell therapies involve the direct introduction of cells into the appropriate 
structure in the patient e.g. stem cells injected into the myocardium to restore cardiac function 
(Perin et al, 2003 and Menasche, 2004) and fetal dopaminergic tissue implantation into 
the substantia nigra area of the brain for Parkinson's disease (Helmuth, 1999). However 
the direct addition of cells alone is not always possible e.g. where an organ's architecture is 
irretrievably lost such as occurs when atherosclerosis blocks an artery or the tissue or organ is 
lost in entirety e.g. bone resection for the surgical treatment of sarcoma. In such situations, the 
regenerative medicine option is to grow a replacement organ or tissue - tissue engineering. 
This can be done either outside the body, inside the body or by a combination of the two 
approaches (Vacanti and Longer, 1999). Regenerative medicine thus has a continuum of 
overlapping treatment options for a broad range of complex pathologies.
Virtually all surgical procedures that restore failing or damaged organs require some form of
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replacement components. Conventionally, these components include totally artificial prosthesis 
(e.g. metal hip joints), non-living processed tissue (e.g. porcine derived heart valves), 
autologous transplant (e.g. saphenous vein for cardiac artery bypass grafting), live donor 
transplant (e.g. kidney transplant between siblings) or cadaveric donor transplant (e.g. heart 
transplant). Unfortunately all these components have inherent limitations. Tissue engineering is 
emerging as a significant potential alternative, whereby organ failure or damage is corrected 
by implanting living tissue or organs that are either fully functional prior to implantation or 
that grow or direct growth in vivo in order to gain the required functionality.
Regenerative medicine including tissue engineering are no longer just the dream of the 
research scientist. At of the start of 2003, there were over 2600 scientists and support staff 
spread over 89 companies with an annual spend of just under $500M - see Figure 1.1. 
This figure is based on a number of surveys by Michael Lysaght at CytoTherapeutics/Brown 
University over almost a decade. Lysaght has chosen to sub-divide his "tissue engineering" 
market into three categories:
1. Cellular (stem cell and therapeutic cloning)
2. Metabolic (bioartificial liver, pancreas and kidney)
3. Structural and three-dimensional tissue-surrogates (cells plus scaffold)
In this thesis, for simplicity and uniformity, Lysaght's all encompassing category of "tissue 
engineering" will be reclassified as regenerative medicine (excluding gene and protein 
therapies) and "structural tissue engineering" will be referred to as tissue engineering. 
This approach is in keeping with the definition, "Tissue engineering is the regeneration 
of biological tissues through the use of cells, with the aid of supporting structures and/or 
biomolecules" which was provided by the European Commission in 2001 and adopted again 
by the Commission in 2003 (European Commission 2001 and 2003). Thus it is only the tissue 
engineering subdivision of regenerative medicine and in particular the potential automation 
of this subdivision which this thesis addresses. Figure 1.1 shows the underlying trend in 
progressive growth of both the regenerative medicine industry and the tissue engineering 
subdivision until 1997 which is then followed by a period of extremely rapid expansion and 
then decline which by 2002 left the industry at approximately its 1997 level. During this 
turbulent time, the market leaders, Organogenesis (Canton, MA, USA) and Advanced Tissue 
Sciences (La Jolla, CA, USA) filed voluntary petitions for reorganisation under Chapter 11 
of the US Bankruptcy Code. Many of the other companies in the subsector either went out of 
business (n = 13) or downsized (n = 8) during the period 2000-2002 (Lysaght and Hazelhurst, 
2004). In 2002, despite substantial investment over a decade, there were only three FDA 
approved tissue engineered products; Apligraf (Organogenesis), Dermagraft (Advanced 
Tissue Sciences) and OrCel (Ortec, New York, NY, USA) with sales of $23M (25,000 units),
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Year ending 1994 1997 2000 2002
Regenerative medicine 
- Excluding gene and protein 
therapies
Annual spend $256 $453M $610M $487M
Companies >40 39 73 89
Scientists and support staff >1,500 2,380 3,300 2,611
Cumulative investment since 
1990 $1.3B* $2.0B* $3.5B $4.5B
Tissue engineering subsector
Annual spend $41M* $161M $363M $185M
Companies 6* 13* 34* 25
% Total industry's annual 
spend 16% 36% 60% 40%
Scientists and support staff 240* 955 1,980 975
% Total industry's scientists 
and support staff 16%* 40% 60% 37%
Annual spend per employee* $171,000 $169,000 $183,000 $188,000
‘Estimated/extrapolated from other data
Figure 1.1
Comparison of the trends in the economic parameters underlying both the entire regenerative 
medicine industry and its subsector industry, tissue engineering (Lysaght, 1995, Lysaght et 
al, 1998, Lysaght and Reyes, 2001, Lysaght 2003 and Lysaght and Hazelhurst, 2004).
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$4.5M (4,500 units) and less than $100,000 respectively. Total sales for the period were less 
than $50M - (Carticel by Genzyme was the only other regenerative medicine product with 
FDA approval and sales of 2,500 units ($25M), is not included since it is an autologous cell 
therapy) (Lysaght and Hazelhurst, 2004). These market trends are in agreement with other 
independent market research reports for the period e.g. Clinica (Bromley, 2001 and 2003). 
Ironically during 2002, sales of Dermagraft more than tripled from $1M in the first six months 
to $3.5M in the last six months. The economic data for the period 1994 - 2000 indicates that 
the tissue engineering industry out-paced the general regenerative medicine industry, but then 
declined faster losing out to cell based therapies mainly stem cells. This divergence in part 
reflects the difference in complexities and perceived closeness to market between cell only 
versus cell and scaffold products. However many complex medical products had a history of 
early poor results followed by major success as they underwent the essential transition from 
research and development to product based enterprises e.g. modern pharmaceuticals (1945 
- 1955), controlled release/drug delivery (1970 - 1980) and monoclonal antibodies (1985 
-2000) (Lysaght, 2003).
The long term aim of tissue engineering is to facilitate the routine surgical replacement of 
failing organs. The established general principles of tissue engineering involve starting with 
a cell friendly polymer, shaping it into the desired geometry to form a scaffold, seeding the 
scaffold with living cells and then growing it in tissue culture medium. As the cells multiply they 
populate the scaffold and synthesise extracellular matrix to create a three-dimensional tissue. 
To date only a handful of structural tissue engineered products have been FDA approved; 
Apligraf (Organogenesis, Canton, MA, USA), Dermagraft (Smith and Nephew (formerly 
Advanced Tissue Sciences), La Jolla, CA, USA) and OrCel (Ortec, New York, NY, USA). 
All are skin substitutes and all are made using low volume "cottage industry" techniques 
e.g. Organogenesis, which at its peak as the undisputed market leader, only produced 
Apligraf at the rate of 500 seven centimetre diameter discs of skin per week, this was despite 
being Medicare approved in all fifty US states and with a potential FDA approved market 
(venous and diabetic ulcers) in the order of 1 - 2 million patients in the USA alone. These 
first generation products came directly from academia and thus did not have the necessary 
and important commercial considerations incorporated into to their initial research stage e.g. 
overall design of the construct, preclinical/clinical trials and FDA approval planning, quality 
control and scalable economic manufacture, marketing, distribution and reimbursement 
strategies (Kemp, 2003a).
Tissue engineered products could benefit a vast number of patients. In pivotal clinical trials of 
the first tissue engineered product, Apligraf (skin) has admirably demonstrated its benefit over 
traditional treatment both in terms of number of ulcers healed, speed of healing and reduced
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recurrence (Falanga et al, 1998) but has so far failed to show the substantial cost benefits a 
new product requires if it is to universally displace current therapy and best practice (Schonfeld 
etal, 2000, Sibbald etal, 2001, Redekop etal, 2003). The European Commission noted that, 
"the comparison of treatment costs alone is not sufficient, as different treatments can result in 
different outcomes. The effectiveness of treatments needs to be included in the comparison" 
however even taking these wider cost implications into account, the current data on tissue- 
engineered products did not provide clear economic evidence of their superiority (European 
Commission 2003). This shortfall is mainly due to the high cost of manufacture associated 
with low volume production e.g. Organogenesis reported "...Cost of product sales continues 
to exceed product sales due to the high costs associated with low volume production..." 
(Organogenesis, United States Securities and Exchange Commission, Form 10K, 20 /5 /02).
Today's increasing emphasis placed on cost containment by healthcare providers is an 
important issue. Without efficient scale translation techniques, the resulting high cost of tissue 
engineering products will effectively limit their market despite the potentially overwhelming 
benefits to both the patient and society (Mason, 2003). In addition, aside from the issue of 
tissue-engineered products being expensive to produce, it is also no use being only able to 
make a few organs at a time when the potential demand is orders of magnitude larger e.g. 
today two million US patients with chronic leg ulcers could potentially benefit from current 
tissue engineered products. Presently tissue engineers are almost exclusively focused on proof 
of principle techniques rather than economic "mass production". This issue was amongst those 
highlighted by Lysaght and Hazlehurst when discussing the industries poor performance to 
date, "although scientifically strong, the companies lacked the skill sets required to develop 
low-cost manufacturing procedures" (Lysaght and Hazlehurst, 2004). Griffith and Naughton 
have also suggested that, "there are still many technical challenges to overcome before 
we create 'off-the-shelf7 tissues that represent the translation of scientific discoveries into 
treatments for millions of patients. The successful large-scale production of engineered tissues 
requires an adequate source of healthy expandable cells, the optimization of scaffolds, and 
the creation of bioreactors, which mimic the environment of the body and that are amenable 
to scale-up" (Griffith and Naughton, 2002). These same issues, were highlighted by the 
National Institutes of Health Bioengineering Consortium, "For tissue engineering to meet the 
true clinical demands, the products must be manufactured reproducibly, in large numbers, 
and be available on demand. The use of an allogeneic cell source permits an 'off-the-shelf' 
product to be made. Scaleable manufacturing processes permit many units to be made in a 
unified manner, and allow diseases that effect large patient populations to be addressed in 
an efficient and cost effective way" (National Institutes of Health Bioengineering Consortium, 
2001).
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This thesis describes a novel platform technology, which potentially allows any flat sheet or 
tubular organ to be fabricated using an easily scalable technique ideally suited to automated 
mass production. It is novel in that it employs low cost disposables technology to produce a 
single multitasking chamber that functions as:
•  The initial "mould" to give the cell-scaffold construct a specific geometry
• The bioreactor in which to grow the construct
•  The delivery package for transport to the surgeon
• Potential to act as a cartridge for loading into a robotic surgical system
By keeping the tissue engineered organ in the same chamber from initial "creation" to just prior 
to implantation has both bioengineering (e.g. no human handling is required and therefore 
reduced chance of contamination) as well as major cost benefits e.g. ease of automation. 
Automation in turn potentially could allow cost effective operation including minimising the 
requirement for specialist technical support whilst reducing human error whilst satisfying 
the general desire by clinicians to provide a high level of quality assurance to their patients 
(Armstrong et al, 1995).
To date, in order to protect the intellectual property generated by the project a number 
of patents have been filed which after clustering together into discrete families/areas has 
resulted in 4 international and 2 national patent applications (Mason, 2000, Mason and 
Town, 2002a, 2002b, 2003a and 2003b, Mason et al 2003). Whilst the methodology is 
potentially suited to a range of organs and tissues, the focus of this thesis is on laying the 
foundations for automated production of arterial blood vessels suitable for coronary artery 
bypass surgery where globally over a million metres of vessel are transplanted each year.
In addition to the direct clinical applications, engineered tissue is beginning to be considered 
for an important role in drug discovery and development (Barnes, 2004 and Kelm and 
Fussenegger, 2004) including vascular applications (L'Heureux et al, 2001). Coupled to the 
established concept of high-throughput technologies such as tissue microarrays (Sauter et al, 
2003), the automated engineering of human tissue could provide a far better alternative to 
current pharmaceutical research for new drug compounds (Kelm and Fussenegger, 2004). 
For example, if multiple "mini" human blood vessels could be produced in an automated 
manner and using current high throughput microwell or microfluidic based technology, then 
potentially, new blood pressure control compounds could be discovered more easily and far 
more reliably than using current "single cell thick" microwell and animal models. Likewise 
the testing of potential drug candidate compounds e.g. uptake, toxicity and pathogeneicity, 
is also a potential option.
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1.1 Historical perspective
Transplant surgery to replace damaged or failing organs has had a long history of development. 
Physicians in India were performing skin grafts for reconstructive surgery from about 800 
B.C. (Patrick et al, 1998a). The best known operation practiced in India at that time was 
rhinoplasty. This was performed by rotating a skin flap in order to reconstruct a nose, that 
had been amputated either in battle or as a punishment (Burnand et al, 1998). The basic 
concept of allografting is an ancient idea, Saint Cosmas and Saint Damian were third century 
AD twins who trained to be doctors in Syria, who having been martyred for their Christian 
beliefs triggered a number of "myths". The most well known example is of a Caucasian 
man with an ulcerated leg who collapses, the deceased twin doctors instruct the surgeons to 
amputate the affected leg and to replace it with the leg of a Moor who had just died in the 
next bed. This myth is graphically depicted, in the fresco by Fra Angelico, where a black 
skinned leg is attached orthotopically to a white male body. The concept of replacing one 
tissue with another by the 16th century was well recognised and practiced. In 1597 Gasper 
Tagliacozzi of Bologna published De Curtorum Chirurgia per Institionem (On the Surgery of 
the Mutilated by Grafting). This work was the first "manual" of plastic surgery. It gave step 
by step instructions on how to reconstruct noses, ears and ear lobes e.g. a description of how 
to use a forearm flap to make a nose replacement. It is interesting to note that The Roman 
Catholic Church condemned this "manual" for attempting to improve God's own handiwork! 
In reality it was probably because early nose reconstructions were attempts to restore the 
devastating stigmata of syphilis.
Complex organ transplants were not possible until "modern surgical techniques" were 
developed e.g. general anaesthesia by William Morton in October 1846 (In December 1846, 
Robert Liston performed an above knee amputation under ether anaesthetic at University 
College London), antisepsis by Joseph Lister in 1867 and the ability to precisely anastomose 
blood vessels by Alexis Carrel in 1902 (Burnand et al, 1998). Baronio of Milan in 1804 
using free skin grafts on sheep was the first to demonstrate that autografts generally took 
very successfully whilst allografts were "rejected". Rejection remained the major obstacle 
to allografts until Peter Medawar in 1943 conducted a series of experiments showing that 
rejection of allografts was due to immunological attack. In 1951 Medawar demonstrated that 
immunosuppression significantly prolonged the survival of skin allografts in rabbits (Burnand 
etal, 1998). David Hume and Joseph Murray in Boston used immunosuppression in the first 
successful human kidney allografts in the 1950's. The first successful liver transplant was 
performed in 1967 by Thomas Starzl at the University of Colorado. Christiaan Barnard (who 
trained under David Hume) transplanted the first human heart on 3rd December 1967 in Cape 
Town. Barnard's patient Louis Washkansky was a 54 year old dentist who lived for 18 days
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after the procedure (Stark, 1996a).
As of December 2003, nearly 80,000 US citizens were on transplant waiting lists compared 
to just over 50,000 in 1996 (1996 and 2003 Annual Reports of the US Organ Procurement 
and Transplantation Network and the Scientific Registry for Transplant Recipients, Richmond 
VA, USA). Transplant lists whilst ever growing also grossly underestimate the massive size 
of the problem, for example many patients who would benefit from a transplant organ are 
excluded from being placed on the waiting lists due to defined exclusion criteria e.g. only 
patients under 65 years of age with end stage renal failure are eligible under Medicare for 
renal transplantation. Increasing numbers of patients die whilst waiting e.g. there were over
6,000 reported US waiting list deaths in 2003 as compared to 3,000 in 1996 (1996 and 
2003 Annual Reports of the US Organ Procurement and Transplantation Network and the 
Scientific Registry for Transplant Recipients). Some organs due to their high demand do not 
have "formal" waiting lists e.g. there are nearly 20 million insulin dependent diabetics in the 
USA who would greatly benefit from pancreas transplantation, thus this huge group is not 
accounted for in waiting list figures.
Demand will continue to out pace supply as the average life expectancies of the populations 
in the Western World continue to rise, mainly due to the reduction in infectious diseases 
among infants and children. Furthermore, over the next three decades most of the "baby- 
boomer" generation will reach retirement age e.g. today, 10% of the population is now over 
the age of 60, and by 2050 this figure is expected to rise to 20% (US Census Bureau 2004). 
Other factors compound this overall increase in demand including the "obesity epidemic" 
which is sweeping the Western World. Obesity is associated with many diseases including 
type 2 diabetes, hypertension, cardiovascular disease and osteoarthritis (House of Commons 
Health Committee. Obesity Report. May 2004).
Many attempts have been made to increase the supply of organs including government funded 
publicity campaigns, donor card systems and organisations set up in order to coordinate the 
exchange of organs between countries e.g. Eurotransplant (Benelux countries, Austria and 
Germany) (Stark, 1996b). Unfortunately none of these attempts has worked.
Another possible alternative is the use of xenografts i.e. the transplant of an organ from one 
species into the body of an animal of a different species. The earliest attempts were made 
in France and Germany. In 1906, Mathieu Jaboulay in Lyon transplanted a pig kidney into 
a 48 year old woman. The pig's kidney survived two days during which time it performed a 
physiological role including the production of urine. On the third day the kidney was rejected. 
Jaboulay tried again, this time using a goat's kidney but with no more success. In 1909, Ernest 
Unger in Berlin transplanted the kidneys from a Borneo macaque monkey into a 21 year old
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seamstress who promptly rejected the kidneys and died the following day. After these failures, 
few surgeons were prepared to try again. Chimpanzee kidneys were transplanted secretly 
in the 1960's with reasonable results by Keith Reemtsma at Tulane USA e.g. Reemtsma's first 
patient, a 43 year old dock worker survived nine weeks after the operation. Once this work 
and other primate transplant work became public knowledge, emotive public outcry put an 
end to virtually all future primate donors. Primates being our closest "relative" in the animal 
kingdom are the most logical choice for organ donation. However, on ethical grounds, primates 
as sources of organs continued to be regarded as being too close to humans for comfort by 
society. As a direct result, xenograft research moved onto the pig. Pigs were selected on the 
basis that pig organs are of similar size to human plus pigs are slaughtered in vast numbers 
everyday to provide food, therefore it was thought that there would be little in the way of 
ethical objection. John Wallwork a transplant surgeon and David White an immunologist 
formed Imutran in Cambridge UK to investigate the use of pigs as xenograft material. Funded 
by the merchant bank, Warburg Pincus (New York, USA), work commenced in 1984. By the 
early 1990's genetically modified pigs were bred by Imutran which contained certain human 
genes which reduced early hyperacute rejection due to the species difference between pig 
and man. Once again emotive public opinion curtailed the research programme. Leaving 
aside ethical considerations, there are still a number of major scientific questions to be fully 
answered including whether potential "exotic" infectious elements e.g. porcine retroviruses 
and prions can be transmitted from the pig into the human recipient and then on to the public 
at large (Fox, 2001). Reportedly, the FDA is however willing to permit xenotransplant trials 
but only on a case-by-case basis, whilst the rest of the Western World is far less enthusiastic 
e.g. Japan has an outright ban on xenografts (Couzin, 2002).
Today it is surgically possible to transplant well over 20 different allograft organs including 
bone, cartilage, bone marrow, cornea, hearts, lungs, kidney, liver and pancreas. Due to supply 
and economic pressures i.e. a massive imbalance between limited supply and overwhelming 
demand, a new industry has been born.
The alternative source of organs and tissue is to engineer them. In the spring of 1987, the 
Engineering Directorate of the National Science Foundation (USA) held a major discussion 
meeting focused on the future of bioengineering. Whole organ replacement systems and cell 
culture based methods were discussed and grouped together under the working title, "tissue 
engineering". At this meeting the term "tissue engineering" was coined by Professor Y.C. 
Fung. Further meetings on tissue engineering later in 1987 involved the National Science 
Foundation, National Institutes of Health, National Aeronautics and Space Administration, 
other US government departments and US academia working in the fields of cell, molecular 
biology, medicine and bioengineering. In October 1987, the National Science Foundation
-  22 -
recognised that tissue engineering was an emerging technology with potential for rapid 
industrial expansion and recommended that a workshop be held to identify appropriate 
areas of tissue engineering research. This workshop was held in February 1988 at Lake 
Tahoe California. At this meeting the term "tissue engineering" was formally accepted for 
the fledgling industry. Following this meeting the National Science Foundation started an 
initiative to fund tissue engineering projects (Patrick et al, 1998a).
In principle tissue engineered organs could overcome the majority of problems associated with 
a vast shortage of available organs. Tissue engineered products need to be easily available 
as well as more cost effective overall than conventional donor organs e.g. allowing successful 
surgical intervention at a far earlier stage in a disease thus cutting hospitalisation costs whilst 
waiting for transplantation, reducing working days lost due to illness, improving the quality 
of patient's lives earlier whilst avoiding critical illness and death due to worsening organ 
failure.
The early pioneers of tissue engineering include Levi, Chick, Bell and Yannis. For example, 
Levi in the late 1970s experimented with calf skin derived collagen as an artificial mucosa 
for the repair of experimentally prepared wounds in the oral cavity of rabbits and dogs. No 
adverse effects were observed and a possible slight improvement in the rate of healing may 
have been observed (Levin et al, 1979).
In the 1980s there was a great increase in R&D in tissue engineering and biomaterials 
(Persidis, 1999). In 1981, a bilayer artificial skin consisting of a temporary Silastic (Dow 
Corning, New York, USA) epidermis covering a porous collagen dermis cross-linked with 
chondroitin sulphate was used to treat patients with severe burns with promising functional 
and cosmetic results (Burke et al, 1981).
In the 1990's, several tissue engineered products reached the U.S. market. For example, in 
1993 Interpore International's (Irvine, USA) Pro-osteon coral-derived bone graft material 
was introduced, in 1996 Integra Lifescience's (Plainsboro, USA) Artificial Skin was approved 
as an in vivo, nonbiological tissue regeneration product (Persidis, 1999). In May 1998, the 
General and Plastic Surgery Devices Advisory Panel to the US Food and Drug Administration 
recommended unconditional approval of Apligraf (Graftskin) Human Skin Equivalent for 
the treatment of venous leg ulcers. Apligraf, produced by Organogenesis, was the first 
manufactured living human organ to obtain FDA approval.
1.2 Current status
To date the majority of funding for tissue engineering in the US has come from the private sector 
whilst in the rest of the world government funding has been more dominant (albeit at a much
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lower level) (World Technology Evaluation Centre (WTEC) Panel Report on Tissue Engineering 
Research, January 2002). However, some of the interest and support for tissue engineering 
comes from diverse areas including the armed forces and very recently the prevention of 
bioterrorism campaign, for example, numerous battlefield related medical applications exist 
for tissue engineered products and biomaterials. Advanced Tissue Sciences had part of its 
clinical trial for Dermagraft for the treatment of chemical burns funded by the US Army 
Institute of Chemical Defence (Persidis, 1999). Dermagraft is an engineered living human 
dermis produced by seeding dermal fibroblasts onto a three dimensional bioabsorbable 
scaffold. Likewise other groups have received funding to create hybrid bio-electronic sensors 
using tissue-engineering techniques. These sensors are aimed at being part of the "front-line 
defences against biological attack" (Griffith, 2003).
A major nonclinical application of tissue engineered products is in the field of toxicology and 
the "in vitro" testing markets, as alternatives to certain types of animal testing e.g. cosmetics. 
Currently there are only a few companies in this field but their numbers are growing. For 
example in March 1995 Stratum Laboratories (La Jolla, CA, USA) acquired part of the In vitro 
Laboratory Testing business of Advanced Tissue Sciences for US$5 million. Stratum received 
licence rights to manufacture and sell Skin2 in vitro laboratory testing kits. Skin2 is living 
human skin tissue equivalent used to test skin care, household, chemical and pharmaceutical 
products for a variety of indications. Skin2 is already approved by the US Department of 
Transportation and Transport for use in corrosivity testing (Persidis, 1999). In Europe, a 
similar product Episkin (Imedex-Saduc, Chaponost, France) is approved by the European 
Commission (European Centre for the Validation of Alternative Methods -  Ispra, Italy) for 
corrosive and pharmaceutical in vitro skin studies as a valid alternative to many animal 
studies. Other companies also employing tissue engineering technologies for toxicology 
testing include MatTek (Ashland, MA, USA) and SkinEthic (Nice, France).
1.3 Current good tissue practice
Good manufacturing practices for tissue engineering is a major challenge for the industry, as 
a result, there is continuous effort by both the regulatory authorities and the tissue engineering 
industry to create appropriate quality control standards and evaluate them (Mayhew et al, 
1998). For example, the Food and Drug Administration (FDA) requires that human cell, 
tissue and tissue-based products (HCT/P) establishments must follow current good tissue 
practice (CGTP). Following two FDA discussion documents in the late 1990s ("Reinventing 
the regulation of human tissue" and "A proposed approach to the regulation of cellular 
and tissue-based products"), the FDA has now published three rules for CGTP with respect 
to HCT/Ps. The first rule to come into force (January 2004) , required tissue facilities to 
register with the FDA and to list their products ("Establishment, registration and listing for
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manufacturers of human cellular and tissue based products"). The two other rules, "Suitability 
determination for donors of human cellular and tissue-based products" which concentrates on 
donor screening and testing in order to prevent contaminated tissue entering the production 
process, and "Current good tissue practise for human cell, tissue, and cellular and tissue- 
based establishments; Inspection and enforcement" which requires manufacturers to recover, 
process, store, label, package and distribute HCT/Ps in a way that prevents the introduction, 
transmission or spread of communicable diseases, will both come into effect in May 2005. 
(Interestingly, in light of the financial failure of the major pioneers in the field inpart due to 
regulatory issues, the FDA's goals with these rules is to improve protection of the public health 
whilst keeping regulatory burden to a minimum, and thus encourage significant innovation in 
the field.) (Federal Register, 2005 and FDA News, 2004)
Industry is likewise developing standards, for example, Genzyme BioSurgery (Cambridge, 
USA), has an ongoing quality control program (Genzyme Cartilage Repair Registry) for 
its Carticel (autologous cultured chondrocytes) used to repair damaged knee cartilage (as 
of spring 2000 there was over 4000 patients being monitored). The control program is 
based on the analysis of several quantifiable parameters, including viability and freedom 
from pathogens as well as more subjective clinical function tests e.g. Cincinnati Knee Rating 
System. Results to date (48 months of data) are highly favourable both in terms of patient 
satisfaction and in the standard of the quality of the follow up programme (Genzyme Cartilage 
Repair Registry).
1.4 The role of the engineer
The specific role of the engineer in the construction of a neoorgan can best be appreciated 
by examining the separate phases of tissue engineering an organ. For example, a much 
simplified view of tissue engineering can break the process down into eight discrete steps, 
each of which can then be studied separately (Modified from Hutmacher et al, 2000):
1. Fabrication of a bioresorbable three-dimensional scaffold
2. Harvest cells from animal or human patient
3. Cell seeding onto the scaffold in a suitable bioreactor
4. Cell proliferation and differentiation
5. Growth of mature tissue
6. Storage and transportation
7. Surgical implantation
8. In vivo assimilation and adaptation
Each phase must be fully understood in order to create a fully functional, reliable and 
reproducible tissue engineering construct.
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1.5 Components
Yannas at MIT (Cambridge, MA, USA) has attempted to crystalise the interaction of the 
various components required to synthesis c/e novo tissues and organs into some universal 
"rules" (Yannas 2004). Interestingly, Yannas's conclusions include:
1. Following severe trauma of an adult organ in which the stroma has been 
severely injured, the wound closes by contraction and scar synthesis. When 
the stroma has been spared, the wound closes by spontaneous regeneration; 
contraction is not observed
2. The synthetic barrier to overcome during induced regeneration of most organs 
is the synthesis of the non-regenerative tissue, the stroma
3. The central problem in the synthesis of most organs is stroma synthesis, a 
process that requires the presence of an active scaffold
What therefore are the components for the successful engineering of tissue? The European 
Commission defined tissue engineering as the regeneration of biological tissues through the 
use of cells, with the aid of supporting structures (scaffolds) and biomolecules (European 
Commission, 2001). Thus the important basic components that the tissue engineer can 
choose from in order to make a product include; cells, scaffolds, and bioactive molecules. A 
bioreactor, not a component of the tissue is needed to combine them together. One or more 
of the components may be required depending upon the final desired product.
1.5.1 Cells
The source of cells to use is an interesting topic. The "ideal" cells must function physiologically 
and biochemically, integrate fully and be non-immunogenic which at the present day means 
from the patient themselves e.g. Carticel (a sample of healthy cartilage is arthroscopically 
removed from the patient. The chondrocytes are grown in vitro (Genzyme Biosurgery 
(Cambridge USA)) for several weeks to obtain a sufficient quantity of cells prior to surgical 
implantation back into the same patient). Since these cells are autologous, immune rejection 
is not an issue. The drawbacks to autologous cells is time and cost. Culturing takes weeks and 
may not always be successful, thus these cells would not be an ideal choice in anything other 
than elective procedures. Furthermore there is significant interpatient variability e.g. biopsy 
size, sterility, endotoxin levels, cell viability and population doubling times (Mayhew et a\, 
1998). Cost is another factor, growing up individual batches of cells is much more expensive 
than batch processing of a single cell line (Lowel, 2003).
Cells from nonself i.e. allograft have advantages e.g. easily available but also have drawbacks 
e.g. potentially immunogenic and potentially can carry pathogenic agents. Cells producing 
immunogenic effects would require long term immunosuppressive drugs (far from ideal) in
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order to avoid tissue rejection, fortunately not all cells produce such a reaction. For example 
Organogenesis uses human dermal fibroblasts and epidermal keratinocytes derived from 
neonatal foreskins to produce Apligraf. These cells are non immunogenic because they do 
not express Major Histocompatability (MHC) Class II surface proteins. In order to reduce the 
chance of pathogen transfer Organogenesis treats the harvested cells with antibiotics and 
antifungals. Also prior to production of a master cell bank, the maternal blood and neonatal 
foreskins are screened for viruses e.g. HIV, Hepatitis A, B and C. Once the master bank 
was produced the cells are repeatedly tested for viruses, bacteria, yeasts and mycoplasma. 
Furthermore, each bank is also tested for carcinogenic potential, biochemical defects and 
chromosomal abnormalities.
Since allogenic cells are much more suitable for the production of off the shelf tissue engineered 
organs, it may well be an option to genetically engineer the cells in order to reduce immune 
rejection, but to do this and ensure safely is likely to be a protracted process.
Recently pluripotent embryonic stem cells (ES cells) have become a serious option for 
tissue engineering. Stem cells are self replicating and can also generate a number of more 
specialised cell types as they multiply. Stem cells are highly plentiful in the early embryo but 
very difficult to find in the adult. At conception, the egg and sperm fuse to produce a zygote 
(one single cell), this then divides countless times to generate the 216 different cell types 
to produce a human. The zygote and the 8 cells created by the first 3 divisions are each 
capable of developing into an entire human, these stem cells are termed totipotent stem cells. 
As the cells continue to divide the number of different cell types each stem cell can produce 
becomes reduced. After 5 days a hollow ball of cells (blastocyst) is formed. The outer layer of 
cells goes on to form the placenta whilst the inner group (approximately 50 cells) is ready to 
produce the embryo. This inner group of cells can make most embryonic cell types, but cannot 
make all the cell types needed to develop an entire functional human, these stem cells are 
termed pluripotent embryonic stem cells. As the cells divide further so the cells become more 
specialised (differentiated) and lose their ability to produce different cell types (multipotent) 
(Medical Research Council, 2000).
Human ES cells were gown for the first time in vitro in February 1998, by James A. Thompson 
at the University of Wisconsin USA, (John D. Gearhart of John Hopkins University and 
researchers at Geron Corporation (Menlo Park, CA) were also carrying out related studies). 
Thompson's blastocyst derived ES cells after a 4 month period of undifferentiated proliferation 
were capable of deriving all three embryonic germ cell layers i.e. ectoderm, endoderm and 
mesoderm. This revolutionary work was published in Science on the 6th November 1998 
(Thompson et al, 1998). Previously only mouse stem cells had been successfully cultured in 
vitro. The basic technique for producing human ES cells involves; culturing a human blastocyst,
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removing the outer layer of cells to leave only the inner cell mass, this inner cell mass is then 
chemically disaggregated in order to separate the individual cells. Individual cells can then 
be grown up into colonies on a feeder layer of non-dividing mouse fibroblasts. Finally, by 
adding specific differentiation factors, different differentiated cell types can be produced e.g. 
"gut epithelium (endoderm); cartilage, bone, smooth muscle, and striated muscle (mesoderm); 
and neural epithelium, embryonic ganglia, and stratified squamous epithelium (ectoderm)" 
(Thompson et al. 1998). However to date, mouse embryonic stem cell work continues to be 
more advanced than its human equivalent e.g. Klug in 1996 at Indiana University, produced 
a greater than 99% pure culture of highly differentiated cardiomyocytes from murine ES 
cells which in vitro rhythmically beat and in vivo survived for a minimum of 7 weeks when 
implanted into the hearts of adult dystrophic mice (Klug et al, 1996), it was not until recently 
that similar in vitro observations have been reported using human embryonic stem cells (He 
at al, 2003).
One potential problem of using ES cells for tissue engineering is that all the cells must become 
sufficiently differentiated so as to be incapable of producing unwanted cell types within the 
finished product. Rigorous purification of ES cells will therefore be required. Another challenge 
is in the area of immunogenicity. One potential option is to take cells from the specific patient, 
remove the DNA and then inject this into donated human eggs (the fundamental step in 
therapeutic cloning) which have previously had their own DNA removed (usually termed: 
somatic cell nuclear transfer), this "egg" is then matured to form a blastocyst and the above 
procedure performed. This method should produce cell types genetically identical (apart from 
the mitochondrial DNA) as the patient, thus in theory no rejection problems. The drawbacks 
include time and cost. A potential alternative could be to produce a "universal donor" ES cell 
i.e. an ES cell which is compatible with any recipient. In order to create such a cell type all 
the molecules recognised as foreign by the host's immune system would have to be altered/ 
removed probably by disrupting or altering a significant number of genes (Denning and 
Priddle, 2003). However, in theory if such an ES cell were constructed it could potentially be 
used to make universal tissue engineered products which could then be an off the shelf item.
An alternative source of stem cells is from bone marrow and includes adult mesenchymal stem 
cells (MSCs). These could either be autologous or like ES cells be potentially modified to avoid 
detection by the host's immune system thus allowing a universal cell line to be created. Osiris 
Therapeutics (Baltimore, USA) was one of the first tissue engineering companies to develop 
MSC technology. Under the direction of Mark Pittenger, Osiris is working with MSCs in the 
areas of orthopaedic and cardiovascular regeneration (Cahill et al, 2003).
A final potential source of cells is from animals i.e. xenogeneic. Animals cells are easy to 
produce, however, since they are from a different species these cells will require extensive
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genetic manipulation in order to make the cells "invisible" to the human immune system. 
Furthermore/ as in the case of whole organ xenotransplantation concerns over pathogen 
transmission e.g. prions and retroviruses, has not yet been conclusively settled.
In conclusion, whilst autologous cells are very unlikely to be the long term future for tissue 
engineering, initially these cells are likely to be the best route forward for the majority of 
applications. This strategy provides the highest level of patient safety as it avoids the potential 
disease transmission and immunological complications inherent in the alternative options, 
but does incur more challenging processing issues posed e.g. initial biopsy collection, 100% 
reliable tracking from the biopsy leaving the patient to the tissue being implanted back and 
interpatient cell variability.
1.5.2 Scaffolds
In order to produce an in vitro biological tissue or to repair tissues in vivo there is very often a 
need for an initial structure, which is generally referred to as a scaffold. This scaffold is itself 
assembled on a solid object either a mould or a former, which will be referred to as a mould/ 
former. Thus the mould/former sets the overall structure and dimensions of the scaffold. In 
principle to create organs, donor material is obtained, the tissue is dissociated into individual 
cells, the cells are attached to a scaffold, and this device is implanted into the patient in a 
favourable location where the immobilised cells grow and function.
Scaffolds must ideally possess the following characteristics; be an adhesive substrates for 
cells, promote cell growth, and allow retention of differentiated cell function. Materials used 
as scaffolds for cell transplantation must be biocompatible and biodegradable, processable 
into desirable shapes, highly porous with large surface:volume ratios, and finally possess 
adequate mechanical strength. The scaffold can take the form of a simple sheet, tube or a 
more complex three-dimensional structure. The scaffold allows the transplanted cells a means 
to organise into a newly forming organ.
If cells are to be seeded onto preformed scaffolds, these need to be highly porous structures 
in order to allow large numbers of cells to both penetrate the three-dimension shape and 
to be accommodated. Furthermore, to allow initial access, the pore diameter must be much 
larger than the specific cells that are intended to populate it plus as most cells are anchorage- 
dependent, total pore surface area must be large enough to accommodate high cell growth 
rates. Thus a homogeneous interconnecting pore network is essential for uniform cell seeding, 
growth and diffusion of nutrients and metabolites (Vacanti etal, 1991).
1.5.3 Bioactive molecules
The biochemical environment of a tissue plays a major role in its development, maturation
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and physiology e.g. co-ordination, both in vitro and in vivo.
The co-ordination of cell activity allows physically associated cells to act in a coordinated 
manor. In multicellular organisms, information is transmitted from a single cell back to itself 
(autocrine), one cell to another by direct intercellular communication (paracrine), systemic 
fluid transport of soluble signalling molecules (endocrine), and local cellular deposition of 
insoluble signalling molecules i.e. the extra cellular matrix (ECM). It has been proposed that 
"dynamic reciprocity" exists between cells and their extracellular matrix, which partially 
determines cell shape, biosynthesis, migration and attachment (Bornstein et al, 1982). Two 
way communication between the cells and their surrounding ECM is essential for embryonic 
development, wound repair, and tumour metastasis.
In tissue engineering a range of bioactive molecules have already been experimented with 
ranging from simple ions e.g. copper ions (Ahmed et al, 1999) to more complex molecules 
e.g. growth factors. Several cell receptors are known to be sensitive to copper and zinc ion 
concentration. Ahmed et al (1999) have shown that individual cell types behave differently 
when exposed to different copper ion concentrations e.g. Schwann cells grew in a fibronectin 
mat incorporating 1 pM copper ions but their growth was inhibited above 10 pM, this is 
a stark contrast to fibroblasts whose growth was unaffected at up to 200 pM incorporated 
into the mat (Ahmed et al, 1999). These ions can regulate the adhesion and mobility of cells 
to a surface or to each other. Growth factors can either stimulate or inhibit cell division, 
differentiation, and migration. They can up regulate or down regulate cellular processes 
such as gene expression, DNA and protein synthesis, and autocrine and paracrine agent 
release. Growth factors can interact with one another in additive, cooperative, synergistic or 
antagonistic manners (Patrick etal, 1998b). These factors have long been added to cell culture 
media in vitro to enhance cell proliferation. Alternatively, growth factors can be added to the 
scaffold either during its manufacture or coated onto the scaffold after manufacture in order to 
influence subsequent cell behaviour. Controlled delivery of growth factors is possible by using 
a scaffold made from an appropriate biodegradable materials loaded with the desired factor. 
The growth factor can be strategically located within the scaffold, thereby creating a gradient 
to preferentially enhance cell attachment and/or direct cell migration. Possible growth factors 
for successful tissue engineering include; basic fibroblast growth factor (bFGF) for endothelial 
and smooth muscle cells and vascular endothelial cell growth factor (VEGF) for endothelial 
cells (Moses et al, 1995). Scaffolds can be made more "cell friendly'' by the incorporation 
of specific bioactive sequences. Short peptide sequences derived from cell binding regions 
of extracellular matrix proteins can be utilised to achieve biospecific adhesion of cells to 
biomaterials e.g. arginine-glycine-aspartic acid (RGD) (fibronectin, collagen, vitronectin, 
laminin A and B and thrombospondin active repeat cell binding sequence), valine-glycine-
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valine-alanine-proline-giycine (VGVAPG) (elastin active repeat cell binding sequence). 
Hydrogels containing RGD peptide sequences significantly improve the healing of diabetic 
ulcers, a notoriously difficult lesion to treat (Steed et al, 1995). Similar constructs again using 
the RGD fragment have been demonstrated to be of benefit in treating partial thickness burns 
(Hansbrough et al, 1995). Specific short peptide fragments e.g. RGD have an advantage 
over the complete "parent" protein in that they may be more stable during processing i.e. 
able to better resist denaturation and degradation that can occur with "natural proteins" thus 
be more amenable to processing without losing their vital biological function.
A complicated area of research is the effect of growth factors on one another e.g. they 
may up-regulate or down-regulate the production of other growth factors. Another important 
factor is whether the cells are quiescent or active in the construct. Whether they are in a two or 
three-dimensional arrangement will influence endogenous growth factor production and thus 
also the response to exogenously applied bioactive molecules. For example, when growing 
a tissue engineered blood vessel it will be necessary to co-culture smooth muscle cells and 
endothelial cells at the same time, these two cell types cultured together may well respond 
differently to exogenous growth factors than will cultures of each cell type alone due to their 
own interactions.
Johnson of Alkermes Inc (Cambridge, MA, USA) has successfully incorporated a bioactive 
protein (recombinant human growth hormone (rhGF)) into PLGA microspheres using an 
encapsulation technique which is "cryogenic, non aqueous and did not utilise surfactants or 
emulsification", i.e. near ideal for preserving protein bioactivity. Since no water is present 
during the encapsulation process this greatly reduces unwanted chemical modifications, 
denaturing and aggregation. The rhGF retained its bioactivity, which was demonstrated both 
in vitro and in vivo. In vivo experiments included injecting subcutaneously the microspheres 
into rhesus monkeys resulting in elevated serum levels of recombinant human growth hormone 
for more than one month. This period of time was twenty times the length of the control i.e. 
unencapsulated rhGF (Johnson et al, 1997). This result suggests that possibly any protein 
could be stabilised in a similar manner i.e. forming a complex with zinc, atomising this 
protein-zinc complex followed by lyophilising into a powder and finally encapsulation within 
a polymer which can release the protein in an unaltered and controlled manner.
1.5.4 Bioreactors
Freed and Vunjak-Novakovic have defined tissue-engineering bioreactors as, "in vitro culture 
systems designed to perform at least 1 of the 4 following functions:
1. Establish spatially uniform cell distributions on three-dimensional 
scaffolds
2. Maintain desired concentrations of gases and nutrients in the 
culture medium
3. Provide efficient mass transfer to the growing tissue
4. Expose developing tissues to physical stimuli" (Freed et al, 2000)
To this list needs to be added the ability to be produced in an economically viable and 
scalable manner which is compliant with CGTP, quality control and other regulatory issues 
plus allowing close monitoring of its environment including dissolved oxygen tension, pH, 
temperature, nutrient uptake and allowing the living construct to be directly visualised e.g. cell 
and overall construct morphology (Griffith and Naughton, 2002, National Institutes of Health 
Bioengineering Consortium, 2001).
The simplest bioreactor is a static culture, where mass transfer from the culture medium is via 
molecular diffusion since there is no fluid movement within the bioreactor and gas exchange 
is via culture medium/gas surface aeration. More complex bioreactors involve the movement 
of the culture medium relative to the construct e.g. rotating vessels ideally have a laminar flow 
of culture medium over the developing construct (Martin et al, 2004).
A great variety of different bioreactors aimed at tissue engineering have been tried. These 
include spinner flasks, rotating vessels, rotating wall perfused vessels, perfused columns and 
perfused chambers (Temenoff et al, 2000 and Freed et al, 2000). These different bioreactors 
employ a host of different properties including; the constructs are either fixed in place, or 
allowed to freely move and medium exchange is either batchwise or continuously recirculated 
and exchanged. Gaseous exchange is usually continuous either by an internal or an external 
membrane. Laminar culture medium flow is aimed at in the reactors. To date no one method 
has been proven to be any better than any other, nor has any one approach proven to be 
entirely satisfactory. Niklason, however, has demonstrated that a pulsatile bioreactor which 
mimics embryonic blood vessel development does produce tissue engineered blood vessels 
with much greater wall strength and superior histology to previous attempts at blood vessel 
engineering using non-pulsatile reactors (Niklason et al, 1999).
1.5.4.1 Mechanical and physiological stimuli
Mechanical forces on cells and tissue engineered constructs like the biochemical environment 
play a significant role in their development and maturation (Guilak, 2002). The mechanical 
environment provides physical stimuli to the cells. These stimuli are "translated" by the cells 
into biochemical stimuli resulting in a change in the cells behaviour e.g. up or down regulating 
gene expression, release of autocrine or paracrine factors. Mechanical forces on cells are a 
natural event occurring all the time in vivo e.g. when a skeletal muscle contracts its tendon 
exert a force on its bone attachment likewise cartilage responds to mechanical forces by
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remodelling itself to match the local requirement i.e. load bearing surfaces are thicker and 
stronger than non load bearing surfaces within the same joint. A good example of the role of 
mechanical stimuli is the artery. Arteries are subjected to repeated pressure changes (cyclical 
strain) due to the rhythmical nature of the pumping action of the heart. Furthermore, the 
blood flowing through the arteries exerts a shear force on the lining endothelium. These forces 
produce significant biochemical changes in both the endothelium (Patrick etal, 1995) and the 
smooth muscle cells in the wall of the vessel (Owens, 1995). Blood flow induced wall shear 
stress and cyclical strain modulate gene expression of certain bioactive molecules synthesised 
and secreted by endothelial cells (Patrick etal, 1995). Excessive i.e. pathological intraluminal 
pressure via the cells in the vessel wall as in hypertension, leads to an overall increase in the 
absolute amounts of both collagen and elastin in the wall (Wolinsky, 1970).
Niklason of Duke University USA and others have demonstrated that the mechanical 
environment in which a tissue engineered construct such as an artery is grown and matured 
has a significant effect upon its biological and functional properties (Niklason et al, 1999). 
Niklason tissue engineered small calibre arteries using a PGA tubular scaffold and a pulsatile 
perfusion system. Experimental constructs were cultured under conditions of pulsatile radial 
stress for eight weeks with control constructs cultured without this stress. After 8 weeks, the 
histological appearance of the pulsed constructs was much more similar to natural artery than 
the control vessels. The mechanical properties of tissue engineered blood vessels is due to the 
smooth muscle cells and the extracellular matrix which they produce since the PGA scaffold 
fragments and degrades with time. Pulsed constructs had thicker walls and far higher burst 
strengths than non-pulsed constructs. This is in part explained by the fact that collagen level in 
pulsed vessels was statistically similar to native artery whereas non pulsed vessels contained 
significantly less. In in vivo studies the pulsed constructs performed significantly better than 
their non-pulsed controls.
1.5.5 Storage
Having been manufactured using CGTP, it will be necessary to make the finished product 
easily available to the surgeon to implant. Presently this issue revolves around the question; 
deliver fresh with a short shelf life or deliver in a cryopreserved form with a much longer 
shelf life but with more overall product complexity. Cryopreservation of cell lines is relatively 
well understood, however, successfully cryopreserving three-dimensional tissue constructs 
is still in its infancy. Organogenesis opted to deliver their skin product Apligraf fresh with 
its own temperature controlled packaging with a life span of five days (Parenteau, 1999). 
Advanced Tissue Sciences instead opted to cryopreserve their skin product, Dermograft at 
-70°C (Naughton, 1999). Long shelf life is highly desirable if tissue engineered products 
are to be widely used and especially if these products are to be employed in non-elective
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procedures.
1.6 Project aims
Overall the challenges for tissue engineering are not discrete entities isolated from one another. 
Therefore this thesis study investigated the topic in a holistic manner by addressing a number 
of overlapping and interacting factors centred on the brief to provide a foundation for the 
design of a commercially viable, automatable and scalable bioreactor platform technology. 
The areas covered include bioreactor design, construct fabrication, polymer selection and 
derivatisation with bioactive molecules, cell selection and monitoring/imaging solutions.
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2.0 Alginate
After thorough discussions and review of the scientific literature, and for certain characteristics 
required by the tube fabricating devices described in later chapters, it was decided to focus 
on alginate as the scaffold polymer. This chapter contains the background relating directly to 
the choice of alginate, while in Appendix I, there is a review of some of the other potential 
polymers that were considered.
2.1 Background
In 1883, the Scottish manufacturing chemist Stanford was the first to describe algic acid 
and algins now termed alginic acid and its salts, alginates respectively (Stanford, 1883a; 
Stanford 1883b). Two years earlier Stanford had patented a process to extract algin from 
seaweed and subsequently set up a company to exploit the technology (Stanford, 1881; 
Draget et al, 2004). The patent outlined how alginate could be extracted under pressure from 
a solution of pulped seaweed using sodium carbonate and then precipitating the alginate 
from the resulting solution by the addition of acid. From his research, Stanford demonstrated 
that alginic acid contained only carbon, hydrogen, oxygen and nitrogen (the entire nitrogen 
component is now attributed to impurities) (Stanford, 1883c; Draget et al, 2004). However, 
in the 1920's various groups concluded that alginate was in fact composed of polyuronic 
acid residues. Later these residues were shown to be p-D-mannuronic acid (abbreviated to 
M) and a-L-guluronic acid (abbreviated to G). These residues are either in continuous runs to 
create blocks of one type of uronic acid residue or in mixed runs. There are four main types 
of seaweed which produce commercial alginate, see Figure 2.1.
Younger seaweeds are richer in polyM but as seaweed matures the proportion of G residues 
increase. This increase is due to the action of epimerases. The alginate content of seaweed 
is in the range 10 - 50% depending upon species, season of the year and part of the plant. 
There is also variability within the plant with respect to the M:G ratio, this is to allow different 
parts of the plant to have different and thus structurally appropriate roles i.e. the M:G ratio 
decreases from the fronds to the stem (stipe) to the anchor/holdfast. This change in ratio 
provides good strength at the anchor and good flexibility at the fronds (Tombs et al, 1998).
In the 1990's the total annual production of alginate was in the region of 30,000 tonnes 
(Rehm and Valla, 1997). Currently commercial alginates are extracted from seaweed by 
initially milling and washing, this is followed by dissolution by heating with alkali and then 
precipitation with calcium chloride. The precipitate is decolourised, acid treated and soaked 
in sodium carbonate solution (3%). Finally the product is dried and milled to produce an 
off-white powder (Draget et al, 2004). Alginates are either single source or often blends of 
alginates with different M:G ratios to give an alginate of a desired property e.g. Manucol DM
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Seaweed source Harvestinglocation
Seaweed
component
Average 
alginate content
%
Average M:G 
monomer ratio
Laminaria
hyperborea
Scotland + 
Ireland
Fronds
2 5 -3 8
1.1
Stipes 0.5
Laminaria
digitata
Norway + 
France N /A 18-26 1.5
Macrocystis
pyrifera
North America Fronds 20-31 1.6
Ascophyllum
nodosum
Scotland + 
Ireland N /A 19-30 1.5
Figure 2.1
Table demonstrating the variability in both quantity and composition of alginate from the 
most common seaweed sources.
(Based on Chaoyuan, 1990)
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(Kelco, San Diego, USA).
In 1964, Linker and Jones were the first to describe alginate to be a natural product of bacteria 
(interestingly isolated from the sputum of a cystic fibrosis patient with a Pseudomonas chest 
infection) (Linker and Jones, 1964). This discovery has helped pave the way for alginate to be 
potentially produced by industrial fermentation, a far more controlled process than harvesting 
seaweed (Sabra et al, 2001). However, exploitation has not been rapid due to the current 
pricing of seaweed alginate at an average of $5 - 20 Kg'1 (Rehm and Valla, 1997). At this 
price range, bacterial alginate cannot currently compete. However, this may change due to 
environmental concerns associated with the harvesting and processing of seaweed. Another 
important driver is there is a rising demand for high purity alginates by the pharmaceutical 
industry where the average price is nearer $40,000 Kg'1 (Sabra et al, 2001; Rehm and Valla, 
1997)
2.2 Alginate chemistry
Alginate is a family of unbranched binary copolymers composed of G and M subunits (Thu 
et al, 1996a). The copolymers are highly variable with respect to the order of the G and M 
monomers with both inter and intra organism variation (Figure 2.1). Furthermore, variability 
is also effected by external influences e.g. seasonal changes and different growing conditions 
(Saraswathi etal, 2003, Chaoyuan, 1990). In general, the monomers are in continuous runs 
(blocks) of either M or G interrupted by regions of alternating structure i.e. -MG-. No regular 
repeat sequences have been observed (Thu etal, 1996a). Characterisation of the coploymers 
e.g. quantifying the frequency of short runs of -GGGG-, can be performed using nuclear 
magnetic resonance (NMR) technology (Grasdalen, 1983).
For alginate, X-ray diffraction studies have revealed that polyM acid regions bind divalent 
ions to form an extended "three fold ribbon like" conformation, whereas polyG acid regions 
bind with divalent ions to form a "buckled two fold " structure (Atkins et al, 1973). Both types 
of structure can bind calcium ions, however, homopolymeric polyG continuous sequences of 
approximately 20 residues or greater bind far more strongly than polyM segments and mixed 
polyG/polyM segments, thus polyM segments and mixed polyG/polyM segments only play a 
very minor role in alginate gel binding. The homopolymeric polyG 20+ continuous sequences 
leads to the formation of "junction zones". Junction zones are terminated when polyguluronic 
residues are no longer continuous i.e. a mannuronic residue disrupts the sequence (Morris 
et al, 1978). The "three fold ribbon like" structure has been likened to an "egg box" (Grant 
et al, 1973). Positively charged calcium ions (eggs) occupying negatively charged cavities 
within the overall structure (egg box). This egg box structure is relatively unchanged when the 
water is removed from the hydrogel. To further clarify: the egg box process involves intrachain
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polyG regions interacting with divalent ions e.g. calcium, strontium and barium. Calcium ions 
are commonly used for gelation processes in the food industry. There is an optimal calcium 
ion concentration depending upon the amount of polyG residues in the specific alginate, 
usually to a maximum of 0.5 M (Tombs et al, 1998). In general, higher polyG alginates at an 
appropriate calcium ion concentration give stronger gels, however, higher polyM alginates 
are less sensitive to calcium ion concentration.
The calcium ion concentration and the speed with which the calcium ions are added is 
crucial to the overall properties of the resulting gel. Too few calcium ions gives rise to weaker 
gels, however, if too many calcium ions are added too quickly this results in the formation 
of a precipitate and not a pure hydrogel. Cross-linking to form alginate hydrogels can be 
accomplished either by allowing divalent ions to diffuse in (diffusion setting) e.g. exposing 
sodium alginate to CaCl2 solution or by internal setting where a slower acting cross-linking 
agent is premixed with the alginate e.g. CaS04. The two methods have totally different 
gelling kinetics, diffusion setting is very rapid whilst internal setting is far slower and is 
therefore generally considered to be more controllable (Draget etal, 2004). For the diffusion 
setting method, upon addition of the cross-linking solution e.g. CaCl2 solution, interfacial 
polymerisation is instantaneous with precipitation of calcium alginate followed by a more 
gradual gelation of the interior as calcium ions diffuse through the alginate (Zhang et al, 
2000). One of the main characteristics of the diffusion setting method is that the final gel 
distribution is not homogeneous i.e. a high concentration at the interface but gradually 
decreasing towards the centre of the gel (Skjak-Braek et al, 1988). Maximum inhomogeneity 
is achieved with a low molecular weight alginate cross-linked with a dilute cross-linking 
solution; conversely maximum homogeneity is achieved with high molecular weight alginates 
cross-linked with high concentration cross-linking agents. One other factor of importance is 
the presence or not of non-gelling ions These ions result in increasing homogeneity with their 
increasing concentration (Draget et al, 1997).
As alginate gels set, there is an initial overall volume reduction (shrinkage) of the initial 
volume of unset alginate (Martinsen etal, 1989). The degree of initial shrinkage is dependant 
on a number of factors including the concentration of the cross-linking agent (increased 
concentration leads to increased shrinkage), alginate composition (overall higher G contents 
leads to lower shrinkage) and average length of the monomer runs/blocks (higher fractions 
of G blocks results in less shrinkage) (Martinsen etal, 1989). After this initial shrinkage, which 
is complete in minutes depending upon environment (e.g. pH), both further shrinkage or 
swelling (volume expansion) can occur. The time frame for these secondary volume changes 
is hours to months (Zhang etal, 2000).
Alginate gels are thermostable and only melt when heated to in excess of 120°C (Sutherland,
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1990). The physical properties of alginate gels depend upon the ratio of homopolymeric 
polyguluronic 20+ continuous sequences to other sequences. Gels high in homopolymeric 
polyguluronic 20+ continuous sequences are much more brittle than gels low in homopolymeric 
polyguluronic 20+ continuous sequences which are weaker but more flexible (Sutherland, 
1990). The stiffness of gels increases in the order poly MG, poly M, poly G, i.e. gels 
composed predominantly of poly MG gels are the weakest, whereas gels composed mainly 
of homopolymeric polyG 20+ continuous sequences are strongest. The average degree 
of polymerisation of an alginate gel varies between different seaweed species (80 - 700) 
giving a wide range of molecular weights (150,000 - greater than one million Daltons). By 
comparison alginates produced from bacteria tend to be far smaller (Tombs et al, 1998).
2.3 Regulatory issues
In order for alginate hydrogels to be used as a tissue engineering scaffold, the polymer 
must meet certain key pharmacological and toxicological requirements including high 
biocompatability, predictable degradation and excretion. Oral administration of alginate (a 
long-standing indigestion medication) has an impeccable track record e.g. routinely prescribed 
in pregnancy with no known significant safety concerns (Lindow et al, 2003). Animal studies 
deploying radio-labelled alginate have demonstrated that oral administered alginate is not 
absorbed systemically (Hagen et al, 1996). Data e.g. elimination rate, bioavailability and 
tissue distribution for non-oral administration (intravenous, intramuscular, intraperitoneal and 
subcutaneous routes) is starting to become available in the scientific literature. For example, 
the fate of alginate following intravenous and intraperitoneal (intraabdominal cavity) injection 
has been found in a rodent model to be dependent upon its molecular weight. Fractions less 
than 48,000 KDa were excreted in the urine, whilst the larger polymer fraction remained in 
the circulation but with little deposition in organs at 24 hours (Al-Shamknani et al, 1995). 
Similar data were recorded by Hagen et al, who also found some alginate accumulation in 
the tissues (spleen, liver and kidneys). This data suggests that since alginates are not readily 
degraded under physiological conditions, the molecular weight of any alginate implanted in 
the body needs to be below the renal filtration threshold (in man, the renal filtration threshold 
is approximately 69,000 KDa which equates almost exactly to the size of the smallest plasma 
protein albumin (Guyton, 1986). With the increasing biomedical and pharmaceutical 
applications of alginate during the late 1990's, more data was deemed necessary (Skaugrud 
et al, 1999). In response, the American Society for the Testing of Materials (ASTM) (West 
Conshohocken, PA, USA) in May 2001 produced a guide (F 2064 - 00) titled "Standard 
guide for characterisation and testing of alginates as starting materials intended for use 
in biomedical and tissue-engineered medical product applications" in response to the 
growing interest of alginate for tissue engineering. The regulatory issues covered include;
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documentation, impurity levels, safety and toxicology, good manufacturing practice (GMP)/ 
ISO 9000 guidelines and regulatory standards. Included in the guidelines is information on 
the selection of appropriate testing methodologies and safety criteria. Critical parameters 
are also described including; G and M monomer content, molecular weight, viscosity, dry 
matter content, heavy metal content, bioburden and endotoxin content. This guide represents 
some of the drive ASTM is making to ensure quality and standardisation of tissue-engineered 
medical products (TEMPS) whilst being an aid for success clinical applications plus helping 
expedite the necessary regulatory approvals (Dornish et al, 2001).
Today, the majority of commercially available alginates are not fully characterised with respect 
to the endotoxin levels, impurities, M:G ratio, their source or viscosity. Implanted impure 
alginates are known to trigger the host's immune system e.g. foreign body response (Zhang 
et al, 2001). Because there is much confusion in the scientific literature, the source of this 
immune reaction in well characterised alginates and whether human monocytes/macrophages 
produce a fibrotic response to alginates is under investigation by the FDA, Centre for Devices 
and Radiological Health, Office of Science and Technology (Annual Report, May 2000). 
Commercial alginates have been demonstrated to contain at least 10 - 20 immunoreactive 
contaminants which if removed by electrophoresis results in a highly significant reduction in 
fibrotic reaction when implanted for three weeks into a rodent model (Zimmermann et al,
1992). Pronova ultrapure (UP) sterile sodium alginates manufactured by Nova Matrix (FMC 
Biopolymer, Oslo, Norway) are produced in compliance with current Good Manufacturing 
Practice (cGMP - 21 CFR 210,211) using validated analytical methods and documented in 
a Drug Master File (DMF) submitted to the FDA. The process operations are compliant with 
ISO 9001:2000 and ISO 13485:2003 (medical device directive). Furthermore Pronova UP 
alginate satisfies ASTM F 2064 - 00 for use in tissue engineering.
On an historical note, many researchers have reported that alginates with M and MG runs/ 
blocks both in vivo and in vitro resulted in an inflammatory response and fibrotic over-growth 
(foreign body reaction) (Zimmermann et al, 2000; Otterlei et al, 1991; Draget et al, 1997). 
For example, Otterlei et al, showed that human immune cells (monocytes) secreted various 
inflammatory cytokines (tumour necrosis factor alpha (TNF-alpha), interleukin 1 (IL-1) and 
interleukin 6 (IL-6) in response to alginates. Low G alginates were an order of magnitude 
more potent in inducing inflammatory cytokine production compared to high G alginates. 
Similar results were obtained by others and the conclusion drawn was that the M component 
was suspected as being the causative agent (Otterlei et al, 1991; Sabra et al, 2001). Today, 
with the availability of purified alginates, this conclusion is generally agreed to no longer 
hold, and that the adverse events observed were the result of contamination and not the M or 
G components of the polymer (Klock et al, 1994; Klock et al, 1997).
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2.4 Life science research and clinical applications
Whilst alginates have many commercial human applications including extensive utilisation in 
the food and drink industry; see Figure 2.2, it is its existing roles in life science research and 
clinical applications which potentially justify its deployment for tissue engineering. The major 
applications are in pharmaceuticals, surgery and wound care and cell encapsulation.
2.4.1 Pharmaceutical applications
Alginate is currently deployed by the pharmaceutical industry as both a treatment and as an 
excipient (a harmless substance added to a drug to assist its administration).
Oral alginate-based treatments for the symptomatic relief of gastritis and oesophagitis 
("heart burn") e.g. Gaviscon (GlaxoSmithKline, Brentford, Middlesex, UK) have been a part 
of routine clinical medicine since the 1940's (Mandel et al, 2000). The mechanism of action 
being that in the presence of stomach acid, alginates precipitate to form gels. If bicarbonate 
is included in the preparation, the bicarbonate in the presence of stomach acid reacts to form 
carbon dioxide which is trapped in the gel, thus creating a foam which floats on the gastric 
contents. These so called, "raft-forming" formulations have full FDA approval, minimal if any 
side effects, non toxic and are therefore sold freely as over-the-counter medicines. (The FDA 
does not specify an acceptable daily intake (ADI) for alginate - this is the highest possible 
classification for a food additive.)
The use of alginate as an excipient in oral drug formulations is because of their unique 
thickening, gel forming and stabilising properties (Tonnesen et al, 2002). Traditionally and 
in the main, alginates have been used as tablet binding agents (with a high margin of safety 
given their lack of toxicity), however their other roles include controlled release systems and 
as masking agents for unpleasant tasting medications (Tonnesen et al, 2002, Office of Science 
and Technology Annual Report 2000 and Skjak-Braek et al, 1996). (Microencapsulation 
and controlled release systems using alginate are used for the immobilisation and controlled 
release of pesticides, biocatalysts products (Skjak-Braek et al, 1996))
The use of alginate as an excipient in parenteral (non-oral) preparations is also being 
evaluated in animal models e.g. subcutaneous injections for chemotherapy agents (Yoshikawa 
etal, 1999).
2.4.2 Surgical applications
Anecdotal evidence suggests that the use of seaweed for dressing wounds has a long history, 
going back possibly thousands of years (Thomas, 2000). However the modern use of alginates 
in surgery and wound management can trace its origins back to Major George Blaine of
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Industry Sub-sector
% Total 
alginate 
used
Examples of use/products
Textile printing All 50% Thickening agents
Food All 30% Gelling, thickening agents + stabilisers
Paper coating All 6% Paper coating - surface sizing
Health
Medical
5%
Wound dressings and stomach 
ulcer medication
Pharmaceutical Microencapsulation and controlled release additives
Dental Dental impressions
Welding Welding rods 5% Flux for welding rods
Other All 5% Pigment suspension in paint
Figure 2.2
Table giving examples of alginates extensive use in a range of diverse industries.
(Adapted from Chaoyuan, 1990)
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the Directorate of Biological Research, War Office and Royal Army Medical Corps. During 
World War II, Blaine was actively looking for new materials for dressing wounds. The current 
bandages were inadequate for a number of important reasons including toxicity, wound 
adhesion (making removal painful and difficult without disrupting the healing surface), slow 
wound healing and lack of ability to decrease/control capillary haemorrhage (Gensheimer,
1993).
Initially Blaine conducted two types of experiment using calcium alginate and animal models; 
either direct injection into damaged tissues or by topical application (Blaine, 1946 and Blaine, 
1947). Blaine's conclusions from his pioneering work in both the laboratory and aboard 
troopship hospitals in the Far East, concluded that, alginate accelerated wound healing by 
keeping wounds moist but not sticking to the healing wound, was sterilisable by autoclaving, 
absorbable by tissue, non-toxic (even when directly injected into the wound) and importantly 
for the time, compatible with penicillin (Blaine, 1946; Blaine, 1947; Blaine, 1951 and Oliver 
etal, 1950).
Because of a lack of facilities and "exigences of the Services", full follow-up of the clinical 
cases was not possible. However, encouraged by the preliminary findings, a three month 
clinical trial at Croydon Hospital (Surrey, UK) was conducted. Burns, lacerations, ulcers and 
amputations were all treated with alginate. The results confirmed the beneficial advantages 
of alginates in wound care (Bray et al, 1948).
Additional successful clinical pilot studies have also been undertaken in aural wound healing, 
neurosurgery and in the management of pulmonary tuberculosis (sealing of bronchi) (Passe 
et al 1948, Oliver and Blaine, 1950 and Blaine 1946).
Because of the early successes with alginate dressings, commercial products soon followed, 
thus bringing alginate dressings into routine clinical practice. Unfortunately in the 1970's due 
to market forces (large-scale production of alginate fibre ceased due to an overall drop in 
demand - alginate medical products were less than 10% of the total market) and expensive 
production technologies, these products were withdrawn (Thomas, 2000). However by the 
1980's, technology advances and improved production techniques led to a major comeback 
for alginate dressings. Today, there are numerous types of alginate dressings including 
Kaltostat (ConvaTec, Princeton, NJ, USA), Tegagen (3M, St Paul, MN, USA), Sorbsan (Maersk, 
Lynge, Denmark) and Algisite (Smith and Nephew, London, UK). A major additional benefit 
of these dressings is the calcium ions involved with the gelling process further assist wound 
healing by promoting the blood coagulation process thus these dressings also have a degree 
of haemostatic activity. This property also allowed alginate to be used to produce absorbable 
surgical haemostats to control internal blood loss during surgery (Blaine, 1951). Absorbable
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haemostats have the big advantage of being able to be left in situ prior to being harmlessly 
absorbed post operatively by the local tissue.
Since Blaine's initial work in the 1940's, there have been numerous clinical trials of alginate 
based dressings mainly in Europe plus a few in the U.S.A. The general conclusions are that 
alginate dressings are preferable to conventional bandages in the two key areas; improved 
quality of patient life (faster wound healing, little/no pain during dressing changes, reduced 
wound odour, non-sensitizing, non-toxic and shorter hospital stays) and lower healthcare 
provider costs (faster healing rates, shorter hospital stays, less nursing time required per 
bandage change due to ease of application and removal) (Gensheimer, 1993).
Other surgical applications of alginate include "bone wax substitute" to control intra operative 
bleeding from the cut ends of bones and biodegradable stents (Oliver and Blaine, 1950, 
Office of Science and Technology Annual Report 2000 and Ronan and Thompson, 2001).
2.4.3 Cell encapsulation
Whilst the encapsulation of microbial cells, subcellular organelles and enzymes has a long 
history dating back to the 1970's, mammalian cell encapsulation is still at an earlier stage in 
its development (Kierstan etal, 1997 and Hackel etal, 1975). Alginate has a combination of 
unique properties which enable it to be deployed as an artificial matrix for encapsulation of 
biological materials and cells:
•  Relatively inert aqueous environment
•  Mild room temperature encapsulation process not requiring harsh solvents
• Rapid (almost instantaneous) initial gelling property
•  High gel porosity which allows high diffusion rates of macromolecules
• Potential to control porosity with simple coating process e.g. poly-L-lysine
• Dissolution and biodegradation occurs under normal physiological conditions 
(Adapted from Gombotz et al, 1998)
Stable alginate hydrogel beads are formed by dropping a mixture of sodium alginate and 
cells into calcium chloride solution i.e. diffusion setting. Alginate has the ability to encapsulate 
mammalian cells in order to both physically protect as well as immunoprotect if used in 
vivo. Alginate gels are biocompatible. Examples of the use of alginate encapsulated cells 
include: hybridoma cells in the production of monoclonal antibodies, hepatocyctes in the 
extracorporal detoxification of blood in patients with acute liver failure and the isolation of 
islets of Langerhans insulin producing cells for the potential in vivo treatment of diabetics 
(clinical trial data only) (Soon Shiong et al, 1994). High polyG alginates tend to be the 
alginates of choice for these applications i.e. where cells are encapsulated in alginate beads. 
Beads can be produced ranging from a few pm to several mm in diameter. Encapsulation
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devices are available commercial e.g. Inotech Encapsulator which is based on a harmonically 
vibrating nozzle (Inotech Biosystems International, Rockville, Maryland, USA). Commercial 
devices allow the production of defined bead diameters and high throughput for drugs, 
animal cells, plant cells, microorganisms and enzymes. High polyG alginates give stronger 
beads with high resistance to gel degrading agents e.g. monovalent ions which compete with 
calcium ions and calcium ion sequesters. In comparison, polyM alginates produce weaker 
but much more flexible beads (Thu et al, 1996b). Porosity also correlates with G content, 
alginate beads with high G content having the largest pore sizes, ranging from 5 - 200 nm 
(Martinsen et al, 1989 and Miura et al, 1986). Pores of this size allow the free diffusion 
of macromolecules in and out of the bead. Furthermore, the host immune response can be 
reduced substantially by using alginate with a low M:G ratio (Otterlei et al, 1991). Smaller 
pores reduce the size of the macromolecules, which can get in and out of the bead whilst still 
allowing the nutrients, metabolites and gas to freely permeate the bead. Coating the surface 
of alginate beads with a cross-linked alginate-polycationic polymer e.g. poly-L-lysine helps to 
stabilise the bead and also helps improve the quality of the pore controlled release system.
Microencapsulation of mammalian cells involves suspending the cells in an ultra pure sodium 
alginate solution (typically 1 - 2% weight/volume) to a density in the region of a million cells 
per ml of alginate. The suspension is sprayed through a 22 G needle located inside an air jet 
head droplet forming apparatus into a solution containing calcium ions (typically a 1 - 2% 
weight/volume calcium chloride solution), alginate microspheres containing cells are formed 
which gel on contact with the calcium ions. Beads can now either be used directly or coated 
with poly-L-lysine prior to use. An example of this technique is that of Joki (Joki et al, 2001), 
who genetically engineered baby hamster kidney epithelial cells to express endostatin (an 
antitumour agent) and then encapsulated them in sodium alginate to form beads. The beads 
were then coated in poly-L-lysine. The beads contained immobilised cells in an "artificial 
extracellular matrix" which allows free exchange of proteins, nutrients and oxygen between 
the encapsulated cells and the animal host. These beads where injected into mice, which had 
been previously treated to produce primary glioma tumours. Biologically active endostatin 
was released from the beads resulting in a significant reduction of the tumour mass. Similar 
results were observed by Read (Read et al, 2001), on performing a similar experiment, 
except the beads did not receive a poly-L-lysine coat.
There have been many successful animal studies involving surgically implanted encapsulated 
cells with some of these studies starting to progress into the clinic including; Chondrogel 
(Reprogenesis now Curis, Cambridge, MA, USA) implantation for urinary dysfunction, 
islets of Langerhans transplantation for diabetes and parathyroid gland transplantation for 
hypoparathyroidism (Caldamone etal, 2001, Elliott etal, 2000 and Hasse etal, 1997). Whilst
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all three applications deploy cells mixed with alginate, the functional role of the alginate differs 
greatly. Chondrogel uses autologous cells (chondrocytes) and therefore the alginate functions 
more as a scaffold or bulking agent. The islets of Langerhans and parathyroid glands were 
either allogeneic or xenografic in origin, thus the alginate is required to function as a barrier 
to protect immune attack whilst allowing hormones to be released from the encapsulated 
cells. In general, for alginates suitable to act as a protective barrier high M content alginate is 
preferable since high G gels exhibit very high permeability towards antibodies compared to 
the much lower permeability of the gels rich in mannuronic acids (Klock et al, 1997). A brief 
description of each of the above applications follows.
2.4.3.1 Chondrogel
Chondrogel was developed as an autologous chondrocyte in alginate gel suspension for the 
treatment of vesicoureteric reflux following the successful animal experiments of Vacanti and 
Atala (Vacanti et al 1991, Atala et al, 1993 and Atala et al, 1994). Vesicoureteric reflux is 
a congenital condition (affects 3% of children) which presents early in life with urine flowing 
backwards up the ureters i.e. from the bladder towards the kidney. If uncorrected, this results 
in frequent urinary tract infections and eventually renal damage. Chondrogel is a structural 
tissue product composed of autologous chondrocytes and alginate. Atala has demonstrated 
that the alginate acts as a substrate for delivery purposes and then harmlessly degrades, the 
remaining cells secrete extracellular matrix which maintains the volume of the initial cells/ 
alginate solution. This results in autologous cartilage being produced de novo (Atala etal, 1993 
and Atala etal, 1994). For Chondrogel, cells are harvested from the patient's ear, expanded 
in culture (six weeks), mixed with alginate and cross-linked immediately prior to injection via 
a cystoscope into the tissue adjacent to the vesicoureteric (bladder/ureter) junction. Injection 
volumes varied from 0.16 - 3 ml in total. The results of the phase II clinical trial was reported 
at both three months and at greater than one year (some up to 3 years) (Diamond et al, 1998 
and Caldamone et al, 2001). A total of 29 children (age range: 1 - 1 5  years) were enrolled 
into this study, each requiring a minimum of one injection of Chrondrogel at initial operation 
(the majority requiring two i.e. one for each ureter). If there was no improvement by three 
months, the therapy was repeated using chondrocytes which were stored for this purpose. 
The conclusion drawn from this study were that Chondrogel was a safe and reasonably 
effective treatment for vesicoureteric reflux. There was no significant complications, however 
the relapse rate (35% of patients at 1 year) was deemed unacceptable and as a result the 
alginate underwent reformulation prior to the phase III clinical trial (Relapses were mainly 
due to loss of bulk at the site of injection). Commencing February 1999, a total of 61 patients 
(age range: 6 months to 18 years) were enrolled into the phase III clinical trial by September 
2000 (FDA Office of Orphan Products Development Study ID Number 199/14267 REPRO-
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FDR001514;REPRO-99-07). The results of this phase III study are as yet unpublished due to 
Curis in February 2002 deciding to halt several of its programmes including Chondrogel in 
order to focus on stem cell therapies (Curis company press release, February 2002). Curis 
plans only to revive the programmes if a pharmaceutical company is prepared to act as a 
strategic partner.
Chondrogel has also been trialed as a therapy for intrinsic sphincter deficiency. Intrinsic 
sphincter deficiency is a severe form of urinary stress incontinence caused by either an inherited 
or acquired deficiency in the urethral sphincter mechanism (Bent et al, 2001). A preliminary 
study of 32 patients (age range 36 - 81) each received an injection of Chondrogel in to the 
tissue surrounding the neck of the bladder in order to cause an occlusion. At one year follow- 
up, once again Chondrogel was demonstrated to be safe and clinically effective (Bent et al, 
1999 and Bent et al, 2001).
2.4.3.2 Islets of Langerhans encapsulation
Type I diabetes results from the destruction of the insulin secreting cells (islets of Langerhans) 
in the pancreas. Whilst insulin therapy can be beneficial, it remains far from ideal. Another 
option is to transplant either autologous or xenogeneic islets. Following successful animal 
studies, a number of groups have moved into pilot studies in the clinic using alginate to 
encapsulate the cells (Sambanis, 2003 and Soon-Shiong, 1993). The alginate is deployed 
to prevent both allogeneic immune response as well as the autoimmune component which 
caused the patient's type I diabetes whilst allowing insulin to freely leave. Soon-Shiong in 
1993 first demonstrated the principle on a 38 year old man, Steven Craig (Soon-Shiong et 
al, 1994). Craig had long standing type I diabetes with multiple complications including renal 
failure which necessitated a living related donor transplant. This transplant required him to 
be on low dose immunosuppression therapy (cyclosporin and azathiopine). Human islet cells 
were isolated from eight cadaveric donor pancreases, expanded in culture for 22 days and 
encapsulated in alginate prior to being implanted into the abdominal cavity (peritoneal space). 
The initial dose was 10,000 islet cells per kilogram of body weight (approximately half the 
number required to achieve full insulin production). After six months a further 5,000 islet cells 
per kilogram were encapsulated and implanted. At five years, there have been no side effects 
from the therapy and whilst not fully producing adequate insulin (total replacement was not 
the aim of the study) to be a total replacement for insulin therapy, had resulted in a much 
reduced requirement (King, 1998). In 1994, the FDA granted Soon-Shiong permission to 
perform the same technique in a further 19 patients, all immunosuppressed kidney transplants 
(King, 1998).
Scharp also implanted encapsulated allogeneic islet cells but into non-immunosuppressed
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patients (Scharp et al, 1994). To avoid the necessity to use immunosuppression, islet cells 
were mixed with alginate. This suspension was then injected into acrylic-copolymer hollow 
fibres which had a permselective membrane on both its outer and inner surfaces (molecular 
weight cut off 65,000). The alginate was gelled by briefly immersing the fibres in a dilute 
calcium chloride solution after which the ends of the fibres were sealed with adhesive. Fibres 
were implanted in nine patients and explanted after 2 weeks. The results demonstrated that 
the biocompatability of the devices was excellent, there were no adverse patient complications 
and islet cell survival was also observed.
Elliott in his clinical study involving two type I diabetic patients, deployed porcine islet cells 
(Elliott et al, 2000). Porcine islet cells were encapsulated in alginate by VivoRx (now AmCyte) 
(Los Angeles, LA, USA) and implanted into the abdominal cavity. Follow up was reported to 
19 months post implantation. Both patients benefited from the procedure by requiring less 
insulin therapy with no side effects.
Following the successes of these early studies, in May 2004, a larger clinical study (ten 
patients) was commenced by Calafiore at the University of Perugia (Perugia, Italy). The study 
uses allogeneic islet cells encapsulated only in alginate implanted into the abdominal cavity of 
nonimmunosuppressed patients with type I diabetes. Early results from the first patient treated 
at 40 days post implantation are highly encouraging including requiring 30 - 40% less insulin 
and "absolutely no side effects from the graft" (Calafiore, 2004).
As the clinical successes continue, biotech companies have started to take up the challenge 
to commercialise these alginate based therapies including Cerco Medical (formerly, Islet 
Sheet Medical, San Francisco, CA, USA) and AmCyte (formerly VivoRx). For example, Cerco 
Medical plans to cure type I diabetes by means of bio-artificial pancreases built as thin sheets 
for implantation.
2.4.3.3 Parathyroid gland encapsulation
The clinical value of alginate microencapsulated cells has also been demonstrated in the field 
of parathyroid allotransplantation without immunosuppression (Hasse et al, 1997). Hasse 
reported on 2 female patients in their 50's who underwent subtotal bilateral thyroidectomy 
for multinodular goitre. Both subsequently became profoundly hypoparathyroid (tetany, bone 
pain, depression and impaired vision) despite intravenous calcium and high dose vitamin D 
(The parathyroid glands (usually 4) are intimately related to the thyroid gland and being only 
2 - 3 mm in diameter and variable in both location and total number, accidental removal 
is a recognised surgical complication of a thyroidectomy (Greatorex, 1991). Subsequent 
blood tests failed to detect the presence of parathyroid hormone. Allogeneic parathyroid 
cells were provided by an ABO matched HLA mismatched donor. Microcapsules were made
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by adding these cells to an alginate solution and then cross-linking with 10 mmolL'1 barium 
chloride for 7 minutes. The microcapsules were cultured for 2 days prior to 20 of them being 
implanted into the patients' forearm muscles. The alginate allowed nutrients and parathyroid 
hormone to freely pass whilst preventing antibodies and immune mediators from coming 
into contact with the allogeneic cells. Both patients' symptoms dramatically improved and 
no immunosuppressive therapy was required. No side effects of complications have been 
reported in either patient.
2.4.4 Alginate and tissue engineering
Alginate can be processed to form microcapsules, fibres and three-dimensional hydrogels, 
this coupled with a good record of in vivo biocompatibility (Klock et al, 1997), low cost (Jork 
etal, 2000) and availability make it a potential choice for tissue engineering applications. An 
example of its potential is that it can be gelled using reagents and conditions which are not 
harmful to cells e.g. low concentration CaCl2 solutions at between 4 - 37°C. Likewise, alginate 
can be turned from its hydrogel state to a liquid merely by increasing the monovalent cation 
concentration i.e.
Ca2+ + Na-Alginate (solution) -» 2Na+ + Ca-Alginate (hydrogel)
This property potentially gives control over the rate the alginate leaves the newly forming 
tissue. A balance between scaffold strength due to the hydrogel and tissue due to extracellular 
matrix produced by the cells is critical. However, currently alginate does have some challenges 
including:
1. Alginate dissolves in culture medium or in vivo due to the substitution of 
divalent ions from the alginate construct with monovalent ions e.g. sodium. 
This may or may not be a problem depending upon the desired outcome, 
however, predictable degradation will be essential.
2. Alginate is unable to specifically interact with mammalian cells in terms of cell 
attachment and proliferation. However, cell "friendliness" can be achieved 
e.g. covalently coupling RGD cell adhesion peptide sequences to alginate 
prior to cell seeding (Rowley et al, 1999).
3. Sterility is also an important issue with commercial alginates. There are currently 
only two routes for obtaining sterile alginate. Firstly a few groups including 
Zimmermann's from IBMT (St. Ingbert, Germany) carefully manufacture their 
own alginate from carefully selected seaweeds and then assay the finish product 
(Leinfelder et al, 2003). The only other alternative source of sterile alginate 
is from NovaMatrix (FMC BioPolymer. Oslo, Norway) who manufacture in 
accordance with FDA guidelines for current good manufacturing practice
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(cGMP).
Voluntary guidelines for the development of tissue-engineered products have been suggested 
which could be used with respect to alginate and tissue engineering (Omstead et al, 1998). 
However, more significantly, the American Society for the Testing of Materials (ASTM) in 
May 2001 produced their guide "Standard guide for characterisation and testing of 
alginates as starting materials intended for use in biomedical and tissue-engineered medical 
product applications" (F 2064 - 00) in response to the growing interest of alginate for tissue 
engineering. This interest would appear to be fairly substantial. It is generally recognised 
that the field of tissue engineering in general is rapidly expanding especially since the late 
1990's. This can be from both the expansion of the intellectual property in the field (Figure 
2.3) and by the increasing number of scientific publications (Figure 2.4). Alginate is likewise 
undergoing an increasing popularity (Figure 2.3 and Figure 2.5). Interestingly however is the 
extremely rapid period of growth that the combination of alginate - tissue engineering has 
undergone since the year 2000 Figure (2.3 and Figure 2.6). Whilst patenting and scientific 
publications can only suggest a trend, the trend does appear to be gaining momentum.
2.5 The focus of the thesis
The sharp rise in publications and patents in the field of regenerative medicine in the last 
five years is an indication of the perceived promise. However, the recent commercial set 
backs are also a pointer to the difficulty in achieving a consistent outcome which can yield 
affordable materials. The thesis topics focus on this aspect whilst taking a whole bioprocess 
approach. An initial scoping study on powders helped to sharpen the view of what was 
needed (not included in this thesis for the sake of brevity) and the selection of engineered 
tubular constructs as a test target. There followed detailed design and testing of a potentially 
disposable bioreactor which would ultimately allow automated construction and maturation 
of the tissue. The rapid scientific developments in stem cell science encouraged a switch 
from a rodent immortalised smooth muscle cell line to human stem cells and a preliminary 
examination of the differentiation to smooth muscle cells to populate the construct made with 
derivatised alginate. To allow the properties of the tubes to be evaluated without sacrifice of 
precious tubes, beads of the same material were prepared using a novel device. Finally, the 
issues raised by the study were summarised as a basis for future work.
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Area U.S. patents issued since 1976
U.S. patent applications 
published since 15th March 
2001
Tissue engineering and
related to tissue engineering 780 1,277
Alginate - All areas 22,146 10,718
Alginate tissue engineering
and related to alginate tissue 
engineering
187 396
Figure 2.3
Table of U.S. patents and patent applications published for tissue engineering, alginate 
and the combination of alginate and tissue engineering.
Source: United States Patent and Trademark Office - 9th December 2004.
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Figure 2.4
Graph of cumulative number of scientific publications for all of tissue engineering 1983 
-2003.
Source: MEDLINE Plus - Ovid Technologies Inc.
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Figure 2.5
Graph of cumulative number of scientific publications for alginate in life science journals 
1963 - 2003.
Source: MEDLINE Plus - Ovid Technologies Inc.
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Figure 2.6
Graph of cummulaiive number of scientific publications for alginate in all of tissue 
engineering 1992 - 2003.
Source: MEDLINE Plus - Ovid Technologies Inc.
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3.0 Materials and methods
This chapter contains the materials and methods relating to Chapter 7 (the study of cell in 
alginate scaffolds) and Chapter 8 (the study of cells in derivatise alginate scaffolds).
3.1 Cell lines
Two cell lines have been employed during this research:
•  Immortalised rat embryonic smooth muscle cells.
•  Adult human mesenchymal stem cells.
Initial experiments were performed using an immortalised rat smooth muscle cell line - A7r5 
(American Type Culture Collection, Manassas, Virginia, USA. Catalogue Number CRL-1444). 
A7r5 is a rat embryonic smooth muscle cell line derived from thoracic aorta and immortalised 
using chick embryo extract (Kimes et al, 1976).
Latter experiments were performed using human adult mesenchymal stem cells (MSCs) provided 
by Professor Chris Boshoff (The Wolfson Institute for Biomedical Research, UCL, London, UK). 
All appropriate ethics committee approvals were in place at UCLH. Cells were isolated from 
the bone marrow aspirate using a Ficoll gradient (see below). The MSCs were selected on 
the basis of being anchorage dependent cells which were capable of attaching to polystyrene 
tissue culture flasks and negative for surface marker CD34. In contrast, bone marrow derived 
haemopoietic stem cells do not attach to polystyrene flasks and are CD34+ve.
The method used for MSC isolation was to tak? a fresh human 10 ml bone marrow aspirate, 
diluted it with 10 ml of phosphate buffered saline (PBS) (BioWhittaker, Walkersville, Maryland, 
USA) and then filter the resulting solution through a 40 micron filter. The filtrate was then 
layered on 20 ml of Ficoll and centrifuged at 1800 rpm for 30 minutes using a refrigerated 
centrifuge. Bone marrow mononuclear cells were removed from the Ficoll interface and 
pelleted by centrifugation (1,800 rpm for 30 minutes). The cell pellet was resuspended in 20 
ml of PBS and centrifuged at 1,200 rpm for 10 minutes. For the final isolation of the MSCs, 
the cell pellet was resuspended in 10 ml of mesenchymal stem cell media, Mesencult (Stem 
Cell Technologies, Vancouver, British Columbia, Canada).
Both the rat and the human cell lines were grown in sterile polystyrene T-flasks (Corning, 
Corning, New York, USA], which were of the pretreated variety (negatively charged and 
hydrophobic surface) to aid cell attachment. The rat cell line was grown in supplemented growth 
media comprised of Dulbecco's Modified Eagle's Medium with 4.5 gL'1 glucose but without 
L-glutamine, (DMEM) (BioWhittaker, Walkersville, Maryland, USA), with 10% fetal bovine 
serum (FBS) (BioWhittaker, Walkersville, Maryland, USA), 2 mM L-glutamine (BioWhittaker, 
Walkersville, Maryland, USA), 100 U penicillin per ml with 100 pg streptomycin per ml
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(BioWhittaker, Walkersville, Maryland, USA). The volume used was 30 ml in a T150 flask. 
The stem cell line was grown in identical T150 flasks (Corning, Corning, New York, USA) to 
the immortalised rat smooth muscle cells. The media was however specific for maintaining 
the stem cells in their multipotent phenotype. The media used was Mesencult (Stem Cell 
Technologies, Vancouver, British Columbia, Canada) supplemented with mesenchymal stem 
cell supplements (human) (Stem Cell Technologies, Vancouver, British Columbia, Canada), 
recombinant human fibroblast growth factor (rFGF, R&D Systems, Minneapolis, Minnesota, 
USA) and 100 U penicillin per ml with 100 pg streptomycin per ml (BioWhittaker, Walkersville, 
Maryland, USA). The volume of this supplement media used per T150 flask was 20 ml.
In collaboration with Julia Markusen (UCL), cell banks of both cells lines were produced and 
stored in cryovials (Nalgene, Nalge, Rochester, New York, USA) in liquid nitrogen in order to 
be able to perform reproducible experiments over a long period of time.
3.2 Cell preparation and cell culture methodologies
In order to produce adequate numbers of cells, for example a typical experiment requires 
106 - 107 cells per ml of alginate solution, the cell lines were passaged using the following 
protocol.
A cryovial of banked cells was thawed and seeded into T150 flasks containing the appropriate 
supplemented media. Once the cells approached 80 - 100% confluence on the surface of 
the flask (viewed by light microscopy) e.g. approximately 3-5 days for the rat cell line and 
approximately 2-3 days for the stem cell line, the spent media was then drawn off using 
a pipette and the cell layer washed with 25 - 30 ml of phosphate buffered saline (PBS), 
(BioWhittaker, Walkersville, Maryland, USA) to prevent any residual proteins (e.g. from the 
FBS) interfering with the trypsin and thus reducing its enzymatic activity. Following rinsing, 
6 ml of 0.25% trypsin in 0.03% EDTA (Sigma, St. Louis, Missouri, USA) was pipetted into 
the flask and by gently rocking the flask, spread over its growth surface in order to bring the 
trypsin into contact with the entire sheet of cells. After 5 - 7 minutes, the flask was manually 
tapped in order to dislodge the cells from the surface of the flask. In order to prevent cell 
membrane damage due to the non-specific protease activity of the trypsin, the reaction was 
quenched by immediately adding 12 - 18 ml of supplemented media and rocking gently to 
mix homogeneously. A 500 pL sample was then removed in order to count the number of 
live and dead cells and then to be able to extrapolate the result for the entire T-flask. At least 
three independent 100 pL samples with an equal volume of trypan blue dye (Sigma, St. Louis, 
Missouri, USA) in an Eppendorf tube (Eppendorf, Hamburg, Germany), were prepared by 
mixing thoroughly using the repeated action of a micropipetter.
After a brief vortex, a 20 pL sample was then removed and added to a freshly prepared
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Improved Neubauer Haemocytometer slide with an in place cover-slip. The cover-slip was 
thoroughly cleaned before being applied to the haemocytometer with gentle pressure until 
Newton's rings were visible and remained visible during use, (Newton's rings are coloured 
interference fringes). The trypan blue dye works as an exclusion medium since the dye 
permeates all cells but only dead cells will retain the blue dye whereas live cells will exclude 
the dye and therefore will not permanently stain. Live cells therefore appear with a birefringent 
halo around them when viewed under a light microscope. Using a light microscope the grid 
etched on the Improved Neubauer Haemocytometer is easily discernable consisting of two sets 
of nine main squares each measuring 1 x 1 mm. Each of these main squares is subdivided 
into smaller squares each of which is 1/400 mm2 in area.
By counting the number of live/dead cells, aided by a manual counter recorder, in the 10 
squares, (the 4 corners plus 1 centre square of each of the two sets of 9 squares etched on 
the cytometer slide) and allowing for the dilution due to the addition of the trypan blue/EDTA 
solution, it is possible to estimate the cell density in the sample and hence extrapolate back to 
the original T150 flask. Since a properly applied cover-slip limits the height of the chamber 
to 0.1 mm, the volume contained in each square can be quickly calculated i.e. total volume of 
the 10 main squares is: 10x1 x 1 x 0.1 =1 mm3. Repeating the cell count and averaging 
was used to improve the statistical estimate for the original flask. Increased accuracy was 
also achieved using all 18 squares of the slide. It is essential to avoid all air bubbles plus the 
slide must have all main squares totally covered with the sample cell/trypan blue suspension. 
Furthermore, to get the best accuracy the cell solutions were diluted until the cell counts 
were in the range 15 - 50 cells per 1 mm2 square. The convention by which counting cells 
touching/crossing the two sides next to the boundary line and not the cells touching/crossing 
the other two sides was adhered to. The accuracy of this means of estimating the total live/ 
dead cell number in the original T flask will be reduced if the sampling technique is poor i.e. 
non homogeneously distributed cells e.g. clumping due to poor trypsinisation. Furthermore, 
if the sample is left for a period of time (greater than 15 minutes) even the live cells will 
unfortunately take up the dye. Individual T150 flasks at 80 - 100% confluence tended to 
contain 1 - 5 x 106 cells. The cells were either then added to alginate solutions to produce 
tissue engineering scaffolds or split into a number of fresh T-flasks in order to further expand 
the cell population. Typically a single flask would be split into 3 new T150 flasks and made 
up to an individual total flask volume of 30 ml of media by adding additional supplemented 
media. Flasks were then returned to the humidified incubators, set at 37°C containing 10% 
COz (Galaxy S, R.S Biotech, Irvine, Ayreshire, UK).
Cell mixing with alginate needed to result in a totally homogeneous cell distribution, with 
no clumps and little (ideally zero) cell death. Furthermore, early range experiments had
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demonstrated that final cell densities less than 105 cells per ml of alginate were distributed 
very sparsely in the finished scaffold i.e. allowing no cell-cell contact. Close proximity of 
the cells was deemed a prerequisite. This only occurred at 106 cells per ml of alginate and 
greater. Since the quenched trypsinised cell suspensions were typically <2 x 105 cells per ml, 
direct addition to the alginate was not a possibility.
By knowi ng the approxi mate nu mber of cells i n the suspension (from Neubauer haemocytometry), 
the appropriate number of cells in suspension could be transferred into centrifuge tubes and 
centrifuged (Hutton Universal Centrifuge) at 100 g for 10 minutes. The supernatent was then 
carefully removed so as not to disrupt the cell pellet, this also removes any remaining trypsin, 
which would be undesirable in the final cell/scaffold construct. The pellet was then carefully 
resuspended to the desired volume by adding culture media or physiological saline (adding 
any polyvalent cations resulted in premature partial crosslinking of the alginate which was 
unacceptable). Likewise, excessive residual EDTA resulted in poor scaffold strengths due to 
the ion chelating nature of the EDTA on calcium ions which are essential for the integrity of 
the alginate hydrogel scaffold. Resuspension was performed using a micropipette and gentle 
repeated action.
3.3 Reagents and alginate solution preparation
Alginate solutions were prepared in the following manner. Physiological saline was initially 
produced by adding 9 gmL'1 of sodium chloride to water for injection (WFI - BioWhittaker, 
Walkersville, Maryland, USA) and then correcting the pH to approximately 7.4 using 1 M 
sodium hydroxide solution (Sterile filtered - Sigma, St. Louis, Missouri, USA). After adding 
the desired quantity of alginate powder to the physiological saline, the alginate required 
extensive mixing prior to autoclaving in order to obtain a homogeneous solution (alginate 
powder easily traps air to create "fish-eyes" which greatly hinder the mixing process).
Since the alginate was known to be non-sterile, prolonged mixing was thought undesirable 
as during this time any bacteria would rapidly replicate, thus increasing both the bacterial 
load and endotoxin level. Experiments with simple in line 0.2 pm syringe filters (Sartorius, 
Goettingen, Germany), on fully mixed alginate solutions lead to the retention of the long 
alginate chains within the filter. The resulting gels produced were extremely weak evidently 
being only produced using cross-linking of short alginate chains - not desirable for tissue 
engineering constructs requiring weeks/months to grow and mature to a point where the 
scaffold's function is replaced by cell synthesised extracellular matrix. To potentially reduce 
this loss of heavy chain, sequential filtration was carried out e.g. 1.2 pm followed by 0.8 pm 
before attempting the desired 0.2 pm size required to sterilise the alginate solution. However, 
this serial filtration failed to improve the strength of the final hydrogels. It was therefore
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decided to autoclave the alginate/water for injection mixtures for 121°C for twenty minutes. 
This had the advantage of not requiring a prolonged mixing step since the alginate powder 
melts at approximately 90°C and goes into solution prior to reaching the 121 °C sterilising step. 
This process is known to reduce viscosities of alginate (Vandenbossche and Rem on, 1993), 
however, the effect upon the final alginate hydrogel scaffolds was not as deleterious as the in 
line filtration and therefore became the sterilising treatment of choice. Following autoclaving, 
all alginate solution were rolled on a roller mixer (SRT2 - Stuart Scientific, Redhill, Surrey, UK) 
to ensure homogeneity and allowed to cool to < 37°C prior to combining with cells.
Calcium chloride solutions were prepared by adding calcium chloride powder (Sigma. St. 
Louis, Missouri, USA), to physiological saline, pH corrected using 1M sodium hydroxide 
solution (Sigma, St. Louis, Missouri, USA), and then after thorough mixing, filter sterilised 
using a vacuum assisted 250 ml volume 0.2 pM Nalgene disposable filter, (Nalge Company, 
Rochester, New York, USA). Storage was at 4°C. Care was taken with storage of the calcium 
chloride powder as it is highly hygroscopic and therefore was kept in air tight containers at 
all times.
Calcium chloride solutions were prepared at different concentrations ranging from 0.5% 
to 2%, however, the majority of the research was performed at 0.5-1% concentration since 
concentrations below 0.5% resulted in highly variable gel strengths (on occasion not even 
forming a structural hydrogel). Concentrations above 1% appeared to have no obvious 
advantage. However, since calcium ions have a physiological effect on smooth muscle cells 
it was decided to limit the exposure - hence 1 % was chosen. In vivo, human plasma contains 
calcium in three different forms; bound to protein (mainly albumin), complexed with citrate 
and phosphate and free ions. Only the free ion form is physiologically active. Thus of the 
total calcium plasma of 2.25 - 2.6 mmolL'1 only 47% is physiologically active (1.1 -1 .2mmolL' 
1). Since the calcium chloride preparation used was in fact calcium chloride (dihydrate) i.e. 
CaCl2*2H20 , with a formula weight of 147.01, a 0.5%, 1 % and 2% cross-linking solution 
contains 3.4 mmolL'1, 6.8 mmolL'1 and 13.6 mmolL'1 respectively of free calcium ions.
3.4 Producing three-dimensional cell/alginate hydrogel structures
Three distinct three-dimensional cell/alginate structures were produced for experimental 
studies:
• Flat sheets.
•  Round beads.
• Hollow tubes.
3.4.1 Flat sheet fabrication
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Flat sheets were produced in the following manner. Round borosilicate glass cover-slips 
(BDH, Poole, Dorset, UK) of 13 mm in diameter were placed with forceps onto a flat block 
of stainless steel which had just been heated strongly with a blow-torch for 5 to 10 minutes. 
The cover-slips were left for approximately 30 seconds prior to being lightly sprayed with a 
20% solution of calcium chloride (Sigma, St.Louis, Missouri, USA) in water for injection (Bio 
Whittaker, Walkersville, Maryland, USA) using a Badger B250-2 airbrush (Badger Air-Brush, 
Franklin Park, Illinois, USA). The aqueous solvent quickly evaporated leaving a thin film of 
calcium chloride on the cover-slips. Using sterile forceps, the cover-slips were then removed 
from the hot stainless steel block and being 13 mm in diameter could be easily dropped into 
the base of 24 well microwell plates, (Corning, Corning, New York, USA) with individual well 
diameters of 15.7 mm. Alginate only or homogeneously mixed cell-alginate solutions were 
then added, typically 500 pL of 1% alginate (dry weight/volume) in physiological saline. 
Care was taken to perform the removal of the coated cover-slip from the hot metal block to 
finally adding the alginate solution part of the process in an efficient manner since calcium 
chloride being highly hygroscopic easily attracts water from the surrounding air causing a 
wet film of calcium chloride solution to be present on the cover-slip and not the desired dry 
powder coating. The powder coating which was an opaque white in colour, stayed in place 
during the addition of the transparent alginate or cell-alginate solutions. By adding the 
alginate solutions using a micropipette carefully in a continuous action just above the centre 
of the glass cover-slip, the alginate solution would easily flow across the cover-slip creating a 
flat layer. Calcium ions from the coating then diffused into the liquid producing a hydrogel. 
The 24 well microwell plates were put into the humidified 37°C Galaxy S incubator for 20 
minutes to aid this setting step. The sheets were then washed repeatedly with WFI and/or 
culture media e.g. adding 1 ml of solution and leaving for 5 minutes prior to pipetting it 
back off. Physiological saline was originally tried but this disrupted the hydrogels due to the 
presence of excess sodium ions competing with the calcium ions for the alginate cross-linking 
sites. The aim of the wash steps was to remove excess calcium chloride from the scaffold.
Sheets created in the above manner tended to adhere well to the glass cover-slips although 
on occasion separation would occur making the removal of wash solutions and later medium 
changes challenging. Also since the glass cover-slips were 13 mm in diameter compared to 
the 15.7 mm diameter of the wells, occasionally alginate solution would flow over the edge 
of the cover-slip and enter the area under the cover-slip, thus potentially trapping material 
in a physiological dead space e.g. poor mass transfer characteristics. However in the vast 
majority of experiments, surface tension prevented any unwanted flooding from occuring. 
The microwells with their clear glass cover-slip and transparent hydrogel sheet could easily 
be examined with a normal light microscope (Olympus 1 x 70 phase contrast microscope,
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Olympus, Tokyo, Japan). Similar experiments were also performed with larger diameter 
round cover-slips and 12 well microwell plates.
3.4.2 Bead production
A basic overview of the preparation of cell/alginate solutions is depicted in Figure 3.1. In 
detail; cells were obtained by harvesting 80 - 100% confluent T150 flasks as previously 
described in Section 3.2. Known numbers of cells were pelleted (lOOx g for 10 minutes), 
the supernatant carefully withdrawn using a pipette and fresh supplemented media added to 
produce the desired cell/media volume. Thus it was possible to arrive at cell/media/alginate 
solutions with a final alginate concentration of 1 % and a predetermined final cell density.
The desired cell densities aimed for were in the range of 105 - 107 cells per ml of cell/media/ 
alginate solution, but the majority of bead experiments were in the 106 per ml to 107per ml 
range. The cell/media/alginate was thoroughly mixed in a sterile 5 ml screw top polystyrene 
tube (Bibby Sterilin, Stone, Staffordshire, UK) by gentle swirling action using a micropipette 
and then rolled for 5 minutes prior to being drawn up into a 1 ml syringe (Becton Dickenson, 
Franklin Lakes, New Jersey, USA). All the air bubbles were carefully expelled prior to adding 
a 0.1 mm inside diameter syringe needle which had had its bevelled end previously machined 
off leaving a squared off tip to the needle. By holding the tip of the needle perpendicular to 
a bath (45 ml in a sterile 50 ml screw top polystyrene tube) (Corning, Corning, New York, 
USA) of 1 % (weight/volume) calcium chloride in physiological saline and slowly depressing 
the syringe, small drops were produced. On falling a few mm from the truncated needle to 
the surface of the calcium chloride solution, the drops became more round (c.f. originally tear 
drop shape). On entering the solution the outer surface of the beads quickly cross-linked. 
In order to achieve complete cross-linking of the interior of the beads, the beads were left 
in solution for an extended period, typically 10 - 20 minutes during which time the 50 ml 
screw top container was sealed and gently rolled. After this cross-linking phase, the beads 
were rinsed. This task was completed by pouring the entire contents of the calcium chloride 
bath through a sieve, thus trapping the beads. The beads could then be put into a fresh 
container by inverting the mesh and gently tapping. Repeated washing was undertaken 
using supplemented culture media thus reducing excess calcium chloride levels.
Washed beads were then carefully added in pairs to 24 well microwells (Corning, Corning, 
New York, USA) containing 1 ml of supplemented culture media per well (as described in 
Section 7.1.1) using a sterile stainless steel "spoon". The microwells were then incubated at 
37°C in humidified, C 02 supplemented (10%) air. The beads produced varied in morphology, 
ideally round spheres were produced but often the beads had a more tear-dropped shape i.e. 
had a distinct tail. Another variant with manual production was a doughnut shape i.e. a ring
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Figure 3.1
Overview of preparation of homogeneous cell/alginate mixtures.
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with a hole in the centre. All the morphologies, however, had a similar starting volume e.g. 
the volume of each bead was fairly constant as its volume is determined by viscosity, needle 
orifice diameter and gravitational force, all of which stayed constant during a single manual 
production run.
The round beads when measured using a light microscope with a calibrated eye piece were 
in the order of 2.2 mm (+ /- 0.5 mm) in diameter. Since thorough mixing was undertaken, it 
was assumed that the cell-alginate solution was reasonably homogenous in nature, thus the 
volume of the bead could be used to determine a bead's average cell load. For example, 
when using 10* cells per ml of cell/media/alginate to form beads of average diameter 2.2 
mm each bead was estimated to contain on average 5,000 - 6,000 cells. This equates to 
approximately 28 - 33 cells per mm3.
In order to make comparisons, a control well in the microwell plate was seeded with an 
approximate number of cells i.e. if 2 beads were being used, then approximately 10,000-
12,000 cells were seeded per well. This equates to approximately 50 - 60 cells per mm2. This 
results in similar celkmedium ratios for both the bead and microwell control experiments.
3.4.3 Tube fabrication
A basic overview of the preparation of cell/alginate solutions is depicted in Figure 3.1 and 
described in Section 3.2. The fabrication of cell/media/alginate hydrogel tubes deployed 
homogeneous mixtures of 1 % Manugel alginate (ISP, Tadworth, Surrey, UK) in physiological 
saline, (0.9% sodium chloride, Sigma, St. Louis, Missouri, USA), in WFI (BioWhittaker, 
Walkersville, Maryland, USA) with a cell density of approximately 105 cells per ml were 
employed. A 1 % calcium chloride solution (Sigma, St. Louis, Missouri, USA) in physiological 
saline was used as the cross-linking agent. Constructs were removed after 20 minutes and 
placed in fresh culture media in sterile Petri dishes (Bibby Sterilin, Stone, Staffordshire, UK). 
Incubation was at 37°C, humidified and 10% C 02 atmosphere.
The protocol below is for the tube fabrication device whereby the float is activated by a 
pneumatically driven piston i.e. producing a cell/media/alginate hydrogel tube with an 
outside diameter of 9 mm, length 140 mm (i.e. dimensions determined by the particular 
glass tube chosen) and of the order of 0.25 mm hydrogel wall thickness (i.e. determined by 
the outer diameter of the piston within the glass tube). Cells were harvested as previously 
described, pelletted, resuspended to a known final volume with supplemented media and 
mixed carefully with 3% alginate solution (alginic acid salt from brown algae - Fluka, St. 
Gallen, Switzerland). Final concentrations were 2.7% alginate with a cell density of 106 ml'1 
of cells/media/alginate. The device was used as described in Chapters 4 - 6 and Appendix
2. The concentrations of calcium chloride solution deployed ranged from 0.5 - 1 %. Once
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the cell/hydrogel tube was fabricated, the construct was left for a further 20 minutes in order 
to allow further cross-linking to occur prior to removing the glass tube/piston assembly from 
the device. This allowed the tubular construct to be withdrawn from the glass tube. The 
construct was placed in a sterile Petri dish (Bibby Sterilin, Stone, Staffordshire, UK) containing 
supplemented media. Because of the high alginate concentration and thick wall, the construct 
was easily handleable despite the 106 cells present per ml.
In the Petri dish, the 9 mm diameter tubes would collapse flat - like a fireman's water hose. 
Once flat, the tubes could be cut into a number of 7 mm in diameter discs using a specially 
fabricated 7 mm (inside diameter) "cookie cutter". Pressing the cutter on the collapsed tube 
resulted in 2 discs being produced (i.e. one from the upper most part of the tube wall and 
one from the lower most part). In this way each tube was theoretically capable of producing 
40 discs, thus like the bead experiments, allowing parallel experimentation to be undertaken. 
Again, like the beads, 24 well microwell plates (Corning, Corning, New York, USA) were 
used each preloaded with 1 ml of fresh supplemented media. Care was taken to keep the 
tubes/disks submerged in fluid at all times since on exposure to air syneresis soon occurs i.e. 
water loss from the hydrogel leading to unwanted construct shrinkage.
The average number of cells in each disc was estimated from the cell density in the cell/ 
media/alginate solution and the discs dimension i.e. 7 mm diameter. The average disc was 
calculated to have 9600 cells from an initial 106 cells per ml of cell/alginate solution. Again 
control wells were also produced matching the discs' cell number but containing no alginate, 
thus again matching the celkmedium ratio. Discs were incubated in 10% C 0 2, humidified 
incubators at 37°C. Cells were also freed from the hydrogel using 0.1 M sodium citrate and 
cell numbers and viability estimated using trypan blue and Neubauer haemocytometry counts 
using light microscopy.
3.5 Alginate polymer/cell survival and proliferation studies
Cell/alginate homogeneous mixtures were prepared as previously described. Using the 
mixture, the Mark I tube forming device (i.e. float activated by a pump driven fluid) was 
used to create tubes of approximately 4 mm outside diameter and 12 cm in length from 
a 2% alginate (Fluka - St. Gallen, Switzerland) in physiological saline solution containing 
cells at a final concentration of 106 per ml. Cross-linking was carried out using 1% calcium 
chloride made up in physiological saline corrected to a pH of 7.4 with sodium hydroxide 
solution as previously described. The resulting tubes had a wall thickness of approximately 
150 pm. Cross-linking was carried out for a total of 15 minutes prior to being rinsed with 
either supplemented media or physiological saline. The volume of rinsing agent used was 
either 1.5 ml, 12.5 ml or 125 ml. The rinsing agent was flushed through the hydrogel tube
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whilst still in situ within the glass forming tube using a syringe driver (Harvard PHD 2000, 
Harvard Apparatus, Holliston, Maryland, USA) coupled directly to the base unit. The rates 
used were 1.5 mlmin'1 (1.5 ml volume), 6.25 mlmin'1 (12.5 ml volume) and 8.33 mlmin'1 
(125 ml volume). In order to count the cells and access their viability, the cells needed to 
be separated from the alginate hydrogel. Therefore, immediately following rinsing, sodium 
citrate solution (0.1 M) was flushed through the hydrogel tubes (still in situ in the glass forming 
tubes) using the Harvard PHD syringe driver and left until the tubes were fully dissolved prior 
to visual inspection using a light microscope. The glass forming tube and base unit when 
all the openings/ports are carefully stoppered off using small rubber bungs, can be easily 
mounted horizontally on a light microscope stage for viewing. Once the hydrogel tube was 
dissolved the resulting solution was expelled from the glass forming tube by removing all the 
stoppers, inverting the device and then gently pushing air through the device via a syringe 
inserted into the base unit. Cells were now counted and their viability assessed using trypan 
blue stain and Neubauer haemocytometry.
Control experiments were performed in parallel using identical cell numbers . The viability of 
these control cells was assessed following harvesting (trypsinisation from the T-flask) with no 
further manipulation i.e. only essential unit operations were performed to be able to obtain 
cells for viability assessment from a standard T-flask.
The A7r5 cells were rescued from the hydrogel using 0.1M sodium citrate as per Section 
3.4.3.
3.6 Effect of media composition on cell survival and proliferation
Two different alginates were chosen for this particular experiment namely Fluka (alginic acid 
salt from brown algae - Fluka, St.Gallen, Switzerland) and Sigma (high viscosity alginic acid 
from macrocystic pyrifera [Kelp] - Sigma, St.Louis, Missouri, USA).
In order to have a comprehensive study, two three-dimensional structure types were constructed; 
discs from tubes and beads. Discs were made from tubes as per Section 3.4.3 and beads 
were produced as per Section 3.4.2. Overall there were six experimental conditions, all using 
1% alginate weight/volume solutions. See Figure 7.5 for an overview of the experimental 
matrix. Experimental observations were carried out over a 16 day period.
3.7 GRGDY peptide synthesis
The initial batches of the GRGDY peptide were synthesised with the assistance of Dr. Patricia 
Zunszain in the Department of Chemistry at UCL. In brief, the synthesis of the pentapeptide 
deployed a Millipore 9050 OM peptide synthesiser, using standard FMOC resin based 
methodology and FMOC amino acids (Bachem, Bubendorf, Switzerland). In order to carry
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out the peptide sythesis, both the arginine (R) and the aspartic acid (D) amino acids required 
side-protecting groups: Arg(Pfb) and Asp(otBu). After removal from the resin, these protective 
side groups were hydrolysed prior to the peptide being purified via preparative HPLC using a 
Vydac Cl 8 (10 pm) 22 x 250 mm column (Grace Wydac, Columbia, Maryland, USA) and 
finally lyophilised and stored at 4°C.
3.7.1 GRGDY-alginate derivitisation
An overview of the derivitisation process is depicted in Figure 3.2 (reagent steps) and Figure
3.3 (dialysis steps). In detail; a 1% weight/volume solution of alginate (DMB pharmaceutical 
grade, Manugel, IAP, Tadworth, Surrey, UK) was prepared (allowing for the water content 
retained in the stock alginate powder) using 0.1 M MES buffer (Sigma, St. Louis, Missouri, 
USA) solution. This buffer was prepared using WFI (water for injection) (BioWhittaker, 
Walkersville, Maryland, USA) and 0.3 M sodium chloride solution (pharmaceutical grade, 
Sigma, St. Louis, Missouri, USA). The pH of the buffer was adjusted using 1M sodium 
hydroxide solution (pharmaceutical grade, Sigma, St. Louis, Missouri, USA) to pH 6.5. (This 
saline concentration and pH was the optimal conditions found by Mooney's group (Rowley et 
al, 1999 and 2001). The alginate was finally autoclaved at 121 °C for 20 minutes in a bench 
top autoclave (Prestige Medical, Blackburn, UK), rolled (Stuart Scientific Roller Mixer SRT2) 
and allowed to cool to room temperature before use.
Initial experiments were performed using 1 mg of peptide per gram of alginate powder (dry 
weight). The other reactant ratios were: sulfo-N-hydroxysuccinimide (Sigma) (Sulpho-NHS) 
at 38 mg per mg of peptide and 1 -ethyl-(dimethylaminopropyl)carbodiimide (Sigma) (EDC) 
at 67 mg per mg of peptide. These ratios were approximately the same as Rowley et al had 
previously described (Rowley et al, 1999). The EDC is a water soluble carbodiimide capable 
of forming amide linkages between amine containing molecules and the carboxylate moieties 
on the alginate polymer backbone. The co-reactant, sulfo-NHS, stabilises the reactive EDC- 
intermediate against a competing hydrolysis reaction, thus increasing the overall efficiency of 
the amide bond formation. The GRGDY pentapeptide was covalently bonded to the alginate 
polymer backbone via the terminal amine present on the peptide - see Figure 8.5 (Rowley 
et al, 1999). Both the EDC and Sulfo-NHS were made into solutions using WFI and then 
sterilised using a 0.2 pm in line filter (Sartorius, Goettingen, Germany). Wherever possible all 
manipulations were performed in a biological safety cabinet to try and protect experimental 
sterility (Gelman Sciences BH48 modified with a double HEPA filter). The Sulfo-NHS solution 
was added to the autoclaved alginate solution and thoroughly mixed by vigorous shaking 
prior to being rolled for 5 minutes. The EDC solution was then added and again thoroughly 
mixed and rolled for a further 30 minutes prior to adding the peptide which was predissolved 
just prior to use in WFI and filtered through a 0.2 pm filter.
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After combining all the reactant, including the peptide, the solution was then rolled for 24 
hours. All the reactions were carried out at room temperature in light protected containers, i.e. 
aluminium foil applied to all containers. In order to remove excess reagents, the solutions were 
extensively dialysed using a molecular weight cut off (MWCO) of 3,500. Snake skin tubing 
(Pierce, Rockford, Illinois, USA) or Slide-A-Lyzer dialysis cassettes of maximum capacity 3 ml 
(Pierce, Rockford, Illinois, USA) supported by purpose made foam floats were operated in 
autoclaved reverse osmosis (RO) water in 5 L sterilised containers for a 48 - 96 hour periods 
at 4°C. During which time the RO water was stirred (magnetic bar/stirrer base -211,  Bibby, 
Stone, Staffordshire, UK) and replaced every 12 hours with fresh sterilised RO water. Care 
was taken to reduce possible contamination by keeping all the containers covered. This 
dialysis was carried out in total darkness apart from when changing the dialysis solution. 
After dialysis, activated charcoal (clinical grade - hydrochloric acid washed - Sigma, St. 
Louis, Maryland, USA) at 0.5 gm per 1 gm of alginate powder (dry weight) was added and 
mixed thoroughly prior to rolling for thirty minutes. Finally, in order to remove the charcoal 
plus any other impurities the solution was past through a ready prepared Celite Hyflo (acid 
washed diatomite filter aid - Celite, Lompoc, California, USA) column (sinter funnel) facilitated 
by a vacuum pump. This process took 3 - 6 hours depending upon the degree of agitation 
supplied to the mixture. The resulting solution was collected in a sterile flask and either 
stored immediately at 4°C or lyophilised using an Edwards Freeze Drier and then stored 
at 4°C. One other variation was to use polyethylene glycol (PEG) solutions (Slide-A-Lyzer 
concentrate solution - Pierce, Rockford, Illinois, USA) or PEG solid (35,000 MWt, Fluka, 
Buchs, Switzerland) to reconcentrate the dialysed samples to desired final concentrations 
(during the prolonged dialysis, water would enter the dialysis tubing/cassette thus diluting the 
alginate). Thus after dialysis, water could be drawn out in a relatively controllable manner 
using PEG either in solid form or in a Concentrated Solution (Slide-A-Lyser concentrating 
solution - Pierce, Rockford, IL, USA). The Concentrating Solution was poured into the small 
plastic bag provided and then the Slide-A-Lyzer Dialysis Cassette containing the derivitised 
alginate was added. The bag was then placed on a rocking table at it minimum movement 
setting. Using serial measurements obtained by carefully drying and accurately weighing the 
dialysis tube or cassette, the final concentration of the alginate could be controlled. Solutions 
of final concentration of either 1 % or 2% were aimed at. This concentration step took 9 - 1 2  
hours and was performed on a steady-state rocking table at approximately 10°C (purpose 
built cold room) in total darkness.
3.8 Imaging techniques
The additional imaging techniques included:
• Live/dead viability/cytotoxicity imaging.
- 6 9 -
3.8.1 Live/dead viability/cytotoxicity imaging
The live/dead viability/cytotoxicity assay kit (L-3224 - Molecular Probes, Eugene, Oregon, 
USA) has previously been demonstrated for use with aell/alginate beads (Read et al, 2001). 
This assay simultaneously positively identifies live from dead cells by using 2 probes. These 
probes measure 2 different aspects of cell viability namely intracellular esterase activity and 
plasma membrane integrity. Live cells are identified by the presence of intracellular esterase 
activity which is detected by the enzymatic conversion of nonfluorescent calcein AM to which 
cell membranes are permeable. Thus calcein AM is converted into fluorescent calcein in 
live cells only, thus staining them green when viewed using ultraviolet microscopy. Similarly 
dead cells fluoresce red when the second probe, ethidium homodimer-1 enters the membrane 
damaged cells and binds to nucleic acids thus increasing its concentration and therefore 
intensity (approximately 40x). Ethidium homodimer-1 is excluded by intact cell membrane 
(i.e. the same as for trypan blue stain). Bacteria and fungi, possible contaminants, are not 
affected by these probes i.e. there should be no false positives (Molecular Probes spec sheet 
MP 03224 24 January 2001).
Using the Molecular Probes kit it was possible to view both non-derivitised and derivitised 
alginate/cell constructs. For example using confocal microscopy it was possible to observe 
balled-up cells in derivitised alginate immediately after construction and then 12 - 24 hours 
later to observe the cells in the process of elongation throughout the structure.
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4.0 Scaffold-cell combinations: Options and demonstration of principle
This chapter brings together the material selected with the options available for combining 
this material with cells and from the method selected puts forward a concept on how this may 
be achieved in a way that allows consistent preparation of many units of tissue.
4.1 Options
4.1.1 Scaffold seeding
Since a tissue engineered construct typically consists of a scaffold and cells/ the first objective 
was to establish criteria for choosing the mode of scaffold seeding. There are two broad 
options for combining them:
• The scaffold can be fabricated first and then seeded
• Cells can be mixed with the scaffold material prior to or during scaffold fabrication
Both options have advantages and disadvantages, there now follows an analysis of the two 
approaches.
Fabricating the scaffold first allows a large host of materials and methods to be employed. 
Because the cells only come into contact with the finished scaffold, there is no need to be 
constrained to "cell friend I / '  conditions during fabrication. Thus fabrication can use materials 
which may require high temperature, extremes of pH and harsh chemicals e.g. polyglycolic 
acid (PGA) can only be melt moulded at temperatures in excess of 160°C. Provided the 
fabricated material is thoroughly washed and sterilised prior to cell seeding there are no 
difficulties. Furthermore, scaffolds made from many of the candidate materials e.g. PGA, 
polylactic acid (PLA) and PLA-PGA co-polymers can be easily stored prior to seeding. In 
contrast scaffolds created from pre-seeded material cannot be easily stored but must be used 
immediately. Suitable materials for preformed scaffolds include the thermoplastics discussed 
above plus natural polymers such as freeze-dried collagen (Butler et al, 1999) and fibronectin 
(Ahmed et al, 2000).
Seeding a preformed scaffold is a complicated task. Two difficulties arise. Firstly, it is 
essential to seed the scaffold homogeneously and secondly the cells must attach and migrate 
homogeneously throughout the material. Homogeneity and attachment are required in order 
for the cells to migrate through the scaffold, divide, differentiate and finally organise into the 
desired living structure. However, seeding preformed scaffolds usually involves adding cells 
suspended in culture media (Niklason etal, 2001). Seeding of preformed scaffolds has proven 
to be highly wasteful. Loses of a whole order of magnitude are not uncommon (Yacoub and 
Taylor, 2001). Ensuring that the cells are exposed to the scaffold in a homogeneous manner 
is "implied" by assuming that the cells are evenly dispersed in the culture media. This may not
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be the case, e.g. because cells have a relative density just greater than media, they therefore 
have a tendency to settle due to gravitational force. Having the cells and the scaffold in close 
contact is the prerequisite for cell attachment. Assuming that cell attachment to the surface is 
even, the cells are then required to migrate evenly through out the porous scaffold in order to 
achieve a homogeneous cell-scaffold construct.
Alternatively, the cells can be mixed with the scaffold material prior to or during fabrication. 
Homogeneous mixing is essential and must be capable of being validated if a cGMP cell- 
scaffold construct is to be formed. Once again, the cells must remain evenly disbursed during 
the fabrication step. All the mixing and fabrication steps must not be hostile to cells e.g. high 
shear forces during mixing could result in cell damage. Dead cells would lead to unfavourable 
cell debris being released into the scaffold. Suitable materials for this cell premixing technique 
include collagen (Bell et al, 1991) and alginate (Kuo et al, 2001).
4.1.2 Sterility issues
Sterility is a major issue irrespective of which cell-scaffold construction is used, since tissue 
engineered constructs are currently likely to take weeks or months to fully form. Thermoplastics 
e.g. PGA can be sterilised by gamma irradiation post fabrication i.e. prior to cell seeding. 
However, natural polymers such as collagen need to be kept sterile throughout the fabrication 
process unless they are freeze-dried. Freeze drying allows gamma irradiation to be employed. 
However, this does change the nature of the polymer (Johnson et al, 1999 and Roe et al. 
1992). In short, natural polymers need to be kept sterile at all times since both bacteria and 
sterilisation will degrade the polymer.
Long-term sterility and total number of unit operations (e.g. physical handling) are intrinsically 
linked to one another. Ideally handling must be kept to a minimum or avoided. One potential 
solution is to mix scaffold material and cells immediately prior to scaffold formation. Ideally 
the scaffold formation would be in a "device" which could also act as a bioreactor to grow 
and mature the fledgling construct, allow ease of monitoring and also act as the "delivery 
device" i.e. the first time the scaffold formation device is opened is in the operating theatre 
immediately prior to implantation into the patient.
4.1.3 Materials options
From an engineering process prospective, constructing a cell-scaffold from cells premixed 
with the scaffold material appears in principle to have a considerable number of advantages 
over the alternative method including:
•  Being able to mix cells homogeneously in the material theoretically resulting in a 
scaffold that is uniformly seeded. Thus potentially easing validation of the seeded
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scaffold
• Cell wastage is kept to a minimum since there is not the "hit and miss" attachment 
and migration into the scaffold problem
• Reduced culture times by achieving a high cell density within the material prior to 
fabrication end employing cells of exactly the right phenotype and maturity. Reducing 
culture times potentially leads to reduced contamination risk and lower inventory 
levels. The ideal situation would be where no culture time was required/ i.e. cell 
density and their arrangement was near normal for artery, the scaffold sufficiently 
strong and most importantly, the ability of the cells to produce extracellular matrix 
optimised
• Bioactive molecules (e.g. to produce cell attachment or cell signaling effects) could 
also be incorporated homogeneously into the scaffold by premixing prior to 
fabrication
• Potential economic advantage due to reduced culturing times, less cell waste 
and inventory. This optimal situation fits the highly successful, "just-in-time" (JIT) 
manufacturing management philosophy (Cheng and Podolsky, 1996).
In order for the material to be suitable for combined cells-scaffold production, it must possess 
properties, which, allow a scaffold to be formed without harming the cell population; likewise 
the cell population must not substantially hinder the material from forming the desired scaffold 
e.g. too higher cell density (i.e. cells effectively "diluting down" the scaffold material).
The choice of material for premixed cell-scaffold fabrication is limited to those which can be 
fabricated into three-dimensional structures at "cell friendly" conditions, since mammalian 
cells are only capable of surviving in a narrow temperature range, they do not tolerate 
extremes of pH and are easily harmed by caustic chemicals. Some of the other major criteria 
include:
• Capable of being formed into a porous structure which has adequate strength
• Overall the material and its breakdown products must be non-toxic both in vitro 
and in vivo. Ideally, the scaffold material (and its breakdown products) should have 
totally left the construct prior to implantation
• The human body must be able to safely eliminate these molecules if still present at 
implantation
• Cell attachment ability may or may not be a prerequisite depending upon the cell 
type
• The material needs to breakdown in a predictable/controlled manner such that as 
the strength of the fledgling construct increases (due to the production of extracellular 
matrix) so the strength of the scaffold material decreases as it breaks down
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•  Preferably low cost
•  Well characterised (Ideally with existing FDA/Conformite Europeene [CE] 
approval)
•  Ideally a wealth of publications in peer reviewed journals - i.e. existing skill base
• Easily mixable with cells and bioactive molecules
•  Free from pathogens.
The suitable scaffold materials available to this particular project are presented in Figure 4.1 
together with their characteristics matched against the above criteria. Other possible materials 
were not included if availability was an issue e.g. hyaluronic acid on account of cost.
4.2 Selected materials
Using the above criteria, sodium alginate was selected as the ideal scaffold material for further 
evaluation. Its major advantages being its cell friendly fabrication conditions coupled with its 
absent pathogenicity. Its major disadvantages being poor characterisation and known batch- 
to-batch variability. An unknown issue was whether cell attachment sites were essential with 
respect to smooth muscle cells. There is a vast wealth of scientific literature on virtually every 
other mammalian cell and its ability to be grown whilst encapsulated in alginate hydrogel 
(at the start of this research project, over 250 refereed journal articles have been published 
on cells successfully encapsulated in alginate beads). Furthermore, relatively simple chemical 
modification was possible if attachment sites were required (Rowley et al, 1999). Finally, 
alginate hydrogel beads had already been demonstrated to be able to successfully deliver 
bioactive molecules successfully e.g. encapsulated freeze dried vascular endothelial growth 
factor (VEGF) had been demonstrated to stimulate endothelial cells for a period of two weeks 
in vitro. (Peters et al, 1998).
4.2.1 Alginate options
Sodium alginate was chosen as a model scaffold material since it met the essential requirements 
(or could potentially meet the essential requirements by relatively easy chemical modified) 
and was easily available. Non-pharmaceutical grade (low cost) was chosen and only when 
required was pharmaceutical grade (high cost and short supply) utilised.
Alginate was supplied from four manufacturers - see Figure 4.2. From the figure, it can be 
seen that unfortunately most of the companies distribute very little technical data regarding 
their alginate products. Discussions with Neil Cruttenden at ISP Alginates (UK) Ltd (formerly 
Kelco) (Tadworth, Surrey, UK) revealed that this was due to large inter-batch variability, and 
companies when purchasing alginate from ISP would test samples from a number of different 
batches to evaluate if it met their specific requirements before purchasing a batch usually of
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Characteristic PGA Collagen Alginate
Wealth of relevant 
publications
✓ V V
(Bead encapsulation)
Well characterised ✓
X
(Inter-batch
variability)
X
(Inter-batch
variability)
Inherent pathogens X
✓
(Unless recombinant)
S
Ease of mixing with 
cells N /A
V V
Cell friendly
fabrication
conditions
X s s
Porous structure V s V
Ease of cell 
attachment
X
(Needs physical 
or chemical 
modification)
s
X
(Needs chemical 
modification)
Predictable
degradation
X s 2
Non-toxic
degradation
products
Locally toxic s ✓
Cost Low
Medium - Animal 
origin 
High - Recombinant
Low - Food grade 
Medium - Pharma 
grade 
High - Ultrapure
Figure 4.1
Potential scaffold polymers available to the research project together with their respective 
characteristics relevant to tissue engineering.
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Manufacturer
Product
Manufacturers' Data
Viscosity Molecular weight Other relevant information
ISP Alginates
Surrey, UK
Keltone LVCR Low - -
Keltone HVCR High - -
Manucol DH Medium - -
Manucol DMF High - -
Manugel DMB High - -
Sigma
Dorset, UK
A2158 
Low Viscosity
Approx. 250 cP* 
(2% solution/25°C)
-
High M
A0682 
Low Viscosity
Approx. 250 cP* 
(2% solution/25°C) -
A2033 
Medium Viscosity
Approx. 3,500 cP* 
[2% solution/25°C)
-
A7128 
High Viscosity
Approx. 14,000 cP* 
(2% solution/25°C) -
Pronova
Oslo, Norway
LVG 118 mPas s 189,000 73% G
GMP
man­
ufacture
MVG 287 mPas s 231,000 73% G
LVM 148 mPas s 209,000 38% G
MVM 200 mPas s 226,000 38% G
Fluka
St. Gallen, 
Switzerland
71238 - -
Purity grade: 
Immobilisation of 
microorganisms
71240 - - -
*[1 cP = 1 mPas s]
Figure 4.2
Summary of manufacturers' available data for the commercial sodium alginates (Compiled: 
1999 - 2000).
- 7 6 -
several tons.
The viscosity of the final alginate solution is critical to key aspects of the entire process:
• Ability of the alginate to form a homogeneous solution
• Ease of cell-alginate mixing to obtain and retain a homogeneous solution
•  Relative ease of constructing a desired three-dimensional shape and retaining the 
shape long enough to cross-linking with a polyvalent ion. Lower viscosity solutions 
require much faster times to cross-link compared to the more viscous solutions if the 
three-dimensional shape is to be faithfully retained
Viscosity of the alginate solution is determined by a number of factors including:
• Ratio of G:M monomers. High G:M ratio increases viscosity and strength e.g. Pronova 
MVM and MVG alginate have near identical molecular weights (226,000 and
231,000 respectively) but have different G:M ratios (19:31 and 73:27 respectively) 
resulting in different viscosities (200 c.f. 287 mPas respectively)
• Length of polyG sequences (Long polyG sequences increase viscosity and strength)
• Molecular weight. In aqueous solution, the alginate molecules are long flexible 
polymeric chains that are continually in motion. Viscosity is a measure of how difficult 
it is for these polymeric chains to slide past one another. The longer the chains the 
more difficult it is and hence an increase in viscosity is observed (e.g. both Pronova 
LVG and MVG alginates have a G content of 73% but LVG has a molecular weight 
of 189,000 and a viscosity of 118 mPas compared to MVG's higher molecular 
weight of 231,000 and a viscosity 2.4x larger at 287 mPas
•  Polyvalent ions are present in the aqueous solution. By weight, ISP Alginates 
(U.K.) Ltd. has calculated that pure sodium alginate contains approximately 8% 
sodium and that pure calcium alginate also contains approximately 8% calcium. 
Furthermore, ISP claim that it is not possible to commercially produce alginates 
that are totally free from calcium and ISP's alginates typically contain around 0.2% 
calcium, the balance usually being made up with sodium i.e. a typical analysis 
would be in the region of 7.8% sodium and 0.2% calcium. Some of ISP's products 
intentionally contain a substantially higher level of residual calcium e.g. Kelset 
and Keltose. They do not contain enough calcium to make the products insoluble 
in water, however once these alginates are hydrated, the residual calcium that is 
present binds temporarily to the polymer chains and in doing so, brings about, in 
effect, an increase in alginate molecular weight. This effective increase in molecular 
weight gives an increase in viscosity. Conversely the addition of sequestrants to 
solutions made from alginates containing a relatively high level of calcium removes 
the calcium responsible for providing the added viscosity, and a viscosity loss is
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observed. Sodium hexametaphosphate (Calgon) can be employed to remove the 
calcium that is providing the added viscosity. Therefore, "Calgon viscosities" are 
lower than crude viscosities. This difference in viscosity is referred to as "false 
viscosit/' because the added viscosity does not come from the polymer itself but by 
manipulating the level of the alginate binding calcium ions present in the solution. 
The extent to which the sodium ions in an alginate solution are replaced by calcium 
ions is called "calcium conversion". Reducing the viscosity of alginate solutions 
using sodium hexametaphosphate has been employed to allow the solution to flow 
between parallel glass plates prior to cross linkage to form flat sheets as cell scaffolds 
(Rowley et a;. 1999 and Rowley et al, 2002)
• Percentage of alginate in the aqueous solution. The higher the percentage the higher 
the viscosity and vice versa
•  Raising the temperature leads to a reduction in viscosity and vice versa
• Processing e.g. autoclaving alginate solutions decreases viscosity due to a permanent 
reduction in overall polymer chain length
•  Increasing the density of cells in the alginate solution leads to an increased viscosity 
and vice versa
• Addition of binding sites to the alginate e.g. covalently bonding Glycine-Arginine- 
Glycine-Aspartic acid peptide (GRGD) also affects viscosity.
4.2.2 Cross-linking agent options
Monovalent cations are required to make alginates water-soluble. Multivalent cations form 
alginate salts that are insoluble i.e. the multivalent cations react with multiple alginates 
polymer chains and thus cross-link the molecules together. Therefore when multivalent cations 
are added to a sodium alginate solution they will replace the sodium ions from the alginate 
and cause it to precipitate out of solution. This "ion exchange" reaction is a vital property 
of alginate responsible for its ability to form fibres, films and hydrogels. To date scientists 
have successfully encapsulated cells with alginate using calcium, barium and strontium ions 
(Wideroe and Danielsen, 2001).
4.2.3 Sterility issues
Tissue engineering requires the culturing of cell-scaffold constructs for weeks or months. It is 
therefore essential that the cell-scaffold is sterile prior to this prolonged incubation period. 
Alginate from whatever source is never free of contamination (Cruttenden, 2001).
There are therefore two options:
• Add the cells to a "non sterile alginate" solution and then sterilise e.g. add antibiotic 
to the culture media. This has the disadvantage in that occult infections/antibiotic
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resistant organisms could continue to survive. This option is therefore not feasible
•  Add cells to sterilised alginate. Options for sterilising alginate include/ gamma 
irradiating the powder, ultra high heat treatment (UHT) of an aqueous solution, 
autoclaving an aqueous solution and filter sterilisation through 0.22 pm membrane 
filters. Unfortunately all these approaches apart from filter sterilisation, denature the 
alginate e.g. fragment the polymer backbone resulting in lower viscosity solutions 
for a given alginate percentage (Smisrod and Skjak-Braek, 1990). Membrane 
filtration is only possible when using ultra pure very low viscosity alginates. Both 
UHT (Provided by ISP, Surrey, UK at 121 °C for 1.5 seconds) and autoclaving have 
been used in this project. Raising the pH of the alginate to pH 7 - 8 has been 
reported to help reduce viscosity reductions due to autoclaving (Smisrod et al, 
1990), this practise has been adopted throughout this research project.
4.3 Construct forming device: Concept and first prototype
4.3.1 Options
There are two basic ways to produce a hydrogel tube using a hardenable liquid (sodium 
alginate solution) and a hardening liquid (calcium chloride solution):
• Around another tube e.g. extruded around a mandrel
• Inside another tube e.g. formed on the inside surface of a barrel
The main advantage of the mandrel approach is that the newly formed tube is well supported 
along its length by the mandrel as it is formed. The delicate hydrogel tube (>90% water with 
a wall thickness in the order of a few hundred pm) can easily be handled whilst it is on the 
rigid mandrel. The alginate solution around the mandrel very quickly forms a hydrogel on 
contact with the calcium chloride solution. Following initial gelling there is a period of either 
swelling of the wall thickness + /- shrinkage of the overall tube diameter depending upon 
various parameters e.g. calcium chloride solution concentration, length of time exposed to 
calcium chloride solution, ratio of G:M monomers within the polymer and the presence of 
other cations e.g. sodium ions in the calcium chloride solution (affects gelling rate). Thus the 
newly formed alginate tube is in very close proximity to the mandrel. This is an advantage 
until flow is required down the centre of the tube. Since there is negligible space between the 
mandrel and the alginate tube, virtually no flow is possible between the two. The alginate 
tube must first be removed from the mandrel and coupled at each end in order to allow flow 
of a liquid along its length. This was found to have at least five major disadvantages:
•  Removing the delicate alginate tube from the mandrel was difficult if one wanted to 
avoid damaging the tube (even more difficult if the tube is made from a premixed 
solution of live cells and alginate)
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• Without a central mandrel the tube was unsupported and had a tendency to sag 
thus creating irregular flow within it as well as non-uniform forces along the tube
• Coupling the delicate hydrogel at either end was difficult without harming the 
construct
• Required multiple unit operations thus increasing risk of contamination
• In a commercial application increasing the complexity of the task and increasing 
the risk of contamination potentially leads to increased cost.
A possible alternative is to create the alginate tube within another tube (barrel). As the alginate 
tube is formed the barrel provides both shape and support. Since the alginate tube tends to 
shrink, a space becomes available for addition flow of fluid around the outside of the tube i.e. 
between the tube and the barrel (not just down the central lumen). The "attachment" between 
the alginate tube and the barrel is by weak surface tension forces, which can be very easily 
overcome if desired. Due to these forces, after formation, because the tube receives support 
from the barrel, there is no tendency to sag. Furthermore, since there is space within and 
around the tube, if the tube ends are appropriately fixed as part of the formation process, 
no handling is required in order to install the tube within a fluid circuit. Overall the number 
of unit operations to arrive at a tube in a flow circuit is one. Furthermore, since the tube is 
"held" within the barrel potentially the barrel could act as a bioreactor for the cell-alginate 
construct as well as a "delivery device" which is not opened until it is required in the operating 
theatre. A patent covering the above has been filed (Mason and Town, 2002a) as well as a 
number of related patents (Mason and Town, 2002b; Mason and Town, 2003a; Mason and 
Town 2003b).
4.3.2 First prototype
To achieve the goal of creating an alginate hydrogel tube within a barrel a simple experiment 
was carried out. The equipment consisted of a barrel (15 cm glass tube with a 5 mm inside 
diameter), a piston (similar to a syringe piston) made of PTFE which fitted tightly into the 
bore of the barrel and a regulator element (a piece of Plasticine moulded into the shape of 
a bullet) which fitted into the barrel with a length of approximately 1 cm and a diameter of 
approximately 4 mm, see Figure 4.3. Thus there was an approximately 500 pm space all 
round the regulator element if it located centrally in the barrel. The barrel was positioned in 
an upright position. The piston was inserted from below until it was approximately 4 cm from 
the top of the barrel. Approximately 1 ml of 4% alginate solution (ISP Manugel in water) was 
added directly above the piston. The regulator element was gently dropped into the alginate 
solution, such that it was fully submerged with only its very top exposed. The piston was 
then swiftly drawn down the barrel stopping a few centimetres from the base of the barrel, 
see Figure 4.4. Since there is a gap between the regulator element and the barrel, alginate
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Regulator
Alginate solution
Interference fit piston
Shaft
Glass barrel
Figure 4.3
Tube-forming device - First prototype.
w.
♦
KJ
H
Alginate solution ■ Calcium chloride solution Alginate hydrogel
Figure 4.4
Schematic time progression in the formation of an alginate hydrogel tube.
^  = Direction of travel of the piston relative to the barrel which is fixed
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solution was deposited on the inside of the barrel along its length. As the piston was drawn 
down so calcium chloride (Sigma) solution (2% in water) was rapidly injected into the top 
of the barrel, this on contact with the alginate around the very top of the regulator element 
caused instant gelation and thus a hydrogel tube was constructed within the glass barrel, see 
Figure 4.5. At the end of the process the barrel contained a piston and alginate at its base, 
an alginate tube along its length filled with calcium chloride solution. After a period of 5 - 
10 minutes, due to alginate tube shrinkage, further withdrawing the piston out of the barrel 
resulted in a near perfect alginate tube being delivered from the barrel.
For ease of visualisation, water-soluble food colouring was added to the alginate solution. 
Cutting the middle part of the tube into transverse section revealed an almost uniform wall 
thickness in the order of 200 - 250 pm (measured using a mechanical vernier gauge). These 
measurements are only crude indicators of size due to the difficulty in handling, cutting and 
physically measuring an extremely fragile and permanently deformable hydrogel (see optical 
coherence tomography in Chapter 9 for a more refined measurement approach). Furthermore, 
when alginate hydrogels are exposed to air they dry rapidly, thus reducing their volume. The 
two ends of the tube were of highly irregular dimensions, the bottom end being a solid rod of 
surplus alginate hydrogel encasing the regulator.
Multiple tubes were made using this manual method to test the robustness of the concept. The 
problems encountered were mainly due to poor coordination between the pulling down of the 
piston and the delivery of calcium chloride solution. If the piston is pulled too slowly or paused 
(even momentarily), the calcium ions quickly set the alginate solution trapping the regulator 
element. Also, if the delivery of the calcium chloride solution was delayed or of too low a 
delivery rate, the liquid alginate solution coating the barrel was distorted by the turbulence 
created by the incoming liquid or air bubbles were trapped in the hydrogel. This lead to an 
internal tube surface of a highly irregular nature, totally unsuitable for its purpose of precise 
tissue engineering.
It was noted that the longer the tube was left exposed to the calcium chloride the solution the 
tougher (in terms of tolerating physical handling) the finished tube.
Another point of interest was the degree of shrinkage both axially and longitudinally. Axial 
shrinkage gave the tubes an internal diameter in the order of 3.0 - 3.5 mm (measured by 
carefully passing a series of rods of known diameter down the tube). Longitudinal shrinkage 
was in the order of <0.5 cm per 10 cm length of barrel.
The Plasticine regulator was formed into a number of different bullet shapes, all of which gave 
similar results.
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Calcium chloride solution
Alginate hydrogel tube
Gap: regulator/barrel -
/
Regulator--------
I
I
Alginate solution
I
Interference fit piston
\
Glass barrel--------- ----
Transition zone: 
alginate solution/gel
I
I
I
I
Figure 4.5
Transition zone: alginate solution meeting calcium chloride cross-linking solution and 
instantaneously setting to form a hydrogel.
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The concept was then tried with glass barrels of various inside diameters, including 1.5 
mm (equivalent in diameter to a medium size human coronary artery)/ 8 mm (equivalent in 
diameter to an human upper leg vessel) and 32 mm (equivalent in diameter to a human aorta) 
with matching pistons and appropriate sized bullet shaped regulator elements. Regulator 
elements were made either of Plasticine in the case of the 1.5 mm barrel or of PTFE which was 
used for the larger barrels with a barrel clearance of 500 fjm all round between the barrel 
and the regulator. All reliably produced alginate hydrogel tubes.
4.4 Conclusions
The above preliminary experiments confirmed that the fluid concept could potentially create 
the entire range of vessels required for surgical implantation. The problems encountered were 
mainly due to poor coordination between the pulling down of the piston and the delivery of 
calcium chloride solution, a matter made worse by extremes of diameter. The 8 mm being 
the most reliable to produce. It was therefore decided to construct an automated version of 
the device using the 8 mm diameter glass tubing. There then followed extensive studies of 
improved devices. For the sake of brevity the first of these are described in Appendix 2 and 
the next chapter summarises their outcome before describing the final manual version.
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5.0 Fluid driven tube forming device
The alternative to using a physical piston is to drive the movement of the regulator using 
fluid propulsion. The idea was to use the same major components i.e. precision bore barrel, 
regulator, alginate solution and calcium chloride solution, but in a different configuration in 
order to overcome the obstacles encountered with the piston driven device.
5.1 Fluid driven device prototype -  solid regulator version
A prototype was designed and made which consisted of a 4 mm inside diameter borosilicate 
precision bore glass cylinder of 15 cm in length, see Figure 5.1. As before the device was to 
be used in the upright position. The base of the cylinder had a 2.5 cm Perspex cylinder added. 
This piece was machined such that it had, a strong interference fit to the outside of the glass 
barrel, allowed a syringe to be inserted into its base again creating an interference fit and 
had an internal "collar". All the interference fits were fluid tight. The purpose of the internal 
collar was to create a docking station with a relatively weak interference fit between the collar 
and the lower-most part of the regulator element's wall. Various bullet shaped regulators were 
machined from PTFE with outside diameters ranging from 3 - 3.8 mm (i.e. giving a regulator 
- barrel clearance of 200 - 1000 pm, resulting in a theoretical barrel coatings of 100 - 500 
pm in thickness). All the regulators were 1 cm in length.
5.1.1 Operating sequence
The optimal operating sequence for this prototype consisted of:
1. Holding the barrel in the upright position with the Perspex cylinder at the 
base
2. Dropping the regulator down the barrel with interference fit part at the lower 
end
3. Applying a well fitting air line with a maximum pressure in the order of 3 p.s.i. 
to the top of the barrel. The air pushes the regulator into the collar and gives 
a fluid tight seal via a weak interference fit. Too much force and the regulator 
and collar became tightly jammed
4. Removing the air line
5. Using a modified 2 ml syringe with an extended needle (that reaches the length 
of the barrel), 1 ml of 2% alginate solution (ISP Manugel) was added carefully 
(in order to avoid air bubbles) to just above the regulator. By holding the tip 
of the syringe tightly against the side of the glass barrel, it is possible for the 
alginate to completely flow down and around the gap between regulator and 
barrel (i.e. displacing the air as the alginate flowed) thus leaving no trapped 
air
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Figure 5.1
Fluid driven device - Prototype.
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6. Attaching a 2 ml syringe containing 2 ml of 2% calcium chloride solution to 
the base of the Perspex cylinder. Care had to be taken not to introduce air into 
the device at this stage
7. Applying constant manual pressure to the syringe such that the calcium chloride 
solution is forced into the device, causing the regulator to travel smoothly up 
the barrel, stopping just short of the top or cleanly expelling the regulator out 
the top of the barrel, see Figure 5.2
8. Since there is a constant gap between the barrel and the regulator, as the 
regulator travel up the barrel, alginate solution is left coated on its wall, which 
is instantly cross-linked with the rising calcium chloride solution to form a 
continuous hydrogel tube
9. After leaving the device for 5 minutes in order to allow further cross linkage, 
the hydrogel tube can be expelled by forcing more calcium chloride solution 
into the device from the syringe. The regulator acts as a "stopper" in the 
hydrogel tube and since the lower end of the hydrogel tube is not attached 
to the device, when more calcium chloride solution is added to the device the 
entire hydrogel tube and regulator element are expelled from the top of the 
device
5.1.2 Discussion
This simple hand-held device easily and robustly produced hydrogel tubes, with the advantage 
that the length of the device is only 1 - 2 cm longer than the fabricated tube length, regardless 
of the length of the desired tube -  a big advantage over both the previous piston driven 
method and also over traditional wire coating techniques. Furthermore, the glass barrel acted 
as a support for the fragile hydrogel tube due to surface tension forces between the hydrogel 
and the borosilicate glass. This "supported containment" is also a potential advantage if 
ultimately the blood vessel tissue engineering project requires any of the following:
•  Fragile alginates (e.g. alginates with low G percentage/short G blocks)
• Low percentage alginate solutions
• Low percentage calcium chloride solutions
•  Short cross-linking times
• Modified alginates to increase cell friendliness potentially at the expense of cross-
linking ability
• Thin walled tubes
•  Cells and/or bioactive molecules premixed with the alginate solution
This final point highlights a potential area of concern in general when premixing cells and 
a scaffold polymer. The problem is that the addition of cells even with negligible cell culture
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Alginate solution Calcium chloride solution Alginate hydrogel
Figure 5.2
Production schematic of an alginate hydrogel tube from the loaded device to a finished 
tube with the regulator element having been expelled from the barrel.
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media dilutes the polymer due to the physical volume of the cells themselves. Each smooth 
muscle cell has a negligible volume but when bulked up, this total cell volume becomes 
significant. This dilution reduces the polymers ability to form a strong scaffold tube i.e. 
forming a weaker tube or not being able to form a tube at all. By forming the tube within 
the barrel and not physically having to handle it potentially allows higher celkpolymer ratios 
to be employed. Higher cell concentrations in turn leads to potentially much reduced culture 
times for the cell-scaffold construct. However due to physical constraints, there is a maximum 
density that cells can be mixed with alginate. Figure 5.3 gives an indicator of where the 
maximum cell concentration that is potentially achievable. This table assumes that the pelleted 
cells are resuspended in alginate solution. However, a more probable scenario is that the 
pelleted cells will require resuspending in cell culture media prior to mixing with alginate 
solution. Minimum resuspension volumes have been determined experimentally, when these 
volumes are included further dilution is inevitable - see Figure 5.4. Based on the extrapolated 
data, it would appear that the upper limit of cell density in any polymer is in the order of 107 
cells per ml. Further experimental work is required to confirm the above extrapolated cell 
volumes using 108 cells densities and greater. This thesis uses cell densities in the range 105 
- 5x107cells per ml of alginate solution.
The prototypes main drawbacks included:
• Sealing difficulties at the collar/regulator interface allowing alginate solution and 
the linking agent to prematurely combine, thus forming a hydrogel around the 
regulator before it has started to move and thus fouling the run
• Difficulties in reliably adding alginate solution without trapping air bubbles around 
the regulator. Trapped air bubbles around the regulator cause the regulator to be 
tilted (i.e. no longer align with the barrel) and thus once sent into motion, ricochets up 
the barrel creating a hydrogel of highly variable wall thickness or with discontinuous 
stretches of wall. This was observed and recorded using coloured alginate (food 
colouring) by a NAC HSV 500 Digital High Speed Video System recording at 
500 frames per second (Loan machine courtesy of the EPSRC). Furthermore, these 
bubbles become trapped in the hydrogel further reducing its consistency.
• Difficulties in reliably preventing the trapping of air bubbles below the regulator of 
any size greater than the hole drilled into the underside of the regulator. Provided the 
trapped air did not protrude beyond the base surface of the regulator, it appeared 
to function correctly. However, if more air was present, then this excess air which is 
trapped below the regulator resulted in erratic regulator movement e.g. causing the 
regulator to travel only partially up the barrel before coming to a halt and letting the 
calcium chloride charge rush by it.
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Approx. 
number of 
smooth muscle 
cells
Approx. volume 
of cells only 
when pelleted
pL
Target cell 
concentration 
per ml of 
alginate 
solution
Approx. volume 
of alginate 
solution 
required to 
resuspend cells 
to 1 ml
pL
Fraction of 
alginate 
solution in final 
1 ml volume
%
105 Unmeasurable 105 1,000 100.0
106 <10 106 990 99.0
107 75 107 925 92.5
108 750 108 250 25.0
109 7,500 109 Not possible N /A
Figure 5.3
Potential cell concentrations in alginate solutions.
Experimental data was obtained using rat aortic smooth muscle cells (The European Collection 
of Cell Cultures (ECACC): A7r5 pelleted at 100 RCF (relative centifugal force) for 10 minutes 
and media drawn off using a pipette. These conditions produced easily resuspendable cells 
with greater than 97% viability. Cells were resuspended using a 500 pL pipette. The data for 
the target cell concentrations of 108 and 109 has been obtained by extrapolation.
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105 Unmeasurable 50 105 950 95
106 <10 50 106 940 94
107 75 75 107 850 85
108 750 750 108 Not possible N /A
Figure 5.4
Potential cell concentrations in alginate allowing for a media resuspension step.
Experimental data using rat aortic smooth muscle cells (The European Collection of Cell 
Cultures (ECACC): A7r5 pelleted at 100 RCF (relative centifugal force) for 10 minutes and 
media drawn off using a pipette. These conditions produced easily resuspendable cells in 
culture media with greater than 97% viability. Cells were resuspended using a 500 pL pipette. 
The data for the target cell concentration of 108 and has been obtained by extrapolation.
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5.2 Fluid driven device prototype -  Gas bubble regulator version
Having established that the fluid driven method was potentially a superior device to the previous 
piston driven prototype, refinement was now required to overcome the disadvantages. A very 
interesting observation was the air trapping had produced varying results in the prototype 
since an air bubble produces a discrete barrier between the alginate solution and the linking 
agent. A vital question needed answering -  Was an air bubble alone capable of acting as 
a regulator element? To answer this essential question, a series of prototypes were produced 
to see whether or not a solid regulator was required. A non precision bore quartz glass tube 
with an inside diameter of 1.5 mm and 15 cm in length was used. Holding the tube in the 
vertical position, 0.25 ml of 2% alginate solution (ISP Manugel) was injected carefully into 
the base of the glass barrel. Covering the top (so as to create an air tight seal) prevented the 
alginate solution leaking out as the syringe was removed. A second syringe (2 ml) with 0.5 ml 
of air and 1.5 ml of 2% calcium chloride solution was attached to the base and the air tight 
seal removed from the top. Since air is lighter than the linking solution, on initially applying 
pressure to the vertical syringe, only the air is introduced into the glass barrel. This discrete 
air bolus is then followed by the liquid linking agent. Since the air bolus acted as a regulator 
element i.e. separating the main bodies of the alginate solution and calcium chloride solution, 
whilst still allowing alginate solution to coat the barrel where it could then be cross-linked 
immediately after the bubble had passed, a hydrogel tube was produced.
5.2.1 Initial conclusions
Repeated experiments at 1.5 mm (non-precision bore), 4 mm (precision bore) and 8 mm 
(precision bore) inside barrel diameters and varying quantities of air failed to reliably 
produce tubes of anything other than highly variable wall thickness. The proximal parts of the 
tubes were frequently of much greater thickness than the more distal parts. Variation in wall 
thickness was also more pronounced as the inside diameter of the glass barrel increased. 
However, on occasion an evenly walled tube (screened using a simple micrometer gauge) 
was produced. Overall from this series of simple experiments, the bubble regulator was 
indeed a possible option, however, the solid regulator produced much more reliable results 
for the same amount of experimental time.
The potential major advantages of a gas regulator over a solid regulator include:
•  Reduced manufacturing time and costs
• Reduced number of unit operations
• No regulator to stick/jam
• Reduced chance of premature contact between the alginate and linking solutions
•  No regulator to remove
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A potentially suitable application for bubble regulators is where multiple short small-bore 
tissue constructs are required e.g. high throughput drug discovery. This is a potential area of 
convergence between ultra scale down, tissue engineering and high throughput screening. A 
simple experiment using a glass capillary tube (inside diameter 1.5 mm) robustly manufactured 
tubes when employing an air bubble as the regulator. This inside diameter of this capillary 
tube is less than for both 384 (4.5 mm) and 1536 (2.25 mm) microwell plates (Draft standards 
suggested by the Society of Biomolecular Screening 2002) making this a potential technology 
for a wide range of microwell sizes.
At this stage in the research it was decided to focus on the solid regulator approach.
5.3 Mark I design
Modifications to the fluid driven device were considered in order to overcome the three main 
difficulties encountered with the original solid regulator prototype:
•  Failure to produce an adequate seal between the collar and the regulator
• Trapped air between the regulator and the barrel
•  Excess air trapped under the regulator
A number of modifications were experimented with. These modifications cumulated in the 
Mark I version, which consisted of retaining the 4 mm inside diameter, 15 cm long borosilicate 
precision bore glass rod acting as the barrel but not the Perspex cylinder base. Instead a 
new cylinder base, a dual injector base was machined from polypropylene which had the 
benefit of allowing alginate solution to be introduced below the regulator, thus purging air 
out easily above it, see Figure 5.5 and Figure 5.6. The dual injector base consisted of a 
cylinder measuring 19 mm high by 22 mm in diameter. At its top protruded a small central 
stub measuring 6 mm high and 4.05 mm outside diameter. This stub allows the glass barrel to 
be attached to the base with a fluid tight seal just by pressing the stub firmly all the way into 
the glass tube. Careful machining of this interference results in perfect alignment of the glass 
barrel with the cylinder base.
A 1.55 mm hole was drilled through the body of the cylinder and out the base. Through this 
hole was pressed (strong interference fit) a stainless steel tube with an inside diameter of 1 mm 
and an outside diameter of 1.5 mm. This stainless steel tube became the injector nozzle.
This arrangement resulted in two concentric tubes i.e. a 4.05 mm outside diameter 
polypropylene hollow tube, with an inner stainless steel tube of 1.5 mm outside diameter 
protruding from the stub by 6 mm. A side port was drilled to allow a 2.5 ml syringe to be 
attached via an interference fit to provide a connection to the channel created between the 
outer polypropylene tube and the inner stainless steel tube. A similar base port was also
- 9 4 -
Glass barrel
Stainless steel tube, 
(injector nozzle)
Stub to locate glass barrel-
Side port - Alginate solution
Polypropylene cylinder 
body/base unit
+
Base port 
Calcium chloride solution
Figure 5.5
Mark I cylinder base unit with a short glass barrel attached - longitudinal section.
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Stub protruding from 
body for interference 
fit with glass barrel
Polypropylene 
injector body
Stainless steel tube
Glass barrel
Alginate solution port ^  Calcium chloride solution port
Figure 5.6
Mark I cylinder base unit with glass barrel attached - viewed from above 
demonstrating the concentric nature of the device and its ports.
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drilled to allow connection to the lumen of the stainless steel tube.
The above arrangement allowed two discrete fluid delivery channels within the base unit:
1. Base port => injection nozzle [Calcium chloride solution]
2. Side port =9 channel around injection nozzle -  [Alginate solution]
A series of different regulator elements were machined such that all were 1 cm tall and 
approximately 1.5 mm diameter, with a 6 mm long hole machined in their base. This hole 
was machined such that the regulator would sit on the stainless steel tube with minimal 
interference. Turning the device upside down resulted in the regulator falling easily away 
from the injector nozzle.
The regulators, as before, were made of various diameters to give hydrogel tubes of different 
wall thicknesses. Regulators were either simple bullet shaped or the finned design.
5.3.1 Mark I operating sequence
A typical operation cycle consisted of:
1. Hold the assembled device vertically
2. Attach a 2.5 ml plastic syringe containing calcium chloride solution, with any 
air purged, to the base port. Gently introduce the linking agent until just level 
with the top of the stainless steel tube. It is essential that no linking solution 
escapes and enters the alginate solution pathway within the device
3. Place the regulator on protruding stainless steel tube -  injector nozzle
4. Attach polypropylene base unit to glass barrel
5. Firmly hold the regulator down onto the base with a small diameter rod
introduced from above. This step also helps centre the regulator in the barrel
6. Attach a plastic 1 ml syringe to the side port and slowly inject in 0.6 ml of
alginate solution. Care must be taken not to introduce or trap air and the
regulator must be held firmly in place by the rod to stop it being displaced thus 
allowing premature contact of the two agents
7. Carefully withdraw the rod
8. Inject the calcium chloride solution via the base port into the device; this results 
in the regulator being forced off its stainless steel tube and being despatched 
up the glass barrel. Since alginate is left attached to the wall after the regulator 
has past, this is immediately cross-linked by the rising column of calcium 
chloride solution. In this way a hydrogel tube is created
By adding excess cross-linking agent the regulator could be expelled from the barrel driving 
the tube formation. This resulted a hydrogel tube supported by the glass barrel, which was
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open at the top end and firmly attached at its base. This attachment consisted of an alginate 
plug extending all round the 6 mm of protruding stainless steel tube and extending back to 
the side port. With this attachment it was easy to add fluids via the base port e.g. additional 
calcium chloride solution, tissue culture medium etc. Unfortunately the side port where the 
alginate was introduced was blocked by cross-linked alginate. The calcium ions diffused 
slowly back through the alginate solution from the barrel to the port resulting in an excellent 
attachment for the tube at the expense of the loss to this port.
If a relatively strong hydrogel was produced e.g. 2% ISP Manugel, then 5 minutes after 
producing the tube, if the base was pulled away from the barrel, the hydrogel tube was 
delivered perfectly from the barrel firmly attached to the base unit.
This arrangement robustly produced tubes when using a variety of different alginates, alginate 
concentrators, calcium chloride concentration and regulator sizes.
Typically, high G alginates and /o r high alginate concentrations (>2%) solutions produced 
tubes which could easily be delivered from the glass barrel. High M and low concentration 
solutions produced tubes, but these were invariably impossible to remove perfectly intact from 
the barrel even with additional help e.g. flowing calcium chloride solution down the barrel. 
To assist visualisation of the experiment, small quantities of glycerol based food colouring 
(Supercook (Leeds, UK)) or blue dextran (average molecular weight 2,000,000 -  Sigma) was 
added to the alginate solution.
Early on it was discovered that scrupulous cleaning of the inside to the barrel, base unit 
and regulator was essential. Cross-linked alginate if allowed to dry was fairly resistant to 
removal from a surface, plus when wet was hard to visualise. The layers of alginate deposits 
caused two problems:
• Increased (and unwanted) interaction between the regulator and the stainless steel 
tube resulting in the regulator sticking.
• Irregularly decreased bore diameter which resulted in fouled runs.
Therefore, all components were washed in 4M sodium citrate solution prior to being dried 
using a compressed air source. The sodium citrate solution contained excess monovalent 
ions thus causing a phase shift from hydrogel (calcium alginate) back to the aqueous sodium 
alginate.
5.4 Conclusions
The above preliminary experiments with both the prototype and the Mark I manually powered 
and controlled fluid driven devices demonstrated that fluid drive was a feasible option for 
the production of alginate hydrogel tubes. The next chapter discusses the semi-automation
-  98 -
of this methodology to create an integrated system in order to achieve the goal of producing 
consistent cell/hydrogel tubular constructs.
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6.0 Semi-automation of fluid driven device - Hydraulic drive
6.1 Design challenges, improvements and semi-automation
The manually powered fluid driven device consistently outperformed the pneumatic driven 
piston device in terms of the proportion of successful tube production runs (See Appendix 
2). However, both approaches lacked tube consistency with respect to wall thickness and 
also premature "stalling" of the regulator in the barrel. Both these problems share a common 
aetiology, namely inconsistent propulsion mechanisms e.g. variable calcium chloride solution 
delivery rate. The challenge was therefore to semi-automate the fluid driven process in order 
to improve the consistency of results achieved manually. Accurately controlling the timing, rate 
and volume of the cross-linking agent entering the device was predicted to have a positive 
impact on tube quality and reproducibility, both important factors which had been poor to 
date. Unlike the pneumatic driven device whose performance was erratic in part due to the 
compressibility of its driving agent, air, a liquid driven device i.e. hydraulically operated 
suffers no such disadvantage.
Other important factors included:
• Overall wall thickness - In theory the wall thickness is directly proportional to the 
gap between the regulator and the barrel. However, the actual wall thickness may 
be different in size to the predicted for a number of reasons including the particular 
alginate solution's property of either shrinking or expanding as it cross-links.
• Tube length - Likewise the length of the tube formed is determined by a number of 
factors including, the volume of alginate solution loaded into the device, viscosity of 
the alginate solution, gap between regulator and barrel, volume of calcium chloride 
solution delivered and ultimately the length of the barrel.
• Inconsistent regulator travel - If calcium chloride solution "escapes" and enters the 
space between the regulator and the barrel, the alginate gels, and the regulator 
becomes stalled in the barrel and the calcium chloride solution flows up past the 
jammed regulator and makes direct contact with the bulk of the alginate solution 
thus gelling it in a highly irregular manner. The end result is a hydrogel tube being 
produced only until the regulator stalled. Causes of the "escape" of the calcium 
chloride solution include, non homogeneous alginate, trapped air bubbles, imperfect 
regulators, poor alignment e.g. due to the wear of polypropylene stub at the glass 
barrel interference fit surface (disassembly and reassembly of the device between 
runs and meticulous cleaning are absolutely essential between runs) and variable 
calcium chloride solution delivery.
6.2 Potential design solutions - Semi-automated Mark I version
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Solutions to some of the above challenges were straight forward and quick to implement. These 
modifications were incorporated into the semi-automated Mark I device and its operating 
procedure. These changes included:
• Alginate was made homogeneous by careful premixing prior to autoclaving and 
further mixing immediately after autoclaving (whilst still warm) and again just prior 
to use. The most crucial step is the initial addition of the alginate powder to the 
water, physiological saline or buffer. This was best achieved by constant swirling 
of the flask as very small amounts of the powder were added in order to avoid 
clumping. Alginate powder does not dissolve quickly into solution. Further mixing 
was achieved using a roller bottle mixer but this does not resolve an initially poorly 
mixed solution. Alginate solutions were initially made using powder straight from 
the manufacturers container. However, later batches were desiccated for 48 hours 
prior to use thus removing excess water (e.g. ISP Manugel contains approximately 
12% water by weight) in order to improve the direct comparisons between different 
alginates for a given percentage solution.
• Air bubble trapping was avoided by the careful addition of both alginate solution 
and calcium chloride solution into the device e.g. careful bleeding of the syringe and 
device prior to a tube production run.
• Regulators and polypropylene cylinder bases were accurately machined to avoid 
imperfections and precision bore borosilicate glass tubing was used extensively 
after thorough in-house checking (at least one batch of precision grade glass tubing 
was delivered with very poor tolerance control -  requiring the manufacturer to 
remanufacture the mandrel the glass tube was made on). It was essential that base 
cylinder, glass barrel and regulator were all aligned at the start of a tube forming 
run. Wear of the polypropylene stub due to frequent disassembly and assembly 
caused both misalignment and reduction in the quality of the essential interference 
fit (i.e. to maintain a fluid tight seal plus hold the assembly together). If this design is 
retained, future work will require the cylinder base to be manufactured from a more 
durable material to overcome this wear issue.
The far more challenging area to resolve was that of erratic calcium chloride solution delivery. 
The components involved were the syringe driver and its electrical control system, syringe 
size and type and the path from the syringe to the stainless steel injector outlet. Two methods 
were selected to monitor the dynamic formation of individual tube constructs throughout their 
fabrication. [Complex fluid dynamic modelling was deemed outside the scope of this thesis, 
allowing a more visual based methodology to be adopted.] The techniques deployed were:
1. Digital high speed video imaging
2. Dynamic pressure recording
6.2.1 Digital high speed video imaging
The syringe driver chosen for semi-automating the calcium chloride solution delivery was a 
Harvard Apparatus PHD 2000 (High Power) lead screw type (Harvard Apparatus, Holliston, 
MA, USA). This is a microprocessor controlled syringe pump capable of driving two syringes 
in parallel (ranging from 0.5 \jl - 140 ml) using a 1.8° incremental stepper motor. Its flow 
range can be set (depending upon the syringe chosen) from 0.0001 pL -13.2 litres per hour). 
Rated at 65 Watts, it delivers an "average nominal force of 66 lbs". Its accuracy is claimed 
to be +/-1 %, with a reproducibility of +/-0.1 %. The syringe "pusher" travel rate ranges from
0.18 pm -109 mmmin'1. Due to the close proximity of the two syringes it is easy to link them 
together via a "T-piece" to double the maximum flow rate for a given "pusher7' rate.
After a large series of initial experiments using plastic syringes ranging from 1 - 60 ml (1,2.5, 
5, 10, 20 and 60 ml) and also coupling the syringes via a T-piece at a range of delivery rates 
ranging from 1 - 2 1 2  mlmin'1, using different viscosity alginate solutions, no reproducible 
results were obtained. The vast majority of runs failed to produce a tube. The most promising 
combination was a flow rate of 100 mlmin1 (1.67 mlsec'1), 60 ml Becton Dickinson Luer lock 
plastic syringe, 4 mm inside diameter barrel, 3.5 mm diameter regulator, 0.6 ml of 4% Fluka 
alginate solution and 2% calcium chloride solution in physiological saline at room temperature. 
However, even this combination had a tube production success rate of well under 50%. The 
problem consisted of near perfect runs punctuated by failures when using absolutely identical 
equipment, reagents and conditions including temperature. Wall thickness was measured 
using a simple mechanical micrometer once the tube was slit longitudinally. It is important 
to note that using exactly the same set of conditions except manually injecting the calcium 
chloride solution in a smooth manner resulted in a perfect tube virtually 100% of the time 
-  the duration of production being of similar length of time. It was therefore decided to record 
individual runs using high speed digital video and then to watch the 'movies7 generated in 
slow motion in order to better understand the high rate of failure and thus be able to make 
the appropriate modifications.
6.2.1.1 High Speed Camera Equipment
The apparatus consisted of a Mark I tube-forming device directly coupled to a vertically 
positioned Harvard Instruments PHD 2000 syringe driver. Directly behind the barrel of the 
Mark I device was positioned a clear Perspex rule behind which was mounted a sheet of matt 
white card. Illumination was provided using simple bench lamps, one on each side. A NAC 
HSV 500 Digital High Speed Video system (NAC Image Technology Inc., Tokyo, Japan) was 
positioned directly in front of the glass barrel such that the base of the Mark I device could just
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be seen in the lower most part of the view finder with a further 140 - 150 mm of glass barrel 
occupying the remainder of the view finder. An overall barrel length of 20 cm was used in 
order that the regulator was "still in play" i.e. making a hydrogel tube at the very top of the 
image. The camera was set to record at its maximum of 500 "frames' per second (fps) these 
images were stored as .tiff files (tag image file format - Adobe Systems). The NAC camera 
was kindly loaned by the Engineering and Physical Science Research Council (EPSRC).
Alginate solutions were produced using different alginate concentrations (ISP - Manugel) in 
physiological saline/ thoroughly mixed using a roller mixer and then autoclaved. Immediately 
after autoclaving i.e. whilst still hot, food colouring dye was added to the solutions and then 
further mixed on the roller mixer in order to improve the homogeneity of the solutions. A 1 % 
calcium chloride solution was produced using physiological saline and its pH adjusted to 
7.36-7.40.
A standard Mark I tube-forming device was used including polypropylene regulators with 
diameters ranging from 3.6 - 3.9 mm (increasing in a 0.1 mm incremental manner). All 
experiments were performed at room temperature.
The experimental sequence of events commenced with the Mark I device being carefully 
loaded and put into position as described above, the high speed camera was manually 
triggered followed by the immediate manual starting of the syringe driver. The NAC camera's 
maximum record time at 500 fps was 5 seconds. Each completed film run thus produced 
2,500 .tiff files (individual .tiff files were approximately 500 Kb in size). Each run's data was 
in turn burnt to a CD-ROM for later processing.
The .tiff images were subsequently processed in two distinct ways:
1. 'Movie' generation
2. Individual 'still' analysis
6.2.1.2 'Movie' generation
'Movies' were produced by linking all the .tiff images together to produce an AVI file (Audio 
Video Interleave, the file format for Microsoft's Video for Windows standard). Initially, this was 
performed using an IBM compatible PC, in two steps using PicaView (ACD Systems - www. 
acdsystems.com) to convert the .tiff files into JPEG format (Joint Photographic User Group) and 
then stringing the JPEG's together using AVI Constructor (www.aviconstructor.com) to form a 
continuous AVI 'movie'. This produced informative AVI's regarding the overall movement of 
the regulator and the coloured alginate column directly above it. Unfortunately this software 
combination had a number of major drawbacks including; poor data compression, poor 
replay management e.g. speed control, and very slow processing times. Having seen the
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potential value of building AWs from the data and needing to be able to quickly process the 
tube-forming runs, the software was switched to Adobe Premier 6 /6 .5  (Adobe Systems, San 
Jose, CA, USA). Premier is a professional package design for the production and editing 
of digital video. Using this software, .tiff images could be linked together to produce a high 
quality continuous 'movie' of each run. The resulting AWs were 20 - 30 Mb in size (a large 
reduction from the original 1 - 1.5 Gb of .tiff files). Premier allowed the frame rate to be 
controlled. The original shooting rate was 500 fps, the Premier "movies' were produced to 
run at 15 fps i.e. approximately 3% of the original speed. Furthermore image resolution was 
optimally preserved by Premier being able to retain the .tiff file at its original size of 496 x 
332 pixels. These slow motion 'movies' when played back either using the Premier built-in 
viewer or for simplicity, Apple QuickTime Pro (Apple, Cupertino, CA, USA), both allowed 
very detailed viewing. These AVI's demonstrated the overall characteristics of an individual 
tube forming run including:
1. Overall movement of the regulator and alginate column e.g. did the regulator 
travel all the way to the top in a smooth and controlled manor or did it travel 
in a staccato manor
2. Indication on whether a run was successful or failed. If a tube was formed then 
the region below the regulator was a pale blue/green (due to the colouring 
agent which had been added to the calcium chloride solution) extending 
continuously from the injector nozzle. The nozzle itself was always in a region 
of slightly darker blue due to the alginate 'plug' formed in the region just 
below the base of the regulator in its loaded position. When a tube run failed, 
this light blue colouring was virtually absent
3. Allowed accurate timing of events due to both the slow motion and viewer 
forward/reverse control. Both viewers have built-in timers. By accurately 
locating both the start and the finish of each run the 'movies' could be cropped 
to just contain the tube-forming run and not the excess prior to after the run, 
thus reducing AVI file size and improving playback
4. Demonstrated additional unexpected information e.g. very small air bubbles 
were trapped under the regulator as it travelled up the barrel. These revealed 
an area of high turbulence immediately under the regulator base. Ricochetting 
of the regulator was also occasionally observed
6.2.1.3 Individual 'still' analysis
Individual 'stills' were analysed by processing discrete .tiff files. By locating the exact start 
points of each run using the AVI 'movie', it was possible to quickly locate the actual .tiff file 
immediately prior to the regulator moving. This .tiff file subsequently became the reference
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point for both time and regulator position i.e. the position of the stationary regulator at time 
zero.
Each .tiff file was processed in the following manner using Adobe Photoshop 6 or 7 (Adobe, 
San Jose, CA, USA). The .tiff file was opened in the image window which had both a grid 
and rulers. It was quickly apparent that on some of the runs the Mark I tube-forming device 
was not absolutely vertical. This was digitally corrected by rotating the image so that the 
glass barrel became parallel with the vertical grid lines. The maximum rotation required by 
any run was 1.25°, the majority of runs required no correction. Using the grid function, a 
redefined zero point was set at the midpoint of the uppermost edge of the Mark I device (x 
= 0, y = 0). The measuring process was performed at the base of the regulator, tip of the 
regulator and air/alginate interface using the scroll function at the 1600x enlargement. By 
placing the cursor exactly over the centre of the pixel at the point of interest, Photoshop 
displays the x and y coordinates in mm for the actual image. Care was taken to have a value 
of x = 0 (long central axis of the device) at all measuring points since both the top of the bullet 
and the air/alginate interface are curved. Since x = 0 is the approximate midline, this should 
approximate to the inflection point of the curves. Finally each .tiff was cropped to show just 
the device and ruler and saved as a native Photoshop file (.psd file). These .psd files were later 
directly imported into Adobe Illustrator 10 (Adobe, San Jose, CA, USA) a vector graphics 
piece of software which is tightly integrated with bit-map imaging capability of Photoshop, 
to create the chronological sequences and saved as native Illustrator files (.ai files). See 
Figure 6.1 for a sample of two time points 0.45 seconds apart (225 frames separate the two 
images).
Initially every 100th .tiff was processed (i.e. 0.02 of second intervals). However it as soon 
apparent that the very first part (0 - 0.05 seconds) of the run required further investigation 
and therefore shorter time intervals of sampling were used during this period.
The data generated was processed using a computer spread AppleWorks 6 (Apple, Cupertino, 
CA, USA) From the data, graphs were drawn using Adobe Illustrator 10.
6.2.1.4 Data processing
Each .tiff image has a computer generated file number which places the image precisely in 
its overall sequence. Since each .tiff has a displacement of 0.002 seconds from its immediate 
neighbour it was easily possible to calculate the time displacement for each file.
Finally, all the distances were adjusted to a common reference point which coincided with the 
very base of the regulator in the loaded position. This position is the theoretical start of the 
actual hydrogel tube that is produced (i.e. not the plug of alginate hydrogel which attaches
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Figure 6.1
Two sample images from one tube production covered by 225 frames (0.45 seconds 
apart) images.
The first image is shortly after the opening snap - the injector is just becoming exposed (Dx). 
The second image shows the run at a known time later when the regulator has travelled a 
further distance (rD) and the volume of coloured alginate above the regulator has 
decreased from rV to rV
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the base of the tube to the stainless steel injector rod which is below the regulator). The data 
was then plotted in a graph.
6.2.1.5 Typical successful tube-forming run
A typical successful tube-forming run is described below during which a continuous alginate 
tube was produced. Continuity was checked by leaving the device full of calcium chloride 
solution for a minimum of 20 minutes (in order to increase the degree of cross-linkage and 
therefore strength) prior to detaching the Mark I base from the barrel. If detachment was 
performed using a gentle pull in the direction of the axis of the barrel, the hydrogel tube 
could be safely delivered. If any excess rotation occurred, the hydrogel tube was sheared 
from its attachment on the injector nozzle and therefore remained in the barrel and could 
only be removed by flushing it out. The hydrogel tube was then inspected. If still attached to 
the injector nozzle fluid added via the base port would flow through the alginate tube.
The conditions used were: 4% alginate solution, 1% calcium chloride solution, 3.8 mm 
diameter regulator, 10 ml plastic Becton Dickinson syringe and the syringe driver rate set at 
40 ml per minute.
6.2.1.5.1 'Movie' analysis
The AVI 'movie' in slow motion (15 fps) showed a continuous tube forming run with four 
distinct phases:
Phase I This was the time interval from starting the syringe driver to just prior
to 'lift off' from the injector nozzle. During the whole of this phase I the 
regulator does not move, it is stationary on its 'launch pad', however, 
the Harvard PHD syringe driver is running 
Phase II This started at the point of the regulator 'lifting off' and in this example
lasted for a maximum of 0.05 seconds during which time the regulator 
travel no more than 7 mm from its loaded position.
Phase III This was a brief period (in this example < 0.01 seconds) which consisted
of an almost instantaneous halt of the regulator prior to entering the 
fourth and final phase.
Phase IV This final phase continued until the regulator went out of camera shot
In this example, the cumulative time for the final three phases was 2.2 seconds. Each of the 
individual phases is covered in more depth in the paragraphs below:
Phase I
By definition, no movement was observed nor too was there any movement of the a ir/ 
alginate interface i.e. there is no discernable leakage of calcium chloride solution 'around'
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the regulator prior to lift off'. Any leakage would lead to a premature exposure of the two 
reagents and a failed run.
Phase II
The regulator was seen to rapidly rise in the barrel forcing the alginate solution column 
above it to also rapidly rise. Phase II included a short part of the run where the regulator is 
in contact with the uppermost part of the stainless steal injector nozzle plus a short distance 
above it.
Phase III
This transition phase appeared to be a short (<0.01 second) linking the rapid velocity first 
phase to the slower velocity fourth phase. It is a period of extremely rapid deceleration where 
the regulator almost appears to come to a complete halt before entering the final phase.
Phase IV
The longest phase which lasted approximately 2 seconds before the regulator left the field 
of view. During this phase tiny air bubbles, less 500 pm in diameter were seen travelling 
randomly around at high speed just under the regulator as is travelled up the barrel. These 
tiny air bubbles could possibly have come from a tiny volume of air trapped in the internals 
of the Mark I but this is most unlikely as the system was thoroughly bled prior to positioning 
the regulator and final assembly of the device. More likely it was from the small pocket of 
air trapped inside the regulator where it interacts with the stainless steel injector nozzle. The 
air possibly left the regulator due to rapid pressure changes in the calcium chloride solution 
which was propelling the regulator. The volume of air trapped in the regulator was negligible 
since the total space into which the stainless steel injector nozzle fits is less than 20 pL and 
virtually all of this air was expelled as the regulator was carefully lowered onto the injector 
since the two components fit together in a close but loose manor i.e. there was minimal 
interference between the two components. The injector nozzle was filled to its opening with 
calcium chloride solution prior to regulator positioning.
6.2.1.5.2 'Stills' analysis
The series of individual 'stills' from the successful run had their data plotted in a graph with 
distance/length plotted on the y axis with time on the x axis - see Figure 6.2. The position of 
the air/alginate interface and regulator were plotted - see Figure 6.3. This graph like the AVI 
'movie' had the same four distinct phases.
Phase I
From the experiment, the duration from starting the syringe driver to lift off is unknown. 
Therefore the start of phase II is the origin of the graphs.
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Graph of distance against time for the alginate/air interface and regulator overlaid on Figure 6.2.
(Labelling as per Figure 6.1)
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Phase II
Lines of best fit was created through the data for the first 0.05 seconds and their correlation 
values (r2) calculated - see Figure 6.4. The difference in velocity between the air/alginate 
interface and the regulator was due to alginate solution travelling past the regulator, which 
on reaching the base of the regulator came into contact with the calcium chloride solution 
and cross-linked to form a hydrogel tube. Both the air/alginate interface and the regulator 
data for this phase correlated reasonably well with their lines of best fit. The reasonable 
correlation between the lines of best fit for both the air/alginate interface and the regulator 
suggest that the velocity during this period was relatively constant i.e. no acceleration, thus 
achieving a steady-state. This suggests that the regulator reached velocity over a very short 
period of time relative to this first phase, analogous to a billiard ball being cleanly struck with 
a billiard cue.
Of great interest was the difference between the observed values for the air/alginate interface 
and the regulator compared to the theoretical calcium chloride solution height. The a ir/ 
alginate interface was 2.2x (119.1 c.f. 53 mmsec'1) the theoretical value whilst the regulator 
was 2.8x (147.9 c.f. 53 mmsec'1). This suggests that the regulator was virtually Tired off' 
its injector nozzle due to a pressure build up under the regulator, i.e. there was a time lag 
between starting the Harvard PHD 2000 syringe driver and calcium chloride solution being 
injected into the Mark I device. When the regulator 'lifts off' the pressure instantaneously 
drops. Since the regulator has a large momentum, it carries on up the barrel, despite the 
reduced propulsion pressure. The billiard cue analogy again holds true since immediately 
after being struck the billiard ball is no longer in connection with the cue.
In conclusion phase II was a period of extremely rapid change in the displacement of both the 
alginate column and the regulator from their resting positions.
Phase III
Phase III was the extremely short transition phase witnessed from the AVI 'movie'. It was 
the period where the propulsion fluid pressure re-establishes itself and again propels the 
regulator and the head of alginate solution above. It is as though the billiard cue had after 
the initial strike of the ball lost contact and then followed through to re-establish contact with 
the decelerating/stopped ball.
This phase was extremely short and was not discernible from the individual 'stills'. Either a 
higher speed camera and/or a higher .tiff file resolution rate is required to isolate this brief 
event.
Phase IV
Lines of best fit were again drawn for the data (0.05 seconds - end of the visualised run) and
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Location Gradient = Average velocitymmsec'1 Correlation (r2)
Air/alginate interface 119 Acceptable (0.942)
Top of regulator 148 Acceptable (0.903)
Theoretical top of CaCl2 
column 53.0 N /A
Figure 6.4
Phase II average velocities for a successful tube forming run generated from digital high 
speed video imaging data.
Location Gradient = Average velocitymmsec1 Correlation (r2)
Air/alginate interface 49.5 Excellent (0.999)
Top of regulator 56.9 Excellent (0.999)
Theoretical top of CaCl2 
column 53.0 N /A
Figure 6.5
Phase IV average velocities for a successful tube forming run generated from digital high 
speed video imaging data.
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their correlation values (r2) calculated - see Figure 6.5. As in phase II the regulator velocity 
was greater than the air/alginate interface velocity. It was approximately 14.9% faster which 
is less than the phase II similar comparison of 24.1%.
All of the best fit lines correlated excellently with the data. This was highly suggestive that the 
velocity of all the components during this fourth phase were constant. This phase lasted 2.2 
seconds and thus made up the majority of the tube-forming run time (97.7%). The length of 
hydrogel tube formed during this phase (excluding cross-linking changes e.g. shrinkage) was
111.6 mm.
As in phase II, the observed velocities of both the air/alginate interface and the regulator 
were different to the theoretical calcium chloride solution column height but to a much lesser 
extent - see Figure 6.6. The acceptable correlation with the best fit lines during phase II 
and the excellent correlation with the best fit lines during phase IV suggest that the velocity 
transition takes place during phase III i.e. the average velocity of phase II 'shifts' to the lower 
velocity of phase IV, since no acceleration/decceleration is seen during these phases (dv/dt 
is a straight line for both graphs).
If phase III was analogous to the billiard ball being restruck by the cue, then phase IV is 
analogous to the cue remaining in contact with the ball at all times. It is as if the ball were 
being pushed against a constant resistance and cannot break away from the cue as it had 
done on initially being struck (phase II). The resistance in the tube-forming system being the 
head of alginate solution above the regulator plus the forces exerted by the alginate solution 
as it passed around the regulator.
The difference between phase II and phase IV was that the former required considerably 
more propulsion force (pressure) to start the system moving from rest, whilst in phase III, the 
regulator and the alginate column above it are probably moving and only required a change 
in velocity. Thus overshoot of the regulator was observed in phase II but not in phase IV.
The difference between the air/alginate velocity and the theoretical calcium chloride column 
height velocity was probably due to back pressure in the system due to the extra work required 
to push the regulator and alginate column compared to the free flowing aqueous system used 
to verify the syringe drivers stated performance. The back pressure effectively dropped the 
delivery volume from the pre-set 40 mlmin'1 to 37.3 mlmin'1, a 6.7% reduction.
6.2.1.6 Varying alginate concentrations
The above experiment was repeated using identical conditions but using different concentrations 
of alginate in order to be able to compare the effect of viscosity on the process. Alginate 
solutions (1 %, 2%, and 4% Manugel) were made up as before.
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Location
Phase II 
velocity
mmsec'1
Phase II 
velocity as a % 
of theoretical 
CaCl2 velocity
Phase IV 
velocity
mmsec'1
Phase IV 
velocity as a % 
of theoretical 
CaCl2 velocity
Air/alginate
interface 119 225% 49.5 93%
Top of regulator 148 279% 56.9 107%
Figure 6.6
Comparison of phase II and IV average velocities for a successful tube forming run 
generated from digital high speed video imaging data.
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The measurements, data manipulation and calculations for each different viscosity alginate 
solution were performed in exactly the same manner as that described above. The data 
was averaged from three successful runs for each alginate concentration. The same phase 
nomenclature has been used.
6.2.1.6.1 'Movie' analysis
Provided the run was a successful run i.e. an alginate tube was produced which stretched the 
length of the visible (to the camera) part of the barrel, all the AVI 'movies7 were very similar 
in overall appearance to the 4% alginate run described above. (Failed runs were of totally 
different appearance and will be dealt with in detail later, this next part of this chapter will 
only be concerned with successful tube-forming runs.)
The AVI 'movies7 did reveal differences in duration for both specific phases as well as the 
duration of the overall run for the different alginate concentrations. As before there was still 
the rapid velocity phase II followed by an extremely brief phase III transition followed by a 
smooth phase IV. Phase I again demonstrated no discernable leakage of calcium chloride 
solution prior to regulator 'lift off'. This typical sequence of events seems to be the hallmark 
for a successful tube production run.
6.2.1.6.2 'Stills'analysis
Looking at the individual .tiff files as before allowed precise measurement of the events 
described above.
Phase I
For all the different alginate concentration there was no discernable increase in the height of 
the air/alginate interface until the regulator 'lifted off', nor was a clear layer observed in the 
region of the regulator at any time.
Phase II
Phase II lasted in the order of 0.05 seconds for all the sample alginates. Precise determination 
of the end of phase II was difficult to find from the 'stills'. Certainly no phase II lasted longer 
than 0.05 seconds. Plotting a distance against time graph for the air/alginate interface and 
using lines of best fit together with calculating its correlation value (r2) suggested that for all 
the samples a dramatic slowing of velocity (change in gradient) occurred no later than 0.05 
seconds. An r2 value in the order of 0.95 was taken as the cut off point, thus the time points 
were reduced until approximately this value was reached.
The average values for the air/alginate interface are shown in Figure 6.7. Likewise the data 
was used to find the average regulator velocity. The average regulator volume is shown in
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Alginate
concentration
Average 
velocity for 
phase II 
air/alginate 
interface n = 3
mmsec 1
r2
Phase II air/alginate interface 
velocity as a % of theoretical 
CaCl2 velocity
1% 186 >0.95 351%
2% 170 >0.96 321%
4% 119 >0.94 225%
Figure 6.7
Comparison of the average velocities of the air/alginate interface during Phase II of a 
successful tube forming run deploying alginate solutions of different concentrations.
Alginate
concentration
Average 
velocity for 
phase II 
air/alginate 
interface n = 3
mmsec 1
r2 Phase II regulator velocity as a % of theoretical CaCl2 velocity
1% 180 >0.95 340%
2% 191 >0.96 359%
4% 146 >0.90 276%
Figure 6.8
Comparison of the average velocities of the regulator during Phase II of a successful tube 
forming run deploying alginate solutions of different concentrations.
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Figure 6.8. The lines of best fit correlated well with the data, with all the r2 values exceeding
0.9.
Phase III
As previously described for the 4% alginate solution, the Phase III was extremely short and of 
similar character.
Phase IV
Results for the three different alginates were near identical to the Phase IV results for the 
original 4% alginate (see Figure 6.5) with average air/alginate interface and regulator 
velocities approximately identical to the theoretical calcium chloride solution velocity.
6.2.1.7 Description of a typical failed tube-forming run
Characteristically the hallmark of a failed tube-forming run was that the regulator would lift 
off and then slow or completely stall in the barrel. This resulted in calcium chloride solution 
escaping past the regulator and thus coming into contact with the alginate in an uncontrolled 
manor. Understanding why runs failed is crucial to producing the essential robust process 
required for future clinical material.
6.2.1.7.1 'Movie' analysis
The run described below is a typical example of a failed run. The conditions were all identical 
to the previously described successful tube production run including the alginate concentration 
(4% Manugel), regulator diameter (3.6 mm) and syringe driver flow rate setting (40 mlmin 
’). The measurements, data processing and calculations were performed in exactly the same 
manner. The same phase nomenclature has been used.
An overall view of the AVI 'movie' in slow motion (15 fps) showed the regulator smoothly 
lifting off from the base unit. Immediately the regulator was seen to ricochet of the barrel 
walls as it made its way up. By approximately 0.5 seconds from the start of movement, an 
extremely thin clear layer could just start to be seen above the regulator instead of the dark 
blue of the dyed alginate solution. This thin layer was presumably calcium chloride solution 
which had escaped up passed the regulator i.e. a backflow. The amount of calcium chloride 
solution above the regulator increased slowly over approximately the next 0.3 seconds to a 
few millimetres in height. Turbulence was easily seen in this evolving layer due to traces of 
the dyed alginate mixing with it. At approximately 0.8 seconds into its journey the regulator 
slowed abruptly whilst the clear calcium chloride layer above increased rapidly. The regulator 
carried on slowly up the tube in a staccato manner whilst ricochetting from side to side. The 
total time for the run from 'lift off' to the regulator leaving the field of view completely was in 
excess of 2.5 seconds (compared to the successful run under the same conditions which was
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2.2 seconds).
Examining the individual phases observed during the AVI "movie7 revealed great differences 
to the successful run except for phase I.
Phase I
As for the successful run there was no increase in the length of the alginate column until the 
regulator "lifted off". This suggests that the later failure was unlikely to have been caused by 
calcium chloride solution leaking between the regulator and injector nozzle prior to "lift off".
Phases II, III and IV
Following "lift off" there was a visibly slow journey up the barrel by the regulator with no 
discernible phase III i.e. phase II blended into phase IV with no visible change in velocity. 
Phase IV was abruptly ended by a rapid deceleration in the regulators velocity. After this 
"terminal event" the alginate-calcium chloride cross-linking zone was above the regulator and 
not at its trailing edge. Thus from approximately 0.8 seconds into the run, the regulator was 
propelled through the alginate gel precipitated above it, hence the highly staccato ascent 
from this moment on.
Previous unrelated experiments have demonstrated that a very irregular shaped "tube" can 
be produced even when no regulator element is present provided the flow is moderately slow 
(1 0 -2 0  mlsec'1), however, as the velocity of the linking agent increases, the more common 
occurrence was that the two reagents mixed and no precipitate was formed thus leaving an 
empty barrel. These previous observations possibly explain the two different alginate-calcium 
chloride interactions which were observed:
1. The initial mixing of the calcium chloride solution with the alginate solution 
above the regulator. The alginate probably failed to cross-link due to the high 
turbulence which was observed in the region immediately above the dome at 
the top of the regulator.
2. The AVI "movie" showed that once sufficient calcium chloride solution had 
accumulated above the regulator, the turbulence at the alginate-calcium 
chloride interface was much reduced. This was because the alginate~calcium 
chloride interface was now clear of the very turbulent zone immediately 
above the dome of the regulator. This reduced turbulence led to hydrogel 
precipitation and hence the staccato regulator movement as it tries to break 
through this rapidly forming barrier just ahead of it.
6.2.1.7.2 "Stills" analysis
Stills were selected at 0.2 second intervals and were combined into a time-distance study
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- see Figure 6.9 for a typical sequence of stills for a failed run. The collection of sequential 
images relate extremely well to the above detailed description of the "movie7. Detail; analysis 
of this data failed to add any further clarity to the "movie7 data.
6.2.1.8 Conclusions
The AVI's suggested that the most crucial moment in the process is the lift off of the regulator
-  ""opening snap"". Factors affecting this opening snap include the syringe driver, coupling of 
syringe to injector, fit between stainless steel tube injector and regulator, viscosity and head 
of alginate i.e. alginate level above the regulator, calcium chloride solution flow rate and 
syringe size used. These issues were each addressed and modifications where appropriate 
were incorporated into the semi-automated Mark II device and its operating procedure.
Since the Harvard PHD syringe driver produced flow rates comparable with the successful 
manually produced hydrogel tubes it was decided to persist with this driver. Furthermore, a 
thorough check of the market showed this to be one of the highest calibre units available. 
After checking its accuracy (by accurately weighing volumes of water delivered by the device 
and observing a very high agreement between the machine set value and the weight of water 
delivered over a recorded time period) it was decided to strip and rebuild the device exactly 
to the manufacturer's specifications since this information gave no indication about the initial 
volume delivered (i.e. at the opening snap) and the device in question had already had a 
fairly hard life. The mechanical part of the device consisted of a series of gear wheels and one 
toothed drive belt, all of which were stripped and reassembled in a manner aimed at reducing 
backlash in the device. Backlash was a possible cause for an irregular opening snap. The belt 
assembly had the most attention since this potentially could produce the most backlash in the 
device. It was noted that should the rebuild not cure the opening snap problem then replacing 
the belt set up with gear wheels was an option in order to reduce backlash. After the rebuild 
the accuracy of delivery was checked as before. Finally, all experiments were performed only 
after the pusher had moved a short distance in the driving (c.f. filling) direction in order to 
minimise any backlash in the drive mechanism and also to try to standardise the direction of 
deformity in the plastic syringe seal into the fluid delivery position.
All couplings between the device and the syringe were made either of Perspex or stainless 
steel in order to prevent wall distortion. Luer lock fittings were used wherever possible. The 
length and shape of the coupling appeared to be a factor but not the main factor. A straight 
coupling over 2 - 3 cm in length appeared to be better than a shorter coupling or coupling 
the device directly to the syringe. This is possible due to turbulent boundary layer effects 
persisting leading to non laminar flow in the device. The inlet length for laminar flow [L] to 
be re-established can be calculated from the equation:
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Figure 6.9
Stills selected at discrete time points (0.2 seconds apart) during the course of a typical failed tube forming run.
(Labelling as per Figure 16.1)
L = 0.0575 x Reynolds Number x diameter of the inlet
Where Reynolds Number = (fluid density x velocity x inlet diameter)/fluid viscosity.
As a direct consequence, the Mark II version was designed with a larger diameter of stainless 
steel injector nozzle (2.1 mm c.f. 1 mm for the Mark I). Also for the Mark II the fit between 
the regulator and the stainless steel injector was machined such that this was a totally loose fit 
with no discernable interference. Any friction here was perceived as potential to exacerbate/ 
cause the variable opening snap.
The percentage of alginate in solution was kept exactly as for the successful manually 
produced tubes. The viscosity was not measured for every batch, however, it was assumed to 
be relatively constant for a given percentage of a specific alginate made up in physiological 
saline and used at approximately the same temperature. Most of the study was carried out 
with either ISP Manugel or Fluka at 4% concentration in physiological saline made up to 
between pH 7.35 - 7.4. The head of alginate solution was kept constant by using the same 
volume of alginate solution that had performed best in the manual experiments i.e. 0.6 ml 
per experiment. Of the 6 ml, 0.5 ml was lost into the dead space of the device. The choice 
of pH was made on the basis that human arterial blood has a pH normally of 7.4 (The 
lower limit compatible with human life for more than a few hours is 6.8 with an upper limit 
of 8.0). Venous blood and interstitial fluids have a pH of approximately 7.35 due to the 
extra quantities of carbon dioxide that forms carbonic acid in these fluids. Intracellular pH 
normally ranges from 6.0 - 7.4 depending upon the cell type (Guyton and Hall, 2000). 
Using physiological saline at physiological pH was aimed at providing an environment with 
minimal adverse characteristics for cells when they are to be added in future experiments. 
Furthermore, both pH and monovalent cation concentration play a major role in the calcium 
divalent ion cross-linking mechanism. The volume of 0.6 ml was arrived at from calculation, 
the aim at this stage to make a 10 - 30 cm length tubes depending on the wall thickness.
Likewise, the calcium chloride solution was made using the same physiological saline that 
was used to produce the alginate solution. After adding the calcium chloride powder and 
thorough mixing, the final solution was again adjusted to give a pH in the human arterial 
blood physiological range of 7.35 -  7.4.
The calcium chloride solution flow, coupled with the choice of syringe type were clearly 
important issues. The manually produced tubes had mainly been produced using plastic Beckton 
Dickinson Plastipak 2.5 ml syringes injecting in 2 ml in a controlled and smooth manner. From 
the NAC HSV 500 camera system produced AVI's, the calcium chloride solution injection 
rate was again determined to be approximately 1.67 mlsec1 and this again corresponded 
well with our more successful syringe driver experiments. However, a 2.5 ml plastic syringe
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in the syringe driver failed to be able to deliver at this desired rate -  the maximum flow rate 
deliverable by the pump with a 2.5 ml syringe is 0.13 mlsec'1. The maximum flows for the 
PHD 2000 syringe driver is tabulated in Figure 6.10. All flows are in mlsec'1 since the device 
typically only requires a few ml to produce a hydrogel tube e.g. a 20 cm long tube with a 
4  mm outside diameter requires less than 10 ml of calcium chloride solution. From the data, 
it can be seen that only the 20 ml syringe doubled up, 60 ml, 100 ml and 140 ml syringes 
could deliver at the speeds required (i.e. 1.67 mlsec'1). However, 2 x 20 ml syringes failed to 
perform as well as 1 x 60 ml syringe both set ups delivering calcium chloride solution at the 
same rate. The reason being that the hydraulic pressure being generated by the syringe driver 
reduces as the syringe piston diameter increases. The approximate values were provided by 
the manufacturer of the syringe driver (Harvard Apparatus) - see Figure 6.11.
The pressure that a syringe pump can generate is a function of the force of the pump, diameter 
of the syringe and the overall set up e.g. syringe stiction and tubing diameter. Average pump 
pressure is calculated by dividing the average pump force (30 Kg for the PHD 2000 High 
powered version) by the surface area of the syringe piston. If two syringes are used the their 
respective surface areas are summed. Harvard Apparatus advised that:
•  Higher pressures may be achieved at minimum speed and lower pressures at 
maximum speed
•  Pump speed and force are inversely proportional
Given the ease and relatively low cost of supply of 50/60 ml plastic syringes compared to 
the bigger syringes, it seemed an obvious choice to continue with this syringe size. Two 20 
ml syringes did not seem to perform as well. This could possibly be due to turbulence created 
by the two flows meeting at the T-junction, however, the theoretical average pump pressures 
are very similar due to the near identical piston surface areas (2 x 20 ml -  575 mm2 c.f. 
1 x 50/60 -  519 mm2). The larger syringes (with their bigger piston diameters) have the 
advantage of running at lower pusher speeds for the same output and therefore more force is 
generated by the fluid. Another probable benefit of the larger diameter syringes is that since 
they deliver the same volume of linking solution per unit time a slower syringe driver pusher 
speed is required and therefore the period of time required to accelerate to this lower speed 
is less. Since this period of time is closely linked to the critical opening snap, this plays a 
significant role in whether a tube run is successful or not.
A comparison of syringe driver pusher speeds is tabulated in Figure 6.12. Thus using the 
Beckton Dickinson 50/60 syringes required the PHD 2000 syringe driver to work at its totally 
capacity in order to deliver the required 1.67 mlsec'1 of calcium chloride solution, whilst the 
Saco and Sherwood Medical largest syringe offerings due to their large piston surface areas 
required much slower pusher cruise velocities to deliver identical volumes over the same
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Syringe size
ml
Maximum flow rate
mlsec'1
Maximum flow rate 
achievable when coupling 
2 identical size syringes 
together via a non- 
deformable T-piece 
mlsec 1
1 0.06 0.11
2.5 0.13 0.26
5 0.36 0.73
10 0.53 1.05
20 0.91 1.83
50/60 1.78 3.56
100 3.04 6.08
140 3.68 7.36
Figure 6.10
Maximum flow rates for the Harvard PHD 2000 syringe driver when used in combination 
with either a single syringe or two identical sized syringes coupled together in parallel via 
a stainless steel T-piece.
Syringe piston diameter
mm
Nearest equivalent Becton 
Dickinson syringe size
ml
Average pump pressure
bar
Single syringe
<5 1 >69
10 2.5 32.8
15 10 14.6
25 50/60 5.2
Comparison: Single vs. dual 
syringes
1x23 1x25 5.4
2x 23 2x25 2.7
Figure 6.11
Comparison of various syringe piston diameters with average pump pressure for the 
Harvard PHD 2000 syringe driver.
(Data - Harvard Apparatus)
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Manufacturer/ 
syringe model
Piston diameter
mm
Required 
volume injected
mlsec1
Pusher speed
mmsec1
Fraction of 
maximum 
speed of PHD 
2000 syringe 
driver*
%
Beckton 
Dickinson 
Plastipak 50/60
25.7 1.67** 3.2** >100
Lux Bloc 50 ml 26.7 1.67 2.98 94
Saco 100 ml 34.9 1.67 1.75 55
Sherwood 
Medical 140 ml 38.4 1.67 1.43 45
Figure 6.12
Comparison of syringe driver pusher speeds for four different manufacturer's largest 
syringes.
"The PHD 2000 syringe driver has a maximum pusher speed of 3.17 mmsec1 
**Only just achievable given the PHD 2000's maximum pusher speed
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period of time.
6.3 Dynamic pressure recording studies
Prior to constructing an semi-automated Mark II system, it was decided to investigate further 
the perceived number one problem - the opening snap. i.e. the precise moment that the 
pusher in the syringe driver started to move coupled to the action of the regulator via a 
continuous column of liquid in a rigid tubular system (i.e. a non compressible linkage). It 
was therefore decided to study the pressure in the semi-automated Mark I system during the 
process of making a hydrogel tube.
6.3.1 Materials and methods
The semi-automated Mark I system comprised of; the PHD 2000 syringe driver was set up in 
a vertical position such that when a syringe was installed its opening was upper most. The 
syringe was coupled via a Luer fitting to a pressure transducer which was in turn coupled to 
the device i.e. the pressure transducer was in the direct path of the fluid going to the injector. 
The distance between the syringe nozzle outlet and the injector was significantly greater (90 
mm) than the minimum optimal length (20-30 mm) for this path due to the length of the AD 
Instruments pressure transducer fixing device.
The pressure transducer was an AD Instruments (Castle Hill, Australia) MLT844 device. It is 
a piezo-resistive device designed for measuring animal intravascular arterial and venous 
pressures via an indwelling vascular catheter. Its working range is minus 20 to plus 300 
mmHg. The transducer signal was amplified by connecting up to an ADInstuments ML110 
bridge amplifier. The ML110 is a single channel bridge amplifier with an claimed accuracy 
of + /- 1% and is capable of low pass filtering (1 - 2000 Hz in 8 steps) which is important 
for filtering out background signal. The bridge amplifier was connected to an ADInstruments 
PowerLab 4S Precording unit. This unit is capable of recording from 0 - 200,000 samples per 
second continuously to disk with further high and low pass filtering capability if required. The 
PowerLab was connected via a universal serial bus (USB) to an Apple Macintosh PowerBook 
G3 233 MHz computer running ADInstruments Chart software. This software allows the 
computer to act as a digital chart recorder that can simultaneously record and display data 
in real time, at a sampling rate of up to 200,000 per second.
At the start of the experiment the pressure recording system was calibrated using a mercury 
sphygmanometer at 0 and 300 mmHg. A series of experiments were carried out using 
the following standard equipment, reagents and conditions: a 4 mm diameter 20 cm long 
precision bore borosilicate glass barrel, a Mark I device, 3.5 mm diameter 1 cm long regulator, 
2% calcium chloride solution (normal physiological saline at pH 7.4), room temperature
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(approximately 21 °C), calcium chloride solution flow rate of 100 mlmin'1, Fluka alginate 
solutions were prepared in normal physiological saline at pH 7.4 and 0.6 ml of alginate 
solution was injected per experiment. Syringe types and alginate solution concentrations 
were then varied.
6.3.2 Results
All the experiments performed produced a characteristic pressure trace over time, see Figure 
6.13 for a typical trace. Figure 6.14 depicts major components of the characteristic traces 
with the associated labelling of the trace defined in Figure 6.15.
Standard plastic Becton Dickinson 50/60 ml syringes were initially tried with 3% alginate 
solution. The resulting pressure traces were highly variable, but did have the characteristic 
overall shape described above. Keeping everything else the same, the plastic syringe was 
substituted with a Lux Bloc (Italy) glass 50 ml syringe with Luer lock fitting. The subsequent 
traces were all near identical in both overall shape and magnitude -  a unique and highly 
reproducible fingerprint was observed for that set of conditions. Measurement of the wall 
thickness with a micrometer gauge after slitting the tube longitudinally revealed a wall 
thickness of approximately 200 pm at selected points along its length. Furthermore, the glass 
syringe runs worked 100% of the time with no regulator stalling. It would appear that a major 
component of the previously experienced reproducibility was due to stiction in the plastic 
syringes i.e. the deformability of the plastic seal against the wall of the syringe. Another 
factor may have been the slight out of alignment of the syringe driver pusher and the plunger 
shaft of the syringe. A plastic syringe plunger is only supported in its syringe body by the seal 
whereas a glass syringe plunger is supported along its entire length thus preventing pivoting 
at the seal.
Having established glass syringes as the new "gold standard" further pressure experiments 
were only carried out using the same Lux Bloc glass syringe. These included varying the alginate 
percentages. Three different percentages were; 1%, 2% and 3% and all in physiological 
saline at pH 7.4. All had unique and highly reproducible fingerprint pressure tracings. See 
Figure 6.16 for a summary of the results and Figure 6.17 and Figure 6.18 for graphical 
representation.
6.3.3 Discussion
Closer examination of the data for each of the four different sets of experiments above 
suggested that:
1. Becton Dickinson 50/60 ml plastic syringe -  3% alginate solution
Overall the data was extremely variable. Opening snap pressures were on average much
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Figure 6.13
Example of a typical pressure trace recorded using the ADInstruments system (Apple OS
9.2 screen shot).
Pressure is recorded on the y axis against time on the x axis. Particular example is for a 
50/60 ml Beckton Dickinson Plastipak syringe injecting calcium chloride solution at 1.67 
mlsec1 in order to cross-link 3% Fluka alginate solution.
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Figure 6.14
Schematic of a characteristic pressure trace against time for a complete tube forming 
run.
See table - Figure 6.15 for explanation of labels.
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Letter Description of graph Position or action of regulator
a Zero mmHg System primed and loaded
b Point of inflection Syringe started -  regulator still on injector
c Steep upward gradient as pressure rises quickly Regulator still on injector -  No movement
d Peak Opening snap -  the moment the regulator lifts off the injector
e Steep downward gradient as pressure falls
Regulator rapidly propelled up the barrel 
-  initially quickly accelerates and then slows
f Trough Regulator at its slowest velocity during ascent
g Upward gradient Regulator accelerates
h Inflection point Regulator attains its "cruising speed"
i Plateau "Cruising"
i Inflection point Regulator at moment of leaving barrel
k Downward gradient Pressure drops as no regulator element in barrel
1 Inflection point Pressure release overshoot
m Upward gradient Stabilisation of system
n Inflection point Return to new baseline pressure level
o Plateau Plateau (above zero mmHg) due to retained column of calcium chloride solution in the device
Figure 6.15
Labelling for characteristic pressure trace depicted in Figure 6.14.
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Experimental
conditions
Number of runs
(n)
Range of point 
d (First peak) 
[Opening snap]
mmHg
Average of point 
d (First peak)
mmHg
Range of 
duration of run 
(points j minus b)
secs
Average duration 
of run (points j 
minus b)
secs
Range of integral 
value under the 
curve from points
b - j
Average of 
integral value 
under the curve 
from points b - j
50/60 ml plastic 
B-D syringe 
-  3% alginate
6* 149 - >300** N /A 1.65-3.29 2.11 92 - 249 171
50 ml Lux Bloc 
glass syringe 
-  3% alginate
6 165-168 167 1.51 - 1.54 1.53 8 7 -9 0 89
50 ml Lux Bloc 
glass syringe 
-  2% alginate
3 60-61 60 1.54 - 1.58 1.56 71 -76 74
50 ml Lux Bloc 
glass syringe 
-  1% alginate
3 5 7 -6 0 58 1.56-1.61 1.59 7 0 -7 5 73
* O n ly  successful runs are included out o f the 10 runs performed in total -  4  o f which failed 
** Values out o f calibrated range
6.16
Summary of the AVInstruments system generated data.
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Average opening snap pressure with respect to alginate solution concentration.
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Average duration of tube forming run with respect to alginate solution concentration.
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higher (> 200 mmHg) and very much more variable than the glass syringe experiments. 
Frequently the opening snap pressure exceeded the 300 mmHg limit of the transducer's 
calibration. The overall time to produce a tube was also on average much longer (>2 seconds 
compared to the 1.5 seconds taken using the glass syringe) and very much more variable 
than the glass syringe experiments. The duration of runs varied from 1.65 - 3.29 seconds, 
a much greater range than the 1.5 - 1.6 range typically displayed by the glass syringe 
experiments. The graphs produced with the plastic syringe all had points f - h combined i.e. 
there was no f trough. The pressure therefore dropped from the opening snap pressure to 
the plateau pressure (i) with no overshoot. The plateau had an average pressure in the order 
of 60 mmHg. Overall the h - j plateau undulated in a sine wave pattern and had a slight 
negative gradient.
2. Lux Bloc 50 ml glass syringe -  3% alginate solution
The characteristic a - o graph was observed, with now repeatable values e.g. opening snap 
values ranging from 165 - 168 mmHg and duration of runs ranging from 1.51 - 1.54 
seconds. These values are much tighter grouped than for the equivalent plastic syringe values. 
Similarities to the plastic syringe date included:
• h -  j plateau showed a sine wave pattern.
• h -  j plateau had a pressure in the order of 60 mmHg.
• Slightly negative overall gradient of h - j plateau.
3. Lux Bloc 50 ml glass syringe -  2% alginate solution
The characteristic a - o graph was again observed, with highly repeatable values. The opening 
snaps were in the range 60 - 61 mmHg with run duration times very similar to the 3% alginate 
solution and glass syringe experiments. Once again the plateau showed a sine wave pattern 
and had an average pressure in the order of 60 mmHg. However, the opening snap pressure 
(d) was a similar size to the average plateau pressure and interestingly the average gradient 
of the plateau (60 mmHg) was overall slightly positive.
4. Lux Bloc 50 ml glass syringe -  1% alginate solution
Data and a - o graphs were nearly identical to the Lux Bloc 50 ml glass syringe - 2% alginate 
experiment. The only minor difference being a slightly lower value for the opening snap (d)
i.e. 58 c.f. 60 mmHg. Overlaying graphs produced by the 1 % and 2% alginate solution runs 
confirmed near identical traces from points f - o.
6.3.4 Conclusions
The dynamic pressure experiments diagnosed the major cause of the erratic performance to 
be due to the plastic syringes and that a substituting the plastic syringe by a glass syringe 
improved reliability greatly.
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The viscosity of the alginate solution was a major factor affecting the opening snap pressure, 
with a major transition from 2% to 3% (60 c.f. 167 mmHg). 1% and 2% showed no real 
difference.
The ideal pressure trace would probably be a square wave i.e. a very rapid rise in pressure, 
followed by a plateau, followed by a rapid fall in pressure. See Figure 6.19 which uses the 
same labelling as Figure 6.14 for consistency.
Presently, only the plateau and the rapid drop in pressure have been demonstrated by 
the system using the Lux Bloc syringe system. The 1 % and 2% Fluke alginate solutions best 
approximate to the ideal square wave graph in that their opening snap pressure is very 
similar in value to the plateau and both have the "ideal" h - o part of the curve.
6.3.5 Future Work
On the basis of the conclusions drawn from both the digital high speed video imaging and 
the dynamic pressure recordings, the semi-automated Mark II system was designed and 
fabricated - see Section 6.4. However, to more fully understand the dynamics of the various 
semi-automated fluid driven devices in the future it will be necessary to simultaneously combine 
continuous pressure recording and high speed digital imaging and correlate the data, for 
example, to precisely locate the position of the regulator in time and space compared to the 
pressure trace. This probably is best done using a second channel on the AD Instruments 
PowerLab, so that a high speed camera can record simultaneously with the pressure recorder. 
This may better elucidate whether the sine wave pattern superimposed on the h - j plateau 
is real or an artefact. Also simultaneous pressure and flow rate monitoring would also be of 
great value e.g. using a Transonic flow rate detector (Transonic Systems, Ithaca, NY, USA) 
which can be plugged directly into the AD Instruments PowerLab system.
Finally, it may be possible that by better understanding of the pressure trace and achieving 
a high level of reproducibility that the trace could be used in real time to predict whether a 
particular hydrogel tube is of an acceptable quality during its fabrication rather than trying 
to image the entire tube for flaws post production. The expensive component, the transducer 
e.g. AD Instruments MLT844 Pressure Transducer (>£400) merely clips onto a disposable 
Perspex/plastic part of the circuit e.g. AD Instruments MLA844 Disposable Clip-On Blood 
Pressure Domes (<£7) to get the readings. By incorporating this low cost disposable part 
into the bioreactor circuit allows not only tube production monitoring but also intraculturing 
pressure monitoring of the sealed bioreactor e.g. pulsatile flow monitoring.
[One other option which was successfully trialed but not incorporated into the final Mark II 
System was to control the pressure above the alginate solution. For example, it was possible to
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Zero
Zero
Time (seconds)
M  Ideal pressure trace
Charachteristic pressure trace
Figure 6.19
Schematic of a ideal pressure trace against time - characteristic pressure trace in 
background for comparison.
(Labelling is exactly the same as fo r Figure 6.14).
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produce a tubular construct by just applying a negative pressure above the alginate solution 
without the regular drive syringe, thus drawing the liquids and regulator up the tube. It 
may eventually prove necessary to control pressure simultaneously both above and below 
the liquids/regulator (i.e. a balanced push-pull arrangement) to get the very high level of 
reproducibility required for clinical grade constructs.]
6.4 Semi-automated Mark II System
6.4.1 Materials and methods
The semi-automated Mark II fluid driven device was fabricated incorporating the knowledge 
gained from digital high speed video imaging and the dynamic pressure studies together 
with a number of additional experiments to improve the shape of the regulator. All the 
previous regulators had been missile-shaped i.e. pointed at one end and with fins at the 
other. The fins (3 - 4) were long enough to touch the inner wall of the barrel and thus 
give the missile shaped regulator increased stability by establishing a loose interference 
fit between barrel and regulator. However, frequently ricocheting would produced a failed 
fabrication run. Many of the overall designs e.g. diameter to length ratios were adapted 
from established designs described by Nielsen (Neilsen, 1960). The majority of these designs 
were for travel through air after being launched off a purpose made pad using their own 
power and not through alginate in a barrel using fluid drive. It was therefore decided to 
experiment with other regulator shapes. The idea was therefore to go back to basics, since 
complex missile regulators were also very demanding to fabricate and delicate to handle e.g. 
thorough cleaning between fabrication runs. The round cannonball regulator was therefore 
considered. A collection of different ball regulators were used with the Mark II device. After 
many experiments, it emerged that the ball regulator was highly suitable to the application if 
it were precision-made and had a specific gravity of less than 1 (The ratio of the weight of the 
moulded piece as compared to the weight of an equal volume of water ASTM D792) . The 
Mark II device therefore differed from its predecessors in that instead of a stub which inserted 
into the base of the missile-shaped regulator, an egg-cup arrangement was present for the 
ball to sit in (loose interference fit) prior to a fabrication run.
The ball regulators used were 3.4 mm diameter high density polyethylene (HDPE) and 3.175 
mm diameter polypropylene (Precision Plastic Ball Company, llkey, West Yorkshire, UK). Both 
types were precision manufactured to + /-10 pM. Of particular importance was their specific 
gravity which was 0.96 and 0.92 respectively (earlier attempts with precision-made balls of 
denser materials had all conclusively failed including polystyrene (1.05) and nylon (1.01)). 
The reagents were 1 % solutions of sodium alginate (Manugel DMB) made up in physiological 
saline and 2% calcium chloride solutions.
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Figure 6.20 shows a photograph of the complete Mark II system with Figure 6.21 being a 
close-up view of the base unit demonstrating the ball and egg-cup arrangement. Aside from 
the use of a ball regulator the only other significant diversion from the Mark I device was 
the use of a Saco 100 ml glass syringe instead of the original 60 ml plastic Becton Dickinson 
syringe resulting in the requirement for far slower syringe pusher speeds (45% less - see Figure 
6.12). The device was used in an identical manner to the Mark I except that the syringe driver 
was run at 20mlmin'1 thus reducing the pusher speed further. Dynamic pressure recording 
studies had suggested that slower pusher speeds lead to improved inter-run consistency.
Experiments were carried out with a rule attached directly behind the glass barrel (as per 
the digital high speed video imaging experiments), known volumes of alginate solution with 
added colouring to aid viewing were loaded into the device using either a 0.5 or 1 ml 
precision ground glass syringe (Hamilton, Reno, NV, USA) and a tube then fabricated. The 
distance to the exact point that the ball just started to brake through the air/alginate interface 
(i.e. at the point that the alginate solution reservoir above the regulator was exhausted) was 
recorded. A number of the runs were also imaged using the high speed video equipment as 
before to confirm consistency of regulator progress within the barrel. Finally a small number 
of samples were imaged using optical coherence tomograpy (OCT) to confirm consistent wall 
dimensions - see Chapter 9. This final piece of research with the Mark II semi-automated 
system was in collaboration with Garr Chau (UCL).
6.4.2 Results and discussion
Figure 6.22 shows the data for different volumes of alginate solution (200 - 800 pi) and the 
maximum length of tube that was fabricated when using the 4 mm inside diameter barrel/3.4 
mm regulator combination. The graph shows a highly linear relationship over the entire 
range of values. When extrapolated, the graph cuts the x axis at 87 pm, this figure represents 
a combination of the physical dead-space in the device's base unit plus the contribution from 
the plug of alginate around the egg-cup securing the tube (The switch from a stub/missile to 
a ball/egg-cup arrangement not only improved tube consistency but also greatly improved 
tube attachment at its proximal end). Further experiments were performed to study the effect 
of different ball sizes (see Figure 6.23) and different barrel diameters (see Figure 6.24). All 
the experiments resulted in linear relationships between the volume of alginate used and the 
maximum length of the resulting tube suggesting a consistent wall thickness (this was later 
confirmed for a number of samples using OCT - see Chapter 9). The lines of best fit for each 
distinct set of barrel/regulator combination however all had different gradients reflecting the 
rate the alginate solution flowed past the regulator as it travelled up the barrel. This difference 
in rate of flow past the regulator results in tubes of different wall thickness. Thus by changing 
the barrel/regulator combination alginate constructs of different diameter and wall thickness
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Figure 6.20
Semi-automated Mark II System.
(Photographer: Dave Sayer - ©  The Wellcome Trust Medical Photographic Library - 2005)
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Figure 6.21
Semi-automated Mark II device - base unit only.
Left-hand image - Empty egg-cup. Right-hand image with ball regulator in situ. 
(Photographer: Dave Sayer - ©  The W ellcome Trust M edical Photographic Library - 2005)
350
300
250
200
"o
3>c
150
_a>
E3
E
I
100
0 100 200 300 400 500 600 700 800
Volume of alginate loaded into device
I 4* 14 mm I/D  barrel + 3.4 mm ball
Figure 6.22
Graph of data generated using the combination of a 4 mm inside diameter barrel and
3.4 mm regulator ball (n = 21) demonstrating the linear relationship between the 
quantity of alginate loaded into the device and maximum length of tube formed.
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Graph indicating the effect of change in regulator ball diameter when the barrel 
dimensions remain constant.
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Graph indicating the effect of change in internal diameter of the barrel when the ball 
regulator dimensions remain constant.
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can be constructed. Overall the Mark II system greatly improved the fabrication success rate 
(approaching 100%) and tube physical consistency regardless of inside tube diameter and/ 
or regulator ball diameter.
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7.0 Cell - alginate constructs
7.1 Overview
One of the aims of this thesis was to produce constructs consisting of a homogeneous 
distribution of cells and supporting polymer matrix in contrast to the almost universal tissue 
engineering approach of adding cells to a preformed scaffold e.g. Niklason etal, 1999. This 
approach tends to result in an incomplete, non-homogeneous distribution plus large amounts 
of cell wastage - only approximately 10% of the cells enter a preformed tubular scaffold, 
(Taylor, 2000). Also in order to be easily automated, one potential option is that all the stages 
prior to the actual homogeneous cell/polymer construct being fabricated are fluid in nature.
In order to successfully produce a tissue engineering construct from cells premixed with a 
polymer prior to scaffold formation, the following criteria with regard to the cells must be 
met:
1. Cells must be viable after the three-dimensional scaffold formation process 
is complete. Furthermore they must not be permanently damaged e.g. 
permanent change of phenotype
2. Anchorage dependent cells must be capable of interacting with the scaffold 
material after the formation process e.g. attach, elongate and correctly 
orientate
3. Cells must be capable of interacting with one another after the formation 
process
4. Mass transfer of nutrients, dissolved C 02/ 0 2 and intercellular messenger 
signals must be adequate
5. Cells must be capable of synthesising normal extracellular matrix
6. Adequate strength of extracellular matrix must be achieved prior to predictable/ 
controlled polymer degradation
Since artery was the chosen tissue for the project, the strategy adopted was to attempt to 
grow a uniform tube composed of vascular smooth muscle and extracellular matrix which 
could then be seeded with endothelial cells. A series of experiments was therefore planned 
to evaluate the potential to grow smooth muscle cells or potential smooth muscle cells (stem 
cells) in alginate and also to evaluate the potential to use these cells mixed with alginate 
solution in the tube fabrication devices i.e. the float activated by a pneumatically driven piston 
device, the float activated by hand driven fluid device and the float activated by pump driven 
device.
The initial choice of smooth muscle cells included: commercial immortalised animal cell lines, 
commercial human non-immortalised cell lines and human or animal explants. The choice of
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stem cells included both embryonic and adult stem cell again of human or animal origin.
Probably for the near future, autologous explants will be the cell lines of choice for the clinic 
for most organs apart from possibly skin. In the long term, the ideal might be "genetically 
modified universal non-immunogenic cell lines". The disadvantages of using explant material 
at this stage in the research is the lack of reproducibility between explant material. Human 
explant material available for basic research can only be obtained as "clinical surplus" 
from surgical operations, provided proper ethical permission is obtained beforehand. Such 
material is therefore not in large supply and only limited numbers of cells can be obtained 
for culturing. Furthermore, using such cells, only a finite number of passages is possible 
(Grunwald etal, 1983). This effectively means that only a few experiments per patient sample 
would be possible and since there is known to be significant variability between individuals7 
cells, reproducibility of experiments would be limited.
Commercial human non-immortalised cells lines are an option since the cells are obtained 
from a cadaver which allows a much greater number to be harvested. Unfortunately these 
cell lines are relatively expensive and again the cell type of interest, smooth muscle cells do 
not possess long term vigorous growth over multiple passages.
The option chosen for initial experiments was an immortalised animal cell line. Whilst being 
better in terms of cost, safety and availability, two distinct drawbacks were present:
• Immortalised cells behave differently to their non immortalised form, plus there is a 
potential to mutate further between passages
• Animal cells behave differently to human cells
Overall, however, the choice of an immortalised cell line does provide a potentially excellent 
model for the above work. The plan was to start with such a cell line and then progress on to 
human non-immortalised cell lines and/or stem cells.
Later, using the alginate tube forming devices described previously, a series of cell based 
experiments were performed using either immortalised rat smooth muscle cells or human 
adult mesenchymal stem cells (MSCs). Whilst the above cell types were selected on the basis 
that the project was to grow coronary artery, in fact all hollow organs (excluding bone) 
are predominantly composed of smooth muscle cells and extracellular matrix with a layer 
of epithelial cells (endothelium in the case blood vessels) on their lumen wall, i.e. there is a 
common architecture between hollow visceral organs. Thus, a universal platform technology 
is potentially possible for all soft tissue tubular structures e.g. gastrointestinal tract and urinary 
tract.
A generalised overview of the experimental procedure is depicted in a flow chart - see Figure
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3.1. The materials and methods are fully described in Chapter 3. Some of the extended time 
course experiments were conducted with Julia Markusen (UCL).
For all the experiments (bar 1 preliminary experiment), one of two cell lines has been 
employed:
• Immortalised rat embryonic smooth muscle cells
• Adult human mesenchymal stem cells
7.1.1 Immortalised rat embryonic smooth muscle cells
Initial experiments were performed using an immortalised rat smooth muscle cell line - A7r5 
(American Type Culture Collection, Manassas, Virginia, USA. Catalogue Number CRL- 
1444). A7r5 is a rat embryonic smooth muscle cell line derived from thoracic aorta and 
immortalised using chick embryo extract (Kimes and Brandt, 1976). Kimes and Brandt minced 
thoracic aortas and then placed them in media containing 20% fetal calf serum (FCS) and 
2% chicken embryo extract (CEE) and incubated at 37°C. After these primary cultures had 
become nearly confluent, they were enzymatically dissociated in to single cell suspensions. 
These cells were then replated in fresh culture dishes. After 40 - 90 minutes, approximately 
90% of the cells had become attached to the dish. The floating cells were aspirated and 
transferred to a new dish where they were allowed to attach to the dish and to grow to 
confluency. They were then passaged again. Each successive passage of these cells was 
accomplished in an identical manner until the increased multiplication rate of the cells in the 
culture indicated that a cell line had become established. This method of obtaining muscle cell 
lines is known as "selective serial passaging" and is based on the observation that for some 
types of muscle cells, fibroblasts and endothelial cells have a faster rate of attachment to the 
surface of tissue culture flasks than myoblasts (Yaffe, 1968 and Blondel et al, 1971). Once a 
cell line had emerged, the CEE was omitted from the medium. From each cell line, individual 
clonal cell lines were subsequently obtained including cell line A7r5, by isolating colonies 
derived from single cells. Cell line A7r5 was reported to have been grown under continuous 
cell culture conditions for over one year with no change in morphology, biochemistry or 
physiology properties. Characterisation of A7r5 suggested that A7r5 was a muscle cell line 
due to electrophysiological studies (capable of generating overshooting action potentials) and 
biochemical studies (synthesis of creatine phosphokinase-MM isoenzyme c.f. the BB dimer 
found in fibroblasts and neurones plus the ratio of myokinasexreatine phosphokinase activity 
is comparable with other established muscle cell lines, (Kimes and Brandt, 1976)). With 
this data and because the A7r5 line was derived from aorta, Kimes and Brandt therefore 
hypothesised that the cell line was smooth muscle. Their hypothesis was further supported 
by ultrastructural studies of internal cellular architecture including visualising the presence of 
bands of thin filaments (6 - 8 nm) orientated in parallel to the long axis of the cell - a feature
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commonly observed in smooth muscle both in vivo and in vitro. However, the studies did 
reveal that the contractile mechanism of the cells appeared to be underdeveloped and at no 
stage did Kimes and Brandt witness cell contraction. A7r5's ultrastructure also set it aside 
from both cardiac and skeletal muscle. Interestingly, later studies by other researchers have 
elicited contraction of A7r5 cells (Fultz et al, 2000 and Fultz and Wright, 2003).
The A7r5 cell line was chosen because it was an immortalised well characterised adult rat 
aortic cell line with over 300 published papers (Ovid Medline search from 1966 to 2001), plus 
being immortalised it would provide more reproducible cell growth over multiple passages 
which would reduce inter-experimental variation such as would occur with explant material. 
It is only possible to perform a few limited experiments with cells obtained from original 
patient material due to smooth muscle cell's limited potential to divide. Furthermore the ATCC 
A7r5 cell line was certified free of various pathogens. The morphology of the commercially 
available A7r5 cells has been described as "fibroblastic" (ATCC specification sheet) and 
"flat 'ribbon-like' cells differentiating to parallel arrays of spindle shaped cells" (European 
Collection of Animal Cell Cultures - specification sheet for A7r5 in their collection - ECACC 
86050803).
7.1.2 Adult human mesenchymal stem cells
The human adult mesenchymal stem cells (MSCs) were kindly provided by Professor Chris 
Boshoff and his group (The Wolfson Institute for Biomedical Research, UCL, London, UK). The 
MSCs were surplus clinical material obtained from bone marrow aspirates from live related 
donors of patients awaiting bone marrow transplants following high dose chemotherapy 
treatment. All the appropriate ethics committee approvals were in place at UCLH. MSC cells 
were isolated from the bone marrow aspirate using a Ficoll gradient as described in Section
3.1. The MSCs were selected on the basis of being anchorage dependent cells which would 
attach to polystyrene tissue culture flasks and negative for surface marker CD34. In contrast, 
bone marrow derived haemopoietic stem cells do not attach to polystyrene flasks and are 
CD34+ve. The rationale for using MSCs was that unlike explant material their vigour to grow 
and divide over multiple passages was better, although not infinite (Kobune et al, 2003 and 
Zimmermann et al, 2003). The aim of using MSCs was to add them to the alginate solution, 
produce a homogeneous mixture prior to forming a homogeneous tube and then to correctly 
orientate/align the stem cells prior to permanently differentiating them into smooth muscle 
cells, ideally coronary artery smooth muscle cells. [Provisional data had suggested that it was 
possible to switch MSCs in a three-dimensional alginate matrix into smooth muscle using 
preconditioned media and a patent filed (Mason et al, 2003)]
7.1.3 Cell and polymer mixing
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In order to produce adequate numbers of A7r5 and MSC cells, for example, a typical 
experiment required 106 -107 cells per ml of alginate solution, the cell lines were cultured 
using the techniques described in Sections 3.1 and 3.2. Known quantities of cells in known 
volumes of culture medium were added to known volumes of alginate solutions to produce 
desired cell/alginate concentrations.
A basic requirement, was that the cell mixing with alginate process needed to result in a 
totally homogeneous cell distribution, with no clumps and little (ideally zero) cell death. 
Furthermore, early range-finding experiments had demonstrated that final cell densities less 
than 105 cells per ml of alginate were distributed very sparsely in the finished scaffold i.e. 
allowing no cell-cell contact. Close proximity of the cells was deemed a prerequisite. This 
only occurred at 106 cells per ml of alginate and greater. The techniques employed to produce 
cell concentrations greater than 106 cells per ml of alginate are described in Section 3.2. Final 
mixing was by using the repeated action of a manual micropipette. This final step does not 
lend itself to robust reproducibility and is highly operator dependant. Therefore other options 
were sought.
An alternative to using a micropipette to create a homogeneous cell/alginate solution is a 
static mixer e.g. Kenics mixer. This type of mixer consists of a series of elements within a 
tube. The helical mixing elements direct the flow of material radially toward the tube walls 
and back to the centre. Additional velocity reversal and flow division results from combining 
alternating clockwise and counter clockwise elements, thus increasing mixing efficiency. The 
greater the number of elements the greater the degree of mixing. The advantage of this system 
is that it is an in-line mixing system (ideal for automation) and the device produced shear 
forces which are very low and therefore theoretically cell friendly. A Kenics mixer of 192 
mm in length, 4.8 mm O /D , 3.5 mm I/D  made of surgical grade stainless steel containing 
32 elements (Chemineer Kenics, North Andover, Massachusetts, USA - Part number 37-03- 
075) was tried. However, whilst its mixing ability was never in doubt its construction was not 
suitable for multiple cell experiments in quick succession. The reason being that the elements 
are sealed (welded) into the 22 gauge tube thus making thorough cleaning and sterilisation 
between runs impossible. Furthermore, the volume lost by being retained in the device and 
its associated tubing was unacceptable (>1 ml, equating to > 106 cells lost per experiment). 
Whilst in the long term static mixers may well be the way forward since they can be put in-line 
with the tube forming device and since at present no simple plastic sterile disposable versions 
were available, it was decided to continue with the manual cell/alginate mixing using a 
micropipette and gentle aspiration and keep reviewing the availability of sterile disposable 
static mixers.
(As of early 2004, disposable static mixers have become available from: TAH Industries
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(Robbinsville, New Jersey, USA). The smallest diameter device in their range is a 2.36 mm 
element diameter device with either 8 or 12 elements resulting in retained volumes of 0.07 ml 
and 0.1 ml respectively). Individual mixing elements are also available from TAH, allowing a 
bespoke mixer to be fabricated.)
7.1.4 Alginate Polymer
A variety of different manufacturers7 alginate products has been obtained as potential 
candidate polymers during the course of developing the alginate tube forming devices. These 
alginates therefore continued to be used for the cell/alginate work since the tube forming 
device development and the cell/alginate research experiments were running in parallel.
The choice of aqueous solvent was limited by certain key parameters including being 
cell friendly and maintaining scaffold integrity. Typically, alginate powder was added to 
physiological saline in final concentrations ranging from 0.5 - 6%. Ideally the lowest alginate 
concentration that produces the desired structural strength needs to be used since it has 
been shown that increasing alginate concentration decreases diffusion across the hydrogel 
(Martinsen et al, 1992). Preliminary experiments had demonstrated that if water for injection 
(WFI - BioWhittaker, Walkersville, Maryland, USA) was used instead of physiological saline, 
then upon mixing the alginate solution and cells, cell lysis would quickly ensue. This was 
due to the hypotonic nature of the solution relative to the cell cytoplasm. PBS with or without 
calcium ions/magnesium ions, (Dulbecco7s Phosphate Buffered Saline, DPBS) (BioWhittaker, 
Walkersville, Maryland, USA), was also originally tried since it had the correct osmolarity 
and pH; but when DPBS alginate solution came into contact with the calcium chloride cross- 
linking agent, the calcium was precipitated thus reducing available calcium ions for cross- 
linking and therefore significantly weakening the hydrogel construct. Furthermore, calcium 
insoluble precipitates are undesirable in the construct since calcium has a physiological effect 
on smooth muscle cells e.g. causes them to contract. This effect is not desirable during the 
proliferation and growth phase as it is necessary for the smooth muscle cells to spread out i.e. 
elongate in order to form good cell-cell interactions throughout the construct.
The reagents and alginate solution preparation techniques are described in Section 3.3.
7.2 Producing three-dimensional cell/alginate hydrogel structures
Three distinct three-dimensional cell/alginate structures were produced for experimental 
studies:
•  Flat sheets
• Round beads
• Hollow tubes
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Studies on these three-dimensional constructs included cell survival assays (trypan blue dye 
or live/dead viability/cytotoxicity kits (Molecular Probes L-3224, Molecular Probes, Eugene, 
Oregon, USA) cytology and optical coherence tomography.
7.2.1 Flat sheets
The simplest of the structures produced were flat sheets. These structures either had cells 
embedded in them or cells added immediately after the gels had totally set. These sheets were 
primarily used in order to study the interaction between the polymer surface and the cells e.g. 
attachment. The sheets were produced by the method described in Section 3.4.1.
7.2.2 Beads
The next more complicated three-dimensional structure produced was alginate/cell beads i.e 
cells immobilised in alginate beads. Cell encapsulation using alginate has a long and rich 
literature (Martinsen etal, 1989).
Virtually every mammalian cell has been encapsulated, although the literature at the time did 
not include any references to smooth muscle cells for reasons which later become apparent, 
(Uludag et al, 2000). The potential advantage of bead studies was that the three-dimensional 
structures have embedded cells whilst using minimal material, effectively a microscale down 
version of the desired tube experiments e.g. 600 pL of alginate will produce one 25 cm tube 
with a wall thickness of approximately 150 pm (allowing for losses within the tube forming 
device). Whereas the same 600 pL will produce well over 100 beads of approximately 2 mm 
in diameter (also allowing for losses within the bead making device). Thus effectively 100 
parallel experiments can be performed with the same 600 pL sample volume. The manual 
bead fabrication technique is described in Section 3.4.2.
The potential drawbacks to beads produced manually using a small bore needle and syringe 
include possible mass transfer problems due to the distance from the bead's surface to centre 
plus manually fabricated beads lack uniformity of shape and size. After experimenting with a 
range of needle sizes it appeared that the smallest diameter bead which could be manufactured 
using the manual technique was 2 mm + /- 20%. It was therefore decided to switch to an 
automated method built in collaboration with Dr. Julian Mason (Kingston University, Kingston, 
Surrey). All later experiments were performed with an automated bead forming devices since 
beads could be made in the range 100 pm and upwards. This reduction in bead diameter 
improved mass transfer through the individual beads whilst also allowing increased numbers 
of parallel experiments to be performed for a given volume of cell/alginate solution.
In order to assess the number of cells contained in the beads plus also their variability it 
was essential to be able to free them from the alginate. Placing beads in 0.1 M sodium
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citrate (Sigma, St. Louis, Maryland, USA) resulted in the excess number of sodium ions 
competing with the far fewer calcium cross-linking ions resulting in the alginate hydrogel 
quickly becoming a liquid once again, thus releasing the cells. Once freed, the cells were 
counted using the Improve Neurbauer Haemocytometer as previously described in Section
3.2. The ratio of live:dead cells was important in determining the viability of the cells. It 
is worth noting that the trypan blue stain dye only reflects the status of the cell membrane 
and not any long term detrimental changes which may have taken place e.g. commencing 
apoptosis. Possible ways to monitor this include DNA microarrays and/or two-dimensional 
protein gel electrophoresis (Boshoff, 2003). Finally, the culture media used for these microwell 
experiments was typically the supplemented media previously described or aMEM (minimal 
essential media with ribonucleasides and deoxyribonudeasides) (Gibco-BRL, Gathersburg, 
Maryland, USA). This alternative media was used following a personal communication with 
Dr Clare Seldon (2000) who had had extensive experience in the encapsulation of liver 
cells in alginate whilst fabricating extra-corporal liver assist devices (Seldon et al, 1998 and 
Seldon et al, 1999 and Seldon et al, 2000 and Khalil et al, 2001) and with whom we briefly 
collaborated.
7.2.3 Tubes
Since the aim of the research was to produce tissue engineered vessels it was essential to 
produce cell/media/alginate hydrogel tubes. All the devices previously described (excluding 
the initial powder spraying research - which for the sake of brevity is not included in this 
Thesis) were used in all their various forms as they evolved. The first preliminary studies were 
performed with Professor Ian Charles and his group (The Wolfson Institute for Biomedical 
Research, UCL, London, UK) using their genetically engineered tetracycline-inducible nitric 
oxide generating cell line (T-Rex 293 clone 22). This is a human transformed primary 
embryonal kidney cell line (Xu et al, 2002). The nitrite concentration of the surrounding 
growth medium was used as a reflection of the nitric oxide (NO) produced by the cells. The 
nitrite concentration was determined using the Greiss reaction (1% sulfanilamide, 0.1% n- 
1 -naphthylene diamine dihydrochloride). Absorbance was then measured at 540 nm using 
sodium nitrite as a standard. The tube fabrication process used the original device, whereby 
the float is activated by a pneumatically driven piston, the method is described in Section 
3.4.3. The combination of the 9 mm inside diameter/14 cm long glass forming tube together 
with an 8.5 mm diameter regulator was used. The control consisted of T-Rex 293 clone 22 cells 
encapsulated in manually produced alginate beads (1% Fluka) - made from the same batch 
of homogeneously mixed cells and alginate as that used to fabricate the tubes. The identical 
cross-linking conditions were employed (1% calcium chloride solution for 20 minutes). After 
fabrication the tubes were cut using a scapel blade into approximately 1 cm long sections.
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At three time points, 24, 48 and 96 hours, the NO induction agent, tetracycline was added 
to the media of both the tubes and the beads and the NO levels determined. Whilst the cells 
encapsulated in the beads produced measurable levels of NO, the cells in the tubes did 
not. These very preliminary studies quickly demonstrated that tubes with cells in could be 
fabricated, however, the process appeared to possibly interfere with their biochemistry. A 
repeat set of similar experiments resulted in the same conclusions. In all the experiments, the 
morphology (light microscopy with no staining) of the encapsulated cells appeared identical 
with no obvious areas of cell death/necrosis. The difference between the beads and the 
sections of tubes may have been the result of the beads being efficiently optimised for the 
conditions (the conditions used were the standards used in Professor Charles' lab at that time). 
The sections of tube contained 10 - 20x more cells and alginate than the individual beads 
they were compared to. The rationale was that at this elevated level an NO reading should 
be easily obtainable. However, in hindsight, it may well have been that the quantity of media 
the sections were placed into (1 ml per well - the same as the beads) was inadequate in terms 
of both the nutrient supply as well as the dilution of residual calcium ions left in the construct 
after the washing steps.
Later experiments in our own laboratories aimed to build on this modest start continued 
to use the tube forming device whereby the float is activated by a pneumatically driven 
piston in order to produce a cell/media/alginate hydrogel tube. Section 3.4.3 describes 
the fabrication. Alginate tubes containing cells were constructed with an outside diameter 
of 9 mm, length 140 mm (i.e. dimensions determined by the particular glass tube chosen) 
and with a wall thickness in the order of 0.25 mm (determined by the outer diameter of the 
regulator within the glass tube). Both tubes and discs cut from tubes were studied. Care was 
taken to keep the tubes/disks submerged in fluid at all times since on exposure to air syneresis 
soon occurs i.e. water loss from the hydrogel leading to unwanted construct shrinkage. 
Rehydration (imbibition) is not an option because whilst the alginate hydrogel might swell to 
its former dimensions, the encapsulated cells are likely to have suffered irreversibly. Despite 
cell damage due to the handling and the cutting of the discs, overall the discs are potentially 
a better and closer analogue to the tubes than beads.
Using a bespoke 7 mm inside diameter "cookie cutter" an exact 7 mm diameter disc could be 
cut (see Section 3.4.3). The average number of cells in each disc could therefore be estimated 
from the cell density in the cell/media/alginate solution and the discs dimension i.e. 7 mm 
diameter. The average disc was calculated to have 9600 cells from an initial 106 cells per 
ml of cell/alginate solution. Again control wells were also produced matching the discs' cell 
number but containing no alginate. Discs were incubated in 10% C 02, humidified incubators 
at 37°C. Cells were also finally freed from the hydrogel using 0.1 M sodium citrate and cell
-  151 -
numbers and viability estimated using trypan blue and Neubauer haemocytometry counts 
using light microscopy.
The results are displayed in Figure 7.1 (cell proliferation over time) and Figure 7.2 (cell 
viability over time). From Figure 7.1 it can be seen that the total cell number for the discs 
stayed constant with time, i.e. on average approximately 7300 (+ /- 40%) cells per disc, this 
contrasts strongly with the initial lag phase and then exponential proliferation phase observed 
in the control (cell in a T-flask). The average of 7,300 cells per disc compares reasonably 
favourably in terms of order of magnitude with the estimated number of 9600 cells per 
disc based on the cell density in the cell/alginate solution prior to tube formation. This 
24% average difference is probably due to a combination of factors including, potentially 
incomplete cell and alginate mixing, poor tube construction with respect to consistent wall 
thickness (a problem if cell aggregates persist and particularly with the early forms of the tube 
fabricating devices), and possible sampling errors.
Visually the discs appeared unchanged over the 9 day study, also the discs retained their 
integrity throughout. These observations suggest that the discs were not significantly degrading 
due to the presence of divalent ions in the culture media over the time course of the experiment. 
Degradation of the discs would lead to cell losses. The possible explanations for the constant 
cell number can be explained in 2 possible scenarios:
1. The cell proliferation rate exactly matched the rate cells were lost due to 
alginate hydrogel degradation and releasing the encapsulated cells
2. The discs stayed intact and the cells failed to proliferate
Scenario 1 is unlikely due to the architecture and integrity of the discs remaining constant 
throughout. Furthermore, the cells remained tightly balled-up (i.e. spherical) throughout the 
experiment. For anchorage dependant cells, without attachment and elongation within the 
matrix, it is highly unlikely that cell proliferation can occur. "In tissue engineering, cell adhesion 
to a surface is critical because adhesion precedes other events such as cell spreading, cell 
migration and often differentiated cell functioning" (Saltzman, 2000).
Scenario 1 is further unlikely when the viability studies are taken into account (see Section 
7.3). Scenario 2 is therefore the most likely explanation of the constant cell number observed 
in each disc over the 9 day period. In contrast, the control cells (i.e. cells not immobilised in 
alginate), proliferated in an exponential manner after a short ( 1 - 2  days) lag phase. This 
extended lag phase was probably due to the cells being seeded at too low a density for the 
surface area of the T flask; by approximately 2 orders of magnitude. It is normal for freshly 
seeded cells to enter a brief lag phase immediately after seeding during which time they 
attach, elongate and then re-enter the cell cycle. This lag is typically less than 24 hours if cells
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Figure 7.1
Total cell numbers for A7r5 immortalised rat smooth muscle cells encapsulated in 
alginate hydrogel 7 mm diameter discs cut from tubular constructs over a 9 day 
time period.
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Figure 7.2
Viability of A7r5 immortalised rat smooth muscle cells encapsulated in in alginate 
hydrogel 7 mm diameter discs cut from tubular constructs over a 9 day time 
period.
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are seeded at an appropriate density (Freshney, 2000).
Figure 7.2 shows that the viability of the cells that were encapsulated in alginate decreased to 
zero over a six day period whilst the control cells in T-flasks retained their viability throughout 
the 9 day period. The viability was assessed by comparing the number of trypan blue stained 
cells versus the number unstained. This assay measures cell membrane integrity. A drawback 
to this approach is that loss of cell membrane integrity occurs late on in the event of cell 
death. Thus there is a tendency to over estimate the viability of cells e.g. the process of 
cell death by apoptosis occurs without cell membrane disruption (da Costa et al, 1999). 
Thus the experimental death ratio observed in the encapsulated cell population is if anything 
underestimated and not an over estimate. It is also possible that virtually all the cells undergo 
irreversible cell damage shortly after the fabrication of the construct, with the eventual 
breakdown of their cell membrane taking between 1 - 5 days to manifest itself depending 
upon the degree of damage the individual cell initially sustains. Alternatively it may be due 
to the different phenotypes present in the polyclonal A7r5 cell population, i.e. some are 
more resistant to this assault than others. Again the control cells maintained a cell viability 
of in excess of 95% throughout the experimental period. The control cells overall exhibited 
the normal events associated with cell seeding i.e. lag phase, a log phase and if left longer 
in culture, a plateau phase once the cells reached confluence in the T-flask. Overall, their 
viability was excellent, the small number of non-viable cells is in part due to the cells being 
harvested for the purpose of being counted. The cells in the discs overall failed to survive the 
encapsulation process apart from a very tiny minority (<3%). These were possibly either a 
much hardier phenotype in the A7r5 cell population or could have been the cells on the very 
top and bottom surfaces of the disc, which were therefore only partially encapsulated in the 
alginate hydrogel and therefore enjoyed better media supply and mass transfer.
7.3 Alginate polymer/cell survival and proliferation studies
From the results obtained in Section 7.2, the essential question needing to be answered was 
whether alginate solution/hydrogel and the actual formation of a three-dimensional structure 
had an adverse effect on the smooth muscle cells, since the published literature did not include 
reference to smooth muscle cell encapsulation in alginate. The basic experiment undertaken 
was to mix cells homogeneously with alginate solution, produce a tubular construct cross- 
linked with calcium chloride solution, rinse and then to immediately release the cells from the 
hydrogel using sodium citrate solution. Full details are provided in Section 3.3 with the results 
recorded in Figure 7.3.
In order to be able to identify the effect of individual aspects of the tube forming process (i.e. 
cell harvesting including centrifugation, mixing with alginate solution, exposure to calcium
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Rinse solution Total rinse volume (ml)
Cell viability following 
release from cell/alginate 
tubular contructs
Trypan blue exclusion 
assay
Supplemented media
1.5 92%
12.5 89%
125 87%
Physiological saline
1.5 85%
12.5 N /A
125 N /A
Harvested control cells
No alginate/calcium chlo­
ride
- 96%
Figure 7.3
Results of cell viability studies for A7r5 immortalised rat smooth muscle cells immediately 
following release from cell/alginate hydrogel tubular constructs using sodium citrate 
solution. Cell/alginate constructs were fabricated and rinsed with different volumes and 
different rinse solutions to remove excess calcium chloride cross-linking solution.
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chloride solution - the cross-linking process and finally being exposed to 0.1 M sodium 
citrate), a collection of control experiments was undertaken in parallel using 24 microwell 
plates. Microwell plates were used since the tube forming device will only work if all the 
components of the steps in the process are undertaken and since the controls were designed 
to have selected components) omitted, microwell plates were the only way forward. In order 
to keep the total volumes identical, supplemented media was used to substitute for the omitted 
components). See Figure 7.4 for an overview of the experimental set.
Control experiments were performed in parallel using identical cell numbers, see Section 3.3. 
In brief, the viability of these control cells was assessed following harvesting (trypsinisation 
from the T-flask) with no further manipulation i.e. only essential unit operations were performed 
to be able to obtain cells for viability assessment from a standard T-flask. The viability of 
these control cells after trypsinisation and the addition of trypan blue was 96%. No data 
was possible for both the higher volume saline rinses as with both experimental conditions 
the calcium cross-linked hydrogel dissolved due to the presence of excess sodium ions. It is 
likely that even the 1.5 ml saline wash as well as the supplemented media wash caused an 
element of tube dissolution. The cross-linking solution of 1 % calcium chloride equates to a 
calcium ion concentration of 6.8 mmolL'1. In contrast the supplemented media has a calcium 
ion concentration of 1.6 mmolL1 (0.018%). Likewise, supplemented media contains other 
polyvalent cations whereas physiological saline contains only monovalent cations and hence 
strongly affects calcium ion cross-linking by out competing the calcium ions with monovalent 
sodium ions.
The A7r5 cells were rescued from the hydrogel using the previously described sodium citrate 
technique. Cells rescued after undergoing the various different conditions created by the 
omission of the various unit operations/componentfs) differed little in their overall viability 
with an overall range of 85 - 92% survival. Unfortunately, it is impossible to make a conclusion 
with respect to the difference in wash solutions i.e. supplemented media versus physiological 
saline due to the physiological saline degrading effect on the hydrogel, however, it would 
appear from the smallest volume (1.5 ml) that supplemented media was better with respect to 
cell survival than physiological saline. Increasing the volume of supplemented media used for 
washing did not improve cell survival. In fact, it appeared to slightly decrease cell survival. 
It would therefore appear that a short wash step with 1.5 ml of supplemented media was 
the best option since increasing the volume of media made no improvement. Since the total 
volume of the 12 cm long glass tube, with a 4 mm diameter, is approximately 1.5 ml and 
the dead space in the device base is approximately 100 pL, this gives a total volume of 1.6 
ml in the total device. Given that the alginate is a 1 % mixture and that the cell pellet was < 
100 pL after centrifugation, this gives an approximate fluid volume in the complete device,
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N /A / / / / /
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/ /
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culture media 
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alginate solution
/
Cells harvested 
only - no further 
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Figure 7.4
Experimental design array for examining the effects of omitting different unit operations required to form a cell/hydrogel construct on A7r5 immortalised 
rat smooth muscle cell viability.
with cell/alginate hydrogel tube in situ, of approximately 1.5 ml. Thus the 1.5 ml wash step 
approximately reduced the calcium chloride to 50% of its original strength i.e. approximately 
3.7 mmolL'1, (taking into account the 1.6 mmolL'1 of calcium ions in the supplemented media). 
It is surprising therefore that this level is compatible with a high level of cell survival i.e. over 
3x the physiological level of free calcium ions. Cell survival is in part due to calcium ions 
being involved in the cross-linking of the hydrogel, plus a number being bound to proteins 
e.g. FBS and thus since no longer in a free ionic form unable to enter the cell and cause 
damage, much the same way as albumen in human plasma acts as a reservoir of bound 
calcium ions. The binding of calcium ions to plasma proteins in vivo renders the calcium ions 
physiologically inactive. Only when they are released are they again biologically active.
Further work on this area needs to include the crucial experiments to quantifying where the 
calcium ions are i.e. what percentage are free and therefore physiologically active and what 
percentage are protein bound or alginate bound and therefore physiologically inactive. The 
12.5 ml and 125 ml wash steps represent a 6.8 fold and 75.6 fold dilution of the calcium ions 
since the wash was a single continuous flow through the device. This approximation again 
takes into account the calcium content of the media. The resulting calcium ion concentrations 
for the 12.5 ml and 125 ml wash step were; 2.2 mmolL'1 and 1.7 mmolL'1 respectively. 
However, their flow rates were higher than 6.25 mlmin'1 for the 12.5 ml wash volume and 
8.33 mlmin'1 for the 125 ml wash volume. Investigation of flow rate may therefore also be 
an important factor for cell survival.
7.4 Effect of media composition on cell survival and proliferation
It was suggested by an early collaborator, Dr Clare Seldon (Department of Medicine, Royal 
Free Hospital, Hampstead, Middlesex, UK) that the choice of media was a critical factor 
in encapsulated cell survival. This opinion was based upon her extensive research on 
encapsulated liver cells for extracorporal liver assist devices (Seldon et al, 1998 and Seldon 
et al, 1999 and Seldon et al, 2000 and Khalil et al, 2001). The suggestion was to use 
cxMEM with ribonucleasides and deoxyribonucleasides (Gibco-BRL, Gathersburg, Maryland, 
USA) with DMEM (Dulbecco Modified Eagles's Medium with 4.5 gL'1 glucose and without 
L-glutamine) as a control. The respective media were used throughout one or other arm of 
the experiment i.e. cell suspension prior to mixing with alginate solution, as wash media and 
culture media during the incubation phase with, in one instance, daily refeeds of fresh media 
(following removal of the spent media).
Two different alginates were chosen for this particular experiment namely Fluka (alginic acid 
salt from brown algae - Fluka, St.Gallen, Switzerland) and Sigma (high viscosity alginic acid 
from macrocystic pyrifera [Kelp] - Sigma, St.Louis, Missouri, USA).
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In order to have a comprehensive study, two three-dimensional structure types were constructed; 
discs from tubes and beads. Discs of 7 mm in diameter, were made from tubes as per Section 
3.4.3 and beads were produced as per Section 3.4.2. Overall there were six experimental 
conditions, all using 1% alginate weight/volume solutions. See Figure 7.5 for an overview 
of the experimental matrix.
Experimental observations were carried out over a 16 day period, the viability results are 
graphically represented in Figure 7.6 (cell proliferation over time) and Figure 7.7 (cell 
viability over time). Both graphs demonstrate the same general trends regardless of the 
experimental conditions. On day zero, i.e. immediately post fabrication of the constructs, all 
the experimental conditions had cell viabilities greater than 90% using 0.1 M sodium citrate 
solution (Sigma, St.Louis, Missouri, USA) to free the cells and the trypan blue exclusion assay 
to assess viability. However, after this initial time point, all the constructs in both aMEM and 
DMEM media underwent a near exponential decline in viability until by day 16 the survival 
range was less than 10% for all the experimental conditions. Over this 16 day period, in a 
highly similar manner to the experiment described in Section 7.2, no cell proliferation was 
observed with the individual beads containing a constant number of cells (approximately
10,000 - 12,000 cells per 2.2 cm in diameter bead).
There was, however, a difference in the rate of decline between experimental conditions 
using aMEM and DMEM. Cells in DMEM suffered a far faster rate of death (i.e. membrane 
disruption) than the cells in aMEM. Interestingly the Sigma beads undergoing daily refeeds 
with aMEM performed far worse than all the other experimental conditions, and not better 
as was hoped.
In conclusion, aMEM did reduce the rate of cell death, but did not prevent it nor did it 
trigger cell proliferation. Dr Clare Seldon had found aMEM to provide the ideal survival and 
proliferation media for hepatocytes encapsulated in alginate (Seldon et al, 1998 and Seldon 
et al, 1999 and Seldon et al, 2000 and Khalil et al, 2001), however, it appeared not to be 
the solution for the immortalised rat smooth muscle cells, A7r5. Both liver cells and smooth 
muscle cells have been reported to form spheroids (Bjorkerud et al, 1994).
The disc from the tube leg of the experiment performed in a fairly average manner with 
respect to the beads. It was thought that using a disc with a maximum thickness of 250 
|jm might fare better than a 2.2 mm diameter bead i.e. 0.125 mm versus 1.1 mm for mass 
transfer at the very centre of the construct.
7.5 Conclusions
Overall, despite an extensive literature on the successful encapsulation in alginate of a very
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Figure 7.5
Overview of the six different experimental conditions with the different constructs, alginates, media and refeeding regimens (Colour coding of the six
conditions as per Figures 7.6 and 7.7).
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Figure 7.6
Total A7r5 immortalised rat smooth muscle cell number for 6 different experimental conditions with different 
constructs, alginates, media and refeeding regimens.
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Figure 7.7
A7r5 immortalised rat smooth muscle cell viability for 6 different experimental conditions with different 
constructs, alginates, media and refeeding regimens.
wide range of mammalian cell types, it was concluded from the above research that alginate 
was not able to support either A7r5 immortalised rat smooth muscle cell or the human adult 
mesenchymal stem cell attachment, which is considered an essential prerequisite for their 
survival in both two and three-dimensional constructs. It is possible that the rat cell line may 
not be truly representative of non-immortalised human cells (although the A7r5 cells attached 
easily to tissue culture flasks), additional experiments with human explant vascular smooth 
muscle cells would resolve this issue. Overall, since alginate did have many of the properties 
deemed favourable for tissue engineering, it was decided to continue with alginate but to 
chemical modify it. This work is described in the following chapter.
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8.0 Controlling cell-alginate interaction
From the data in Chapter 7, it became apparent that alginate hydrogels could not support 
smooth muscle cell activity. Other researchers have observed the need for alginate to be 
modified in order for the final hydrogels to have cell attachment sites (Smentana, 1993). The 
introduction of anchorage sites within the hydrogel scaffold is required to promote not only 
attachment, but cell migration, proliferation and specific gene expression (Hynes, 1992, Yagi 
et al, 1993, Price, 1997 and Rowley et al, 1999). Furthermore due to the hydrophilic nature 
of alginate, cell adhesion molecules from the culture medium are also unable to become 
deposited on the alginate's surface - a process known to facilitate anchorage dependant cell 
attachment (Smentana, 1993).
One recent example is by Chung in South Korea (Chung et al, 2002). Chung reacted 
galactosylated chitosan with alginate forming a highly porous three-dimensional sponge which 
provided specific cell attachment sites for hepatocytes. Galactose is know to be a specific 
adhesive ligand for the asialoglycoprotein receptor found on the surface of hepatocytes. 
Hepatocytes like smooth muscle cells are also anchorage dependent cells.
Smooth muscle cells when harvested from the T150 flasks, using trypsin as described 
previously in Chapter 3, became spherical in shape i.e. balled-up cells. If placed back in a 
T150 flask with media, over the first 6 hours the balled-up cells will attach and spread out into 
a more smooth muscle "spindle" shape morphology. This occurs because the commercially 
available T-flasks are either pretreated with a thin layer of suitable material to encourage cell 
attachment e.g. collagen, fibronectin, poly-D-lysine (Bicoat T150 flasks, Beckton Dickinson, 
Bedford, MA, USA) or made negatively charged and hydrophobic (Corning, Corning, New 
York USA).
It is interesting to note that several authors have observed this balled-up appearance for other 
attachment cells prior to observing proliferation within alginate hydrogels e.g. fibroblasts 
(Shapiro and Cohen, 1997). However, unlike fibroblasts, neither smooth muscle cells nor 
adult mesenchymal stem cells have been observed to proliferate or to produce extracellular 
matrix whilst in their balled-up state during the course of this project. One possibility is 
that vascular smooth muscle only rarely proliferates in a three-dimensional construct/tissue 
and then only as part of a pathological process (e.g. atherosclerosis) (Gordon et al, 1990). 
Furthermore even in pathological processes e.g. neointimal hyperplasia after vascular injury, 
cell hypertrophy (increase in individual cell size) rather than hyperplasia (increase in cell 
numbers) is observed. Likewise in vivo, human mesenchymal stem cells when entrapped in a 
tissue requiring repair/regeneration only demonstrate clonal expansion "under a strong and 
persistent selective pressure", furthermore such replication is "known to be infrequent and a
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slow event" (Wang et al, 2002 and Preston et al, 2003).
Attempts in the present study to overcome this lack of attachment sites on the native alginate 
included seeding at maximal cell density, adding known cell attachment polymers to the 
alginate prior to setting and modifying the alginate by adding specific cell attachment sites.
8.1 Increasing the cell density
The rationale for increasing cell density is that if the density of cells were high enough then 
cell-cell contact would be achieved homogeneously throughout the cell/hydrogel construct. 
Close virtual cell-cell contact is the normal arrangement through out the human body at all 
stages in human development. For tissue engineering this approach has a great advantage, 
namely reduced construct growing times. Bulking patients7 cells up to high numbers is already 
a commercially automated process e.g. Cellmate and SelecT (The Automation Partnership, 
Royston, Hertfordshire, UK). There are currently in excess of 70 Cellmates employed 
worldwide. Using very high densities of cells initially to fabricate the construct would reduce 
the need for cell proliferation within the matrix therefore potentially reducing the period for 
which the construct needs to develop. Furthermore, since it is highly desirable to have the 
polymer creating the scaffold totally removed prior to implantation in the body, having more 
cells and therefore less alginate for a given volume also is an advantage. Finally, more cells 
could potentially produce increased volume of extracellular matrix earlier, thus reducing the 
structural demands upon the scaffold and again potentially reducing the amount of scaffold 
polymer required in the initial construct.
The difficulty in the laboratory is in producing adequate cell numbers using typical laboratory 
T-flasks and incubators. In reality the maximum cell densities achievable were 108 cells per 
ml of alginate. No improvement in cell elongation and proliferation was seen at this order 
of magnitude and higher orders were not practical. It is, however, an area of research that 
does require further investigation because of the advantages listed above plus recent research 
has suggested that in terms of thickness, the number of cells that individual blood vessels are 
composed of at birth is retained throughout life. It is therefore possible that this may be true in 
tissue engineering i.e. that for a certain cell density no further cell proliferation is possible.
Interestingly, since the above work was performed, Cohen's group has demonstrated that 
the more dense the seeding of hepatocytes in alginate mats, the better the cells survive and 
proliferate. For example, a change from a cell seeding density of 0.28 x 106 cells cm'3 to 5.7 
x 106 cm'3 resulted in a change from almost total cell death by day 7, to maintained viability 
for the same time period in the denser seeded mat (Dvir-Ginzberg etal, 2003). Likewise Osiris 
Therapeutics (Baltimore, MD, USA) have demonstrated that increased MSC seeding densities 
leads to increased contact inhibition of proliferation and increased cartilage (extracellular
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matrix) production suggesting that the MSCs were exhibiting a chondrogenic commitment. 
The suggestion made was that there is an inverse relationship between proliferation and 
differentiation (Kavalkovich et al, 2004)
8.2 Adding cell attachment polymers to the alginate solution
If alginate lacks cell attachment sites, then one option is to mix the ''inerf' alginate solution 
with a cell friendly polymer which naturally contains such sites. Similar work with collagen 
and other extracellular molecules incorporated into various hydrogels has previously been 
attempted (Carbonetto etal, 1982, Woerly etal, 1993 and Civerchia-Perez etal, 1980). Type 
I collagen was chosen for this project, since it is a liquid and therefore could be easily mixed 
with alginate and is already extensively used in tissue engineering e.g. Weinberg etal, 1985. 
Collagen is also phylogenetically well preserved and there is little human immunological 
response to animal collagens, hence the FDA approval of bovine collagen as the scaffold 
material for Apligraf (Organogenesis, Canton, Massachusetts, USA). Alginate composites 
have previously been produced using hyaluronic acid combined with alginate. These gels 
were prepared by allowing calcium ions to diffuse into homogeneous acid/alginate mixtures. 
Overall, the mechanical strength of the alginate was improved, but no cell interaction studies 
were performed (Oerther et al, 1999a and Oerther et al, 1999b).
8.2.1 Collagen only matrices
Initial experiments were performed using collagen only in order to assess the ability of the 
immortalised rat smooth muscle cells to proliferate in a three-dimensional collagen structure. 
Later experiments involved the homogeneous mixing of the alginate and collagen prior to 
setting.
Type I collagen extracted from rat tail (First Link (UK) Ltd, Brierley Hill, West Midlands, UK), 
was selected on the basis that this particular supplier's collagen was starting to be investigated 
by other groups, including Professor Sir Magdi Yocoub's group at The Heart Science Centre, 
Harefield Hospital, Middlesex, UK. However, these groups were using the collagen as dry 
mats and then adding cells similar to the original work of Bell in the 1970's and 1980's 
(Coulomb et al, 1984). Instead, the experiments performed for this project involved adding 
the cells directly to the collagen and then setting the cell/collagen construct prior to adding cell 
culture media and incubation. On this occasion for the purposes of clarity, the experimental 
method for this bank of experiments is described below (rather than in the materials and 
methods chapter - Chapter 3) since the reasoning, methodology, chose of reagents and 
results are extremely intertwined.
The rat tail type I collagen was supplied sterile (chloroform treated) and pre-dissolved in
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acetic acid (0.6%) in order to keep the pH below 7, since above pH 7 the collagen will set,
i.e. adding alkali causes the collagen to cross-link and thus retain its shape. However, unlike 
alginate, the cross-linking process takes minutes allowing further mixing and manipulation 
of the collagen before final setting is achieved. The concentration of collagen in each batch 
was in the order of 2 mgml'1 with interbatch variability approaching + /- 10%. Typically 
a collagen sheet was produced by initially adding 400 pL of collagen solution to 50 pL of 
1 Ox Eagles Minimum Essential Media (EMEM) (BioWhittaker, Walkersville, Maryland, USA) 
and homogeneously mixed using a pipette. The 10x concentration media was employed 
for 2 reasons. Firstly, to arrive at the correct concentration for the final solution volume of 
approximately 500 pi thus producing suitable media and pH conditions for the cells. Secondly, 
the EMEM contains a pH indicator, phenol red. Phenol red at the correct concentration i.e. 
a final concentration of 1x, allowed the careful titration from the initially bright yellow i.e. 
acidic collagen solution to bright pink as the solution became more alkali due to the controlled 
addition of 1 M sodium hydroxide solution (Sterile filtered - Sigma, St. Louis, Missouri, USA), 
thus allowing the collagen to cross-link. Care must be taken not to exceed a pH of 7 since 
at higher pHs collagen will also not set. The final titration point was taken to be where a 
permanent colour change to pink occurred. In order to determine the exact volume of sodium 
hydroxide solution required to set the collagen but not to overshoot, different volumes of 1 M 
sodium hydroxide solution were placed in the wells of 24 microwell plates (Corning, Corning, 
New York, USA), (range 37.5-50 pL in 2.5 pL steps) prior to adding 450 pL of collagen/ 
EMEM mixture and then again thoroughly mixing. Immortalised rat smooth muscle cells 
A7r5 had been harvested as previously described, centrifuged into a pellet, the supernatant 
removed and then resuspended in supplemented media containing 10% FBS (BioWhittaker, 
Walkersville, Maryland, USA), 60U penicillin ml’1 combined with 60 pg streptomycin per 
ml (BioWhittaker, Walkersville, Maryland, USA) plus additional glucose (Sigma, St. Louis, 
Maryland, USA) to a final concentration of 3.3 mgml'1. To each collagen/EMEM/NaOH 
mixture was added 50 pL of the cell/aMEM or cell/DMEM suspension. The resulting solution 
in each well was homogeneously mixed using a fresh pipette prior to placing the microwell 
plate in a 37°C incubator with 10% C 02 for 10 minutes in order to accelerate the collagen 
setting process plus to provide a more favourable environment for the cells. The initial 
concentration of the rat tail collagen was 2.16 mgml'1 (0.216% weight/volume), after dilution 
with EMEM, cells and sodium hydroxide solution the final concentration was in the order 
of 1.6 mgml1 - i.e. 0.16% weight/volume (c.f. the typical alginate experiment of 0.5-6% 
alginate dry weight/volume). This concentration of collagen was similar to the concentration 
used by Organogenesis to provide the bovine collagen scaffold for Apligraf (Kemp, 2003b). 
The cell density in the collagen sheets prior to setting was 106 cells ml'1 i.e. identical to 
previous alginate experiments, therefore each well had an estimated cell volume of 0.5 x
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106. By comparison the density of 106 cells ml'1 was approximately four times that used to 
make Apligraf. Interestingly once the cells were seeded, the Apligraf construct was reported 
to contract to a volume of approximately 10% of its original size i.e. giving a collagen density 
of 16 mgml*1 and a cell density of approximately 3.75 x 106 per ml. The disproportionate 
increase in cell density was due to a proliferation rate of approximately 1.5 cell population 
doublings over the 7 day period (Kemp, 2003b).
After cross-linking of the collagen in the microwells was complete, 1 ml of supplemented 
media was added to each well. Like alginate, set collagen is transparent thus allowing easy 
visualisation of the encapsulated cells using light microscopy. Control microwells with no 
collagen/EMEM/NaOH were seeded at a density of 9.6 x 103 cells per microwell and again 
made to up a final volume of 1 ml per well with the supplemented aMEM or DMEM. From 
previous range finding experiments without cells, it was known that 1 M sodium hydroxide in 
the range 37.5-50 pL was adequate (but not excessive) to set the 450 pL of collagen/EMEM 
solution. The addition of the cells to the mixture made no difference to the setting, however, it 
was observed that different sodium hydroxide volumes did result in gels of different physical 
characteristic and morphology when viewed using light microscopy. A summary of the results 
is given in Figure 8.1. In all the microwells, by the end of the first twenty four hours, the 
balled-up smooth muscle cells had elongated throughout the encapsulation matrix. These 
day 1 results suggest that the cells are not unduly harmed during the scaffold fabrication 
process including the range of pHs (6.5 - 12) that the cells are initially exposed to on the 
addition to the collagen/EMEM/NaOH solution for approximately 15 minutes during the 
mixing and setting phase prior to the addition of the 1 ml of supplemented aMEM or DMEM 
which retained its red colour throughout the process, i.e. confirming the cultures were within 
an acceptable physiological pH range. On day 1 there was no visible shrinkage of the 
collagen. However, by day 3, shrinkage had become evident at the lower sodium hydroxide 
setting concentrations and especially in the 37.5 pL sodium hydroxide set scaffold. Shrinkage 
would appear also to compromise the ability of the sheets to retain the cells in their elongated 
state, the scaffold appeared to have collapsed leaving the cells without a firm structure to 
attach to. Possibly this observation reflects that the cells were too vigorous in their attachment 
and elongation and the scaffold was too weak because the cells physically collapsed the 
scaffold as they tried to elongate - a possible mismatch (a similar problem has recently been 
reported by Langer's group involving human embryonic stem cells and Matrigel (Levenberg 
et al, 2003). Interestingly at the higher sodium hydroxide concentrations, whilst shrinkage 
was not observed, the cells also return to their balled-up state, again possibly suggesting 
that the collagen sheet had lost strength possibly due to excess alkali. Overall the optimum 
setting conditions appeared to have been in the range 42.5 - 45.0 pL of sodium hydroxide
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Time point 1M NaOH volume (pL)
pH prior to 
addition of 
cells/medium
Cell-collagen
sheet
characteristics
Cell
morphology
Immediately 
post fabrication
37.5 6.5
Fully set 
construct with 
same diameter 
as microwell 
- i.e. no 
shrinkage
Round balled 
up cells 
distributed 
through out the 
construct
40 6.8
42.5 9.0
45 10.5
47.5 11.5
50 12.0
Day 1
37.5 6.5
No change 
from 
immediately 
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- smooth muscle 
appearance
40 6.8
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42.5 9.0
No change 
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Elongated
47.5 11.5
50 12.0 Balled up
Figure 8.1
Summary of results for cell-collage constructs using different quantities of collagen setting 
agent - 1M NaOH solution.
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solution. Having established that the A7r5 rat smooth muscle cells were capable of spreading 
within a three-dimensional sheet of rat collagen the experiment was repeated except with the 
substitution of varying amounts of collagen solution for alginate solution.
8.2.2 Composite coilagen-alginate matrices
Composite collagen/alginate gels were produced using 4% alginate (Fluka, St. Gallen, 
Switzerland) in physiological saline prepared in solutions in order to arrive at a final 
concentration of 1 % alginate in the final composite gel. However, the option of a higher 
concentration stock solution for the collagen was not available and hence the final collagen 
concentration in the final composites was reduced from the previous 1.6 mgml'1 to 1.25 
mgml'1 (a 21.9% reduction). In order to minimize the reduction in collagen composition 
the volume of aMEM or DMEM media used to resuspend the pelleted cells after harvesting 
fully was minimized. Finally, to achieve setting of the composite polymer it was necessary 
to perform the various cross-linking steps in a very precise order, as all other combinations 
proved not to work.
The only order of adding the individual components found to produce a set collagen/alginate 
scaffold containing cells was: collagen solution, 10x EMEM, 4% alginate solution, sodium 
hydroxide solution, cells in supplemented aMEM media and finally calcium chloride solution 
once the collagen had set. Prior to adding each component except the calcium chloride 
solution (as this would have disrupted the freshly set collagen gel) thorough mixing was 
performed using a pipette in order to produce homogeneous mixtures. The final composition 
had a ratio of dry alginate powder:collagen protein of approximately 8:1. Thus the majority 
of the construct was alginate with the collagen acting as a fortifying agent.
This final mixture resulted in a rat cell density of 4.2 x 105 cells ml'1. 300 pL samples of this 
final mixture was placed into individual microwells, resulting in each well containing an 
estimated 1.3 x 105 cells. The microwell plate was then placed into a 37°C incubator with 
10% C 02 for 10 minutes in order to set the collagen solution. Finally 1 ml of calcium chloride 
cross-linking solution was added to each well for a further 10 minutes. Calcium chloride 
solutions at different concentrations (0.1%, 0.5% and 1%) in physiological saline were used. 
After 10 minutes the calcium chloride in physiological saline was carefully removed using a 
pipette and replaced with 1 ml of supplemented media for a further 10 minutes in order to 
dilute the remaining calcium chloride solution and buffer the excess 1 M sodium hydroxide 
solution prior to it being drawn off and replaced once again with fresh supplemented media 
(otMEM or DMEM).
The controls consisted of either identical mixtures except supplemented DMEM media or 
physiological saline was added in place of the calcium chloride solution (since physiological
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saline was used to make up the calcium chloride solutions), or cells were seeded into the 
microwells with no composite scaffold components present. Cells were seeded at a density of
1.3 x 105 per well. All the wells had a final volume of media of 1 ml. The microwell plates 
were finally returned to the 37°C humidified 10% C 02 incubator. The morphological progress 
of the cells and scaffold shrinkage was observed as before using simple light microscopy.
On day 1, cells in both the controls (supplemented media, physiological saline) were no longer 
balled-up but elongating in the same manner observed in the previous collagen only scaffold 
experiment. The 0.1 % calcium chloride cross-linked scaffold exhibited a small minority of cells 
which were elongated but the vast majority remained balled-up. In both the 0.5% and 1 % 
calcium chloride cross-linked scaffold, all the cells remained balled-up. Repeat observations 
over a 2 week period revealed no change from the day 1 cell morphology observations, except 
cell proliferation was observed in both the control conditions - see Figure 8.2. Shrinkage 
over the time course was only observed in the scaffolds not exposed to calcium chloride 
cross-linking agent (i.e. the controls with physiological saline or supplemented media) and 
this was only observed from day 10. However, the shrinkage observed was minor compared 
to the shrinkage observed in the lowest concentration sodium hydroxide cross-linked collagen 
only sheets produced in Section 8.2.1. An extended version of this experiment (20 days) 
was later carried out with similar results including extensive cell attachment, elongation and 
proliferation in the control collagen-alginate sheets - see Figure 8.3.
Calcium chloride solution (at any concentration between 0.1%-1%) would therefore potentially 
appear to act in two different areas:
1. To have a protective factor with respect to composite scaffold shrinkage. 
Shrinkage would therefore not appear to be a factor when considering why 
the higher (0.5% + 1 %) calcium chloride solution cross-linked scaffolds failed 
to show cell elongation
2. To have an adverse effect with increasing concentrations of calcium chloride 
solutions on A7r5 cell attachment, elongation and proliferation despite the 
presence of "cell friendly" collagen within in the composite matrix material
The experiment did, however, possibly suggest that at low calcium chloride concentrations 
(0.1%) it was possible to fabricate a collagen/alginate composite scaffold with embedded 
cells with some degree of success i.e. a small minority at the cells left their rounded-up state 
post harvesting and spread out/elongated into the surrounding composite matrix with similar 
morphology to the cells in the collagen only scaffold. However, following elongation no cell 
proliferation was observed.
The results possibly suggest that alginate is an inert player i.e. it does not behave in
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Control - Saline
Control - DMEM
Control - DMEM
Figure 8.2
Collagen-alginate matrices - Day 14 results.
The control conditions demonstrated good cell attachment and elongation for the A7r5 
immortalised rat smooth muscle cells in the collagen-alginate matrix. Under the control 
conditions, only a few balled up cells were seen whilst the majority were elongated within 
the matrix. However, the 0.1% CaCl2 condition showed only a very small number of cells 
making attachment and elongation (=>). Cell-matrix interaction was not seen at the higher 
CaCI2 concentrations where all the cells remained balled up. The progressively receding 
edge of the collagen-alginate hydrogels can be clearly seen in the control conditions 
images (If) as too can be seen the elongated cells which appeared to be attached to both 
the gel and the exposed surface of the microwell thus straddling the gap (It).
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Figure 8.3
Collagen-alginate matrix - Day 20.
A typical example of the high level of interaction observed between the A7r5 immortalised 
rat smooth muscle cells and the collagen-alginate matrix in the absence of CaCl2 solution 
being added to the set hydrogel prior to the wash stage of the fabrication process. 
Attachment, elongation and migration can be observed in the image, whilst evidence of 
proliferation can be inferred from the high number of cells present relative to the original 
seeding density of 4.2 x 105 ml'1 of matrix.
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a deleterious way towards the rat smooth muscle cells. The provision of attachment sites 
is evidently of real benefit in order to coax the smooth muscle cells into spreading out in 
the scaffold - the first step on the way to possible proliferation. However, the experiments 
had demonstrated the complexity of fabricating cell/scaffolds using an alginate/collagen 
composite. This complexity did not lend itself to the tube device process which was already 
progressing well in parallel towards making consistent tubular constructs using just alginate 
solutions. The experiment demonstrated that the A7r5 immortalised rat cells were not of an 
abnormal phenotype which was incapable of elongating in a three-dimensional scaffold due 
to, for example, the immortalisation technique or extended culturing they had undergone. It 
was therefore decided that having established that A7r5 were capable of elongation when 
encapsulated inside a three-dimensional structure the logical way forward would be to not 
use a composite but to chemically modify the alginate (i.e. return to a single polymer but one 
which was modifiable readily to allow cell attachment).
8.3 RGD-alginate scaffolds
Whilst alginate solutions with their rapid cross-linking times were ideal for tube and bead 
formation, their lack of cell attachment properties was a major disadvantage. Keeping the 
alginate in a solution was an absolute prerequisite since a solution containing cells lends 
itself to the desired process of automation. It was therefore deemed necessary to modify 
the alginate such that it remained a liquid, unlike the collagen/alginate composites which 
required a "collagen-presetting stage".
8.3.1 GRGDY-alginate
The tripeptide arginine-glycine-aspartic acid (RGD) is a common sequence found in 
extracellular proteins e.g. collagen, fibrinogen and laminin. Cell-RGD adhesion is mediated 
by transmembrane cell surface receptors called integrins which recognise and bind directly 
to the RGD site. RGD not only controls cell attachment but also other important cell activities 
e.g. differentiation, by allowing the transduction of signals from the extracellular matrix to 
the interior of the cell. Pierschbacher and Ruoslahti were some of the earliest researchers to 
demonstrate the importance of RGD for the adhesion of anchorage dependent cells in tissue 
culture (Piersbacher and Ruoslahti, 1984). Because RGD is highly important in the process 
of cell adhesion, synthetic RGD motifs have been immobilised on a large number of inert 
polymers with the aim of making the resulting RGD-polymer cell friendly. Polymers which 
have been modified with RGD motifs include PTFE (Massia and Hubbell, 1991 a, polyurethane 
(Lin et al, 1994), PEG (Drumheller and Hubbell, 1994), PEG-diacrylate (Mann and West, 
2002) and PVA (Matsuda et al, 1989). The addition of the RGD motif to these inert synthetic 
polymers has led to cell attachment which would otherwise not occur or only occur to an
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exceedingly limited degree.
A thorough literature search revealed that Mooney's group at the University of Michigan, USA, 
had successfully attached an GRGDY peptide covalently to an alginate using carbodiimide 
chemistry, cross-linked the derivatised alginate and then grown mouse skeletal myoblasts 
(skeletal muscle precursors) on its surface. The cells failed to grow on the unmodified control 
alginate (Rowley et al, 1999). Rowley and Alsberg later repeated a variant of this work in 
two subsequent paper, (Rowley and Mooney, 2001 and Alsberg etal, 2002), but again only 
demonstrated cells growing on the surface and not within the three-dimensional structure. 
Partly this was due to the method of cross-linking chosen i.e. instead of using calcium chloride 
solution which is extremely fast acting, Rowley used calcium sulphate as a water-based slurry 
directly added to the alginate. Calcium sulphate is very insoluble in aqueous solution unlike 
calcium chloride. The alginate solution/calcium sulphate slurry mixtures were then cast 
between parallel glass plates to set which took minutes/hours to complete i.e. not readily 
suitable for cell encapsulation since the cells would be exposed for a prolonged period to 
calcium sulphate, if encapsulated within the alginate/calcium chloride slurry.
It was therefore decided to modify the Mooney approach in order to retain the rapid calcium 
chloride cross-linking process which lay at the heart of the evolving tube making device.
For the preliminary GRGDY experiments the Rowley protocol was initially followed nearly 
exactly with only minor changes apart from the major change in the choice of cross-linking 
agent, but this proved to be totally unsatisfactory in that cells failed to perform any better than 
alginate alone either on the surface or in the three-dimensional structure. The basic protocol 
consisted of attaching cell adhesion ligands to the alginate backbone using carbodiimide 
chemistry.
Alginates are linear unbranched polymers composed of two different monomers 1 -4-linked |3- 
D-manuronic acid (M unit) and a-L-guluronic acid (G unit) - see Figure 8.4. Alginates are not 
random copolymers of M + G units, but, depending upon the particular type of seaweed they 
are derived, consist of blocks of G or M units or exactly alternating residues i.e. GMGMGM... 
It is the G units that are responsible for the cross-linking process with divalent ions such as 
calcium chloride, creating "ionic interchain bridges" and hence hydrogels between alginate 
chains. Using Rowley's protocol, alginate was chemically modified using a water soluble 
carbodiimide, 1 -ethyl-3-(dimethylaminopropyl) carbodiimide (EDC) (Aldrich, Sleinheim, 
Germany), to activate the carboxylate groups on the G monomers, which were then able to 
react with the amine terminal of the cell attachment ligand (GRGDY - Gly-Arg-Gly-Asp-Tyr) 
to form amide bonds - see Figure 8.5. A co-reactant N-hydroxy-sulfosuccinimide (Sulfo- 
NHS) (Aldrich, Sleinheim, Germany) was used to stabilise the reactive EDC-intermediate
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Figure 8.4
Alginate M ((1,4) linked |3-D-mannuronic acid) and G (a-L-guluronic acid) monomers and their covalent bonding within alginate polymer in an -M-G- 
repeat unit.
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Figure 8.5
Covalent attachment of the pentapeptide GRGDY to a G monomer in an -M-G- repeat unit of alginate using carbodiimide chemistry.
The EDC reacts only with the G (a-L-guluronic acid) monomer to form an o-acylisourea intermediate (stabilised by the presence of sulfo-NHS) prior to 
reacting with the GRGDY pentapeptide.
(o-acylisourea) against a competing hydrolysis reaction thus improving the efficiency of the 
overall coupling reaction. Sulfo-NHS was used in preference to NHS since NHS is virtually 
insoluble but they behave identically with respect to their stabilising action.
The initial batches of the GRGDY peptide were synthesised with the help of Dr. Patricia 
Zunszain in the Department of Chemistry at UCL using a Millipore 9050 OM peptide 
synthesiser - Section 3.7. After the preliminary proof of principle experiments were successful, 
the peptide was purchased commercially from Neosystem Group SNPE (Strasbourg, France). 
This additional source provided the necessary total volume of peptide required to progress 
the project forward at a reasonable pace. The commercially supplied material was certified 
95% pure and supplied in 11 mg lyophilised aliquotes in sealed glass vials.
Since sterility is vital, it was decided to check the reagents prior to derivitisation. In a 
preliminary experiment, peptide, Sulfo-NHS and EDC had all been made up under sterile 
conditions with WFI but not then sterile filtered. Alginate solutions had been autoclaved. 
To test the sterility of the above reagents, mammalian cell culture media was inoculated 
with freshly made samples of the above individual solutions and incubated at 37°C. At 4 
days no growth was observed. However, as a further precaution it was decided to 0.2 pm 
filter the reagents (excluding the alginate) to ensure maximum possible sterility since future 
experiments would proceed for weeks and months, and 100% sterility was therefore absolutely 
essential. The alginate was not filtered since it was too viscous for a 0.2 pm filter also since it 
had been autoclaved and had never raised any sterility issues in previous experiments was 
considered sterile. The vast majority of experiments described in this thesis were performed 
with a batch of ISP Manugel DMB which upon autoclaving appeared to be rendered sterile, 
however, later batches of Manugel alginates were shown to contain a bacteria resistant to 
autoclaving. The resistant bacteria was purified with assistance from Dr. Vanya Gant and 
Mike Wren (Centre for Infectious Diseases, UCLH, London). The purified samples were sent to 
the Central Public Health Laboratory (Specialist and Reference Microbiology Division, Health 
Protection Agency, Colindale, London) for final identification. The organism was identified 
as Bacillus licheniformis. The reason for the later batches containing Bacillus licheniformis 
is unknown. Discussions with ISP failed to resolve the issue. The scientific literature contains 
reports regarding the effects of sterilisation on the properties of commercial alginates but not 
whether total sterility had been achieved (Leo et al, 1990, Vandenbossche et al, 1993 and 
Wong et al, 2001).
Bacillus licheniformis is a gram-positive, motile, spore-forming, anaerobic rod bacteria. It 
is well known to be thermophilic in nature (Alvarez-Macarie et al, 1999, Wu et al, 1993, 
De Bartolomeo et al, 1991 and Palop et al, 1996). Commonly found in soil where it leads 
a saprophytic existence it is also found in various human food products including diary
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products (Chopra and Mathur, 1984). Information regarding Bacillus licheniformis in 
relation to human safety is however limited. Food poisoning by Bacillus licheniformis is well 
described (Mikkola et al, 2000 and Salkinoja-Salonen et al, 1999). Other pathologies are 
also described including persistent bacteraemia (blood poisoning), prosthetic aortic valve 
endocarditis and indwelling catheter infections (Hannah and Ender, 1999, Santini etal, 1995 
and Blue et al, 1995). The ISP Manugel batches testing positive for Bacillus Licheniformis 
were either destined for the manufacture of food stuffs (batch number: 200792) or destined 
for the manufacture of pharmaceuticals (batch number 281011). Studies by Souw and Rehm 
have shown that Bacillus licheniformis isolated from alginate readily degrade alginate (Souw 
and Rehm, 1975). Spores of bacteria liceniformis have been reported to have temperature 
resistance of 135°C (Janstova and Lukasova, 2001) and hence the inability to achieve sterility 
with standard autoclaving (121 °C for 20 minutes). Furthermore, this particular bacteria 
has been demonstrated to be resistant to a wide range of sterilisation techniques including 
microwaves (Wang et al, 2003).
The first derivitisation experiments were performed using 1% weight/volume solutions 
of Manugel DMB alginate as per Rowley (Rowley et al, 1999). After combining all the 
reactants, the solution was then rolled for 24 hours. All the reactions were carried out 
at room temperature in light protected containers. In order to remove excess reagents, the 
solutions were extensively dialysed (see Section 3.7.1). After dialysis, activated charcoal was 
added and mixed thoroughly prior to rolling for thirty minutes. Finally, in order to remove 
the charcoal plus any other impurities the solution was past through a ready prepared Celite 
Hyflo (acid washed diatomite filter aid - Celite, Lompoc, California, USA) column (sinter 
funnel) facilitated by a vacuum pump. This process took 3 - 6 hours depending upon the 
degree of agitation supplied to the mixture. The resulting solution was collected in a sterile 
flask and either stored immediately at 4°C or lyophilised using an Edwards Freeze Drier 
and then stored at 4°C. One other variation was to use polyethylene glycol (PEG) solutions 
(Slide-A-Lyzer concentrate solution - Pierce, Rockford, Illinois, USA) or PEG solid (35,000 
MWt, Fluka, Buchs, Switzerland) to reconcentrate the dialysed samples to desired final 
concentrations, since during the prolonged dialysis, water would enter the dialysis tubing/ 
cassette thus diluting the alginate. Using serial measurements obtained by carefully drying 
and accurately weighing the dialysis tube or cassette, the final concentration of the alginate 
could be controlled - there was found to be a straight line relationship between time and 
water removed from the cassette (data not shown). Solutions of final concentration of either 
1 % or 2% were aimed at. This concentration step took 9 - 1 2  hours and was performed 
using a steady-state rocking table at approximately 10°C (purpose built cold room) in total 
darkness.
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As with non-derivatised alginate, the GRGDY-alginate could be readily cross-linked with a 
1% calcium chloride solution to form beads, sheets or tubes. Also these three-dimensional 
constructs could be easily dissolved using sodium citrate solution (Sigma, St. Louis, Missouri, 
USA).
Experiment were performed using exactly the same techniques to produce tubes, beads 
and sheets as were performed for the non derivatised alginates in Chapter 7. Subsequent 
examination of the constructs included, trypan blue exclusion assay, live/dead viability/ 
cytotoxicity kit (L-3224 Molecular Probes, Eugene, Orogon, USA), phase contrast microscopy, 
histology and cytology.
8.3.1.1 GRGDY-alginate sheets
GRGDY-alginate sheets were fabricated as per Section 3.4.1. All the initial sheet experiments 
with the ratio of alginate (dry weight):peptide:SulphoNHS:EDC of 1 gm:l mg:38 mg:67 mg 
(i.e. as per Rowley (Rowley et al, 1999), failed to show any improvement over the standard 
non-derivatised alginate in terms of cell attachment to their surface. One difference was that 
the quantity of uronic acid in the particular alginate chosen, Manugel DMB (ISP, Tadworth, 
Surrey, UK) had to had be estimated. Manugel DMB is high in the G monomer (ISP data 
sheet) and therefore produces high strength gels. Rowley (Rowley et al, 1999) used ProNova 
MVG (Norway) which was also high in G residues, so it seemed sensible to start with the 
same ratio of reactants since Rowley had optimised the reagents for this particular alginate 
using radiolabelled 125I-GRGDY as a tracer molecule. Therefore after the early experiments 
failed with Manugel it was decided to try two different approaches.
Firstly different alginates (including ProNova MVG) and in parallel different ratios of reactants 
were examined. Fluka alginate (Fluka, Buchs, Switzerland) was also tried as this had a good 
history in mammalian cell encapsulation. This was the alginate being used successfully by 
Professor Charles' group in The Wolfson Biomedical Research Institute, UCL to encapsulate 
modified hybridoma cells (Xu et al, 2002) with whom early work with tubes had been carried 
out. However, at the alginate:peptide:sulphoNHS:EDC (A:P:S:E) ratio of 1 gm:l mg:38 
mg:67 mg (1000:1.38:67) no attachment or elongation of cells was observed.
A series of experiments were undertaken to optimise the A:P:S:E ratio. Since there was 
uncertainty with respect to the exact uronic acid content of both the Fluka and the Manugel 
alginates, was decided to keep the SulfoNHS:EDC ratio as per Rowley (Rowley etal, 1999), but 
then to alter the other ratios. The experiments were repeated using Fluka standard grade and 
Manugel DMB alginates using the following A:P:S:E ratios: 1000:1:38:67,1000:10:380:670 
and 1000:50:1900:3350 which are abbreviated to 1 x, 1 Ox and 50x respectively - see Figure 
8.6. The positive control used was cells seeded directly in microwells i.e. no alginate. The
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Reagent ratios - A:P:S:E ratios 
(weight/weight)
Abbreviated
name
Alginate (Dried 
powder)
(A)
GRGDY
peptide
(P)
Sulpho-NHS
(S)
EDC
(E)
Ix 1000 1 38 67
lOx 1000 10 380 670
50x 1000 50 1900 3350
Negative
control 1 0 0 0
Positive control 
(Cells seeded 
directly onto 
microwells)
0 0 0 0
Figure 8.6
Ratios of reagents (weight/weight) used to produce GRGDY derivatised alginates and the 
positive and negative controls.
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negative control was unmodified autoclaved alginate i.e. no exposure to peptide; SulphoNHS 
or EDC. After derivitisation, the alginates were then lyophilised for 48 hours at -70°C at 1 O'1 
mbar (Edwards Freeze Dryer Modulo with a Savant Two Stage VP100 vacuum pump). The 
derivatised alginate powders where then reconstituted in WFI (BioWhittaker, Walkersville, 
Maryland, USA) back to 1 % final solutions. Sheets of the four alginates (negative control, 1 x 
1 Ox and 50x) where formed in microwells (as per Section 3.4.1) including thorough rinsing 
with supplemented medium. Immortalised rat smooth muscle cells (A7r5) were added to 
each well at a density of approximately 3 x 105 cells per well. The media volume in each well 
was topped-up to a total of 1 ml with additional supplemented media. The microwell plates 
were placed in a 37°C, humidified incubator with 10% C 02 atmosphere. The constructs were 
observed for 5 days using light microscopy.
The 1 x and 10x performed no better than the negative control i.e. no elongation was observed 
over the 5 day period. However, the 50x demonstrated a small minority of cell attachment 
and elongation. Manual time interval photography revealed that in a minority of instances 
cells were elongating towards one another on the surface of the GRGDY-hydrogel and in one 
instance making actual contact across an initial 60 * 80 pL gap - see Figure 8.7. The positive 
control (cell/no alginate) cells attached and proliferated as normal.
The indentical experiment with the negative control, 1 x, 10x and 50x derivatised alginates 
were repeated but omitting the lyophilisation step. This step was omitted as it was thought 
that the degree of control was insufficient with the Modulo Edwards freeze dryer e.g. no 
available temperature or moisture probes, therefore it was impossible to assess the extent of 
drying whilst in progress. Furthermore, this step was seen as a high risk for contamination 
e.g. bacteria. Leaving it out, however, meant that the derivatised alginates produced were 
considerably less than 1 % dry weight/volume. Typically they were in the order of 0.5% due 
to the dialysis water being taken up by the dialysis tubing or cassette during the long dialysis 
phase of the process.
However, derivatised alginate sheets at approximately 0.5% were fabricated from lx, 
1 Ox and 50x reagent conditions. This experiment demonstrated only at the 50x level a 
significant improvement in cell attachment and elongation in that it was now the majority of 
cells attaching and elongating. The 50x Manugel out performed the 50x Fluka derivatised 
alginate. Cell attachment and proliferation was similar in appearance to the positive control 
(cells/no alginate) i.e. appeared to be approaching 100% of the cells. The 1 Ox alginates also 
demonstrated a weak degree of cell attachment and elongation (similar to the original 50x 
lyophilised alginate experiment).
Sheets were also made with derivatised Pronova MVG alginate (1, 10, 50x) i.e. the same
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Day 2
Day 3
Day 11
Figure 8.7
Cell interaction with GRGDY-alginate preformed sheet over an 11 day period.
Serial time-point images showing the interaction of A7r5 immortalised smooth muscle cells 
on a preformed sheet of 50x GRGDY-Fluka alginate gel. Two days after being seeded, 
cells can be seen to have attached and then to have elongated and migrated across a gap 
(If) and remain in location over a further 8 days.
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alginate used by Rowley (Rowley etal, 1999). Again the lyophilisation step was omitted. Once 
again/ the 50x performed best but with only a minority of cells attaching and elongating. The 
1 Ox also demonstrated a very small degree of biological activity, whilst the 1 x and negative 
control showed no activity. In the positive control the cells attached and proliferated as 
normal. The differences between these results and Rowley's may have been due to alginate 
inter-batch variability.
Finally it was decided to explore if there was a difference between alginate with a high G 
content versus alginate with a high M content. Gels made with high G content tend to be far 
stronger than their high M counterparts, a factor which may well be crucial when fabricating 
larger tissue-engineered constructs. Sheets were made from derivatised Manugel DMB (high 
G) and Fluka cell culture grade (high M) alginates at the lx , lOx and 50x concentration 
ratios. A representative selection of the results is contained in Figure 8.8 which shows the 
positive control (microwell plate - no alginate), 1 Ox high G, 50x high G and 50x high M 
conditions. In the first 24 hours, the A7r5 cells were able to quickly interact i.e. attach, 
elongate and migrate on the sheets fabricated from 50x alginate regardless of whether the 
alginate was high G or high M in composition. At 1 Ox concentrations the vast majority of the 
cells failed to attach and remained balled up. The 1x concentrations showed no evidence of 
cell interaction (data not shown). Overall the 50x high G Manugel DMB was observed to be 
better at interacting with the A7r5 cells.
In all the sheet experiments performed, attachment and elongation occurred in the first 12 - 
24 hours after cell seeding. From these initial sheet experiments it was decided to discontinue 
any lyophilisation step until better derivatised alginates were produced i.e. excellent cell 
attachment in three-dimensional structures prior to lyophilisation. Then once good biological 
activity was achievable, to investigate the lyophilisation process further in order to retain the 
derivatised alginate's bioactivity.
8.3.1.2 GRGDY-alginate beads
As before in Chapter 7, in order to allow a wider range of experiments, beads were also 
manufactured with the derivatised alginates. The methods of bead production are described 
in Section 3.4.2. Experiments were either performed with the dilute derivatised alginate 
(i.e. immediately post dialysis) or with a more concentrated version following exposure to 
polyethylene glycol solution or solid to bring the concentration back to approximately 1 % prior 
to adding the cells. A series of experiments were performed fabricating beads and sheets 
from the same batches of 1 x, 1 Ox and 50x derivatised alginates. Initially A7r5 immortalised 
rat smooth muscle cells were employed however after extensive studies there was no evidence 
that the A7r5 cells elongated when encapsulated in the GRGDY-alginate despite evidence of
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well
control
High G 
lOx
High G 
50x
High M 
50x
Figure 8.8
Comparison of derivatised alginates.
In the first 24 hours A7r5 cells were able to quickly 
interact i.e. attach, elongate and migrate on sheets 
fabricated from 50x alginate regardless of 
whether the alginate was high G or high M in its 
composition. At lOx concentrations the vast 
majority of cells failed to attach and remained 
balled up. The lx  concentrations showed no 
evidence of cell interaction (data not shown). 
Overall the 50x high G Manugel DMB was 
observed to be best at reproducibly interacting 
with the A7r5 cells.
good interaction between the A7r5 cells and the surface of sheets made from the same batch 
of matrix. The sheets and beads were fabricated one after another over the period of a few 
minutes. Some of the extended time course experiments were conducted with Julia Markusen 
(UCL).
Deploying human mesenchymal stem cells (c.f. immortalised rat smooth muscle cells) in the 
bead experiments, there was excellent correlation between cell interaction on the surface 
of the sheets and elongation and networking of the cells within the beads. Selected images 
from a typical MSC bead and sheet experiment are shown in Figure 8.9, in this experiment, 
derivatised alginate was compared directly with non-derivatised alginate in order to check 
whether MSCs could interact with non-derivatised alginate. In the first 24 hours MSCs were 
able to quickly interact with the Manugel DMB 50x GRGDY-alginate i.e. attach, elongate 
and migrate, on both the surface of the sheets and within the beads, whilst in the derivatised 
beads, intercellular networking can also be observed. On the non-derivatised alginate sheets 
there was no cell interaction, instead the cells were seen to aggregate into clumps by day 1 
which were lost by day 3 leaving just a few unattached cells. There was no cell elongation 
observed within the non-derivatised alginate beads - this result is fully consistent with the 
previous A7r5 work. Parallel live/dead viability/cytotoxicity assays (L-3224 - Molecular 
Probes, Eugene, Oregon, USA) were performed as per Section 3.8.1. They revealed a very 
high percentage of live cells (fluoresce green under ultraviolet light c.f. red when dead) in 
both the derivatised and non-derivatised alginate beads (the Day 7 bead images in Figure 
8.9 are examples of this assay).
Having established that the MSCs required GRGDY peptide to be present (not an unsurprising 
result given that the MSCs are selected from the rest of the bone marrow cells on the basis of 
being anchorage dependent cells), a series of experiments was performed to optimise the type 
of alginate and alginate:peptide:sulpho-NHS:EDC ration (A:P:S:E ratio). This experiments 
suggested that 50x GRGDY Manugel DMB performed best. Figure 8.10 shows the results 
of a typical experiment carried out during this optimisation phase comparing 1 x, 1 Ox and 
50x GRGDY-Manugel DMB alginate, again there is a good correlation between the sheets 
and the beads for a given reagent concentration with respect to MSC interaction. In Figure 
8.10, both the 50x GRGDY sheets and beads showed extensive elongation and migration of 
the MSCs by day 4. In comparison, the MSCs did not interact with the 1 Ox GRGDY sheets, 
remaining balled up or aggregating into loose clumps. A very small minority of cells did 
however interact weakly with the 1 Ox GRGDY beads mainly close to the surface of the bead. 
At the lowest concentration, lx  GRGDY, the MSCs did not interact with either the sheets or 
the beads (data not shown).
Since the 50x GRGDY-Manugel DMB combination performed significantly the best with
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Alginate
Sheet
GRDGY
Alginate
Beads
Alginate
Beads
GRGDY
Alginate
Day 7
Day 7
Figure 8.9
Comparison of the interaction of adult MSCs 
with derivatised and non-derivatised alginates 
on sheets and in beads.
In the first 24 hours the MSCs were able to 
quickly interact with the Manugel DMB 50x 
GRGDY-alginate i.e. attach, elongate and 
migrate, on both the surface of the sheets and 
within the beads. In the derivatised beads, 
intercellular networking can also be observed. 
On the non-derivatised alginate sheets there was 
no cell interaction, instead the cells were seen to 
aggregate into clumps by day 1 (1T) which were 
lost by day 3 leaving just a few unattached cells. 
Likewise there was no cell elongation observed 
within the non-derivatised alginate beads. (N.B. 
Debris is marked li)
Live/dead viability/cytotoxicity assays (L-3224 - 
Molecular Probes, Eugene, Oregon, USA) 
revealed a very high percentage of live cells 
(fluoresce green under ultraviolet light c.f. red 
when dead) in both the derivatised and 
non-derivatised alginate beads (Day 7 bead 
images are examples of this assay).
Sheet
lOx
GRGDY
Sheet
50x
GRGDY
Bead
lOx
GRGDY
Bead
50x
GRGDY
Figure 8.10
Comparison of human adult MSC interaction with sheets and beads made from Manugel 
DMB using different derivatisation reagent concentrations (lx , lOx and 50x).
Both the 50x GRGDY sheets and beads showed extensive elongation and migration of the 
MSCs by day 4. In comparison, the MSCs did not interact with the lOx GRGDY sheets, 
remaining balled up or aggregating into loose clumps. A minority of cells did however 
interact weakly with the 1 Ox GRGDY beads. At the lowest concentration, 1 x GRGDY, the 
MSCs did not interact with either the sheets or the beads (data not shown). (The edges of 
the beads are marked tf).
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respect to cell interaction (i.e. the majority of MSCs would elongate and network) in all the 
bead experiments, it was decided to continue with this combination for all the future GRGDY- 
alginate studies.
8.3.1.3 GRGDY-alginate tubes
Having established the optimum conditions in beads, GRGDY-alginate was used to produce 
tubular constructs using both the float activated by the hand driven fluid device and the 
automated pump driven fluid devices, see Chapter 5 and Chapter 6 respectively. Preliminary 
tube forming experiments used a sterilised 4 mm inside diameter glass tube and a sterilised
3.4 mm float with 50x GRGDY Pronova MVG alginate (preparation process described 
above) and A7r5 cells at 105 per ml. These experiments were performed either prior to, or, 
in parallel with the bead experiments i.e. before the conclusion that A7r5s were not capable 
of interacting within the GRGDY-alginate but after both the collagen experiments (Section 
8.2) which confirm that A7r5s could interact within a three-dimensional matrix and the sheet 
experiments (Section 8.3.1.1) which confirmed the ability of A7r5s to interact with the surface 
of GRGDY-alginate. This mixture was cross-linked with sterile filtered 1 % calcium chloride 
solution. Cross-linking time was 10 minutes and then the tubes were flushed through with 
supplemented media. The entire tube forming apparatus including the construct in situ was 
then transferred to a humidified, 10% C 02 37°C incubator. At daily intervals the tubes were 
flushed through with fresh medium which was pre-equilibrated by being left in the incubator 
in an unsealed container. This experiment was continued for up to one month. During this 
time the constructs could be viewed using a light microscope although the 1.6 mm thick 
curved walls of the 7.2 mm diameter glass fabrication tube meant that viewing was only 
really at its best when totally perpendicular to the glass tube (very small viewing angle) or 
tangentially (i.e. at the very edge), otherwise cells appeared extremely distorted. Being only 
able to view at these locations required the glass tube to be rotated in order to assess the state 
of the entire construct wall at a given point along the its length. Overall viewing tangentially 
proved to be the preferred option and this is reflected in the images in the various figures. 
With the A7r5 cells encapsulated in the GRGDY-alginate, a very small number of cells were 
seen to elongate and this appeared to only happen in the extraluminal gap (i.e. between the 
construct and the inner wall of the glass tube). No elongation was observed within the actual 
construct (a result consistent with the A7r5-GRGDY-alginate bead experiments). The cells 
which elongated in the extraluminal space may have left the construct due to slight hydrogel 
disintegration and then floated onto the glass wall where they became attached. However, an 
experiment seeding cells (i.e. with no alginate scaffold) directly into glass tubes failed to show 
cell attachment over similar periods of time.
Performing the above tube experiment with MSCs and refeeding the constructs either once
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or twice per day did show cell-GRGDY-alginate interaction. Figure 8.11 shows selected time 
points from the first 22 days of such a study whilst Figure 8.12 shows more magnified images 
of the crucial day 1 and day 2 period when the cells are starting to attach and orientate. In 
Figure 8.12, both the images are of exactly the same location on the construct. The day 1 image 
is very difficult to interpret but possibly contains cells starting to interact with the derivatised 
alginate i.e. elongating but in a totally random and disorganized manner. However, by day 
2, the cells have become orientated and aligned in the construct parallel to the long axis of 
the construct. The aligned cells appear to be to a maximum thickness of 4 - 6 cells deep and 
arranged in an overlapping pattern (for comparison, the observed arrangement was very 
similar to that found histologically in normal smooth muscle in vivo). In Figure 8.11, the day 
3 - 1 7  images shown are also in approximately the same location in the same construct. 
The alignment and depth of the aligned cells appears to remain approximately constant for 
the first 7 - 1 1  days but later in the series the "growth" appears to continue but to be more 
disorganised. In addition to the collective "growth" in the construct, discrete cell aggregates 
appear to be forming by day 17 which become mature by day 22. It is possible that these 
aggregates are extraluminal i.e. between the construct and the inner wall of the glass tube and 
formed from cells shed from the construct as the GRGDY-alginates gel starts to degrade.
The tube experiments described above were re-fed by bolus i.e. refeeding medium at discrete 
time intervals. In vivo, bolus refeeding never occurs, nutrient is always continuously delivered 
by the pulsed circulatory system. Ideally a blood vessel bioreactor probably needs to be 
pulsatile flow (Niklason et al, 2001), however, it is generally agreed that at the very least 
it must have flow. It was therefore decided to construct a simple flow circuit where by fresh 
media continuously flowed through the glass tube containing the construct. The system was 
a total loss system i.e. culture media was not recirculated after passing through the construct. 
The circuit consisted of a syringe driver (Harvard PHD 2000) positioned outside the incubator 
with a 60 ml plastic syringe (Becton-Dickinson) filled with supplemented media. The syringe 
was linked to the 4 mm I/D  glass tube using 1.6 mm I/D  sterilised silicon tubing via an 
adaptor to the device's base unit to accommodate the small tube size. An excess length of 
silicon tubing was used in order to allow approximately 0.5 m to be inside the incubator where 
due to the nature of the material, the temperature, 0 2 and C 02 would all equilibrate with the 
incubator prior to the media entering the construct. A visible change in media colour was 
noted between the medium upon immediately entering the C 02 incubator compared to when 
the medium entered the construct. The open end of the glass tube had another piece of sterile 
tubing added to its end in order to allow spent media to be collected in a sterile glass beaker. 
It was decided to set the syringe driver to give a flow rate compatible with approximately 3 
media changes in a 24 hour period i.e. 0.2 mlhr'1, since the fabrication device has a total
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Figure 8.11
Time series for human adult mesenchymal stem cells encapsulated in a 50x GRGDY-Pronova MVG alginate tube viewed with a light microscope whilst in 
situ in the glass walled bioreactor.
The images are taken at the inner edge of the glass tube which both fabricated the construct and is now acting as its bioreactor (marked TT). At this 
location, a tangential view of the inner glass wall of the tube is observed that by previous experiments had been found to be one of the optimum positions 
for obtaining good views despite the lensing effect due to the curvature of the wall of the glass tube (data not shown). Thus by rotating the glass tube 
around its longitudinal axis it was possible to sequentially image the entire construct. The day 3 - 1 7  images shown are all in approximately the same 
location in the same construct. By day 3, the cells start to be seen to be elongated and aligning in the construct parallel to the long axis of the construct. 
The day 7 image shows these aligned cells to be to a depth of up to 4 - 5  cells thick and in an arrangement similar to that found histologically in normal 
smooth muscle in vivo. Later in the series the "growth" appears to continue but to be more disorganised. In addition to the collective "growth" in the 
construct, discrete cell aggregates appear to be forming by day 17 which become mature by day 22. It is possible that these aggregates are extraluminal 
i.e. between the construct and the inner wall of the glass tube and formed from cells shed from the construct as the GRGDY-alginates gel starts to degrade 
(aggregates marked U-).
Figure 8.12
Enlarged images of cell alignment in the first two days of culture following fabrication of a 
tubular construct of human adult mesenchymal stem cells encapsulated in 
GRGDY-Manugel DMB alginate viewed in situ in the bioreactor.
Both images are of exactly the same location on the construct. The day 1 image is very 
difficult to interpret but possibly contains cells starting to interact with the derivatised 
alginate i.e. elongating but in a totally random and disorganized manner. However, by 
day 2, the cells have become orientated and aligned in the construct parallel to the long 
axis of the construct. The aligned cells appear to be to a maximum thickness of 4 - 6 cells 
deep and arranged in an overlapping pattern very similar to that found histologically in 
normal smooth muscle in vivo. (The inner edge of the glass tube is marked ft).
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volume of approximately 1.5 -1 .6 ml allowing for dead space in the base unit. In addition to 
the regular controls, bead controls were also produced. Figure 8.13 shows selective images 
from this experiment which compared the interaction of human adult MSC in beads and tubes 
made from Manugel DMB using different derivatisation GRGDY peptide concentrations (1 x, 
1 Ox and 50x) but maintaining all the other reagent concentrations constant. In all the different 
concentration GRGDY beads there is extensive elongation and networking of the MSCs by 
day 7. In comparison, on day 1 there is some elongation of cells into a random arrangement 
within the tube matrix which becomes more orientated by day 7. However, unlike the beads 
which maintained (or increased) their cell densities, the density of cell in the tube declined 
possible due to GRGDY-alginate degradation. This degradation may have been higher than 
the earlier bolus refeeding experiments due to the continuous feeding regimen washing away 
the Ca2+ cross-linking ions faster. A similar experiment in shown in Figure 8.14 which also 
contains a time series for adult human MSCs encapsulated in a 50x GRGDY-Manugel DMB 
alginate tube. On day 1, the majority of cells are starting to elongate into a patchy random 
network which by day 9 appears to be more densely packed, almost continuous and to have 
some degree of alignment with the long axis of the glass tube. This orientation is continuing 
on day 12 with overall the packing arrangement appearing to be fairly homogeneous along 
the length of the construct. Clearly more work is required to study the effect of continuous flow 
and its rate on GRGDY-alginate degradation.
Overall the MSC-50x tubular constructs displayed similar cell elongation and networking to 
the beads with the addition of the beginnings of regular aligned cell orientation in the long 
axis of the construct. For artery a circumferential (as opposed to longitudinal) alignment is 
probably preferred since this is the arrangement in normal artery in vivo.
8.3.2 Alternatives to using GRGDY for derivatising alginate
It was decided not to limit the derivitisation purely to the covalent bonding of only the 
pentapeptide GRGDY to the alginate, but to also look at other alternatives. GRGDY is a 
relatively short peptide with the functional motif RGD which couples with cell surface integrins 
e.g. a5 P, which is the most abundant p integrin on proliferating smooth muscle cells (Hunt et 
al, 2002). However, due to of the motif's small size and length in addition to its distance (1 
x glutamine residue) from the large alginate backbone, it was decided to produce alginate 
derivatives with the functional RGD motif spaced away from the backbone, in order to 
potentially increase the accessibility of the RGD motif to the cells. The spacer itself may also 
have an effect on the RGD binding site in terms of it efficiency to bind cells. For example, 
Ruoslahti and Pierschbacher have demonstrated that the amino acids surrounding the RGD 
motif greatly affect the receptor-ligand specificity, an effect brought about by their influences 
on the conformational shape of the RGD receptor site (Ruoslahti and Pierschbacher, 1987).
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Figure 8.13
Comparison of human adult MSC interaction in beads and tubes made from Manugel DMB 
using different derivatisation GRGDY peptide concentrations (lx , lOx and 50x) but 
maintaining all other reagent concentrations constant.
In all the different concentration GRGDY beads there is extensive elongation and 
networking of the MSCs by day 7. In comparison, on day 1 there is some elongation of 
cells into a random arrangement within the tube matrix which becomes more orientated by 
day 7. However, unlike the beads which maintained (or increased) their cell densities, the 
density of cell in the tube declined possible due to alginate degradation. (The edges of the 
beads are marked 1T)
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Figure 8.14
Time series for adult human MSCs encapsulated in a 50x GRGDY-Manugel DMB alginate tube viewed with a phase contrast light microscope whilst in situ 
in the glass walled bioreactor.
The orientation of all the images is such that the glass tube wall is at the their lower end (where included marked It). However, the Day 1 and 9 images 
are taken at the inner edge of the glass tube which both fabricated the construct and is now acting as its bioreactor; whilst day 3 and 9 images were 
obtained more towards the midline of the tube to try and capture from another perspective the widespread cell orientation occurring within the tubular 
construct. The trade-off of this viewing location is unfortunately increased distortion due to the lensing effect of the glass walled tube. The horizontal parallel 
lines present in both the day 1 and 12 images are imperfections (scores) in the glass' surface which occasional occur when the mandrel is removed from 
the precision bore glass tube after its extrusion (marked > <). Balled up cells occupying the scores on day 1 but by day 12 these cells are no longer present, 
presumably they fail to attach and die or are washed away on changing the medium. On day 1, the majority of cells are starting to elongate into a patchy 
random network which by day 9 appears to be more densely packed, almost continuous and to have some degree of alignment with the long axis of the 
construct. This orientation is continuing on day 12 with overall the packing arrangement appearing to be fairly homogeneous along the length of the 
construct.
Two approaches were used, namely adding extra glutamine residues (GGGGRGDY) and 
adding a polyethylene glycol spacer (PEG), (PEG4-GRGDY and PEG4-RGDY). Altering 
the specific RGD motif was not undertaken since it has been shown that single amino acid 
substitutions dramatically reduces the biological activity of the peptide (Ruoslahti, 1996).
8.3.2.1 GGGGRGDY-alginate
The octapeptide GGGGRGDY-alginate had previously been covalently bonded to alginate 
by Rowley (Rowley and Mooney, 2001). Rowley had successfully demonstrated myoblast 
differentiation on the surface of preformed GGGGRGDGY-alginate hydrogels. Our aim was 
to examine its potential with respect to smooth muscle cells (and later adult mesenchymal stem 
cells) when the cells are embedded in a precise three-dimensional shape.
GGGGRGDY was obtained from Neosystem Groupe SNPE (Strasbourg, France) in a lyophilised 
form in 10 mg aliquotes. Using the carbodiimide chemistry described in Section 3.7.1 this 
peptide was covalently bonded to the alginate backbone. However, whereas the reaction for 
the previous GRGDY attachment was relatively straightforward, the longer peptide derivative 
posed greater problems; presumably due to its greater length. The resulting compounds were 
unsatisfactory because the GGGGRGDY-alginate would become irreversibly set during the 
dialysis stage. Attempts to reverse the setting process e.g. trying to dissolve the hydrogels in 
high concentration sodium citrate (1 M) for lengthy periods (>24 hours), failed to breakdown 
the gels. The reason for the gel setting during the dialysis step is unknown and informal 
discussions with Dave Mooney failed to resolve the issue. However, it would appear that the 
cross-linked GGGGRDGY compound produced was covalently bonded, hence the inability 
to be broken down by the sodium citrate. When small pieces of the GGGGRGDY gel were 
placed in Microwells with A7r5 cells and supplemented culture media a small number of cells 
attached and elongated. The majority, however, failed to attach and settled on the bottom of 
the microwell where they attached and readily proliferated.
8.3.2.2 Polyethylene glycol-GRGDY-alginate
The rational behind the polyethylene glycol spacer was again to increase the ligand 
accessibility, but instead of using additional amino acids (glutamine residues) the plan was 
to use polyethylene glycol (PEG). Using PEG has several key advantages (Halstenberg et al, 
2002, Eiselt et al, 1999 and Shin et al, 2002):
•  Ease of chemical modification e.g. good control over PEG chain length
• Inert with respect to cell attachment
• Flexible molecule and therefore potentially allows better ligand accessibility
• Low cost of production relative to "amino acid spacers"
• Biocompatible e.g. not immunogenic
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There was also a literature to draw on of previous researchers who had worked with PEG and 
the RGD motif including Drumheller and Hubbell, 1994, Eiselt et al, 1999 and Halstenberg 
et al, 2002.
It has been demonstrated by Houseman, that for a fixed density of an attachment peptide, 
altering the spacer length can be expected to alter the degree of cell attachment and interaction, 
(Houseman and Marksich, 2001).
Another advantage of using PEG is that the amino acids on either side of the RGD motif (i.e. 
the glutamine residue (G) and the tyrosine residue (Y) in Section 8.3.1) have a direct influence 
on receptor-ligand interaction and specificity, (Ruoslahti et al, 1987). Therefore by using a 
PEG spacer with GRDGY motif used in Section 8.3.1, it was possible to directly compare 
the derivatised alginates knowing that the RGD's receptor-ligand specificity was theoretically 
unchanged unlike GGGGRDGY, where the extra glutamine residues may have a direct action 
on the RDG interaction site.
Tetraethyleneglycol-GRDGY (PEG4-GRDGY) was prepared in collaboration with Ros Selfe/ 
Dr. Alethea Tabor in the Department of Chemistry at UCL. Using the same carbodiimine 
chemistry described in Section 3.7.1, this PEG4-GRDGY peptide was covalently bonded to 
alginate (1% ISP Manugel - Pharmaceutical grade in 0.1 M MES buffer made up with 0.3 M 
sodium chloride solution in WFI, final pH adjusted using sodium hydroxide (pharmaceutical 
grade) to pH 6.5). Reactions were set up such that the final peptide densities were 10 mg 
and 50 mg of GRGDY motif per gram of PEG4-GRDGY-alginate. Controls of 10 mg and 50 
mg GRGDY-alginate were produced in parallel (as per Section 8.3.1) in order to allow exact 
comparison between linker and non linker GRGDY. Both beads containing cells and sheets 
for cell surface studies were prepared from the PEG4 -GRDGY-alginate and the controls as 
previously described in Section 3.4.1 and Section 3.4.2.
Overall the use of PEG4 -GRDGY-alginate gave good results. The bead experiments using 
adult mesenchymal stem cells at a final density of 105 -106 cell ml'1 of scaffold material 
demonstrated cell elongation for both the linker and non linker alginate. Figure 8.15 shows 
the results from an experiment to the compare human adult MSC interaction in beads made 
from Manugel DMB using different derivatisation GRGDY peptide methods of attachment 
(PEG4 linker versus non-linker) at different concentrations (lx , lOx and 50x). In the 50x 
concentration GRGDY and PEG4-GRGDY alginate beads there was extensive elongation and 
networking of the MSCs by day 2. Both the 1 Ox conditions showed a moderate degree of cell 
interaction, whilst the lx  conditions failed to support cell interaction (data not shown). Once 
again the 50x concentration was clearly superior, however there was no obvious advantage 
of having the PEG4 linker present.
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Figure 8.15
Comparison of human adult MSC interaction in beads made from Manugel DMB using 
different derivatisation GRGDY peptide methods of attachment (PEG4 linker versus 
non-linker) and concentrations (lx, lOx and 50x).
In the 50x concentration GRGDY and PEG4-GRGDY alginate beads there was extensive 
elongation and networking of the MSCs by day 2. Both the lOx conditions showed a 
moderate degree of cell interaction, whilst the lx  conditions failed to support cell 
interaction (data not shown). Once again the 50x concentration was clearly superior, 
however there was no obvious advantage of having the PEG4 linker present (The edges of 
the beads are marked It).
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Overall for this set of bead experiments, for a given peptide density, considerably more cell 
elongation was observed in the non linker peptide-alginate than in the linker PEG-peptide- 
alginate. Also, the number of cells elongating increased as the peptide concentration increase 
for both the linker and non-linker alginates, i.e. 10 mg of motif per gram of derivatised 
alginate was inferior in cell interaction than the 50 mg per gram version.
Sheet experiments using the same PEG-peptide-alginate had less substantial results and are 
difficult to interpret due to technical problems with the sheet making process e.g. the linker 
alginate was prone to trapping air bubbles which made interpreting light microscope studies 
difficult. Air bubble trapping had not been a problem with linkerless alginates and the effect 
may be due to the change in viscosity or surface tension. However, overall there was little 
difference between the linker and non linker alginates with both appearing to support cell 
surface attachment and spreading. However, once again the linker was out performed by the 
non-linker alginate in terms of cell elongation. Likewise, the higher density peptide (50 mg) 
for both linker and non-linker out performed the lower density peptide (10 mg). Overall there 
was once again good correlation with respect to MSC interaction between the sheet and the 
bead experiments.
Since the higher density peptide had demonstrated a superior performance with respect to 
cell attachment and elongation, it was decided to increase the concentration of the derivatised 
alginate in solution. This would not change the overall peptide:alginate ratio, but might 
potentially increase the overall activity of the motif in the scaffold. In order to concentrate the 
linker-alginate and the control alginate, freeze drying was undertaken for 24 hours at -70°C 
at 1 O'1 mbar (Edwards Freeze Dryer Modulo with a Savant Two Stage VP100 vacuum pump), 
which reduced the overall volume by approximately 50%. Identical cell experiments to the 
above were performed with these lyophilised PEG4 -GRDGY-alginates, which demonstrated 
that this concentrating step greatly reduced biological activity which only partially returned 
on diluting the compound back to its original volume with WFI prior to adding the cells.
The result again confirmed the reduction in biological activity once derivatised alginate is 
flash frozen with liquid nitrogen and then placed in a freeze dryer. Interestingly the ability of 
the concentrated material to cross-link and form beads, gels and tubes appeared unchanged 
except stronger constructs were produced as would be expected by using higher concentration 
alginate solutions.
8.3.2.3 PEG4-RDGY-alginate
In order to further understand the relationship between the RGD motif and its surrounding 
environment, i.e. the glutamine (G) and tyrosine (Y) residues on either side of the RGD motif, 
it was decided that instead of using the pentapeptide GRDGY to use just the quadrapeptide
- 2 0 0 -
RGDY component plus the linker. Glutamine and tyrosine are both amino acids with 
uncharged polar side chains. Because of their uncharged nature, these amino acids tend to 
be relatively hydrophobic and as such are usually found on the inside of the proteins they help 
form. (Albert et al, 1989). It was decided to investigate the loss of the first glutamine residue 
since PEG4-RDGY is slightly easier to produce than PEG4-GRGD. This PEG4-quadrapeptide 
peptide was also made in collaboration with Ros Selfe/Dr. Alethea Tabor in the Department 
of Chemistry at UCL.
Therefore linker-RGDY, (PEG4 -RGDY), was covalently bonded to alginate and formed into 
beads with cells encapsulated and sheets as per PEG4 -GRDGY experiments described in 
Section 8.3.2.2. Non linker GRGDY controls were produced in parallel. Overall a very 
similar result to the linker GRGDY alginate was achieved i.e. cell attachment and elongation 
was facilitated but once again at a lower level than that of plain GRGDY-alginate. Figure 8.16 
shows the results of an experiment to compare adult human MSC interaction in beads made 
from Manugel DMB alginate using PEG4-RGDY with GRGDY as the cell attachment motif at 
1 x, 10x and 50x concentrations. The 10x and 50x concentration conditions showed good 
cell interaction by day 2 - 3, whilst no cell interaction was observed in the 1 x concentrations 
(data not shown). Interestingly over the course of 5 days, there was little difference in the cell 
networks between any of the 1 Ox or 50x concentrations. This results obtained using PEG4- 
RGDY-alginate suggests that the amino acid glycine may potentially not be required at the 
N-terminus of the RGD sequence for cell attachment although more research is required 
to evaluate this fully including the comparison of PEG4-RGDY-alginate with PEG4-GRGDY- 
alginate.
8.4 Conclusion
Experiments performed with non derivatised alginate consistently lacked evidence that the 
cells were attaching or proliferating with the result that the cells stayed balled-up until they 
eventually died. Increasing the cell density to 108 cells per ml of alginate solution also made 
no difference despite the greater cell density bringing the cells into closer contact with one 
another but still less tightly packed than they would be in normal tissue. Possibly raising 
the cell concentration further may have merit since this would produce closer cell packing 
and therefore promote direct cell-cell contact and interaction. Close virtual cell-cell contact 
is the normal arrangement in the human body (Radisic et al, 2003). The final cell packing 
arrangement is vital for smooth muscle to function as an organ. In vivo, smooth muscle the 
organ, is composed of elongated smooth muscle cells (each of which is enclosed by a basal 
lamina and a network of reticular fibres (collagen type III)), blood vessels and nerves. The 
basal lamina and the network of reticular fibres constitute the endomysium, the function of 
which is to combine the force generated by each smooth muscle cell into a concerted action
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Figure 8.16 Comparison of adult human MSC interaction in beads made from Manugel DMB alginate using either PEG4-RGDY or GRGDY as the cell 
attachment motif at either lx , lOx or 50x concentration.
All the lOx and 50x concentration conditions showed good cell interaction by day 2 - 3 .  No cell interaction was observed in the lx  concentrations (data 
not shown). Interestingly over the course of 5 days, there was little difference in the cell networks between any of the 1 Ox or 50x concentrations. (Edge of 
bead where shown marked 1T)
e.g. arterial vasoconstriction. In vivo, smooth muscle cells are fusiform in shape i.e. they 
are largest at their midpoints (which contains the nucleus) and taper toward their ends. To 
achieve the closest packing possible/ the cells line up in parallel with the narrow part of one 
cell lying adjacent to the broad part of neighbouring cells. In this close packed arrangement, 
the smooth muscle cells can function as a syncytium (Junqueira at al, 1986). In vitro, given the 
above close packing arrangement in vivo, smooth muscle cell density may be critical. It may 
be that there is a very precise cut off point i.e. cell densities below a certain value are still too 
dispersed to elongate and proliferate. This is analogous to the cut off seen with adult stem 
cells in GRGDY-alginate where there was little (if any) cell elongation at concentrations below 
106 cells ml'1 and ideally 107 cells ml'1 was required to produce elongation in the majority of 
the cell population.
The other possible concern was that although the cells were capable of elongating and 
proliferation in single layer of flat sheets on the surface of T-flasks, they were not capable 
of elongating in a three-dimensional encapsulated environment. The collagen only matrix 
experiments therefore provided evidence that the A7r5 immortalised rat smooth muscle cell 
line (despite possible phenotype irregularities due to the immortalisation process) was still 
able to elongate in a three-dimensional scaffold, provided there were the necessary cell 
attachment sites.
The addition of alginate to the collagen prior to setting suggested that the alginate did 
reduce the degree of attachment but not totally. The collagen-alginate experiments were not, 
however, optimised but were solely conducted to confirm if the A7r5 smooth muscle cells could 
elongate in the presence of alginate hydrogel in the light of the negative data in Chapter 7. 
Optimisation was not performed since the alginate-collagen setting protocol does not easily 
lend itself to the tube production process for three main reasons. Firstly, the long setting times 
are not compatible with the fast gel forming times required of our particular device. Alginate 
solution becomes a hydrogel (at least at its boundary) in fractions of a second, whereas 
the collagen-alginate gels required minutes. Secondly, there was significant batch to batch 
variability with the commercially supplied collagen solutions. Thirdly, the collagen solutions 
despite being stored at 4°C "aged" such that there were significant differences between 
the setting time of different experiments, even from the same batch of collagen just due to 
short periods of storage (days/few weeks) e.g. later experiments from the same batch would 
demonstrate total loss of their cell attachment properties.
The derivitisation with GRGDY pentapeptide produced alginates with the first indication that 
both A7r5 immortalised rat smooth muscle cells and human adult mesenchymal stem cells 
could elongate on a two-dimensional matrix made from derivatised alginate. However, only 
the MSCs were capable of interacting when encapsulated in the same matrices. The reason
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for the non-correlation between the MSCs and the A7r5s is not clear but may relate to the 
immortalisation process the embryonic rat cells originally underwent to create this immortalised 
cell line. Whilst Mooney and colleagues had demonstrated the ability of myoblasts to attach 
to the surface of GRGDY-alginate (Rowley et al, 1999 and Rowley and Mooney, 2001), the 
experiments with both beads and tubes demonstrated the three-dimensional application of a 
modified version of this approach. It is the ability to produce homogeneously seeded three- 
dimensional structures with viable cells which is key to tissue engineering.
The experiments to distance the attached functional RGD motif from the alginate backbone 
suggest that this area needs further work both in producing satisfactory octapeptide 
GGGGRGDY and also optimising the PEG linker length. Once this optimisation is complete, 
it will then be possible to directly compare the distanced RGD motif with the current "gold 
standard" GRDGY-alginate. The preliminary data suggests that the presence of the spacer 
does adversely effect the ability of the RGD motif to interact with the MSCs.
The experiment using just PEG4-RGDY-alginate suggests that more work is required to better 
understand the minimal requirement for cell attachment. There was insufficient experimental 
evidence to conclude whether RGDY is better that GRGDY as the attachment motif. However, 
it is potentially possible that just RGD-alginate is all that is required. If this was the case, then 
this would significantly reduce both the complexity and cost of the method of derivatising 
alginate such that MSCs (and potentially other suitable anchorage dependent cells e.g. 
primary smooth muscle cells) can attach and elongate.
Finally, the difficulty in freeze drying the derivatised products i.e. the near total loss of 
biological activity, suggests that the peptide may be becoming permanently denatured by 
the process. This area needs focusing on since freeze drying normally represents an excellent 
means of storing such material.
8.5 Future work
The main areas to consider are:
1. Increasing the cell density to test the hypothesis that closer cell-cell distances 
leads to greater cell-cell contact and interaction, this in turn leads to cells 
attaching to one another or producing extracellular matrix (ECM) which 
allows cell-ECM-cell attachment and then proliferation. It raises the important 
question, is cell proliferation required at all in the maturing tissue engineering 
construct? If cells could be added at high enough densities though, not so 
high that the scaffold cannot maintain integrity, then if no further, or minimal, 
proliferation was required, then this could potentially reduce individual 
bioreactor time (and possibly therefore cost) by effectively transferring all the
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cell bulking to the first part of the process, i.e. prior to mixing with alginate 
solution. The biotechnology industry already has a number of tried and 
tested methods for economically bulking-up attachment cells e.g. Cellmate 
and SelecT from The Automation Partnership (Royston, Hertfordshire, UK) and 
Cell Factories from Nunc (Roskilde, Denmark)
2. If it not possible to create constructs with near in vivo cell:synthetic extracellular 
matrix ratios, then cell proliferation within the developing construct will be 
essential. Given that both smooth muscle cells and human mesenchymal stem 
cells are potentially not natural replicators in vivo (Gordon et al, 1990, Wang 
et al, 2002 and Preston et al, 2003), it may be necessary to find low cost 
reagents capable of causing controlled proliferation e.g. ouabain which has 
been demonstrated to stimulate proliferation of vascular smooth muscle cells. 
Ouabain is an endogenous compound with an enormous scientific literature 
(>18,000 publications since 1966) (Abramowitz et al, 2003)
3. An alternative strategy could be to use fibroblasts - a cell type that is well 
known to proliferate whilst encapsulated in alginate. Thus a potential 
alternative option to the differentiation of autologous MSCs into vascular SMCs 
might be to transdifferentiate allogeneic non-immunogenic fibroblasts. Non- 
immunogenic fibroblasts are readily available from neonatal foreskin and 
have already been successfully deployed in FDA approved products including 
Apligraf (Organogenesis, Canton, AAA, USA). Whilst the transdifferentiation 
of fibroblasts into myelofibroblasts occurs in a number of common and well 
described pathological process e.g. hypoxia induced vascular remodelling 
(Short et al 2004, Stenmark et al 2002) and corneal wound healing 
(Funderburgh et al 2001), transdifferentiation into vascular smooth muscle 
has not yet been demonstrated. However, recent research based on animal 
embryological studies by Prof. Karen Hirschi's group at Baylor College of 
Medicine (Houston, Texas, USA) has suggested that this may be possible 
(Hirschi, 2004)
4. Another cell option might be to use immortalised cells since all the arteries 
tissue-engineered to date have required extensive culturing in the order of 
months (Niklason et al, 1999 and L'Heureux et al, 1998). This excludes the 
paediatric applications of Shin'oka - where because of their short length and 
the very young age of the patients, the scaffolds were seeded with cells on 
the actual day of surgery (Matsumura et al, 2003). However, adult somatic 
cells can only divide a finite number of times before undergoing replication 
senescence (growth arrest). This is mainly due to the progressive shortening
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of the cells' telomeres with each cell division. This eventually progresses to 
a critical length which triggers senescence (Sedivy 1998). Depending upon 
the number of cells in the initial sample/biopsy, SMCs may be required to 
proliferate for at least 45-60 population doublings to produce a mechanically 
robust artery in vitro (McKee et al, 2003). Bovine, porcine, human fetal and 
human neonatal cells possess lengthy telomeres, and therefore can divide 
extensively in culture before entering the senescence phase; this has shown 
to be more than adequate to be able to successful engineer arteries in vitro 
(McKee et al, 2003). However, adult human SMCs, a potential source of cells 
to create clinical constructs can only proliferate in vitro to a maximum of 10 -  
30 population doublings before undergoing senescence (Bierman, 1978 and 
Bonin et al, 1999). Furthermore in human SMCs it has been demonstrated 
that their proliferation capacity is inversely proportional to age (Grunwald 
et al, 1983), an undesirable fact given that the majority of patients requiring 
coronary artery bypass surgery will be over 50 years of age.
Human MSCs have also been shown to behave in a similar manner to SMCs 
with growth arrest at approximately 20 population doublings (Kobune et al, 
2003 and Zimmermann et al, 2003). The limited replication life-span of 
both human adult SMCs and MSCs may therefore prove to be a real "show 
stopper" for their use in the construction of tissue-engineered arteries.
One solution to this problem may be to produce immortalised cell lines from 
either MSCs or SMCs. An established method of creating an immortalised 
adult human cell line is to elongate the telomeres using the enzyme telomerase. 
(Nakamura and Cech, 1998) Telomerase is a ribonucleoprotein which in man 
is assembled from a telomerase RNA subunit (hTR) and a telomerase reverse 
transcriptase subunit (hTERT) (Collins and Mitchell, 2002). All human somatic 
cells express hTR, but not hTERT, and thus lack the necessary telomerase 
activity required to maintain telomere length (Collins and Mitchell, 2002). 
However, genetic modification to restore the expression of hTERT in human 
cells has been demonstrated to restore telomerase activity and thus prevent 
senescence (Bodnar et al, 1998). Recently both human MSCs and SMCs 
have been immortalised using hTERT restoration methodology (Okamoto et al 
2002, Kobune etal, 2003 and McKee et al, 2003).
5. The optimisation of the derivatised alginates. All the derivatised alginates 
produced to date require rigorous optimisation to ensure acceptable levels 
of batch to batch variability. This optimisation would need to start with the 
thorough characterisation of the initial alginate. Alginate is a natural polymer
-  206 -
produced from seaweed with highly variable composition in terms of its G 
and M monomer make-up. Batch to batch variability is therefore a potential 
problem unless the material can be characterised. Furthermore, the alginate 
needs thorough purification. At present, even the pharmaceutical grade 
alginate contains unwanted trace elements including lead and arsenic plus 
bacterial and fungal contaminants. Whilst some necessary characterisation 
is performed by the alginate producers which was adequate for proof of 
principle experiments, this is now inadequate for future progress.
6. Future work also needs to include demonstrating the optimal density of cell 
attachment motif to achieve cell attachment and proliferation. Options to 
determine this include using known concentrations of specific monoclonal 
antibodies to the RGD site to compete with the cells for attachment sites. Too 
few RGD motifs and the matrix will not support cell attachment, too many 
may be a hindrance to cell elongation (similar to being embedded in cement), 
detrimentally affect calcium cross-linking or be financially prohibitive.
7. Determination of whether a PEG spacer is beneficial and if so, what is the 
optimum length. Too short and there may be no real benefit (possibly the case 
for the PEG4-GRGDY and PEG4-RDGY experiments). Too long and potentially 
because of its innate flexibility, the PEG linker could fold back onto the alginate 
backbone thus reducing the accessibility of the RGD motif.
8. Thorough investigation of the uronic acid residue component of the chosen 
alginate is required. Rowley etal used 125I-GRGDY as a tracer molecule which 
could then be detected in lyophilised 125l-GRGDY-alginate using a gamma 
counter (Rowley et al, 1999).
9. Determination of the best cell attachment motif to bond to the alginate. Could 
it be just RGD alone or is RGD even the best motif? This work will require the 
use of a non-sense control peptide (Alsberg et al, 2002). An issue specific to 
coronary artery smooth muscle cells is the emerging evidence to suggest that 
coronary smooth muscle cells differ significantly from non cardiac smooth 
muscle cells. (Shi et al, 1996, Scott et al, 1996 and Christen et al, 1999). 
These differences include integrin expression i.e. the very receptor the RGD 
motif is binding to. The integrin adhesion molecules consists of heterodimers 
of non covalently linked a and p subunits. There are (as of 2001) at least 16 
a and 8 P different subunits. (Davenpeck et al, 2001). For blood vessel the 
P1 and p3 integrin families are both involved in the regulation of vascular cell 
functions and pathology (Luscinskas and Lawler, 1994, Sanders, 1994 and 
Shattill, 1995). Of all the integrins expressed on vascular smooth muscle cells
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a5 p, is thought to be the most important for its functioning and proliferation 
potential e.g. a5 (3, plays an important role in vascular smooth muscle cells 
changing from a contractile to an extracellular matrix synthesising phenotype 
(Hedin and Thyber, 1987). Furthermore, in vascular smooth muscle cells a5 
P1 mediates the assembly of fibronectin matrix assembly, which is an essential 
precursor for proliferation (Mercurius and Morla, 1998). This last role of «5 
p, is probably due to it being the primary fibronectin receptor in vascular 
smooth muscle cells. (Takada et al, 1987). Pathologically, another integrin 
v5 P1 has been suggested as a key modulator in arterial narrowing due to 
smooth muscle cell remodelling. (Yee et al, 1998 and Yee and Schwartz,
1999).
However, whilst a5 P, plays an important role in vascular smooth muscle 
modulation, it is not clear whether « v P l  also play a role, albeit to a slightly 
less degree. The integrin av p1 binds to a host of vascular extracellular matrix 
proteins including vibronectin and fibronectin. (Brown et al, 1994). Like a5 
P,, av P1 has also been demonstrated to be involved with fibronectin matrix 
assemble (essential precursor to vascular smooth muscle proliferation) plus 
cellular migration and proliferation. (Charo etal, 1990, Wu, 1997 and Slepian 
etal, 1998). Another integrin, av P3 has been implicated in the pathological 
process of arterial narrowing e.g. neointimal hyperplasia following arterial 
injury. This is the undesirable narrowing of arteries due to individual smooth 
muscle cells expanding in size in response to mechanical stimuli or trauma. 
(Stouffer et al, 1998). Furthermore, competitively blocking av P3 integrins 
after arterial trauma reduces the resultant neointimal hyperplasia. (Srivatas 
etal, 1997).
Davenpeck, (Davenpeck etal, 2001), has demonstrated that porcine coronary 
artery smooth muscle cells express few a5 P3 integrins compared to human 
coronary artery smooth muscle cells. However, Davenpeck suggests that the 
up-regulation of a5 P3 by coronary smooth muscle cells may be a prerequisite 
to their proliferation. This example alone demonstrates the importance of 
identifying and understanding the different integrins and their functions in 
different smooth muscle cell types. Of interest to this project is the difference 
between coronary artery smooth muscle cells and possible sources of these 
cells. Whilst ultimately we require a normal coronary artery for CABG surgery, 
it will be essential to understand the precise phenotype and behaviour of the 
actual autologous cells available to produce such a vessel. To this end, the 
scaffold with its cell attachment sites may be key. Experiments with specific
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integrin binding sites e.g. CRRETAWAC (cysteine-arginine-glutaminc acid- 
threonine-alanine-tryptophan-alanine-cysteine) which is specific for a5 P, 
(Koivunen et al, 1994), may well help resolve which integrins are required 
for cell attachment and/or proliferation of the chosen autologous cell type. 
Finally, it may be essential to switch the encapsulated cells into the desired 
cardiac artery smooth muscle cell phenotype prior to implantation if, for 
example, neointimal hyperplasia is not to ensue.
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9.0 Optical coherence tomography
For tissue-engineered products to become first-line therapies in routine clinical practice, they 
will need to be both more effective than conventional therapies whilst demonstrating a high 
degree of safely. This will require the constructs to be produced in a highly reproducible 
and economic manner. This will necessitate constant monitoring techniques to be employed 
which need to be both non invasive, non harmful to the developing tissue construct and cost 
effective.
The technology chosen for this project to achieve the potential for continuous non invasive, 
non harmful monitoring is optical coherence tomography (OCT). It is believed to be one of the 
earliest deployments of OCT in tissue engineering. Prior applications include various clinical 
applications, namely ophthalmic (viewing pathological progressive eye disease e.g. macular 
degeneration, the leading cause of blindness in those aged over 55 in the Western World), 
new clinical applications (e.g. determining cancerous changes in oesophageal tissue in vivo) 
and examining industrial coatings. Its application to this project includes the monitoring of 
vessel wall thickness plus some very preliminary data on flow through the construct whilst in 
situ (Mason et al, 2004a, Mason et al, 2004b).
9.1 Background on OCT
OCT represents a paradigm shift over conventional optical light microscopes employing 
advanced photonics and fibre optic technology. It is capable of high resolution, cross- 
sectional imaging of materials and biological tissues. OCT is frequently described as the 
optical equivalent of ultrasound scanning (USS) (Schmitt, 1999, Tadrous 2000 and Fujimoto 
et al, 2000). This analogy is made since OCT involves shining a beam of near infrared 
light into tissue and then sensing the magnitude and depth of any light reflected back (back 
reflection or back scatter i.e. the light equivalent of acoustic echo), (Tadrous, 2000) from the 
structures within the tissue.
Professor James Fujimoto at MIT, the principle proponent of OCT, believes it is best for 
illustrative purposes to describe the visualisation of the operation of OCT by thinking of a 
light beam as being composed of short optical pulses, however, in reality whilst OCT can 
be performed using short pulse light, most OCT system actually use continuous wave short 
coherence length light (Fujimoto etal, 2000). The following account therefore uses this "short 
optical pulse" model when describing the various unit operations that make up OCT.
With USS, the relatively slow speed of sound allows the detection of the tissue's structures by 
measuring directly the time of flight of individual pulses of sound from the emitter to the target 
and back to the receiver. The velocity of sound in water is in the order of 1500 msec1 whereas
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the velocity of light in water is in the order of 3 x 108 msec'1. Because the velocity of light is 
many orders of magnitude greater such direct measurement even using the most advanced 
electronics is not possible. Since distance or spatial information can be determined from the 
time delay of reflected light (i.e. equivalent to echo delay in USS) by using the formula:
Reflected light Distance travelled by reflected light
delay Velocity of light
Thus the measurement of distances or spatial dimensions on the 100 pm scale (a typical 
scale for USS) has an echo delay in the order of 100 nsec (100 x 1 O'9 seconds) for sound. 
However, when employing light and resolving at the 10 pm scale (a typical scale for OCT) 
the reflected light delay is in the order of 30 fsec (130 x 1 O'15 sec). Since femtosecond 
timing is not possible using direct electronic detection, an alternative technology is employed. 
The technology is based on Michelson interferometry, an idea which resulted is German 
born Albert Michelson (1852 - 1931) receiving a Nobel Prize for Physics in 1907 (Kyle 
and Shampo, 1981). Michelson's technique when deployed by OCT (termed low-coherence 
optical interferometry) indirectly measures the reflected light delay and the intensity of this 
back scattered light by comparing it to light from the same source that has travelled a known 
reference path length and time delay. In terms of Fujimoto's simplified model, low coherence 
light is made up of a number of pulses of light, each pulse lasting for an identical period 
of time. The time duration of the individual pulses is known as the coherence length of the 
light source. Overall, the shorter the coherence length of the light source, the better the final 
resolution of the particular OCT device.
OCT in its simplest form involves a pulse of low coherence light being split into 2 equal parts, 
see Figure 9.1. One half of the beam is sent to the specimen being investigated and the other 
half to a reference mirror. Light reflected back from the specimen is combined with the light 
reflected back from the reference mirror and detected by a photo detecting diode coupled to 
a computer to store and process the data. By moving the reference mirror, the path length 
travelled by both the beams of light can be made identical, i.e. to within the coherence 
length of the particular light source. When this occurs, the two beams will have their light 
waves in phase, so called constructive interference. The position of the reference mirror 
when constructive interference occurs is therefore an indirect measure of the depth within 
the specimen from which the light was reflected back. The magnitude of the constructive 
interference effect is a measure of the strength of the reflection (Tadrous, 2000). Thus the 
reflected light delay and the intensity of the backscatter from structures within the specimen 
can be indirectly measured by detecting and demodulating the interference output of the
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Figure 9.1
Principle of Michelson interferometry.
Interferometry works on the principle that when two light waves in exactly identical phase 
coincide with one another amplification will occur, however, if they are in exactly the 
opposite phase, they will cancel one another out.
Light from the light source is divided into two paths by the beam splitter (half-silvered 
mirror); one to the sample and one to the reference mirror. This light is reflected back from 
both the sample and the reference mirror, recombined prior to reaching a detector.
If the two path lengths differ by a whole number of wavelengths, constructive interference 
will occur resulting in a strong signal at the detector, whereas if they differ by exactly half a 
wavelength, the outcome will be destructive interference and no light will reach the detector. 
Thus the depth dimension of the sample is explored by scanning the optical path difference 
(OPD). The maximum interference signal is obtained for an OPD = 0. A reflective depth 
profile (A-scan) is obtained by axial scanning. This means changing the OPD by moving 
the mirror back in the reference path (Podoleanu et al, 2004).
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interferometer while scanning the reference path length.
The above process gives a series of measurements along a single line of light delivered 
perpendicularly into the specimen i.e. an axial scan (A-scan). In order to build up a more useful 
two-dimensional data set and then using a computer to generate a two-dimensional image 
of the specimen the specimen is moved perpendicular to the beam of light (transverse scan). 
This creates a single cross-sectional view of the object under examination. Conventionally 
the data is displayed as either a logarithmic grey scale or as a false colour image. By using 
tomographic software, it is possible to process the data in order to view any cross sectional 
plane within the scanned area analogous to a clinical CT or MRI scan.
Two of the most important parameters for characterising the performance of any imaging 
device are:
• Image resolution
• Overall image depth
For USS, the wavelength and frequency of sound used determines the device's resolving 
power. For example, in a typical clinical USS system the sound waves produced are in the 
order of 10 MHz. This order of frequency results in a resolution of approximately 150 pm. 
Because sound waves at 10 MHz are easily transmitted into most biological tissues, it is 
therefore possible to image to a depth of approximately 10 cm, thus being able to image the 
majority of the human body. However, for USS to achieve greater resolving power (15 - 20 
pm), much higher sound frequencies are required (>100 MHz), this higher frequency is much 
less easily able to penetrate the body (maximum of a few mm). Thus, there is a trade-off 
between resolution and tissue penetration. In contrast, OCT has far higher resolving power 
than USS, being able to resolve structures down to 1 pm in size and is sensitive to differences 
in refractive index between different tissue structures (Fujimoto et al, 2000). Unfortunately, 
light unlike sound, is highly scattered by tissue and thus limits penetration to a maximum of 
approximately 4 mm (Fujimoto, 2003b).
Since its invention, OCT has had a very rapid adoption by the clinic. The technique was first 
demonstrated in vitro by Fujimoto in 1991 (Huang et al, 1991). Two years later the first in 
vivo OCT imaging was performed in humans (Fercher et al, 1993 and Swanson et al, 1993). 
By 2000, at the New England Eye Centre alone over 10,000 patients had benefited from 
this imaging modality. Today over 1600 hospitals have OCT machinery installed (Fujimoto, 
2003a) To date, OCT's main clinical applications have been in the field of ophthalmology 
e.g. macula degeneration, an incurable eye disease which affects more than 10 million 
Americans (Drexler et al, 2003). However, its clinical role is now extending into many 
other areas including cardiovascular disease (Brezinski et al, 1996), oncology (Fujimoto
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et al, 1995), dermatology (Welzel, 2001, gastrointestinal medicine (Brand et al, 2000), 
respiratory medicine (Yang et al 2004), neurology (Boppart et al 1998c) and dentistry (Otis 
et al, 2000). Effectively, OCT is producing an optical equivalent (optical biopsy) of the former 
traditional surgical excision biopsy but in real time. By being able to resolve down to 1 pm, 
the method offers the histopathologist a potential alternative to conventional histology and 
cytology. Furthermore, in comparison to conventional excision biopsy, light biopsies are far 
safer and much less painful, being totally non-invasive (OCT does not require direct contact 
unlike USS which requires close contact including the presence of optical coupling gel). Since 
these images are in real time, diagnosis is immediate as too can be necessary advice to the 
surgeon e.g. providing information that all of a cancer has been removed (excision margin). 
In current clinical practise OCT can resolve structures in the region of 2-4 pm (Boppart et 
al, 1998a and Bouma et al, 1995 and Boppart et al, 1997 and Fujimoto et al, 1995 and 
Fujimoto et al, 1998), not yet as good as conventional light microscopy, but adequate to 
distinguish tissue morphology. However state-of-the-art research devices can easily resolve 
individual animal cells and to be further able to distinguish nucleus from cytoplasm with some 
degree of intranuclear detail (Tadrous, 2000). However, in development are OCT systems 
using short pulse Ti:Al20 3 lasers which generate coherence lengths of approximately 2 optical 
cycles which produce resolution in tissue in vivo approaching 1 pm (Drexler et al, 1999 and 
Boppart et al, 1998b). At this level of resolution even cell and organelle membranes are 
clearly visible. At present femtosecond lasers are not an option clinically due to their high 
cost (over $250,000) and complexity. However, the OCT industry is being greatly aided in 
its research and development by the giant global telecommunications industry with its similar 
demands for lower cost light sources and optic fibre cables.
It was against the above background of a fast developing technology with the ability to 
already perform high resolution in situ in vivo light biopsies that it was decided to evaluate if 
OCT has a role to play in the automation of tissue engineering and in the monitoring of the 
fabrication of substitute artery in particular.
In terms of application to vascular studies, OCT has already started to demonstrate its potential 
for imaging blood vessels both in vitro and in vivo, including Fujimoto's research group who 
had been the first to successfully image microvascular tissue (Brezinski et al, 1997). Since this 
preliminary work, in vivo vascular applications started to be reported (Brezinski et al, 1997, 
Brezinski, 2002, Kehlet et al, 1999, Nelson et al, 2001, Barton et al, 2001 and Wong et al, 
2002). The uses to date have included the three-dimensional visualisation of blood vessels to 
assist in assessing the efficacy of laser therapy for port-wine stain birth marks (Kehlet et al, 
1999, Nelson et al, 2001). In order to treat port-wine stains it is necessary to permanently 
and significantly reduce the blood flow to the lesion. This is performed using laser therapy to
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create irreversible microthrombus formations in the vessels to and from the lesion. However, if 
the position and number of the relevant vessels is unknown then a common result is incomplete 
or unacceptable clinical outcomes. However, when optical Doppler tomography (ODT) was 
used as the imaging device, the efficacy of the laser treatment could be observed in real time. 
ODT combines laser Doppler flow studies with OCT, thus it is possible to visualise the vessel 
and the actual reduction in blood flow through the vessel to the specific lesion.
Animal work has demonstrated that OCT has a potential role in improving the efficiency 
of photothermal coagulation beyond the realm of real time monitoring of port-wine stain 
laser therapy (Barton et al, 2001). Wong has demonstrated that sub-surface blood vessels 
can be easily visualised in the skin of rats in vivo (Wong et al, 2002). Wong reported that 
by using ODT it was easily possible to visualise cross-section and vessel diameter as well 
as bidirectional blood flow velocity. Local haemostatic interventions including sclerosant 
injections, heat probes and lasers were observed for their ability to permanently stop blood 
flow in the visualised vessels. These observations were later confirmed by conventional 
histologically.
In order to further improve the usefulness of OCT/ODT, contrast agents are being studied in 
order to enhance the image analogous to barium contrast agents and conventional X-ray to 
visage soft tissue e.g. barium meal to image the gastro-intestinal tract. One promising contrast 
agent for OCT is microbubbles injected into the lumen of the vessel(s) being examined (Barton 
et al, 2002). Microbubbles are already employed in clinical USS to enhance blood vessels 
images (Correas et al, 2001).
The ability of OCT to resolve the structure of blood vessels has been demonstrated during the 
surgical repair of small blood vessels following trauma (Culberton et al, 1990 and Wyrick 
and Stern, 1992). OCT has proven capable of providing the surgeon with real time images 
of the subsurface and the lumen of the vessel being repaired i.e. intra-operative monitoring 
which would otherwise be impossible using a conventional operating microscope. The 
preliminary in vitro work was once again performed in Fujimoto's laboratory (Boppart et al, 
1998c). Using OCT it is possible to view an arter/s morphology i.e. lumen, tunica interna, 
tunica media and tunica adventitia.
9.2 Preliminary Investigations - Kent OCT Device
Since OCT was being used to demonstrate its potential in the field of vascular structures and 
flows, it was decided to evaluate its feasibility for tissue engineering. Professor Fred Fitzke 
at the Institute for Ophthalmology, London, UK, kindly agreed to allow this preliminary work 
to be undertaken on his research/clinical based OCT device (Kent OCT) at The Institute for 
Ophthalmology. The Kent OCT unit was designed and built as a pure research unit by Dr.
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Adrian Podoleanu and Professor David Jackson both of the University of Kent (Canterbury, 
UK). The principle is depicted in Figure 9.1 A brief description of the basic Kent device 
now follows. Light from a pigtailed super luminescent diode of wavelength 850 microns 
was injected into a single-mode directional coupler, which transmits a percentage of the 
optical power into the sample arm. Light in the sample arm was propagated through a phase 
modulator. Light subsequently travelled via a microscope objective, entered an orthogonal 
scanning mirror pair and passed through a converging lens, 6 cm in diameter with a focal 
length of 60 mm, which brought the light to convergence at the lens of the human or animal 
model. The reference beam, which also emerged from the single mode directional coupler, was 
of much higher power than the signal beam and was directed via two sequential microscope 
objectives and mirrors to the detectors, The two mirrors were mounted on a computer controlled 
translation stage, which could be moved continuously at a constant speed or discretely in 
steps. Polarisation controllers were mounted in both the sample arm and in the reference arm. 
Two photo detectors, collected the returned optical signals and their outputs were applied to 
the two inputs of a differential amplifier. The signal was then demodulated and subsequently 
applied to a variable scan digital frame grabber. Since the Kent device was built solely for 
in vivo ophthalmology studies, many of the components e.g. directional coupler, polarising 
controller, microscope objective, orthogonal scanning mirror pair and a converging lens 
were mounted on the chin rest used to accommodate the patient's head (Above description 
adapted from the original description in Podoleanu et al, 1998).
Because the device was primarily designed for imaging the posterior chamber of eyes of either 
small rodents for research purposes or humans for diagnostic/monitoring purposes; the basic 
set up was not ideal for examining long tubular structures compared with the near roundness 
of eye balls. It therefore required an adaptor device to be designed and manufactured in order 
to place the tube to be visualised in an upright position at a distance from the light emerging 
from the "half mirror" of approximately +/-1 mm the same position as an in vivo eye would 
be positioned. Without this adaptor the device had too little gross adjustment. Furthermore, 
the adaptor had to hold the tube assembly perfectly still (i.e. vibration free), hence it was 
bolted to the main optic bench supporting the OCT device, otherwise adjusting the reference 
mirror to obtain the necessary constructive interference would have been impossible.
9.2.1 Materials and methods
Alginate tubes were produced using both the very early pneumatic driven piston device/float 
regulated device as well as the first of the pump driven fluid/regulator devices - During this 
period of time, the far superior pump driven fluid/ball regulator device had not yet been 
evolved - see Section 6.4 - Semi-automated Mark II System. Tubes were fabricated from either 
1 % or 2% Manugel alginate (ISP) in physiological saline. Cross-linkage was performed using
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1% calcium chloride also in physiological saline. After formation, the tube forming glass 
compartment was carefully removed from the rest of the tube forming apparatus with the 
calcium chloride solution and alginate hydrogel still in situ. All the ports were then sealed 
using either small rubber bungs or machined PTFE stoppers to prevent the calcium chloride 
solution leaking out. These sealed components were then either stored at 4°C or transported 
immediately to The Institute of Ophthalmology for OCT visualisation.
With the Kent OCT device it was very easy to visualise the air/glass outer boundary and the 
glass/calcium chloride solution boundary (the alginate hydrogel tubes are not attached to 
the glass formation tube but instead there is a thin layer of liquid between the glass tube and 
the alginate tube). However, it was very difficult to visualise the calcium chloride solution/ 
hydrogel tube boundaries. Increasing the concentration of alginate from a 1% to a 2% 
solution made no discernable difference with the Kent OCT device. Other problems included 
only being able to visualise either the front wall of the tube or the back wall of the tube at one 
time due to the lack of adjustment range built into the device. Thus to visualise the front part 
of the tube, the adapter had to be positioned such that the front wall of the tube was correctly 
placed with respect to the light source and then to view the back wall of the tube, the adaptor 
had be unscrewed from the optical table and repositioned closer to the light source, so that 
now the back wall of the tube was then in the correct plane. The tube could in principle be 
rotated through 180° but this was not compatible with the software to build up the final two- 
dimensional image. The adjustment built into the device was designed to provide detailed 
images of the optic retina, a structure in the order of three hundred microns thick and not a 
glass walled tube of 1.6 mm thick containing a hydrogel tube with a wall of approximately 
100 - 300 pm thick let alone the fact that the glass tube's diameter was overall 7.2 mm in 
diameter - i.e. nearly an order of magnitude out of the range of the device. Altering the 
adjustment was not possible due to the overall design of the Kent device.
Matters were made worse due to the device being designed to be used with the eye. The 
eye has two focusing structures, the main focusing structure is the cornea with the adjustable 
lens providing the necessary fine tuning to focus light onto the retina. The refractive index of 
the human lens and cornea are approximately 1.4 and 1.376 respectively. The device was 
therefore calibrated for this arrangement. The refractive index of the glass wall of the tube 
(Duran© glass) was 1.473 (A, = 587.6 nm) (Data sheet - Schott Glass UK, Stafford, UK). As 
a result, measurements obtained with the tube forming device had a lens-effect factor due 
to the circular glass tube wall e.g. for the 4 mm inside diameter glass tube the magnification 
was approximately 1.6x. This resulted in the reference mirror being required to be move over
2.5 mm just to image the front wall of the tube. Combined with the diameter of the lumen of 
the glass tube (diameter of 4 mm), this made imaging of anything other than the glass wall
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only or the alginate construct alone possible due to limitations of the total amount of gross 
adjustment possible.
Because the hydrogels could not easily be viewed with the device i.e. the liquid/hydrogel 
outer boundary and hydrogel/liquid inner boundary could not be easily discerned, a contrast 
agent was required. Since in practice the alginate tubes would contain mammalian cells 
which were known to be capable of being visualised by the Kent OCT device - the layer of 
rods (elongated cells 50 x 3 pm) and cones (elongated cells 60 x 1.5 pm) making up the 
retina were regularly seen when the device was used to visualise patients' eyes, it was decided 
to use glass beads of similar overall dimensions (Podoleanu et al, 1998). Glass beads of 3 
- 10 microns in diameter (Polyscience, Warrington, Pennsylvania, USA) were added to the 
alginate solutions and then thoroughly mixed for several hours on a roller. Glass beads were 
added at a concentration initially of 0.1% weight/volume. Due to the large refractive index 
difference between the beads and the surrounding hydrogel it was possible to easily visualise 
the bead/hydrogel constructs. A series of range finding experiments were performed with 
different glass bead concentration. In general 0.01% weight/volume bead:alginate solutions 
were used, as this was more economic on the glass bead ($1000 per gm) but still provided 
excellent OCT visualisation. Interestingly it was probable that the lack of substantial refractive 
index difference between the hydrogel and the liquid which made visualisation difficult was 
due to its composition - even a 2% alginate hydrogel is approximately 98% water. Glass beads 
were used as substitute cells in order to allow a large number of preliminary experiments to 
be performed without worrying about the issues involved in transporting and storing actual 
cellular material across London. Also the beads gave a high degree of flexibility in terms of 
working arrangements i.e. allowing experiments to be slotted in between the clinical duties 
of the Kent OCT device. The device, however, was suitable for living cell work since it used 
a 843 nm wavelength near infrared light source which is consistent with the exposure limit 
for permanent intrabeam viewing stipulated by the American National Standard Institute 
(Washington, USA).
Experiments were carried out using cell culture media (Dulbecco Modified Eagle's Medium, 
Gibco BRL, Gathersburg, Maryland, USA) to displace the cross-linking agent, the cell culture 
media made no difference to the device in that it still permitted easy viewing of the bead/ 
hydrogel tube and glass outer tube as discrete entities separated by a thin layer of fluid.
9.2.2 Results and discussion
In order to sample the tube at various positions along its length, the tube had to be physically 
moved up and down in its adaptor. Scanning a number of glass rods (3) along their length 
(15 cm - the maximum length the adaptor/OCT device could accommodate) confirmed that
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the precision bore tube had an average inside diameter of 4 mm + /- 20 pm (after correction 
for the lens effect). This agreed well with the data from Glass Precision Engineering (Leighton 
Buzzard, Bedfordshire, UK) who specify that their manufacturing tolerance is + /-1 0  pm. The 
bead/hydrogel tubes were easily visualised and their wall thickness determined. Overall the 
results were disappointing in terms of physical consistency. OCT tube imaging often exposed 
complete absences of wall for short distances (up to a few cm) and a very wide range of 
thicknesses, up to a maximum of just over 300 pm. The more gross wall discontinuities could 
be confirmed by visualisation of the same sample under a light microscope but only when 
OCT had identified them. The wall discontinuities and a lack of consistency were short­
comings in the reliability of the particular tube fabrication device at its particular stage of 
development and not the OCT device, i.e. they were real and not artefacts. Previous attempts 
to measure the wall thickness in situ using a vernier microscope had suggested this problem 
but the measurements were difficult since visualisation was poor for two main reasons. Firstly 
even when using glass beads:alginate solution at 1% weight/volume it was difficult to detect 
discrete wall edges and secondly the glass acted as a lens which distorted the image.
Measuring the hydrogel tubes out of the glass tubes was complicated, if not impossible, for 
3 reasons. Firstly, handling the tubes i.e. removing the tubes from their glass supports is 
potentially likely to distort the hydrogel's dimensions due to their overall fragility. Likewise, 
trying to measure the hydrogel once out of the glass tube with a vernier gauge is extremely 
difficult since the hydrogel is totally transparent (although food colouring can be added to 
partially overcome this difficulty), but more importantly the fragility of the hydrogel and its 
permanent deformability also hinders any direct measuring process. Finally, if the tubes are 
exposed to air on removal from their glass formers, drying out quickly occurs (syneresis) 
which therefore changes their overall dimensions.
Finally, one preliminary experiment was performed to confirm that alginate constructs 
containing mammalian cells could be visualised without glass beads as a contrast agent. 
Tubular constructs were fabricated using immortalised rat smooth muscle cells (A7r5) at a 
final concentration of 105 per ml of 1 % alginate solution. No glass beads were added and 
the calcium chloride solution was displaced with cell culture media (DMEM) after 20 minutes. 
The constructs were placed on ice for transportation. The construct was then visualised using 
the Kent OCT device approximately 1 hour later (the fastest possible time for travel between 
the two sites). The alginate/cell constructs were clearly visible with the Kent OCT device but 
again wall consistency was extremely poor. In terms of OCT detection, the beads and the cells 
gave almost identical images on the Kent OCT device. Thus confirming that the beads were a 
reasonable alternative for experimental studies.
9.2.3 Conclusions
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The Kent device experiments demonstrated that OCT was potentially capable of delivering 
quantitative data with respect to hydrogel tube wall thickness, however, this particular machine 
was far from ideal being produced solely as a clinical/animal research ophthalmological 
device. Some of the disadvantages could potentially have been over come e.g. using refractive 
index fluid (Cargille, Cedar Grove, New Jersey, USA) formulated for the correct specific 
refractive index for the specific wavelength around the glass tube to try and correct the 
difference in magnifying effect between glass tube and cornea/eye/lens. However, overall 
the capability for visualising the posterior chamber of the eye compared with tissue engineered 
tubular constructs were too deeply designed into the device for any real modifications to 
be made. Furthermore, the particular device was under an ever increasing clinical work 
load and therefore gaining time slots was proving more and more difficult. It was therefore 
decided to look for an alternative, more research orientated OCT source, preferably one 
which was not specifically designed for a particular application such as the Kent device. 
Another requirement was to switch to a totally optic fibre based system, since the design and 
the fabrication of the Kent machine, the optic fibre technology had moved forward at a fast 
pace due to pressures from the booming telecommunications industry. A totally optic fibre 
based system is an essential prerequisite if OCT were to be used for the automation of tissue 
engineering since it is far easier to have an optic fibre connected to each bioreactor rather 
than moving individual bioreactors to the OCT device each time visualisation is required (this 
arrangement is still perfect for the clinical setting).
9.3 Cranfield OCT
Through a collaboration with Professor Ricky Wang (Cranfield Biomedical Department, 
Cranfield University) an alternative OCT device (Cranfield OCT) was made available. The 
Cranfield OCT was based on a fibre optic implementation of the Michelson interferometric 
principle (Wang and Elder, 2002). Below is a brief overview of the Cranfield system, a 
schematic overview is depicted in Figure 9.2. A broad band 1 mW light source (super 
luminescence diode - X -  823 nm with a spectral band width of 25.2 nm (Superlum, Moscow, 
Russia) was coupled to an optic fibre via a collimating lens. The light then travels in the fibre 
to a 5 0 /5 0  optic fibre coupler (the solid state equivalent of a half mirror) where the beam of 
light is split. One beam of light then travels on via optic fibre to a moving reference mirror 
i.e. the reference arm of the interferometer. The other beam travels on and via another 
collimating lens and an objective lens to the specimen i.e. the sample arm. When the light 
reflected from the reference arm is combined with the light from the sample arm, these two 
beams of light will interfere if the two paths are different by less than the coherence length of 
light. A broad band light source is used since the broader the spectral width the greater the 
axial resolution of the particular OCT system.
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Figure 9.2
Schematic overview of the Cranfield OCT.
Key:
C = Collimator lens 
D = Detector
DM = Double pass mirror 
G = Grating 
L = Lens 
M = Mirror
ND = Neutral density filter 
PC = Polarisation controller
Image courtesy of Professor Ricky Wang - Cranfield University.
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The amplitude of the reflected light as a function of depth within the specimen is obtained 
by scanning the reference mirror at a constant velocity and then digitising the magnitude 
of the resulting interferometric fringes. Cross-sectional images were obtained by recording 
sequential axial reflectance profiles whilst the sample is moved transversely across the path 
of the light beam. This movement was carefully controlled using a precision made stage and 
stepper motors.
Using the Superlum 823 nm super luminescence diode as the broad band light source results 
in a 1.2 pm axial resolution in air or 8.8 pm in tissue (assumes that the average refractive 
index of bulk tissue is 1.37) (Wang and Elder, 2002). The transverse resolution was 16 
pm (N.B. axial and transverse resolution are not linked in OCT as they are in conventional 
confocal light microscopy). Imaging was performed by directing low coherence light at 
the glass tubes with the alginate hydrogel tubes in situ and detecting the reflections from 
its internal structures by the use of an optic fibre integrated scanning system. Polarisation 
controllers were used in both the reference and sample arms in order to maximise fringe 
detection. This OCT system employs a balanced detection scheme to minimise the excess 
noise arising from the Superlum light source (Above description adapted from the original 
description in Wang and Elder, 2002). Being a research based instrument and having the 
advantage of being totally fibre optics based, the device was of a far simpler construction 
than the Kent OCT system (plus a 75% reduction in overall physical size) thus allowing far 
easier modification and customisation for a particular application.
Sealed glass tubes with their hydrogel construct in situ were placed flat on a purpose made 
adaptor on a motorised two-dimensional translation stage. Gross focusing was aided by a 
visible light source passing down the sample arm.
Two types of experiment were performed; static and dynamic. The static experiments were 
performed on either hydrogel tubes containing glass beads or hydrogel tubes containing 
mammalian cells. These static experiments were to measure wall thickness and continuity. 
Dynamic experiments were performed using cell hydrogel constructs to explore the possibility 
of using OCT to monitor flow characteristics within constructs.
9.3.1 Alginate/glass bead constructs
9.3.1.1 Materials and methods
Initial experiments were performed exactly as per the original Kent OCT experiments, 
except that the tube forming device will the ball regulator was used through out (Just prior to 
collaborating with Professor Wang, experiments had shown that the use of a ball compared 
to the earlier "missile" shaped regulator resulted in highly consistent alginate construct
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formation - see Section 6.4 - Semi-automated Mark II System), it was therefore decided to 
only use the ball devices for Cranfield University experiments in order to maximise effective 
use of available OCT time). This tube forming device had already demonstrated a linear 
relationship between the amount of alginate solution added to the device and the length of 
tube subsequently produced. Furthermore the results were highly reproducible (see Section 
6.4.2).
Alginate solutions were prepared using Manugel DMB alginate (ISP, Tadworth, Surrey, UK) 
dissolved in normal physiological saline (0.9% sodium chloride (Sigma, St. Louis, Missouri, 
USA)) dissolved in water for injection (BioWhittaker, Walkersville, Maryland, USA). After 
adding the alginate powder, the solutions were rolled on an SRT2 roller mixer (Stuart Scientific) 
overnight. Since visualisation with the Institute of Ophthalmology OCT device had been poor 
when using alginate alone it was decided to again use the glass bead construct agent at 
0.01% weight/volume. The beads were 3 - 10 pm in diameter (Polyscience, Warrington, 
Pennsylvania, USA). After adding the glass beads the mixture was rolled for a further 2 
hours to ensure homogeneity. Calcium chloride solution was produced at 1 % weight/volume 
(Sigma, St. Louis, Missouri, USA) also in physiological saline.
Tubes were constructed from 1 % solutions using a combination of different precision glass bore 
tubes (Glass Precision Engineering, Leighton Buzzard, Bedfordshire, UK) and regulator balls 
(Precision Plastic Ball Company, llkley, Yorkshire, UK). Both the ball and tube manufactures 
claimed a tolerance range of + /-10  pm for their respective products. Three combinations of 
the glass tube/ball regulator device were used resulting in different wall thicknesses - see 
Figure 9.3. The 3.65 mm inside diameter glass tube and 3.4 mm diameter ball regulator 
combination was not used as previous experiments had revealed that the gap between the 
float and the glass wall of 0.125 mm was considered to be probably inadequate to produce a 
useful tissue engineered construct. From previous range-finding experiments, the resulting final 
wall thickness can be estimated to be approximately 45 - 55% of the gap size for this range of 
sizes. Therefore only combinations of ball/tube sizes appropriate for tissue engineering were 
used, i.e. the combination with gap sizes of 0.238 mm, 0.3 mm and 0.413 mm.
The ball regulated device was operated as previously described in Chapter 6. The syringe 
driver (Harvard PHD 2000) was set to deliver the calcium chloride solution at a fixed rate of 
20 mlmin'1.
Aliquotes of the homogeneous glass bead/alginate solution were drawn up into a precision 
1 ml ground glass syringe with care to expel all the air bubbles prior to adding 600 pL to the 
device. At this stage in the research, there was only a limited number of base units available, 
therefore in order to prepare a reasonable size batch of tubes for transportation to Cranfield
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Tube/regulator
combination A B C
Gap between glass 
tube wall and 
regulator (pm)
238 300 413
Inside diameter of 
glass tube (mm) 3.65
4.00 4.00
Diameter of ball 
regulator (mm) 3.174
3.400 3.174
Tube 1* 2 3 4* 5* 6** 7
Average alginate/ 
glass bead 
construct wall 
thickness (pm)
115.6 157.0 154.0 159.0 144.2 173.0 205.6
No of samples 5 6 6 6 5 6 5
Standard deviation 18.83 5.2 8.49 30.15 21.24 12.03 12.04
Wall thickness/ 
Gap 49% 52%
51% 53% 48% 58% 50%
* Careful examination of the raw data suggested that these constructs were slightly flawed possible due to the regulator becoming minimally contaminated by gelled alginate 
shortly after commencing the process (i.e. commencing as a regular walled tube an then suddenly becoming very slightly thinner).
** Larger wall thickness may have been due to this experiment having a 1 Ox concentration of glass beads compared to all the other data in this table. Alternatively, it may have 
been a problem with the size of the regulator and/the glass tube. (The beads and the glass tubes were both precision manufactured to a tolerance of + /-1 0 pm. This degree of 
accuracy could not be checked by UCL micrometers e.g. Mitutoyo PK-0505 has a manufacture's claimed accuracy of + /-2 0  pm and Swiss Precision digiMax has a manufac­
ture's claimed accuracy of -+-/-10 pm).
Figure 9.3
Table of results for experiments conducted using different combinations of glass tube/ball regulator sizes to produce alginate/glass bead constructs with 
walls of different thicknesses.
Data generated in collaboration w ith G a rr Chau (UCL) and Dr. Yonghong He (Cranfield University).
University to undergo OCT evaluation, the glass tubes with the hydrogel constructs in situ 
were carefully removed from the base units and carefully stoppered in order to retain the 
calcium chloride solution. The individual base unit could then be cleaned and attached to a 
fresh glass tube to produce another hydrogel construct. The drawback of this approach was 
that the hydrogel tube had to be disrupted by twisting the base unit through 90 -180° relative 
to the glass tube in order to sever the hydrogel plug attaching the hydrogel construct to the 
base unit. In practise, in a bioreactor this detachment would never be used since the plug is 
essential to maintain the constructs attachment to the base unit. Tubes were transported in 
a vertical position since early experiments quickly revealed that if any bubbles were present 
when carrying the tubes in a horizontal position resulted in the hydrogel tubes being easily 
damaged.
The glass tubes with their hydrogel in situ were mounted vertically on the OCT motorised 
translation stage. The beam of visable light was focused on the glass tube which grossly 
focused the beam of near infrared light in the sample arm of the device. The device was set 
to sample at a frequency of 20,000 samples per second. Because of the drawback to using 
the bungs (potential damage to the extremes of the hydrogel constructs) it was decided to only 
measure the centre portions of the 15 cm long tubes. OCT images were therefore produced 
at the centre of each tube (7.5 cm) plus 2.5 cm in either direction (5 cm + 10 cm). Thus the 
first 5 cm and the final 5 cm of each tube was not examined.
The data set for each scan was converted to computer image via a Matlab programme (The 
Math Works, Natwick, MA, USA) to produce a cross-sectional format with the horizontal axis 
representing the dimension along the tube and the vertical axis representing depth below the 
surface. Because of the 1.6 mm thickness of the wall of the glass tube only the glass/liquid 
interface is present. The air/glass interface was easily detected but due to the design of the 
machine could not be captured if the hydrogel tube was to be included in the scan. Since the 
hydrogel tube was the object of interest the position of the air/glass interface was not required. 
The computer images were exported as high resolution .jpg files for later examination. Using 
Photoshop 7 (Adobe, San Jose, CA, USA) it was possible to measure the thickness of the tube 
walls. (Later experiments did not have this intermediate step, instead a MatLab program was 
written to extract the thickness directly from the data files).
9.3.1.2 Results and discussion
As well as scanning the tubes longitudinally at the 5 cm, 7.5 cm and 10 cm mark, additional 
data was obtained by axially rotating each tube through 180°. The tubes were also scanned 
transversely. Figure 9.4 shows a typical longitudinal image and Figure 9.5 shows typical 
cross-sectional images of an alginate/bead construct in the forming tube. The results for the
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Glass tube (outermost surface not 
shown)
Glass/Culture media interface
Alginate hydrogel construct with 
cell substitute glass beads
Lumen of tube
Figure 9.4
A typical computer generated longitudinal image of an alginate/glass bead construct 
created using the combination of a 4 mm inside diameter glass rod and 3.6 mm diameter 
ball regulator.
Glass tube (outermost surface not 
shown)
Glass/Culture media interface
Alginate hydrogel construct with 
cell substitute glass beads
Lumen of tube
0.5 1 1.5 2 2.5 3 3.5
Figure 9.5
A typical computer generated crosssectional image of an alginate/glass bead construct 
created using the combination of a 4 mm inside diameter glass rod and 3.6 mm diameter 
ball regulator.
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three different tube forming combinations is contained in Figure 9.3.
As with the original Kent OCT experiments, the glass beads provide the contrast agent by 
appearing as bright yellow dots due to their different refractive index to the surrounding 
hydrogel. Both cross-sectional and transverse images show the wall of the constructs are 
independent of the wall of the rigid glass tubes. The cross-sectional image also demonstrates 
that due to the round geometry of the glass tube and distortion is produced. For example, as 
the near infrared beam reaches the air/glass interface due to its curvature at any point other 
than that perpendicular to the beam, refraction will occur. The layer behind i.e. the glass/ 
liquid interface will therefore appear distorted. This arrangement of a series of different 
angles as the beam passes through the sample produces the distorted appearance (inner 
surface of glass tube does not appear as a part of a perfect circle) observed in Figure 9.5. 
Whilst perpendicular to the long axis of the tube longitudinal images are not affected, the 
transverse scanning distortion problem currently prevents direct measurements of thickness 
being taken in a cross-sectional manner. This refractive index problem is however potentially 
resolvable in a very simple manner. Professors Adrain Podeanu and David Jackson (University 
of Kent, Canterbury, Kent, UK) have demonstrated that a computer correction can be made 
if the ratio of curvature, refractive indices and perpendicular specimen thickness are known. 
From this data, corrected images can be produced (Charalambous et a/, 2003, Podoleanu et 
al, 2004). Charalambous has demonstrated for the cornea in eyes that a longitudinal scan 
of 2 mm produces a distortion of greater than 0.2 mm in both the axial and longitudinal 
directions. Since this distortion effect would have dramatic consequences on deploying OCT 
for monitoring refractive index eye surgery, the drive to produce computer correction is well 
established.
The data presented in Figure 9.3 demonstrates that the thickness of the final construct was in 
the order of 50% of the size of the physical gap between the inside of the glass tube and the 
ball regulator. This is due to a combination of the interaction of the ball/alginate/tube and 
also the shrinkage which accompanies the cross-linking process (Martinsen et al, 1989).
In conclusion, having demonstrated that the OCT device was capable of visualising hydrogel 
constructs with glass bead contrast agent and that the tubes had walls of consistent thickness, 
it was decided to undertake similar experiments with cells instead of the beads (Mason et al, 
2004a).
9.3.2 Alginate/cell constructs
9.3.2.1 Materials and methods
A 1% alginate solution (weight/volume) was prepared by adding Manugel DMB (ISP,
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Tadworth, Surrey, UK) to physiological saline (NaCl - Sigma, St. Louis, Missouri, USA; WFI 
- BioWhittaker, Walkersville, Maryland, USA). This solution was then agitated by rolling over 
night. Adult mesenchymal stem cells were harvested as previously described and mixed with 
homogeneous alginate solution by gentle pipetting. The final density of cells was 3 x 106 per 
ml. Aliquotes of 600 pi were drawn up into 1 ml syringes to load the tube forming device.
The same three glass tube/ball regulator combinations were deployed as for the alginate/ 
glass bead experiments (see Figure 9.3 for dimensions). Glass tubes of 12 cm in length were 
used since 600 pm is adequate to produce a 12 cm tube. The syringe driver (Harvard PHD
2000) delivering the calcium chloride was set at the same fixed rate as for production of 
constructs for all the OCT experiments - 20 mlmin1. The syringe driver was run until long 
enough to expel the excess cell/alginate mixture together with the float from the glass tube.
A small quantity (<200 pL) of calcium chloride solution was removed from each tube in order 
to allow a very small air space and thus facilitate the insertion of rubber bungs required for 
transportation. In order to avoid damaging the tubes by needing to detach the base unit, 
and because of the success of the earlier experiments deploying glass beads, addition base 
units were fabricated. The bases could therefore be left connected to the glass/tube and thus 
not disturb the cell/hydrogel attachment plug. The devices with the constructs in situ were 
transported for scanning at Cranfield University in the vertical position.
9.3.2.2 Results and discussion
As previously, the tube forming device was mounted horizontally on the motorised translation 
stage for OCT evaluation. Overall the quality of the OCT images was very similar to the 
alginate/glass bead experiments (a situation witnessed previously with the Kent OCT device) 
despite the difference in size and refractive indices. Like the glass beads, the mesenchymal 
stem cells acted as an excellent "contrast agent" due their relatively high refractive index 
compared to the surrounding hydrogel. Figure 9.6 shows a typical longitudinal image and 
Figure 9.7 a typical cross sectional image. Figure 9.8 shows a series of longitudinal scans 
(arranged in order) along the entire length of an alginate/cell construct. The images show 
the ease with which the flexible tissue-engineered construct is free to move from side-to-side 
within the glass tube. This is inferred by the changing extralumenal gap between the construct 
and the glass tube along the length of the construct. Likewise OCT imaging in exactly the 
same location before and after gentle rotation resulted in images with identical wall thickness 
but different extralumenal gap widths. The 4 mm inside diameter glass tube/ 3.4 mm float 
combination had its construct's wall thickness imaged every 15 mm along two aspects - 180° 
apart - see Figure 9.8. For the other glass tube/float combinations, only the mid point of 
each tube plus one point 15 mm distal and 15 mm proximal. Again the tube was rotated to
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Glass tube (outermost surface not 
shown)
Glass/Culture media interface
Alginate hydrogel construct with 
mesenchymal stem cells
Lumen of tube
0.5 1 1.5 2 2.5
Figure 9.6
A typical computer generated longitudinal image of an alginate/mesenchymal stem cell 
construct created using the combination of a 4 mm inside diameter glass rod and 3.6 mm 
diameter ball regulator.
Lumen of tube
Glass tube (outermost surface not 
shown)
Glass/Culture media interface 
Alginate hydrogel construct with 
mesenchymal stem cells
Figure 9.7
A typical computer generated cross-sectional image of an alginate/mesenchymal stem 
cell construct created using the combination of a 4 mm inside diameter glass rod and 3.6 
mm diameter ball regulator.
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Figure 9.8
OCT computer generated images of an MSC/alginate construct in situ produced using the 
combination of a 4 mm I/D  glass tube/3.4 mm ball regulator. Average wall thickness 
0.145 + /-15 pm (n = 14).
Construct imaged a t 15 mm intervals at 0° and 180° (Glass wall aligned).
provide details of two aspects 180° apart. The results are provided in a tabulated form in 
Figure 9.9. This data was derived directly from the raw data set (i.e. no intermediate steps as 
for the cell/glass bead experiments).
The wall thickness for the three different fabrication combinations of glass tube and ball 
correlate very well between the glass bead and mesenchymal cell experiments. Likewise/ the 
ratio of gapifinal construct wall thickness was also comparable. Examining the individual 
data points for both sets of experiments, revealed that the alginate/MSC tubes were of far 
superior consistency relative to the earlier alginate/bead constructs. This improvement was 
probably due to the increased experience gained from regularly using the device. The physical 
consistency correlates well with data generated by the separate independent method that 
demonstrated a close linear relationship between the volume of alginate solution/beads or 
cells loaded into semi-automated Mark II tube forming device and the length of the resulting 
cross-linked construct - see Section 6.4.2
9.4 Doppler optical coherence tomography and in situ flow imaging
9.4.1 Introduction
Preliminary experiments were also performed to determine whether flow in the constructs 
could be visualised using OCT. Ricky Wang's group had previously demonstrated two- 
dimensional flow mapping of fluids in 1 mm inside diameter capillary tubes (Proskurin et al, 
2003a and Proskurin etal, 2003b).
Flow in a bioreactor is essential for a number of reasons including mass transfer of 
gases, nutrients and waste products (Martin et al, 2004). Flow also has other biological 
consequences. For example in blood vessels in vivo, "high shear stress, as found in laminar 
flow, promotes endothelial cell survival and quiescence, alignment in the direction of flow, and 
secretion of substances that promote vasodilation and anticoagulation. Low shear stress, or 
changing shear stress direction as found in turbulent flow, promotes endothelial proliferation 
and apoptosis, shape change, and secretion of substances that promote vasoconstriction, 
coagulation, and platelet aggregation" (Paskowiak and Dardik, 2003). Flow has therefore 
been almost universally deployed by researchers when producing tissue-engineered blood 
vessels (Tranquillo, 2002). Furthermore, a number of researchers have demonstrated that 
pulsed flow has further possible advantages for arterial substitute fabrication including 
enhancing their physical properties possibly by affecting the rate of extracellular matrix 
deposition and remodelling (Solan et al, 2003).
Ricky Wang's group have described a technique that employs laser Doppler optical coherence 
tomography (DOCT) to estimate accurately two-dimensional flow mapping for a highly light
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Combination A B* C
Gap between glass 
tube wall and 
regulator (pm)
238 300 413
Inside diameter of 
glass tube (mm)
3.65 4.00 4.00
Diameter of ball 
regulator (mm)
3.174 3.400 3.174
Average alginate/ 
mesenchymal stem 
cell construct wall 
thickness (pm)
110 145 195
No of samples 6 14 6
Wall thickness/ 
Gap
46% 48% 47%
’"Published: Mason et al, 2004a
Figure 9.9
Table of results for experiments conducted using different combinations of glass tube/ball regulator sizes to produce alginate/adult mesenchymal stem cell 
constructs with walls of different thicknesses.
Data generated directly from the raw data (error + /-1 5 pm) in collaboration with Prof Ricky Wang and Dr. Yonghong He (Cranfield University).
scattering fluid flowing in a tube (Proskurin etal, 2003b). By combining OCT with Doppler 
velocimetry a technique Doppler optical coherence tomography is possible (Wang et al, 
1995, Proskurin etal, 2003b and Moger, 2003). DOCT is a non-invasive imaging technique 
for determining fluid flows in highly light scattering media or biological tissue. This is based 
on the principle that the Doppler frequency shift in the light that is backscattered from the 
moving objects within a sample either adds to or subtracts from the fixed Doppler frequency, 
depending on the flow direction. DOCT is starting to be used in clinical applications, e.g. 
providing quantitative cross-sectional imaging of flow in retinal blood vessels (Yazdanfar et 
al, 2000). OCT utilises only the amplitude of back-scattered light as a function of depth within 
the tissue, whereas DOCT additionally employs interferometric phase information to monitor 
Doppler shifts in the back-scattered spectrum. The phase-sensitive detection of interference 
of the back-scattered light from the tissue and reflected light from a moving reference mirror 
enables in-depth localisation of the Doppler shifts arising from flow in the sample. Thus, 
DOCT is capable of producing simultaneous imaging of both the tissue's architecture and its 
localised blood flow. To date, DOCT has been used to measure blood flow profiles captured 
in a few milliseconds in human retina (Yazdanfar et al, 2003) and skin (Zhao et al, 2000; 
Nelson et al, 2001).
Data are summarised here as a "gold standard" to judge the effectiveness of the near identical 
DOCT device in a tissue engineering bioreactor setting with an alginate/MSC construct in situ. 
The particular device deployed by Professor Proskurin (member of Professor Wang's group at 
Cranfield University) used a light source with a wave length of 1298 nm with a band width 
of 52 nm delivering 0.5 mW of power. The highly light scattering fluid flowing through the 
target tube was a 0.5% intralipid solution [Intralipid solution is a fat based emulsion which is 
widely used as a phantom material for the investigation of the optical properties of biological 
tissues (Driver et al, 1989)]. The tube was a cylindrical transparent capillary tube with an 
outside diameter of 3 mm with a wall thickness of 2 mm. The capillary was mounted on a 
goniometer that could be set to the desired Doppler angle (perpendicular viewing of flow is 
not possible with DOCT). Flows with Reynolds numbers in the range 30 -100 were created to 
ensure laminar flow. A typical laminar velocity flow profile generated by DOCT is shown in 
Figure 9.10. The figure shows a typical parabolic flow profile for a Newtonian fluid flowing 
in a laminar fashion (Proskurin et al, 2003a and Proskurin et al, 2003b).
9.4.2 Materials and methods
A description for the proof of principle experiments with respect to the potential of deploying 
DOCT to monitor flow through tissue-engineered constructs in situ now follows (Mason 
et al, 2004b). It was decided to use a hydrogel tube constructed using the 4 mm inside 
diameter glass tube/3.174 mm ball regulator combination. Initial experiments with Professor
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Figure 9.10
DOCT proof of concept experiment - Proskurin et al, 2003a, 2003b. DOCT computer 
generated spectroscope image of laminar flow (1.8 ml/min) in a capillary tube with a lumen 
of 1 mm and wall thickness of 2 mm (top picture). For orientation purposes, the bottom picture 
has the same image superimposed on a cartoon of the glass capillary tube (walls shown in 
grey) plus flow direction arrows. The fluid velocity within the lumen was a typical parabolic 
shape for a Newtonian fluid in a fully developed laminar flow with the highest velocity at the 
mid-line and zero flow at the edge. These data are presented as a "gold standard" to judge 
the effectiveness of the near identical DOCT device in a tissue engineering bioreactor setting 
with an alginate/MSC construct in situ. Spectroscopic image courtesy of Prof. Ricky Wang 
(Cranfield).
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Proskurin's 1298 nm device used for his original flow work (Proskurin et al, 2003a and 
Proskurin et al, 2003b) resulted in very poor quality OCT images, but switching to the 823 
nm wavelength device used for the static experiments described above resulted in near perfect 
images after some simple optimisation. Thus from these preliminary experiences, it would 
appear that the 823 nm light source is far superior to the 1298 nm light source for tissue 
engineering applications in terms of image quality (the reason for this discrepancy requires 
elucidation). The circuit of the 823 nm device was therefore properly modified to allow the 
Doppler component from the 1298 nm device to be combined with OCT.
The tube forming device with its construct in situ was placed on the goniometer at an angle 
of 5° from perpendicular to the glass tube. A 0.5% intralipid solution was flowed through 
the device being careful to prevent air bubbles entering the device. Flow was by gravity feed 
from an overhead container at a rate of 20 mlmin*1. After passing through the construct the 
fluid exited via a tube pushed over the glass and was collected in beaker for recirculation. 
Once the system was running with no air bubbles, a haemostat clamp was applied to the 
silastic tube running from the reservoir to the device in order to stop the flow. A series of 
images were taken to demonstrate static conditions.
9.4.3 Results and discussion
A flat velocity profile was obtained, see Figure 9.11. The haemostat was then removed, 
once flow had resumed for several seconds (steady state), another series of images were 
obtained, see Figures 9.12 (Mason et al, 2004b). The only limitation of the set up was that 
because of the thickness of the tube, 4 mm inside diameter with a wall thickness of 1.6 mm 
(compared with the capillary used to generate the image in figure 9.10 which had a 1 mm 
inside diameter and 2 mm wall thickness) is was only possible to image half the tube at a 
time. However, half a parabola can be clearly seen in the partial scan shown in Figure 9.12. 
This parabolic velocity profile suggests that the flow through the lumen of the construct is 
laminar in its behaviour. From the Doppler frequency shifts shown in the spectrogram data, 
the fluid velocity can be estimated. After correcting for the Doppler angle (85°), the estimated 
maximum flow velocity in the centre of the lumen was 54 mmsec'1. Concurrently, there was 
also a very slow flow in the space (approximately 280 pm) between the construct and the 
glass wall (i.e. between points a + b).
The "gold standard" (Figure 9.10) and the experimental data (Figure 9.11) derived from 
the tissue-engineered construct give very similar flow profiles - parabola shape, which for a 
Newtonian fluid would suggest laminar flow. It is believed that this is the first time that flow 
has been imaged in a tissue-engineered construct in situ.
9.5 Conclusions
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In-depth scan (mm)
Figure 9.11
DOCT - No flow through in situ construct.
DOCT computer generated spectrogram image of conditions of no flow in an 
alginate/mesenchymal stem cell construct produced using the combination of a 4 mm I/D 
tube/3.174 mm ball regulator. Only a partial scan is shown (approximately one half of the 
inside of the glass tube). Point a is at the point of the glass tube/fluid interface, point b is at 
the fluid/outer edge of the construct interace, point c is at the inner edge of the 
construct/liquid interface. The distance between points b + c is the thickness of the wall of 
the construct = 220 + /-9 microns. The image shows a flat velocity profile. The outer surface 
of glass tube not shown.
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Figure 9.12
DOCT - Laminar flow through in situ construct.
A spectrogram image of steady state flow (approximately 20 ml/min) through the same 
tissue-engineered construct as in Figure 9.11 together with its corresponding OCT 
structural/depth profile. Only a partial scan is shown (approx. one half of the inside of the 
glass tube). Points a, b and c are as per Figure 9.11. The parabolic velocity profile suggests 
that the flow through the lumen of the construct is laminar in its behavior. From the Doppler 
frequency shifts shown in the spectrogram data, the fluid velocity can be estimated. After 
correcting for the Doppler angle, the estimated maximum flow velocity in the centre of the 
lumen was 54 mm/sec. Coexisting, there was also a very slow flow in the space 
(approximately 280 microns) between the construct and the glass wall (between points a + 
b). This undefined flow profile in this extralumenal region may be as a result of the 
combination of flow along the extralumenal path and flow back and forth through the pores 
of the construct. The outer surface of glass tube not shown.
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In proof of principle experiments, OCT and DOCT have each been demonstrated to be 
capable of both imaging for physical consistency and for quantifying and characterising flow 
through tissue-engineered constructs in situ.
9.5.1 OCT
In summary, the role of OCT for the clinician, the natural scientist including developmental 
biologist, and the material scientist is rapidly evolving. The same demands that are driving 
this progress (real time, non-invasive, non-destructive and low operating costs) match exactly 
the requirements for the tissue engineer. The better repair of human tissue is an urgent 
medical goal and in order to achieve a safe outcome there is a parallel need for sensitive, 
non-invasive methods of assessing the qualify of the engineered tissues and organs prior to 
surgical implantation. OCT can potentially fulfil this role. The preliminary data suggests that 
OCT can be utilised as a real time, non-destructive, non-invasive tool to critically monitor the 
physical consistency of tissue-engineered constructs during their fabrication and growth.
9.5.2 DOCT
There is a complex interrelationship between flows both through blood vessels in vivo as well 
as engineered vessels in vitro. Being able to understand this interrelationship has enormous 
implications for the tissue engineer. DOCT is a novel optical instrument already starting to be 
developed to study rheology properties of tissues quickly, easily and safely in vivo. Capable 
of precise non-invasive real-time imaging, it is potentially ideal for the continuous monitoring 
of engineered tissues in vitro. A detailed velocity flow profile generated in real time can 
directly provide the engineer with a variety of crucial information including the state of flow, 
i.e. turbulent, transitional or fully developed laminar flow. The latter is likely to prove essential 
for the engineering of substitute arteries. Indirectly the flow velocity data allow the shear rate 
to be calculated from the gradient of the derived velocity profiles. For a parabolic profile, 
the shear rate is greatest at the wall of the tube and lowest at the centre. If the viscosity of 
the culture medium is known, the shear stress can be calculated, e.g. for the critical interface 
between the culture medium and the innermost layer of cells forming the lining of the lumen of 
the living construct. Flow characteristics and shear stresses are essential factors to be able to 
monitor in order to control and thus maintain the in vitro tissue in a healthy state. Furthermore, 
accurately manipulating these factors may potentially be a means of stimulating growth 
and maturation of the constructs in a non-pathological manner, thus potentially shortening 
production times and reducing costs.
In conclusion, OCT and DOCT when combined appear to be a promising solution for on-line 
quality control monitoring and analysis of flow in sterile, sealed bioreactors.
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10.0 Final discussion, conclusions and future research
10.1 Final discussion and conclusions
For thousands of years doctors have treated patients with a variety of medications and surgical 
interventions. Depending upon the particular presenting pathology, few of these treatments 
however provide life-long cures. The vast majority of these therapies manage symptoms but at 
a price e.g. side effects and continual financial expense. Regenerative medicine by deploying 
living cells alone or in combination with a scaffold (tissue engineering) potentially offers a 
superior alternative - a permanent cure.
Many challenges lie ahead before regenerative medicine products become first-line routine 
clinical practice, including the mass production (allogeneic therapies) or mass customisation 
(autologous therapies) that will eventually be required if these types of therapy are to be 
produced in adequate quantities to meet clinical demand. Both the discovery phase and 
scaling of the production requires an interdisciplinary approach of far greater complexity 
and magnitude than toda/s biopharmaceutical drugs. Furthermore, production needs to 
comply with current good tissue practices (CGTP) whilst meeting at an overall price which is 
acceptable to both healthcare providers and patients.
The necessary bioprocessing for regenerative medicine products is very different from the 
current biopharmaceutical manufacture where the cells are used as small factories to produce 
a pharmacologically active substance e.g. a monoclonal antibody or a recombinant protein. 
The well-being of the cells in these processes is only of issue with respect to their output 
of the biopharmaceutical. Regenerative medicine bioprocessing is quite different in that 
instead of deploying cells to make pharmaceutical products, the cells are the final product 
and their welfare is therefore the number one priority. Furthermore, the bioprocess starts 
with the collection of living material from a patient (autologous) or donor (allogeneic) and 
ends at the implantation and integration of the living product into the patient. Taking this 
whole bioprocessing approach, this thesis has studied a number of the potentially core issues 
including:
•  Suitable scaffold polymers
•  Semi-automation of the bioreactor
•  Continuous real time non-invasive monitoring
10.2 Suitable scaffold polymers
An extensive review of natural polymers is included in Chapter 2 (Alginate) and in Appendix 
A l (Natural Polymers). A similar extensive review of synthetic polymers e.g. polyglycolic acid 
(PGA) was also conducted (not included in this thesis for the sake of brevity). The purpose was
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to examine in depth the polymers currently available to the tissue engineer but with a view 
to automation since this was perceived from the outset to be key to the consistent production 
of the many units of tissue required to meet the longer term demands of routine clinical 
practice. It was concluded that a sterile liquid-based approach was potentially far easier to 
automate than a pre-formed solid scaffold based methodology. For example, it is potentially 
easier to produce a homogeneously cell seeded scaffold material when the polymer is liquid 
than when the polymer is in a pre-formed three-dimensional shape. However, this requires 
the liquid polymer to be capable of being fabricated into a three-dimensional geometry 
using mild "cell friendly" conditions. This prerequisite rules out the present generation of 
synthetic materials which require high temperature or caustic agents (Thomson et al, 2000) 
hence the focus on natural materials. Animal based products e.g. collagen were ruled out on 
the basis of poor batch to batch variability and more importantly their potential to transmit 
zoonoses e.g. prion and retroviruses. (In the future, when recombinant versions are produced 
in volume, these issues will no longer be a problem.) It was therefore decided to experiment 
with sodium alginate (a polysaccharide derived from seaweed). Sodium alginate has an 
excellent record in medication including its use as a topical agent (bandages), oral medication 
(stomach ulcer therapies) and internally (cell encapsulation). Furthermore it is capable of 
turning almost instantaneously from a liquid into a hydrogel when exposed to calcium ions. 
Its main disadvantage for the tissue engineer is its inability to interact with cells. Whilst the 
cells could survive the process of being harvested, mixed with alginate solution, fabricated 
into a tube and cross-linked with calcium chloride solution, they failed to thrive (Chapter 7). 
This situation was remedied by covalently bonding cell friendly peptides e.g. -GRGDY to the 
alginate resulting in cell attachment, cell elongation and intercellular networking within the 
construct (Chapter 8). It must be noted that there was no evidence of cell proliferation within 
the different derivatised alginate hydrogels when using either immortalised rat smooth muscle 
cells or human mesenchymal stem cells - this also reflects the normal in vivo situation. If this is 
the case, then the implication is that the number of cells required in the finished product would 
have to be mixed with the derivatised alginate prior to initial fabrication. This approach may 
well have major benefits since the expansion of cells in culture is potentially easier and less 
costly than the same expansion in a three-dimensional construct.
10.3 Semi-automation of the bioreactor
Successful tissue engineering bioreactors i.e. ones capable of delivering regenerative medicine 
therapies to meet clinical demands require certain fundamental characteristics including:
•  The ability to retain total sterility through out the entire process
•  Low cost of production including sterilisation prior to use
•  Ease of disposability
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Furthermore, ideally the bioreactor needs to be a multitasking device i.e. one capable of 
taking a few cells from the patient/donor and containing all the unit operations required to 
produce a neo-organ without opening the device (Martin et al, 2004). The multitasking would 
include cell isolation, cell expansion and harvesting, seeding to form a homogeneous cell/ 
scaffold construct and maturation. This thesis addresses some of the seeding and fabrication 
issues plus starts to explore the maturation phase of such a bioreactor.
Initial experiments were conducted using a novel electrostatic spraying methodology using 
fluidised alginate powder to form three-dimensional structures. The hypothesis was, that if 
alginate powder and desiccated cells could be homogeneously mixed prior to or during the 
spray process, then potentially a homogeneous structure could be built up, cross-linked with 
calcium chloride solution (also sprayed) to maintain the three-dimensional shape and the 
cells rehydrated (for brevity, details of this research are not included in this thesis). It was 
during this powder coating study and the insight it gave into alginate as a material, such as 
its ability to rapidly cross-link, that the first of the tube forming devices described in this thesis 
was invented (Chapter 4).
The initial tube forming device deployed a piston and rod to be drawn down a glass barrel 
with a regulator element in tow (Figure 4.3). Whilst this produced alginate hydrogel tubes it 
was far from ideal with respect to the goal of the semi-automation of the fabrication of tissue- 
engineered tubular constructs e.g. substitute coronary artery. The main problem was the 
piston and its drive rod. For example, the overall size of the device needed to be a minimum 
of twice the length of the tubular construct to be fabricated taking into account the length 
of the drive rod and its distance of travel during the fabrication process. This would have 
resulted in the requirement for an overall extremely large container in which to house the 
bioreactor which would have added to production cost (need for a larger production facility) 
plus transportation issues. This would have increased both the fixed and variable costs. 
However the piston driven device both in its manual form (Chapter 5) and its semi-automated 
form (Appendix 2) did demonstrate proof of concept. The fluid driven tube forming device 
(Figure 5.1) was established and refined as a direct response to the potential difficulties 
envisaged with the piston driven device. Furthermore, this alternative design simplified a 
number of steps including:
•  Loading the device with a homogeneous mixture of polymer and cells - an in line 
static mixer could easily be incorporated into the device's base unit during its 
manufacture
•  Capable of deploying standard syringes and syringe drivers instead of a complex 
machinery involving pistons, drive rods and drive units
•  Overall the design was far more compact lending itself toward full automation
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•  Without the drive rods and complex loading of the cell/polymer mixture, the design 
was potentially better for the retention of complete sterility throughout the whole 
bioprocess
Having established a manual version of the fluid driven device (Chapter 5) a semi-automated 
version (Chapter 6) soon followed. Reliability and consistence of product were initially both 
problems (as they also had been with the piston driven versions). Using a number of different 
techniques including digital high speed video imaging (Section 6.2.1) and dynamic pressure 
recording studies (Section 6.3) the operating procedure was improved and the design was 
refined into the semi-automated Mark II system with its ball regulator (Section 6.4). This system 
was capable of both high reliability with respect to tube forming runs (approaching a 100% 
tube fabrication success record even between different operators after only a short training 
period of typically less than half a day) plus capable of the fabrication of cell/alginate tubular 
constructs of high consistency. This was confirmed by both physical measurements (Section 
6.4.2) and by optical coherence tomography (Section 9.3).
10.4 Continuous real rime non-invasive monitoring
An important aspect of any tissue engineering automated production system will be monitoring 
and control. This is especially important when autologous cells are deployed due to a number 
of factors including interpatient variability, biopsy size and site, and storage conditions 
(Mayhew et al, 1998). Monitoring must both allow the process to be controlled as well as 
integrate with standard hospital information systems (HISs) in order to keep the clinicians 
aware of overall progress and predicted availability in order to allow seamless and efficient 
scheduling of the patient's admission, work-up and procedure.
This thesis demonstrates the potential for optical coherence tomography (OCT) as a monitoring 
technology in the tissue engineering manufacturing process. Whilst already successfully 
deployed in the clinic (over 1600 machines already installed in ophthalmology departments 
throughout North America (Fujimoto, 2003a), its role as a low cost monitoring device for 
tissue fabrication is novel (Section 9.3). Furthermore by coupling a laser to create a Doppler 
laser optical coherence tomography (DOCT) system, the same OCT device doubles up as an 
instrument capable of monitoring flow through and around the tissue-engineered construct 
(Section 9.4). To scale OCT and DOCT to a production facility, and in the process enjoy 
some economies of scale, would require the linkage of a large number of bioreactors to a 
central OCT/DOCT device via optical fibres and using the system in a time-share mode. 
Since all these components are already mass produced for the highly competitive global 
communications industry, the cost of OCT/DOCT and the optical connections required to 
couple to the individual bioreadors continue to rapidly fall in price. For example, the Cranfield
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OCT device costs in the order of £30,000 to assemble and could potentially service a large 
number of bioreactors whilst the Kent OCT which was the "state of the art" approximately five 
years earlier was approximately an order of magnitude more expensive to build, required a 
dedicated full-time technician and a large space but could only handle a single bioreactor.
10.5 Current and future research
At the end of a number of chapters are suggestions for future research, In addition, a number 
of the topics within this thesis are continuing to be progressed in the new Regenerative 
Medicine Bioprocessing Facility in the Department of Biochemical Engineering at UCL under 
the guidance of Professor Peter Dunnill, Professor Mike Hoare and myself. They include:
10.5.1 Derivatised alginate polymer
In collaboration with Dr. Alethea Tabor (Reader, Department of Chemistry, UCL) the research 
on the derivatised alginate has progressed via two chemistry undergraduate students and now 
a masters student. The research into the effects of derivatised alginate on human mesenchymal 
stem cells was continued by Julia Markusen (Merck Research Fellow who undertook a PhD 
at UCL) until her return to Merck, Rahway, NJ, USA in late 2004) - Paper submitted to Tissue 
Engineering journal "Characterisation of Adult Human Mesenchymal Stem Cells Entrapped 
in Alginate-GRGDY". This relationship between the derivatised alginate polymer and the 
cells after being cross-linked into a specific three-dimensional shape is being continued by 
Leda Pittarello (PhD student at UCL), Carol Chu (PhD student at UCL) and Charo Scott (Merck 
Research Fellow undertaking a PhD at UCL). In particular, Charo Scott's proposed research 
will expand further the work with the cell/alginate-GRGDY beads but will deploy the ultrascale 
down methodology development by Professor Gary Lye's team at UCL.
10.5.2 Automated tissue engineering bioreactors
This topic has now been sub-divided into a number of sectors which are, however, run as one 
integrated project. The semi-automated fluid driven bioreactor described in Section 6.4 is 
currently being progressed towards a fully integrated and automated system by Alfred Ding 
(PhD student at UCL) in collaboration with Martin Town (UCL) and Dr. Julian Mason (Kingston 
University). The essential parameters within the bioreactor e.g. media flow rate, dissolved 
oxygen tension (DOT), nutrient requirements and metabolite removal are being modelled by 
Spyros Gerontas (PhD student at UCL) under the guidance of Professor Mike Hoare (UCL) 
based on experimental data from a number of researchers within the Regenerative Medicine 
Bioprocessing Group. The models generated will feed directly into the design work for the 
automated bioreactor and its standard operating instructions. Finally the control aspects e.g. 
linking the data generated by the various monitoring modalities associated with the bioreactor
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e.g. pH. temperature, DOT, OCT and DOCT into the control process are being researched by 
Matt Scutcher (PhD student at UCL) under the guidance of Dr. Yuhong Zu (UCL). A tracking 
system is also being devised which will integrate with both the bioreactor work and with 
standard HISs in order to fulfil the requirement to accurately track cells plus communicate with 
the hospital information systems. The research centres around radio frequency identification 
devices (RFID) and is in collaboration with Dr Paul Schmidt (Consultant at Portsmouth NHS 
Trust and CEO of Proxximity Ltd, Portsmouth, UK).
10.5.3 Optical coherence tomography
Garr Chau (PhD student at UCL) under the supervision of Dr. Susana Levy (UCL) has continued 
the OCT and DOCT collaboration with Professor Ricky Wang's group at Cranfield University, 
including beginning to study the actual moment in time and location with respect the regulator 
when the alginate solution becomes a gel and its effect on the final thickness of the wall of the 
newly formed construct. This follows on from a collaboration with Dr. Ian Eames (Department 
of Mechanical Engineering, UCL) and Dr. Mark Landeryou (Department of Medical Physics, 
UCL) to mathematically model the fluid dynamic theory underlying the Mark II semi-automated 
fluid driven tube forming device (paper in preparation for submission to Biotechnology and 
Bioengineering). Garr Chau is also developing the idea of deploying a static mixer for 
combining cells with polymer in order to create a totally homogeneous mixture for loading 
into the tube forming device whilst not effecting cell viability. The data from these mixing 
experiments will be analysed and mathematically modelled by Ju Wei Wong (PhD student at 
UCL) to help produce part of a suite of generic optimisation tools.
10.6 Summary
Overall this MRC funded PhD project has now evolved into an integrated programme of 
research which is continuing to expand in terms of facilities, number of in-house researchers, 
staff involvement and number of external collaborators. During this progression, the bioreactor 
methodology and design received the Overall Winner Award in the Medical Futures 
Innovation Awards in 2002, sponsored by the National Endowment for Science, Technology 
and the Arts (NESTA) and was highlighted in evidence given to the House of Commons Select 
Committee on Science and Technology (House of Commons Select Committee on Science and 
Technology, 2002) as well as receiving both national and international media attention.
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APPENDIX 1
Al .0 Supplementary introductory material
This appendix contains supplementary material on two key topics:
•  Scaffold concepts and physical formats
•  Natural polymers
A l. 1 Scaffold concepts and physical formats
This section collects together the various scaffold concepts currently available to the tissue 
engineer when considering the most appropriate option for a particular application. The 
chosen route potentially has great bearing on subsequent scale-out and manufacture for the 
particular tissue-engineered product to enter routine clinical practise.
1.1.1 Classification of scaffold concepts
A potential biomaterial must be compatible with the desired tissue response. Hubbell classified 
approaches to selecting biomaterials for various tissue engineering applications according to 
the type of tissue response required (Hubbell, 1995):
•  Conducting or guiding an otherwise normal biological response
• Inducing a "super normal" biological response
•  Blocking a naturally occurring but undesirable biological phenomenon
Scaffolds formats therefore require one or more of the above criteria in various combinations 
to meet different tissue engineering requirements.
A l.1.2 Scaffold formats
The various potential formats for tissue engineering have been subdivided by Pachence and 
Kohn of VectraMed (Plainsboro, NJ, USA) into three well defined categories; barriers, gels 
and matrices (Pachence and Kohn, 2000). These subdivisions have been used as a guide for 
the following brief review of scaffold design concepts.
A l.1.2.1 Barriers
Often in surgical procedures it is desirable to have a barrier so that the desired healing cell 
activity on one surface, is not disrupted by unwanted cells and their extracellular matrix 
migrating into the repairing zone. Good examples are; nerve repair, periodontal surgery 
and abdominal adhesion prevention. Barrier layers can either be flat sheets (e.g. prevention 
of intra-abdominal adhesions) or tubes (e.g. guiding peripheral nerve repair).
Successful peripheral nerve regeneration requires proximal to distal axonal growth whilst 
at the same time precluding fibroblast invasion into the gap, which would physically inhibit
-  245  -
the growing axon from reaching its target. Various tubular structures have been tried 
experimentally as suitable conduits in this situation including PGA (Strauch, 2000), poly- 
hydroxybutyrate (Mohanna et al, 2003) and collagen (Kitahara et al, 2000). Polyfvinyl 
alcohol) (PVA) is already commercially available for nerve regeneration. PVA can be formed 
into strong flexible hydrogels that can be easily moulded into a variety of three-dimensional 
shapes. This technology was created by Ku at Georgia Tech (Atlanta, USA) (Ku et al,
1999) and subsequently developed by SaluMedica (Atlanta, USA) as Salubria (McKenna,
2001). SaluMedica are currently investigating Salubria's properties in the field of tissue 
engineering especially in relationship to nerve repair using a cuff of the material to guide 
nerve regeneration (SaluBridge Nerve Cuff). [Peripheral nerves have been demonstrated 
to successfully regenerate across a gap when an entubulation technique is utilized. Thus a 
nerve cuff eliminates the need for a conventional nerve graft, thereby removing the need for 
a donor operation site with its associated potential morbidity (Lundborg etal, 1997).]
Periodontal regeneration means healing after periodontal surgery (e.g. treatment for advanced 
adult periodontitis) that results in the restoration of the tooth supporting tissue i.e. cementum, 
alveolar bone and periodontal ligament attachments whilst preventing epithelial ingrowth 
into the healing site. This can be successfully achieved using Epi-Guide bioresorbable barrier 
matrix (Sulzer Dental, Carlsbad, CA, USA) which organises fibroblasts and epithelial cells 
to help arrest unwanted epithelial migration whilst maintaining space around the teeth for 
development of bone and periodontal support tissues (Vernino et al, 1999). Epi-Guide is an 
18 by 30 mm membrane made of poly(lactic acid).
Post surgical adhesions can occur following virtually all types of surgical procedure. Adhesions 
may cause intestinal obstruction, pain or infertility following abdominal/pelvic surgery. Such 
complications may require subsequent surgical intervention. The avoidance of adhesions is 
highly desirable. Part of the pathological formation of adhesions is due to the unwanted 
migration of inflammatory cells and fibroblasts and their formation of excessive extracellular 
matrix. Hyaluronic acid based sheets are available to combat this problem by acting as a 
physical barrier e.g. Seprafilm bioresorbable membrane (Genzyme Corporation, Cambridge, 
USA). Seprafilm turns to gel in a few days but remains in situ for about a week before being 
fully degraded. Randomised clinical trials have demonstrated that Seprafilm effectively and 
safely reduces the formation of post surgical adhesions for patients undergoing abdominal 
surgery (Becker et al, 1996) and pelvic surgery (Diamond, 1996).
Post implantation, barriers can undergo one of two routes; degrade (totally or partially) 
or become seeded with migrating cells. Any seeding of the material which eventually may 
happen can only occur in vivo, this is a contrast to the gels and three-dimensional scaffolds 
described below.
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A l. 1.2.2 Hydrogels
Hydrogels are used to encapsulate and isolate cells from surrounding tissues e.g. to preclude 
a host antibody response to transplanted allograft and xenograft cells. The gel approach, 
involves premixing cells and the liquid polymer prior to forming a three-dimensional shape 
which is then allowed to set to form a cell-gel construct. The most commonly used materials 
for hydrogel production are collagen and alginate (Wallace et al, 2003 and Drury and 
Mooney, 2003). There are, however, many potential alternative gels including sol-gels and 
fibrin (Mann, 2003, Boninsegna et al, 2003, Peterson et al, 1998, Ye et al, 2000 and Hench 
and Polak, 2002).
An early example of the use of gels for tissue engineering was by Bell who successfully 
used collagen gels as a scaffold to maintain and grow fibroblasts as the basis of a living 
skin equivalent (LSE) (Bell et al, 1981, Bell et al, 1983 and Bell et al, 1991). Bell used this 
technology to establish Organogenesis (Canton, USA) in 1985, and by December 1986, 
over 700 LSEs had been successfully grafted onto laboratory rats. This methodology was 
developed and refined to eventually create the commercial skin substitute product Apligraf 
which obtained FDA approval in May 1998 for the treatment of chronic leg ulcers.
Hydrogels have also been used for the maintenance and immunoprotection of xenograft 
and homograft cells e.g. hepatocytes (Balladur et al, 1995) and islets of Langerhans (Lanza 
et al, 1999) used for transplantation. Maintenance of the integrity of these hydrogels for 
long-term implants is a problem due to in vivo degradation, however, for tissue engineering 
where scaffold degradation is desirable this is an advantage. [Non-biodegradable porous 
materials are better suited to situations where long term integrity is required e.g. implanting 
immunologically non compatible cells e.g. AN69 (acrylonitrile and sodium methyl sulfonate 
coploymer) (Hospa, Lyon, France) (Pakhomov et al, 2002).]
Another application of gels for tissue engineering is organ printing. Several research centres 
are exploring the use of specially adapted of matrix printers to lay down human cells and 
bonding agents in precise three-dimension geometries, described as organ printing. Using 
this methodology, organ printing is automated and fully computer controlled, thus potentially 
capable of the high speed fabrication of tissues (Wilson and Boland, 2003). This platform 
technology is broadly based on personal computers that are bespoke programmed to drive 
highly modified inkjet type printers, plotters or "cell dispensers". The "inks" are cells and 
biodegradable gels (Markwald, 2003). [A recent review of organ printing can be found in 
Mason, 2005.]
A1.1.2.3 Preformed three-dimensional scaffolds
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Preformed three-dimensional scaffolds are currently a key component for the tissue engineer 
for most applications. It is possible to construct an organ without using a scaffold (L'Heureux 
et al, 1998), but the mainstream approach is presently to deploy a scaffold as a temporary 
artificial extracellular matrix. The fundamental difference between gels and preformed 
scaffolds lies in the time of cell seeding with respect to the formation of the desired three- 
dimensional living construct. Cell seeding methodology also differs e.g. cells and solutions 
can be potentially mixed to homogeneity prior to gelling whilst preformed scaffolds are a 
much greater challenge (Radisis et al, 2003).
Professor loannis Yannas at the Brigham and Women's Hospital (Boston, USA) working with 
collagen sponges was one of the first to show that an important property of a successful 
scaffold was pore size (Dagalakis et al, 1980). Pore orientation, and fibre structure are also 
important characteristics in the design of "cell friendly" preformed scaffolds (Yannas et al, 
1980, Yannas and Burke, 1980).
Many techniques have been developed in order to form three-dimensional scaffolds from 
both synthetic and biologically derived resorbable polymers with or without additional 
"cell friendly" features e.g. treating PGA with sodium hydroxide in order to increase cell 
attachment (Nam et al, 1999). Biomaterials such as type I collagen and PGA have been used 
in combination with other extracellular matrix components, attachment factors, and growth 
factors to induce new tissue generation or damaged tissue regeneration.
Because of the rapid growth of tissue engineering over the past decade, several commercial 
companies are now starting to supply commercially ready-made scaffolds e.g. Cellon S.A. 
(Luxenburg) supply sterile PLA sheets and conduits ready for cell implantation.
A1.2 Natural polymers
This section reviews the potential natural polymers currently available to create tissue- 
engineering scaffolds and is supplementary to the overview of alginate and the reasons 
why it was specifically chosen as the scaffold material for this thesis - see Chapter 2. (An 
equivalent review of biodegradable synthetic polymers was also undertaken, but has not be 
included in this thesis)
A 1.2.1 Background
Historically biomaterials were selected on the presumption that implantable medical devices 
should be constructed of inert materials which would not interact with the patient's tissues. 
Thus, their functional performance was restricted to simple mechanical or physical gaols 
with no true integration into the body e.g. the Charnley total hip replacement invented in 
1962 by Sir John Charnley made of a metal ball and a plastic cup. However, these so
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called inert materials are never totally inert in vivo, for example degradation and wear 
debris are common problems (Weightman etal, 1991 and Isaac etal, 1996). Recently, the 
conceptual approach to biomedical device materials is changing and biointeractivity is now 
the major requirement rather than inertness. For example, biomimetic synthetic polymers have 
been created to elicit specific cellular functions and to specifically direct cell-cell interaction 
(Hubbell, 1995). Today the major focus of biomaterials for tissue engineering applications 
centres around their biointeractivity. Often attempts to direct the cellular response with the 
specific biomaterial is a key design consideration e.g. the arginine-glycine-aspartate (RGD) 
peptide sequence has been incorporated into biomaterials in order to stimulate cell adhesion 
to the biomaterial (Massia and Hubbell, 1990) and subsequent cellular migration through the 
material (Massia and Hubbell, 1991 b). Massia demonstrated that when cell-non-adhesive 
glass was covalently coated with the synthetic peptide glycine-argine-glycine-aspartate- 
tyrosine (GRGDY) human foreskin fibroblasts attached and spread by migration over the 
surface. Furthermore, the process of incorporating the RGD peptide into a biomaterial has 
been commercialised e.g. PepTide adhesive coating by Telios Pharmaceuticals (San Diego, 
CA, USA) consists of polytetrafluoroethylene or polyethylene terephthalate coated with RGD 
peptide (Olivieri and Tweden, 1999).
Due to the diversity of biological responses to different biomaterials, it is important for the 
tissue engineer to have multiple well characterised biomaterials options available, since each 
tissue application will probably call for a unique environment for its specific cell population. 
Unfortunately as yet there are only a few biodegradable biomaterials suitable for tissue 
engineering which have sufficient data e.g. in vivo toxicology studies, detailed knowledge of 
degradation mechanism and its rate.
Present day biomaterial research applications include:
•  Support for new tissue growth and maturation with maximal cell-cell communication 
and ease of availability to nutrients and bioactive agents e.g. a tissue engineering 
scaffold
•  Prevention of undesirable in vivo cellular activity i .e. as a physical barrier to unwanted 
tissue growth, e.g. surgically induced adhesions which are highly undesirable.
•  Guided tissue response e.g. enhancing a particular cellular response while inhibiting 
others e.g. tubular conduits for peripheral nerve repair
•  Enhancement of cell attachment and subsequent cellular activation e.g. enhancing 
fibroblast attachment, proliferation, and production of extracellular matrix for dermis 
repair
•  Inhibition of cellular attachment and/or activation e.g. prevention of platelet 
attachment to a synthetic vascular conduit
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• Prevention of a biological response e.g. blocking antibodies against homograft or 
xenograft cells used after transplant surgery to prevent host versus graft rejection.
(Source: a modified version from Pachence and Kohn, 2000)
Commercial biodegradable polymers suitable for tissue engineering must ideally possess:
•  Robust manufacturing feasibility using validated current good manufacturing 
processes (cGMP), including the availability of sufficient commercial quantities of 
the bulk polymer and the capability to form the polymer into the final product design 
at a realistic cost
•  Mechanical properties that adequately address short term scaffold function but do 
not interfere with the long term function of the construct in vivo
• Low or negligible toxicity of degradation products, in terms of both local tissue and 
systemic inflammatory and immunological responses
• Ability to deliver bioactive agents e.g. the manufacturing process is not so harsh as 
to render the bioactive agent inactive
•  Easy to sterilise
•  Possess acceptable shelf life
(Source: a much modified version from Pachence and Kohn, 2000)
A1.2.2 Collagen
Collagen consists of a family of proteins which combined constitute about one third of the 
bod/s protein (Walter and Talbot, 1996). Its major role is as an important structural protein 
which is found in every major tissue that requires strength and flexibility e.g. skin, cornea, 
bone and tendon (collagen comprises approximately 90% of the organic matrix of bone 
(Walter and Talbot, 1996)). Collagens are a major constituent of connective tissue and are 
synthesised by fibroblasts and "fibroblast-like cells" (extracellular matrix) and epithelial 
cells (basement membrane). Collagens are extracellular protein containing three helical 
polypeptide chains each approximately 1050 amino acid residues long. The three strands 
wind around each other to form a superhelical cable, which is held together by hydrogen 
bonds. The amino acid sequence of collagen is highly regular with nearly every third residue 
being glycine. With respect to the hydrogen bonds, the hydrogen donors are the peptide -NH 
groups of the glycine residues and the hydrogen acceptors are the peptide -CO groups of 
residues on other chains. Collagen overall is a rod shaped molecule about 300 nm long and
1.5 nm in diameter (Stryer, 1988). Although collagens are metabolically very stable, they can 
be easily degraded in vivo and removed or remodelled e.g. during growth (once the adult 
stature is attained, the turnover of collagen is slow). The underlying catabolic processes can 
be either by collagenases or non-specific proteases (Walter and Talbot, 1996).
-  250  -
A1.2.2.1 Type I collagen
Currently there at least 14 different types of human collagen described, most of which are 
fibrillar in nature, the most abundant is type I collagen (van der Rest et al, 1990). Due to 
its ease of purification from animal and human tissues (van der Rest and Garrone, 1991), 
abundance, (it makes up more than 90% of all fibrous proteins) and its unique physical and 
biological properties, type I collagen has been used extensively in the formulation of biomedical 
materials e.g. gels, matrices and films for soft tissue repair (Pachence, 1996). Since type I 
collagen is found in high concentrations in mammalian tendon, skin, bone and fascia, these 
are currently harvesting sources for its isolation prior to downstream processing.
Collagen has a long and successful history as an absorbable suture material e.g. catgut sutures 
were in use from as early as 175 AD when they were referred to by the outstanding physician, 
Galen of Pergamon. Galen, who built his reputation by treating wounded gladiators, used cat 
gut sutures in his clinical practice.
Today surgical "catgut"/gut is harvested from sheep intestinal mucosa or serosa of bovine 
intestine. Ethicon gut sutures (Ethicon, Somerville, USA) for example, contain a minimum 
of 97% pure ribbons of collagen (Ethicon Inc., 1994). In order to meet USP specifications, 
Ethicon processed ribbons of intestinal mucosa are electronically spun and polished into 
monofilament strands of the desired diameter with a tolerance of within 5 microns along the 
entire length of the strand using Ethicon's Tru-Gauging process (Ethicon Inc., 1994). Such 
accuracy is required in order to avoid thin and thick spots which if present lead to early 
suture failure due to fraying, which is an inherent problem with collagen. In vivo, plain, i.e. 
uncoated gut, tensile strength is rapidly lost within 7 - 1 0  days and is totally digested by body 
enzymes and macrophages within 70 days (Ethicon Inc., 1994). Since this is a xenograft 
there is a moderate tissue reaction as the catgut is absorbed. Plain gut is indicated for suturing 
tissues, which heal rapidly and require very little strength e.g. suturing subcutaneous fatty 
tissue. Gut suture life can be increased by exposing the collagen ribbons to chromium salt 
tanning solution prior to spinning into strands to form chromic gut sutures. These sutures resist 
in vivo enzymatic degradation and therefore retain their tensile strength for about double the 
time i.e. 1 0 - 1 4  days (Ethicon Inc., 1994).
Other medical applications of collagen based biomaterials include; processed porcine heart 
valves (Strawich et al, 1975), tendons and ligaments. Commercially available porcine valves 
include the St Jude Medical (St Paul, USA) Biocor porcine valve. In order to increase its 
resistance to wear and tear, the Biocor porcine valve is treated with glutaraldehyde. This valve 
has an excellent reputation spanning over 15 years (Myken et al, 2000).
The primary structure of collagen has a high content of proline and hydroxyproline, with every
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third amino acid being glycine and shows a strong sequence homology across genera (Stryer, 
1988). Due to of its phylogenetically well-conserved primary sequence, collagen is only mildly 
immunoreactive (Anselme et al, 1990). Anselme implanted bovine type 1 collagen sponge
into rats and found that after 8 hours the collagen implant was filled with polymorphonuclear
leucocytes, after 8 days fibroblasts had secreted a granulation tissue within the sponge and 
the polymorphonuclear leucocytes had almost gone. The small amount of sponge left after one 
month consisted of densely packed fibrils. Antibodies to type 1 collagen were not detected in 
the rats7 blood.
The characteristics of collagen can be altered by changing the degree of intermolecular cross- 
linking. Collagen cross-linking can be increased through a number of physical or chemical 
techniques. Physical methods include: drying, ageing, anhydrous heating and irradiation 
(UV or gamma irradiation). Chemical modification is by adding various agents including 
either formaldehyde or glutaraldehyde (Pachence et al, 1987). Increasing the intermolecular 
cross-links:
•  Increases biodegradation time by making collagen less susceptible to enzymatic 
degradation
• Decreases the capacity of collagen to absorb water.
•  Decreases its solubility
•  Increases the tensile strength of collagen fibres
(Source: Pachence and Kohn, 2000)
Thus by varying the amount of cross-linking, different properties can be achieved that may be 
suitable for different tissue engineering applications.
Substrate attachment sites are necessary for growth, differentiation, replication, and metabolic 
activity of most cell types in tissue culture (Pachence and Kohn, 2000). Collagen and its 
integrin binding domains (e.g. arginine-glycine-aspartate-threonine [RGDT] and aspartate- 
glycine-glutamate-alanine [DGEA] peptide sequences) allow cells to "dock77 on a surface, 
a vital step in maintaining viable anchorage dependant cell types in culture (Yamada et al, 
1992).
Collagen7s natural cell "friendliness77 lead to it being tried very early on as a scaffold material 
e.g. for the production of a dermal equivalent (Yannis et al, 1980). Yannis and Burke were 
early pioneers in the field of tissue engineering. After promising work with animal models e.g. 
experimental full thickness wounds on guinea pigs (Yannis and Burke, 1980), they successfully 
applied their knowledge to human patients (Burke et al, 1981). Ten patients with extensive 
burns (greater than 50% of the total body surface), had their burns surgically debrided and 
then treated with a skin equivalent constructed of a temporary Silastic epidermis and a
-  252  -
porous collagen-chondroitin-6-sulphate fibrillar dermis. Following grafting with the bilayer, 
fibroblasts from the wound bed quickly populated the structure. Likewise angiogenesis from 
the wound bed into the graft was seen, thus a "neodermis" was formed. After a further period 
of up to 6 weeks, the Silastic top layer was removed leaving a vascularised "neodermis" 
which was then covered with a conventional autologous epidermal mesh skin graft. Patients 
were followed up for over a year and reasonably promising functional and cosmetic results 
were observed. The authors stated that the benefits of this bilayered artificial skin was its ease 
of sterilisation, its ability to be stored at room temperature, the manufacturing process could 
potentially be scaled-up for mass production, and its immediate availability to surgeons.
Another pioneer in the field was Bell, who also worked with collagen based skin equivalents 
but was more concerned with growing the organ in vitro (Bell et al, 1981). His laboratory 
produced living constructs consisting of a dermal equivalent made from fibroblasts cast in 
a collagen matrix and then seeded with epidermal cells to provide an epidermis, thus a 
bilayered structured was formed ready for implantation (Bell et al, 1983).
One of Bell's first living skin equivalents was constructed from human fibroblasts, in soluble 
rat tail collagen in the form of a contracted gel (Bell et al, 1981). Bell, armed with a series 
of successful attempts at using these living constructs formed Organogenesis Inc (Canton, 
USA) in order to further this work, resulting eventually in the FDA approved skin product 
Apligraf. Organogenesis use bovine tendon as the source of their type I collagen. Apligraf 
has demonstrated its clinical advantage over conventional wound healing approaches and 
has gained FDA approval for both venous leg ulcer treatment (May 1998) and diabetic 
foot ulcer treatment (June 2000) (Falanga et al, 1998). An alternative source of collagen is 
deployed by Smith and Nephew (formerly Advanced Tissue Sciences (La Jolla, USA)) who 
initially grew well charachterised human fibroblasts and specifically cultured these cells to 
produce a human collagen scaffold prior to epidermal cell seeding. The resulting product 
Dermograft is also FDA approved for chronic leg ulcers (September, 2001).
Although there are many suggested uses for collagen in medicine, there are presently only a 
few commercially available collagen devices. Possible reasons include:
• High cost of preparing pure type I collagen versus producing synthetic biomaterials
•  Variability of isolated collagen e.g. cross-linking density, fibre size trace impurities
•  Difficulties in handling and storage of collagen c.f. synthetic polymers
•  Potential transmission of pathogens e.g. prions
(Source: a modified version from Pachence et al, 1987)
Mainly due to the concern over the issue of prion transmission, recombinant human collagen 
types I and III have been manufactured (FibroGen Incorporated, San Francisco, CA, USA).
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FibroGen presently produce commercial human collagen using yeast fermentation through 
the insertion of a human collagen gene. However, in collaboration with PPL Therapeutics 
(Edinburgh, Scotland) FibroGen also created human collagen in "safe" (i.e. believed to be 
pathogen free) transgenic animals which secrete human collagen in their milk. Finally in order 
to reduce costs, FibroGen has also demonstrated that human collagen can be produced as 
a transgenic plant product. This last development could have the ability to produce sizeable 
quantities of quality collagen at significantly reduced cost compared to the present yeast based 
process, thus overcoming the present problems of using animal derived collagen. Fibrogen 
currently has an NIH funded program to evaluate its recombinant collagen technology in the 
field of tissue engineering.
A1.2.2.2 Small intestinal submucosa
Small intestinal submucosa (SIS) is a naturally occurring complex extracellular matrix derived 
from xenograft sources, most commonly porcine. The submucosa is found between the inner 
mucosa and outer muscular layers of the intestine. After being harvested, small intestine is 
mechanical stripped of its mucosal layer leaving an acellular tube or if cut open a flat sheet. 
SIS is thus a naturally derived matrix. The in vivo function of the submucosa is to provide 
strength to the intestine and is predominantly a complex of matrix collagens type I, II and 
V. It is also a reservoir for cytokines that guide repair and replacement of the high turnover 
intestinal epithelial cells. SIS is extracted from the intestine in a manner which retains the 
natural composition of the matrix collagen molecules, growth factors (e.g. TGF-p, FGF-2, 
VEGF), glycosaminoglycans (hyaluronic acid, chondroitin sulphate, heparin and heparin 
sulphate), proteoglycans and glycoproteins (e.g. fibronectin). These retained bioactive 
substances signal cells to repopulate the SIS and form new tissue, i.e. the SIS acts as an 
interactive scaffold for cell incorporation and tissue remodelling (Voytik-Harbin et al, 1997). 
The manufacturing process used by one of the main commercial proponents of SIS, namely 
Cook Biotech Incorporated (West Lafayette, USA) has been FDA validated to ensure that any 
retained animal viruses are completely inactivated. Other steps have been taken to ensure 
that SIS is safe including:
•  Strict control of porcine production facilities
•  Use of a validated disinfection process in addition to terminal sterilisation
•  Independent laboratory testing to verify biocompatibility of the material
•  Extensive multicentre preclinical testing
•  No harmful immunological responses observed in either animal or human studies 
e.g. SIS has not been shown to activate the complement cascade in vitro unlike 
the complement involved hyperacute rejection observed in porcine whole organ 
xenografts into primates (McPherson et al, 2000)
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(Source: Cook Biotech Inc. SIS Sales Literature, 2000)
SIS can be cut, rolled or folded in order to produce a specific three-dimensional shape. It can 
then be sutured or stapled in order to retain this desired shape. The shelf life of SIS is in the 
order of 1 year.
Cook Biotech have produced a variety of SIS based products including Oasis (a sheet of SIS 
for skin regeneration), Stratasis (aimed a providing pubourethral support as a sling of SIS for 
use in the treatment of female urinary incontinence), Surgisis (soft tissue bulking implantation 
material), Vivosis (tissue culture disks, sheets and inserts) and VetBiosist for veterinary 
applications.
A l .2.3 Proteoglycans and glycosaminoglycans
Proteoglycans are proteins containing one or more covalently linked glycosaminoglycan 
chains. Human connective tissues are rich in proteoglycans, which consist of units made 
of polysaccharide (approximately 95%) and protein. These very large polyanions bind 
water and cations and thereby form the extracellular matrix (ECM) of tissues. Proteoglycans 
are important in joints and other structures that are subject to mechanical deformation. 
Glycosaminoglycans (GAGs), the polysaccharide chains in proteoglycans, are made up of 
disaccharide repeating units containing a derivative of an amino sugar, either glucosamine 
or galactosamine. At least one of the sugars in the disaccharide has a negatively charged 
carboxylate (e.g. carboxyl group of glucuronic acid in hyaluronic acid) or sulphate group 
(e.g. dermatan sulphate) (Walter and Talbot, 1996). Hyaluronate, chondroitin sulphate, 
keratan sulphate, heparan sulphate, and heparin are the major glycosaminoglycans. In the 
proteoglycan from cartilage, keratan sulphate and chondroitin sulphate chains are covalently 
attached to a polypeptide backbone called the core protein. About 140 of these proteins 
are noncovalently bound at intervals of 30 nm to a very long filament of hyaluronate. GAG 
polymers are present in both the ECM as well as on cell surfaces. GAG's on cell surfaces act 
as docking sites for fibroblast growth factor and other proteins that stimulate cell proliferation 
(Stryer 1988).
A 1.2.3.1 Hyaluronic acid
The largest GAG, hyaluronic acid (HA), is a naturally occurring glycosaminoglycan, consisting 
of a repeating dimer of glucuronic acid and N-acetyl-glucosamine with unbranched units 
containing 5,000 carbohydrate residues (McGilvery and Goldstein, 1983). Hyaluronic acid 
functions in vivo as both a lubricant and a resilient buffer against mechanical damage as 
well as being important for the regulation of water balance in tissue. Its name is derived 
from the Greek word for glass, hyalos, which describes HA's transparent glassy appearance.
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Hyaluronic acid can be isolated from natural sources (e.g. rooster combs) and via microbial 
fermentation (Brache etal, 1985). Unfortunately, the animal source is limited and the microbial 
one currently expensive.
Hyaluronic acid is a widely distributed and highly evolutionarily conserved polysaccharide 
which plays an important role in a variety of vertebrate soft tissues. No species variation 
has been found and hence it is a highly desirable biomaterial since it is not antigenic and 
therefore does not illicit an inflammatory response when use as a xenograft (Pachence et al,
2000). By nature of its ability to form highly hydrated and viscous matrices, HA provides 
stiffness, resilience and lubrication to various tissues e.g. synovial fluid of joints, the vitreous 
humor of the eye, arterial walls, umbilical cord and the ability of connective tissues to resist 
compressive forces. HA is a major constituent of the extracellular matrix where it has a large 
influence on a variety of cellular events e.g. cell migration and proliferation.
Its main disadvantage is a limited range of mechanical properties. In order to change these, 
HA can be chemically modified, e.g. by esterification of the carboxyl moieties (Kvam et al, 
1992) which reduces its water solubility and increases its viscosity. Hyaluronic acid can be 
cross-linked to form molecular weight complexes of the order of 107 Dalton or to form gels 
(Balazs et al, 1987). In Balazs's method, hyaluronic acid is cross-linked using aldehydes to 
form bonds between the C-OH groups of the polysaccharide and the amino groups of the 
protein, thus yielding high molecular weight complexes. The resultant gels can be formed into 
sheets, tubes and other three-dimensional shapes. Extensive esterification produces materials 
which are highly resistant to in vivo degradation by hydrolysis (Hubbell et al, 1995).
The major proponent of HA technology is FAB (Fidia Advanced Polymers, Italy) which has 
dedicated much attention to the chemical preparation of hyaluronic acid, with the aim of 
developing biopolymers which retain the biocompatibility of the parent molecule but have a 
range of different physical properties e.g. elasticity, viscosity and plasticity.
Hyaluronic acid's biological properties make it an ideal candidate for the development of 
innovative biomaterials for various clinical indications. Purified medical grade HA is currently 
employed in a very wide range of medical uses including; reducing the incidence of post 
operative adhesions (Epifilm Otologic lamina discs, Medtronics Xomed, Minneapolis, USA), 
as a component of wound healing formulations (Cystistat, Bioniche Life Sciences Inc, London, 
Canada) and in various cosmetic preparations (Cellex-C Advanced C Skin Hydration 
Complex, Cellex, Toronto, Canada).
FAB has optimised a number of well defined patented chemical modifications to HA that have 
been successfully employed to produce a novel range of viscoelastic biopolymers (e.g. Soranzo 
etal, 2000). These HA derivatives can range from soluble to solid hydrogel. Moreover, these
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derivatives have prolonged and controllable degradation rates compared to the natural HA. 
Al .2.4 Fibronectin, fibrinogen and fibrin
The fibronectins are a family of glycoproteins which function as "molecular glues" since they 
are essential for many cell-to-cell interactions and cell-to-surface interactions (Walter and 
Talbot, 1996). Whilst synthesised by a variety of different cells, the main source is vascular 
epithelial cells. Fibronectin consists of two identical 250 Kd polypeptide chains that are linked 
by a disulphide bond (Stryer, 1988). Possessing receptors for both cells and extracellular 
matrix e.g. collagen, heparin, fibronectin and fibrin, fibronectins are present in plasma, 
on cell surfaces, on collagen fibres and in basement membrane. Their functions include; 
connective tissue organisation and anchorage, cell-to-cell binding, cell cytoskeleton structure 
and motility, wound healing and coagulation (Walter and Talbot, 1996). Interestingly the 
glycine-arginine-aspartate (RGD) peptide was first discovered in fibronectin (Piersbacher and 
Ruoslahti, 1984).
Fibrinogen is a glycoprotein synthesised by the liver and plays an essential part in the blood 
clotting process. Present in plasma (200 - 400 mgl'1), fibrinogen has a molecular weight 
of approximately 340 KDa. It consists of six polypeptide chains of three different types (a, 
p and y) arranged in a symmetrical structure and linked by disulphide bridges. During the 
physiological clotting cascade, thrombin cleaves the a and P chains resulting in the formation 
of fibrin, an important structural component of a blood clot. Fibrin has a long history of 
use in modern medicine e.g. during World War I, Harvey described the deployment of 
fibrin sheets to stop bleeding during surgery (Harvey, 1916). Today, tissue sealants with a 
fibrinogen and/or fibrin component are routinely used in surgery e.g. CoStasis (Angiotech 
Pharmaceutical, Vancouver, Canada) which uses autologous fibrinogen and Tisseel (Baxter, 
Deerfield, II, USA) which uses fibrinogen derived from human pooled plasma. A similar 
allogeneic product is under development by the Scottish National Blood Transfusion Service 
(Edinburgh, Scotland).
The deployment of fibronectin in tissue culture has a long history e.g. coating tissue culture 
plates to assist cell attachment. However, the use of fibronectin in tissue engineering is less 
advanced. Mats and cables made from fibronectin have been suggested as suitable materials 
for nerve guides to assist nerve regeneration (Ahmed et al, 2003). Liquid fibronectin when 
mixed with alginate has also shown potential in nerve repair in rats (Mosahebi et al, 2003).
Combining fibronectin and fibrinogen has also demonstrated potential for tissue-engineering 
scaffolds. Dr. Sarah Underwood at University College London has described a potentially 
appropriate method for the wet extrusion of human plasma derived fibronectin-fibrinogen 
cables (Underwood et al, 2001). This same material has also been demonstrated to be
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potentially superior to fibronectin alone with respect to cell (Schwann cells) migration on a 
scaffold at low fibrinogen concentrations. However at higher concentrations of fibrinogen, 
cell migration is inhibited (Ahmed et al, 2000).
Finally, with respect to processing of allogeneic pooled blood donations, Baxter who 
manufacture Tisseel surgical sealant, process the pooled material using a "patented double 
vapour heat deactivated" procedure which destroys hepatitis B, hepatitis C and HIV (polymerase 
chain reaction tested). However, parvovirus B19, which can easily infect immunocompromised 
or pregnant patients remains active when present (Baxter product information leaflet). This 
deficiency reflects the difficulties experienced when handling allogeneic material especially 
when pooled. Alternative source e.g. bovine and autologous are also not without difficulties, 
namely risk of prion transmission and blood fibrinogen concentration variability between 
patients respectively.
A 1.2.5 Chitin and chitosan
The amino polysaccharide chitosan (poly 1,4 D-glucosamine) is a biosynthetic partially 
deacetylated derivative of chitin (Sundararajan and Matthew, 1999). Chitin is a naturally 
occurring polysaccharide which is the primary structural polymer in arthropod (crabs, spiders, 
insects) exoskeletons and fungal cell walls/structural membranes of mycelia, stalks and 
pores (Hamlyn and Schmidt, 1994). Chitin is commercially produced from both crustacean 
exoskeletons and fermented from fungi e.g. Lentinus edodes and Absidea coerula (Peter,
2002). Commercially available preparations of chitosan have degrees of deacetylation 
ranging from 50 - 90% and depending upon the source and processing method, chitosan 
may have a molecular weight in the order of 300 - 1000 KDa (Sundararajan and Matthew, 
1999).
Chitosan is a (3-1,4-linked polymer of 2-amino-2-deoxy-d-glucose. It is thought that the 
degradation of both chitin and chitosan in vivo is due to the enzyme lysozyme which slowly 
depolymerises these polysaccharides, the end products being simple carbohydrates, C 02and 
water. (Muzzarelli et al, 1988).
Chitosan has been fabricated into three-dimensional scaffolds which could be potentially 
deployed in tissue engineering (Sundararajan and Matthew, 1999). Sundararajan and 
Matthew produced a variety of potential scaffolds including membranes, beads and tubes and 
demonstrated that porous three-dimensional chitosan structures could be easily fabricated with 
good control over pore morphology. These scaffolds were prepared by controlled freezing 
and lyophilisation of chitosan solutions and gels. Mean pore diameters were controlled in the 
range 1 - 250 pm by varying the freezing conditions.
Chitosan has been demonstrated to possess biocompatibility features favourable for its use 
in constructing a tissue engineering scaffold e.g. it can support the growth and phenotypic 
expression (confirmed by reverse transcriptase polymerase chain reaction) of human 
osteoblasts and chondrocytes (Lahiji et al, 2000).
In May 2001, the American Society for the Testing of Materials (ASTM) (West Conshohocken, 
PA, USA) produced a guide (F 2103-00) titled "Standard guide for characterisation and 
testing of chitosan salts as starting materials intended for use in biomedical and tissue- 
engineered medical product applications" in response to the growing interest of chitosan 
for tissue engineering. The regulatory issues dealt with included; documentation, impurity 
levels, safety and toxicology, good manufacturing practice (GMPJ/ISO 9000 guidelines and 
regulatory standards. This guide coincided with a similar guide for alginate and represents 
some of the drive ASTM is making to ensure quality and standardisation of tissue-engineered 
medical products (TEMPS) (Dornish et al, 2001).
Al .2.6 Amino acid and peptide repeats
Al .2.6.1 Peptide repeats
Novel synthetic protein structures based on a repeating pentapeptide (valine-proline-glycine- 
valine glycine) (VPGVG) found in elastin have been produced (McPherson et al, 1992). The 
VPGVG repeat is expressed as a recombinant polypeptide using bacteria, isolated, purified 
and then gamma irradiated in order to cross-link the polymer to form an elastic hydrogel. To 
make this polymer cell friendly the RGD peptide has been covalently bonded to the polymer 
(Nicol et al, 1992). Using bovine aortic endothelial cells, Urr/s group demonstrated that 
these modified polymers were able to support cell adhesion and growth provided the ratio of 
VPGVG :RGD in the polymer was no greater than 60:1 (Nicol et al, 1992).
A range of novel elastin based polymers is produced by Protein Polymer Technologies Inc 
(PPTI) (San Diego, USA). Their technology has enabled the creation of polymers that combine 
the repeating blocks of amino acids responsible for the elasticity of elastin with the repeating 
blocks of amino acids responsible for the strength of silk (Ferrari et al, 2001). These high 
molecular weight polymers can be processed into a variety of forms including gels, sponges, 
films and fibres. PPTI's initial targeted products for this range of "silk-elastin" polymers 
includes, urethral bulking agents for female urinary stress incontinence (clinical phase II trial 
stage), dermal products for cosmetic and reconstructive surgery (clinical phase II trial stage), 
tissue adhesives, localised controlled drug delivery systems and tissue engineering scaffolds 
(McKenna, 2001).
A1.2.6.2 Amino acid repeats
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The deployment of amino acid repeats in tissue engineering is yet to be demonstrated, 
however, there are a number of researchers who have suggested that because of their unique 
advantages, they may have a role to play in tissue engineering (Chiang and Yeh, 2003, 
Deming, 1997 and Pachence and Kohn, 2000).
A1.2.6.3 Poly (amino acids)
One option for the creation of new tissue-engineering scaffold materials is to synthesise new 
polymers derived from novel amino acids sequences. Many different types of polyfamino 
acids) have been investigated for use in biomedical applications. Poly(amino acids) have 
several potential advantages as biomaterials (Palapura and Kohn, 1992):
•  A very large number of novel peptide-based polymers and copolymers can be 
prepared from a variety of amino acids
•  The side chains offer sites for the attachment of small peptides, bioactive agents, cross- 
linking agents, or other groups that can be used to modify the physicomechanical 
properties of the polymer
• Since these polymers release naturally occurring amino acids as the primary 
products of polymer backbone cleavage, their degradation products theoretically 
have minimal levels of systemic toxicity and immunogenicity
Poly(amino acids) have already been used as artificial skin substitutes for covering burns 
(Aiba et al, 1985) and as drug delivery systems (Negishi et al, 1987). PolyfL-lysine) has for 
a long time been involved in the development of gene therapy delivery vehicles e.g. work at 
Genzyme Corporation (Framingham, USA) has demonstrated that complexing recombinant 
adenoviral vectors with polycations such as poly(L-lysine) improves the transgene's expression 
(Kaplan et al, 1998).
Poly(amino acids) despite their potential have yet to find a biomaterial market niche. Their main 
drawbacks include high cost, processing problems and unpredictable in vivo degradation. 
The starting materials for the synthesis of polyfamino acids) are N-carboxy anhydrides. These 
anhydrides are expensive to produce and difficult to handle because they are extremely 
reactive and are very sensitive to moisture (Palapura and Kohn, 1992). In general, most 
polyfamino acids) are highly insoluble and therefore at present they are virtually impossible 
to process in to three-dimension structures. In vivo, polyfamino acids) degrade via enzymatic 
hydrolysis of their amide bonds, it is therefore difficult to control their in vivo degradation 
because levels of enzymes and their activity vary between patients. Because of these difficulties, 
only a few polyfamino acids), usually derivatives of polyfglutamic acid) are currently being 
investigated as biomaterials (Palapura and Kohn, 1992).
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A1.2.7 Silk
Silk is made up of long repeats sequences of alanine-glycine (-AG-J. Using recombinant 
technology the exact length of the AG repeat can be controlled in order to vary the mechanical 
properties of the recombinant silk. In order to create a cell friendly environment the RGD 
or tyrosine-serine-glycine-serine-arginine (YIGSR) peptide sequences can be added, this 
approach has been undertaken by Protein Polymer Technologies Inc (PPTI) (San Diego, USA) 
(Ferrari and Cappello, 2001). This modified recombinant silk can then be spun into fibres in 
order to form three-dimensional shapes.
Silk enhanced with an RGD peptide sequence and parathyroid hormone has been 
demonstrated in vitro to stimulate osteoblast activity (Sofia et al, 2001). Sofia took silkworm 
cocoons and boiled them for an hour in a soap solution to remove sericin (a protein known to 
cause an immunological reaction in vivo). The boiled silk was processed into flat sheets which 
were then coated with the bioactive agents prior to adding bone cells. After four weeks the 
osteoblasts were shown to be producing mRNA coding for procollagen as well as depositing 
extracellular calcium.
Al.2.8 Coral
Coral has a successful history in orthopaedic surgery as a replacement for bone. It has FDA 
approval for jaw reconstruction. Coral used in medicine is commonly harvested from reefs 
in the Indian Ocean. After harvesting, it requires antimicrobial treatment and cutting into the 
required shape prior to implantation. It is highly porous and is composed of hydroxyapatite i.e. 
it has a similar chemical composition to the inorganic component of natural bone. Processed 
coral is biocompatible and degrades minimally in vivo.
An example of its potential in tissue engineering has been demonstrated in restoring part of 
a human thumb (Vacanti et al, 2001). In 1998, the patient, Raul Mercia, was a 36 year old 
male landscaper who suffered an avulsion injury to the distal phalanx of his non dominant 
hand. The wound was initially covered with a pedicle skin graft from the abdomen which 
was divided from its abdominal blood supply by day 19. A block of processed natural coral 
(500 pore ProOsteon, Interpore International, Irvine, USA) was carved using a motorised 
burr into the size and shape of the missing distal phalanx. At 12 weeks, the coral phalanx 
was placed under the skin flap created by the skin graft by the surgeon (John Shufflebarger). 
Twenty million autologous periosteal cells were suspended in 1.5 ml of 1 % alginate in saline. 
This solution was then injected into the coral. Cells were fixed in position by cross-linking the 
alginate with calcium chloride solution (0.5 mmolL'1).
The results of the above procedure were periodically reviewed for approximately 3 years
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after the procedure (Hentz and Chang, 2001). At 3 months after the procedure, Raul Mercia 
was able to resume his work as a landscape gardener. Ten months after the procedure a 
biopsy showed that 5% was new bone, 30% was coral and the remainder was soft tissue. At 
28 months, whilst being cosmetically reasonable, the mechanical result was an unstable weak 
thumb with minimal pinching ability (approximately 25% of normal power). Many surgeons 
would argue that this result was poor compared to either a toe to thumb transfer or using 
autologous bone instead of coral to treat this particular injury. However, the procedure did 
demonstrate proof of principle for using a permeable biocompatible support structure seeded 
with cells suspended in hydrogel (Vacanti et al, 2000).
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APPENDIX 2
A2.0 Piston Driven Devices
Following the earlier experiments with the manual powered and coordinated piston driven 
prototype (Chapter 4), it was decided that a new system built on the same underlying principle 
but semi-automated, would be fabricated. The new system would include a degree of semi­
automation in order to achieve two major goals believed necessary to obtain reproducible 
tubular constructs:
• Precise coordination of the piston movement with the delivery of the calcium chloride 
solution
• Controllable piston acceleration, "cruise" and deceleration at reproducible rates
The crucial moment in time for the process is that at which the piston first starts to move. At 
this precise moment the calcium chloride solution needs to be injected into the barrel to fix 
the newly formed layer of alginate on its wall. If the calcium chloride mixes with the alginate 
before the piston starts to move, cross-linking occurs with the alginate gelling, thus trapping 
the regulator and corrupting that particular run of the experiment. If insufficient or injected 
too late, a tube is formed but is substandard with highly variable wall thickness and trapped 
air bubbles. Thus, the key is to synchronise the start of the movement exactly with the start of 
the injection of the calcium chloride solution. Furthermore, both the rate and the volume of 
calcium chloride injected must be near identical to the rate and the volume displaced by the 
piston. To achieve this, two identical barrels and pistons were employed i.e. both in terms 
of length and internal diameter. Since the barrel with an 8 mm inside diameter had proven 
experimentally most robust during initial testing - see Chapter 4, (i.e. in terms of successful 
manual tube production runs), this diameter glass barrel was selected for the prototyping of 
the semi-automated system.
A2.1 Pneumatic drive
The complete pneumatic drive tube-forming device can be seen in Figure A2.1. The barrels 
were quartz glass tubes of approximately 22 cm in length with an 8 cm internal diameter. The 
pistons were machined from polytetrafluoroethylene (PTFE) to be a 0.05 mm interference fit 
(i.e. the outer diameter of the PTFE piston was 0.05 mm greater than the inside diameter of 
the glass barrel) and mounted on threaded studding to allow for fine adjustment. The barrels 
were mounted in a vertical position one above the other with a gap in between to allow 
the positioning of a rigid piston linking device such that the two pistons moved down in an 
identical manner i.e. start, accelerate, "cruise", decelerate and stop identically, see Figure 
A2.2. The rigid piston linking device was attached via a simple fixed arm to the carriage on 
a slot-type pneumatic ram. The actuator ram selected was a pneumatic double acting slot-
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Figure A2.1
Piston driven tube forming device complete with pneumatic ram.
(Photographer: Dave Sayer - ©  The W ellcome Trust Medical Photographic Library - 2003)
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Figure A2.2
Range of travel - Pneumatic tube-forming device.
(Photographer: Dave Sayer - ©  The W ellcome Trust M edical Photographic Library - 2003)
type rodless linear drive (Hoerbiger-Origa Systems GmbH, Altenstadt, Germany. Part No: 
120S2040) kindly loaned by the Department of Chemical Engineering, UCL. The double 
acting linear actuator consisted of a cylindrical barrel and a rodless piston. The piston in the 
cylinder is freely movable and being double acting it is under the control of the supply air in 
both directions of travel. This particular unit has an operating pressure range of 0.5 -  8 bar 
and an operating speed range of 1 cmsec'1 to 6 msec'1. The unit has a cylinder bore of 40 
mm. Using the equation:
Force (N) = Pressure (N/m2) x Surface area of piston (m2)
The theoretical maximum force that can be generated by this ram is 1006 N at 8 bar (1 bar 
= 100,000 N /m 2). However up to 30% losses are to be expected in real applications (Stacey, 
1998).
The ram was powered by compressed air either from the main laboratory supply or from 
a freestanding cylinder. The control system was an open-loop system i.e. it possessed 
no feedback unlike a closed-loop control system. This setup had the advantage of being 
simple but potentially slightly less accurate. The acceleration and velocity of the pneumatic 
actuator depended upon the rate compressed air entered and exited the unit. Since air is a 
compressible fluid, the volume of a given mass of air depends upon its pressure (Boyle's law) 
and temperature (Charles' law). The change of temperature of the air across an actuators 
is typically negligible and thus can be neglected (Pinches and Callear, 1997), however the 
pressure can vary greatly as the load and flow rates change. Pneumatic actuator speed 
control in general is either achieved by either metering the quantity of air entering (meter-in 
flow control) or leaving (meter-out flow control). The system used had meter-out flow speed 
control, whereby the exhaust air is metered which sets up a back pressure which compensates 
for variations in system loads thus theoretically helping to smooth the operation movement. 
The method used to meter-out the exhaust air was by using an adjustable restricter (bleed 
screw) in the exhaust port. Movement of the ram was therefore controlled via electronically 
synchronised inlet valve and outlet port i.e. compressed air accessed (via one of a pair of 
SMC ASS500 solenoid valves -  non adjustable: open/close only with no in-between positions) 
one end of the double acting drive whilst air was bleed in a controlled manor (via a pair of 
solenoid controlled CompAir Series bleed screw valves - adjustable) at the opposite (exhaust) 
end. Only when air was allowed to bleed from the system could the ram move. By varying 
the pressure of compressed air entering the system via a Norgren gauge and altering the 
exhaust bleed rate it was possible to modify the velocity of the ram. In practise, the device 
only worked (i.e. produced hydrogel tubes) over a very narrow range of settings. If the speed 
was too low then the run would become flawed by the linking agent becoming associated 
with the alginate solution between the regulator and the barrel wall. Too fast a speed resulted
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in visually very erratic regulator movement. In practise, the optimal setting were 1 -2 bar inlet 
pressure coupled to a single 360° + /- 90° outward turn on the exhaust bleed screw from the 
fully screwed-in (closed) position. This pressure range equates to a theoretical force in the 
order of 1250 - 2500 N (ignoring inefficiencies in the system e.g. seal stiction). These settings 
resulted in average piston velocities of 7.5 - 10 cm per second calculated by electronically 
timing a series of tube producing runs of known length. Customised physical stops prevented 
excessive ram movement. The advantage of physical stops was that they gave very precise end 
points with extremely short deceleration times compared to the more conventional cushioned 
stops which block off the exhaust port just prior to the final part of the piston stroke, thus 
controllably slowing its velocity prior to coming to a complete halt. Reduced deceleration 
times were thought essential if run corruption was to be avoided i.e. the premature mixing of 
alginate solution and calcium chloride solution in the last part of the tube-forming run.
The top barrel was for tube fabrication, whilst the bottom barrel was to hold the calcium 
chloride charge. The top barrel and regulator element were an identical set up to the original 
manual device. The bottom barrel had no regulator but was capable of being filled from a 
calcium chloride reservoir via a three-way tap. The three-way tap controlled whether the 
bottom barrel was linked to the reservoir or to an injector nozzle directly above the top of the 
tube fabrication barrel.
A2.1.1 Operation cycle
A basic operation cycle (after presetting all the pneumatic valves) of the semi-automated 
pneumatic driven device consisted of:
1. Filling the calcium chloride reservoir (initially 2% in water was used)
2. Pneumatically lowering the pistons to their lower-most point
3. Turning the three-way tap to connect the calcium chloride reservoir to bottom 
barrel
4. Pneumatically raising the pistons to their uppermost position, see Figure A2.3, 
this creates a vacuum in the lower barrel which sucks the calcium chloride 
solution in from the reservoir, thus charging the lower barrel. The uppermost 
piston position was adjusted such as to leave a space above the upper piston 
sufficient to add the alginate solution and regulator
5. Adding 2 ml of alginate solution (initially 4% Kelco Manugel was used) directly 
to the space above the upper piston
6. Adding the regulator to the alginate solution
7. Finely adjusting the position of the top of the regulator (and therefore the 
alginate-air interface around its perimeter) so as to be flush with the top of the 
glass barrel
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Figure A2.3
Piston driven device - Hydrogel tube-forming barrel (Upper glass barrel).
(Photographer: Dave Sayer - ©  The W ellcome Trust Medical Pnotographic Library - 2003)
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8. Turning the three-way tap such that the injector nozzle and lower barrel are 
connected
9. Pneumatically lowering the pistons. This causes the top barrel wall to be coated 
in alginate at exactly the same time as calcium chloride is transferred via the 
injector nozzle to the top barrel thus cross-linking the polymer
10. Waiting for a period of 5 - 10 minutes before detaching the uppermost 
barrel in order to remove the piston which in turn delivered the hydrogel tube 
complete with embedded regulator
A2.1.2 Trouble shooting
A range of glass quartz barrel sizes were tried including 8 mm (i.e. approximately the same 
dimension as synthetic graft used for peripheral vascular disease bypasses e.g. GORE-TEX 
Vascular Graft) and 4 mm inside diameter (i.e. approximately the same dimension as human 
saphenous vein which is currently used as conduit for coronary artery bypass graft surgery). 
Once again, the device produced hydrogel tubes, however, reproducibility was a major issue. 
One run would produce a full length tube with good consistency of wall thickness (e.g. using 
8 mm inside diameter glass and a 7.5 mm outside diameter PTFE regulator, 4% Manugel 
alginate solution, 2% calcium chloride solution gave wall thicknesses in the order of 250 + /- 
100 pm -  Mitutoyo electronic micrometer gauge), and then the next few runs would either 
"corrupt" i.e. the regulator would travel a short distance down the barrel before prematurely 
becoming entrapped in cross-linked gel and/or the wall thickness would vary widely or be 
total absent. Frequently the resulting tube would be discontinuous for a proportion of its 
length.
A problem identified early on was the quality of manufacture of the glass barrel. Measurement 
of the tolerance range for standard quartz glass tubing showed it varied widely along its length 
e.g. the 8 mm diameter tube varied by up to + /- 0.5 mm (micrometer gauge on different 
parts of two 1 m lengths cut up into 15 - 20 cm length pieces. Since the gap between the 
barrel and the regulator determines the wall thickness, precision bore tubing was required. 
A manufacturer was identified (Precision Glass engineering, Hemel Hempstead, Herts., UK) 
who using a precision machined mandrels produced 8 mm inside diameter tubing + /- 0.01 
mm over a one metre length and also 4 mm + /- 0.01 mm over a one metre length. The glass 
selected was borosilicate (U.S. Pharmacopoeia Specification: 1A) as opposed to regular 
quartz. Using this specification tube did unfortunately not have the desired improvement on 
the success rate, however, this precision bore tubing has been continued with because of its 
potential crucial relationship to wall thickness.
Rigid plastic tubing e.g. Perspex for the barrel was also successfully tried. Interestingly cut-
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down medical syringes (Becton Dickinson Plastipak: 10, 20 and 50 /60  ml) when tried failed 
due to an inability of the alginate solution to coat the wall of the barrel, probably due to 
prior treatment of the plastic inner wall by the manufacturer in order to reduce piston stiction 
forces which might otherwise interfere with the smooth operation of the syringe. Stiction 
(static friction) is friction that prevents relative movement between two movable components in 
their stationary position immediately prior to slipping occurring i.e. initial movement of one 
component relative to the other. Other non-coated plastics were also employed with similar 
results to the Perspex and precision bore glass, thus the process was not just limited to barrels 
made of glass.
A range of different diameter, length and shaped regulators was also tried. Two types of 
regulator (both of which work excellently using the original manual technique) were tried:
•  Pure bullet shaped -  i.e. no contact with the barrel
•  Finned bullet - Bullet shaped but with the addition of little pegs at 90° intervals 
around the circumference at the two ends of the regulator to act as guides in order 
to centralise the regulator. The gaps between the pegs and the barrel were a loose 
fit, in the order of 10 pm. This gap was just sufficient to allow the finned regulator to 
travel smoothly down an empty glass barrel solely under the influence of gravity.
The finned bullet with certain types of alginates (high G content) left continuous grooves 
running the length of the tube (visualised by Leica TCS SP confocal microscopy system in the 
Department of Anatomy, UCL), however, the grooves did not break through the tube wall. 
The big advantage of the simple bullet shape is ease of manufacture and therefore numerous 
different lengths, diameters and shapes could be tried.
One factor which did make a difference was the relative density of the regulator to the 
different alginate solutions. The density of alginate solutions were of the order of just over 
1000 Kgm'3 depending upon the alginate concentration i.e. just greater than water. A 
range of different substances (including Dural (alloy of 95% aluminium, 4% copper and 1 % 
magnesium with a density of 2800 Kgm'3) and PTFE (density 2200 Kgm'3) and polypropylene 
(density 910 Kgm'3)) were machined up with identical dimensions. The lower relative density 
plastic polypropylene (density of 910 Kgm'3) worked best, however, all the materials could 
function as regulators. The only proviso being that the higher density regulators completely 
submerged (and thus aborted the run) if left for any length of time between being added to 
the alginate and drawing down the piston, whereas the polypropylene regulators could be 
left indefinitely. The Dural regulators whilst being relatively strong and more robust than the 
plastic regulators suffered from poor corrosion resistance. The bulk of the experiments were 
therefore carried out with the plastic regulators.
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However, despite trying to optimise the barrel and the regulator components, the consistency 
and reproducibility remained poor. The same barrel, regulator and piston when removed 
from the semi-automation platform and used manually performed substantially more 
reproducibly i.e. virtually always producing a continuous tube with no regulator fouling, 
albeit less scientifically in terms of the timing and force used. Focus therefore shifted towards 
the pneumatic drive mechanism and the pistons themselves.
One weakness in the system is the 1 cm long pistons which were manufactured from PTFE 
to give a 0.05 mm interference fit. PTFE being compressible gives an excellent seal along 
their length when first machined, however, after repeated use the PTFE becomes permanently 
deformed and the seal is eventually lost necessitating frequent replacement. Also as the 
interference fit reduces so too does the force required to overcome the stiction between piston 
and barrel.
Another weakness is the use of pneumatic ram. Using a number of different digital imaging 
devices including a NAC HSV 500 Digital High Speed Video system (NAC Image Technology, 
Inc. Tokyo, Japan) it was possible to view the progress of the regulator and piston during 
a tube forming run. The NAC HSV 500 stores its individual images in digital form in its 
memory. It records at 500 frames per second (fps) as .tiff files (Tag Image file Format -  Adobe 
Systems) with a maximum recording time of 5 seconds. (Kindly loaned by the Engineering 
and Physical Science Research Council (EPSRC)). Using a PC running Windows operating 
system, the individual .tiff files were converted to .jpg files (Joint Photographic User Group) 
using PicaView (ACD Systems -  www.acdsystems.com) before they could be strung together 
using AVI Constructor (www.aviconstructor.com) to create a continuous AVI (Audio Video 
Interleave - Microsoft) "movie". By having a precise scale directly behind the glass barrel and 
knowing that the time difference between two consecutive .tiff files is exactly 0.002 seconds, 
it was possible to calculate the velocity of the regulator and piston. The average velocity 
of the piston was slower than the average velocity of the regulator during a tube-forming 
run. Furthermore, instead of observing the desirable smooth movement down the barrel, an 
erratic staccato movement of the piston and regulator was exhibited on the vast majority of 
runs. On closer examination, there appeared to be two distinct components, an initial judder 
on "dive" (i.e. the moment that the regulator first commenced its downward journey) and a 
random variation down the tube. The "dive" problem was the most significant factor since it 
appeared to correlate well with the success or failure of a particular run. In short, if the dive 
was jerky then the tube was almost certain to be flawed. Simple experimentation revealed 
that the ram with either no resistive force or with high downward force (50  Kg weight hung 
from the fixed linkage between the pistons producing approximately 500 N of additional 
downward force i.e. in the direction of tube production) ran smoothly but with low resistive
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forces ran jerkily and unpredictably. For comparison, the maximum force required to produce 
a tube using the device was < 20 N, which is negligible compared to the theoretical maximum 
force of the ram (>1000 N). This was measured using a simple strain gauge attached to the 
fixed linkage, which was temporarily detached from the ram. After priming and loading the 
system, the strain gauge was manually pulled down to produce a tube in the same manner as 
the pneumatic ram and the maximum value recorded. This value was just prior to "dive" i.e. 
to overcome stiction forces.
The pneumatic ram was therefore stripped and rebuilt to the manufacturer's exact specifications 
just in case it was a fault. Likewise the switching equipment was examined and reassembled. 
After the rebuild, once again with zero load or high downward force the ram ran smoothly 
but connected to the tube-forming device it was once again jerky.
The "ideal movement" of the piston for the tube-forming device is probably one where:
•  The piston is stationary in the cylinder loaded with alginate solution and regulator. 
Extremely rapid acceleration occurs to the ideal velocity of 0.1 - 0.2 msec'1 i.e. the 
regulator's dive starts smoothly and continues in the same manner until the tube is 
completed and the regulator is once again at rest
• Velocity is constant during tube production
• Extremely rapid deceleration to a final halt at the end of tube production.
A simple graphical representation of the above would be a perfect square wave if velocity 
(y axis) were plotted against time (x axis), see Figure A2.4. Instead of this ideal movement a 
more erratic movement was observed which could have be due to a number of factors which 
include:
•  Variability of the compressed air delivery source
• Deformability due to pressure changes of tubing and ancillary components connecting 
the compressed air source to the pneumatic ram
• The volume of air above the bidirectional ram piston
• The volume of air displaced from below the bidirectional ram piston
• Stiction between:
• The bidirectional ram piston seals (2) and its cylinder
• The pistons and cylinders of the actual tube forming device (2)
• Backlash in the system due to deformable seals in:
•  Pneumatic ram assembly
• Tube forming device (2)
Each of the above factors was considered in relation to this "ideal movement".
The compressed air source made little if any difference, neither mains supply nor cylinder
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0 .1 -0 .2 "Dive"
Fabrication
complete
Velocity
(m/sec)
Time (seconds)
Figure A2.4
Graphical representation of the "ideal" movement of the piston.
The regulator ideally would have a similar square wave shape except its velocity would be 
higher since it travels further during the same time period i.e. the gap filled with alginate 
solution between the regulator and piston crown is greater at the top than at the bottom 
when the tube has been formed.
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supply appeared to change the movement characteristics.
Approximately one metre of 4 mm inside diameter purpose made compressed air hose was 
used to connect the regulated supply to the valves and to the ram, thus creating a "dead 
space" (VH) in the order of 12.5 ml. Redesigning the rig in order to reduce this dead space 
was an option e.g. mounting the regulator and valves directly adjacent to the ram uppermost 
compressed air input. This would effectively reduce VH to almost zero.
The volume of air above the bidirectional ram piston (VA) is dictated by the diameter of the 
bidirectional piston (40 mm) and its position relative to its overall stroke length (1200 mm) 
see Figure A2.5 and Figure A2.6.
Therefore to produce a 200 mm tube, 251 ml of compressed air must be delivered to the 
ram. Since the diameter of the ram piston is fixed, only DA can be altered. DA at the start of 
a run could be reduced to zero by repositioning the tube-forming device such that only the 
top part of the ram is used and not the middle part as was originally chosen. The volume of 
air displaced from below the bidirectional ram piston for a 200 mm tube is 251 ml. This air 
is forced out via the pre-set bleed valve. When DA is reduced to zero then a more predictable 
pressure variability is possible.
Stiction forces are present in both the ram and tube-forming device. Since stiction is the force 
required for one solid surface to begin to move while in contact with another solid surface, for 
a piston to move against the barrel after it comes to a complete halt, energy is consumed to get 
initial movement. In general the bigger the piston (i.e. the larger the circumference) and the 
lower the velocity the more pronounced the stiction effects -  these are well known challenges 
to the semi-automobile engine manufactures. Since both the ram piston and the tube forming 
piston and calcium chloride delivery piston are all moving at the same speed due to rigid 
coupling only the diameter of the pistons is an indicator of which component has the most 
significant impact on the overall system. Since the ram piston is 40 mm in diameter (125.7 
mm circumference) it is much larger than the 8 mm and 4 mm pistons (28.0 and 12.6 mm 
in circumference respectively) used in the tube forming part of the system. Therefore stiction 
forces in the ram are probably the more significant although their respective components will 
also further influence this. Stiction in the ram is produced by the barrel of the pneumatic ram 
(anodised aluminium) and its two deformable piston seals (nitrile (NBR) O-rings) at each end 
of the bidirectional piston, whereas stiction in the device is due to PTFE interference fit pistons 
interacting with the glass barrels (2).
The volume above the ram (VA) compounds the stiction problem. The cycle of events 
includes:
1. System is at rest in the loaded position
-  2 7 4 -
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----------------------
—
Compressed air 
inlet port
■ Piston seal
Piston with direct attachment 
to rigid linker
Wall of pneumatic ram cylinder
Exhaust port
Figure A2.5
Schematic of the pneumatic double acting rodless linear drive.
The red arrow indicates the direction of piston movement during the tube forming process. 
VA and VB are the total volume above and below the piston respectively.
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Tube forming event 
(200 mm length tube)
Ram piston - distance from 
top of ram (DA) 
mm
Volume of compressed air 
above the ram piston (VA) 
ml
Start of run 450 565
End of run 650 817
Figure A2.6
Relationship between the position of the piston within the pneumatic ram cyclinder (DJ and 
the volume of compressed air above the piston (VA).
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2. The inlet solenoid and outlet bleed hole simultaneously open
3. Compressed air enters the space above the ram piston, initially VA is unchanged 
as the pressure above the ram piston rises (PA) rises
4. PA rises until is able to overcome all the resistive forces in the system i.e. 
stiction and all the pistons initially move. Air is displaced under the ram piston 
through the bleed hole
5. Once the stiction forces are overcome, less force is required to keep the system 
in motion and therefore due to the now excessive PA the pistons jerk forward, 
however since the compressed air rate of delivery is unchanged, the ram 
piston slows or stops
6. PA again rises until sufficient to restart and/or reaccelerate the ram piston
7. The above jerky cycle continues until the physical end stop is reached and the 
system is once again at rest
8. This jerkiness in the ram piston is directly transmitted to the pistons in the tube 
forming part of the system resulting in erratic exposure of alginate solution 
to calcium chloride solution and hence irregularly walled hydrogel tubes 
or a totally corrupted run with the regulator becoming trapped in alginate 
hydrogel part way down the glass barrel. Once trapped, calcium chloride 
solution rushes past the regulator and the latter part of the run is ruined.
In contrast to the above cycle, the tube-forming device when powered manually does not 
have this jerkiness of movement and therefore better tubes are manufactured. The pneumatic 
ram has a number of dynamic cylinder forces that influence the movement of the piston. 
In its simplest form, the linear actuator converts pneumatic energy into mechanical linear 
movement. Thus the energy supplied is determined by:
• Pressure
• Flow rate
Both these variables were adjusted in attempts to optimise tube production runs. The total load 
is determined by:
• Magnitude of the out required to drive the tube-forming device e.g. stiction in the glass 
barrels between PTFE piston and glass wall due to the required interference fit
•  Seal friction (Stiction)
• Rate of acceleration required
•  Air-flow resistances
•  Back-pressure
As before, the above variables were experimented with in order to improve production 
runs.
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Examining a tube-forming cycle from the pneumatic ram prospective illustrates the potential 
difficulties experienced with the system, see Figure A2.7:
1. At the start of the cycle, both the inlet valve and exhaust port are simultaneously 
opened
2. Pressure (PA) builds up in the volume above the piston (VA) whilst the volume 
below the piston (VB) falls to atmospheric pressure since the exhaust port is 
open to atmosphere (open-loop system)
3. PA continues to rise, but there is no piston movement until the force to initiate 
movement is greater than the forces resisting movement
4. As the piston accelerates from rest, air is forced out of the exhaust port which 
increases the back-pressure under the piston, which in turn reduces the piston's 
acceleration rate
5. Only when the driving and resistive forces are equal will the piston have zero 
acceleration i.e. constant velocity
6. The run ends when the rigid linking piece hits the end stop, resulting in rapid 
deceleration of the piston and rapid rise in PA
The final factor considered was backlash. This was reduced in two distinct ways:
1. All the couplings were rigid
2. All the pistons after travelling in the direction for loading were always moved
a short distance in the opposite direction (i.e. the same direction as for a tube
production run) in order to align the deformable seals in the correct orientation 
prior to a run. Any positioning problems caused by this manoeuvre were then 
corrected by adjusting the threaded portion of the PTFE pistons.
Overall the pneumatic drive under conditions of light load very frequently produced a very 
erratic staccato linear movement and not the smooth movement that was originally envisaged 
for this drive. However a number of tubes have been constructed in this manner with a variety 
of different alginates, alginate concentrations (0 - 6%) and calcium chloride solutions (0.1
- 4%), which had no discontinuities in their walls. Furthermore, tubes consisting of alginate 
hydrogel with embedded glass beads or live cells and also discs cut from their walls using a 
7 mm in diameter "cookie cutter" have been the basis of all the initial cell development work
- described below and in the main body of the Thesis e.g. Chapter 7 and Chapter 8.
Wall thicknesses were measured from tubes produced using different diameter regulators, 
since the difference in diameters between the inside of the barrel and the outside of the 
regulator directly govern the thickness of the wall of the tube. Only tubes which possessed a 
totally intact wall after expulsion from the glass barrel were used. Regulators were constructed 
which produced wall thicknesses that would potentially allow good mass transfer. In humans
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Pressure
Set inlet 
pressure 
(1 - 2 bar)
Time (sec)
Valves Start of piston End of piston
operated movement movement
Atmospheric
pressure
KEY
VA = Pressure above double acting piston (Inlet side)
VB = Pressure below double acting piston (Exhaust side)
1 = Pressure difference required to start piston movement
2 = Pressure difference required to maintain piston movement
Figure A2.7
Theoretical pressure variation in pneumatic ram during tube-forming cycle.
[Modified from Pinches and Callear, 1977]
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the maximum distance of cells from a blood vessel capable of 0 2/C 0 2 gaseous exchange 
(i.e. a capillary) is in the order of 100-200 |jm, it was therefore decided to produce tubes 
with a wall thickness of no greater than 400 pm but preferably in the order of 200 pm. This 
dimension also correlates well with the wall thickness of a normal healthy human coronary 
artery wall. Tubes with wall thicknesses of 100 - 400 pm have been constructed, measured by 
both micrometer gauge and confocal microscopy using glass beads of 3 - 10 pm in diameter 
(PolySciences Inc, Warrington, PA, USA). Using confocal microscopy has a big advantage 
over using a micrometer gauge in that it is much less operator dependant plus it requires 
much less handling and hence reduced handling damage and drying. Micrometers are either 
manual vernier gauges (operator dependant when it comes to actually measuring hydrogels 
plus handling problems) or pressure sensitive micrometer, both types have been used for this 
research project. Pressure sensitive devices such as the Mitutoyo (Japan) made device remove 
the operator variability when actually measuring but do not remove the handling difficulties.
Due to the highly transparent nature of the alginate hydrogel, direct microscopic visualisation 
was impossible. However, upon adding glass beads of 3 - 10 pm in diameter (manufactured 
from soda lime glass with density < 2480 Kgm 3) to the alginate solution, the confocal 
microscope could focus upon the embedded spheres. The beads also act as cell substitutes 
being of similar order of magnitude in terms of overall size. After extensive mixing in 
order to homogeneously distribute the glass spheres in the alginate solution, tubes were 
then manufactured from this mixture. After cutting the tube wall longitudinally along its 
length, disc samples were taken at regular intervals along the entire length using a 7 mm in 
diameter "cookie cutter". Position in the tube did not correlate with wall thickness except at 
the extremes, therefore, the first and last 2 - 3 cm of tube were not measured e.g. the last 
portion of the tube contained the trapped regulator. Furthermore, great care was taken to 
avoid deforming the delicate hydrogel during handling, if there was any doubt, then that tube 
or disc was discarded. At all times the alginate gels were kept in calcium chloride solution (to 
prevent drying and therefore unwanted shrinkage) including under the confocal microscope 
using Sigma Coverwell press-seal imaging chambers. These chambers are made from optical 
grade polycarbonate bonded to a silicone spacer gasket. When pressed against a glass 
microscope slide they form a sealed chamber (20 mm diameter) for an up to 1 mm thick free- 
floating specimens, thus avoiding compression artefacts. The hydrogel discs were scanned 
visually to check for homogeneity of the beads. Selecting the approximate centre of each disc 
(i.e. trying to avoid possible distortion at the edges due to the "cookie cutter" and by focusing 
the confocal microscope on the nearest bead in the microscope field (i.e. the bead at the top 
of the alginate disc) and then focusing through the alginate on the bead furthest away (i.e. 
the bead at the base of the alginate disc) and then using the computational power of the
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microscope's central processor unit to "subtract" the two vertical positions in space gives an 
indirect measurement of the thickness of the disc and hence of the tube wall thickness. Due 
to handling difficulties it was not possible to measure the same disc using both a micrometer 
and the indirect confocal microscopy method.
The data collected using the indirect confocal microscopy method confirmed that the pneumatic 
device formed tubes were highly variable along their length (much more so than the manually 
produced tubes). However, trends suggested that average wall thickness depended upon a 
range of different variables including:
• Barrel/regulator gap (see Figure A2.8)
• Percentage alginate in solution (see Figure A2.9)
Increasing either the barrel/regulator gap or the alginate concentration lead to an average 
increase in wall thickness. However, some factors appeared to make no difference to wall 
thickness including the cross-linking time (see Figure A2.10).
Because cross-linking time appeared to have no effect on wall thicknesses, it was possible to 
prepare hydrogel tubes in advance of confocal microscopy sessions.
Other parameters which require further investigation include:
• Alginate type
• Calcium chloride concentration
•  Presence/absence of competing ions in the calcium chloride solution e.g. sodium 
ions
Preliminary investigations (small sample numbers) suggested that these parameters do play a 
role in hydrogel wall thickness especially alginate type.
Weighing the discs with their known diameters was also attempted but it was difficult to get 
reproducible results due to inability to consistently remove excess moisture from the hydrogels 
which are >96% water. Handling is a particular challenge as it can result in gel deformation 
with water being permanently squeezed out. Prolonged freeze drying (48 hours in an Edwards 
freeze drier) of the discs and weighing also failed to determine the volume and hence disc 
thickness due to the minuscule quantity of solid material left after extended lyophilisation, to 
remove all the moisture for consistence between samples. For example a disc made of 4% 
alginate with a wall thickness of 250 pm and 7 mm diameter has a theoretical volume of 9.6 
x 10‘9 ml. If a 4% solution is used then approximately 3.6 x 1 O'10 ml of alginate solid will be 
present, after extensive lyophilisation.
Optical coherence microscopy has also been used to measure wall thickness. This non-invasive 
method of imaging is covered in Chapter 9.
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Figure A2.8
Effect of barrel regulator gap on final tube wall thickness for a 4% solution of Manugel 
alginate cross-linked with 2% calcium chloride solution for 24 - 30 hours.
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1% M anugel alginate. Average = 1 2 8  mm (n = l 8)
4%  M anugel alginate. Average = 1 7 6  mm (n= l 8)
Figure A2.9
Effect of alginate solution concentration on final tube wall thickness using a 
barrel/regulator gap of 400 pm and cross-linked with 2% calcium chloride solution for 
24 - 30 hours.
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Figure A2.10
Effect of cross-linking time on final tube wall thickness for a 4% solution of Manugel 
alginate cross-linked with 2% calcium chloride solution.
-  284 -
A2.2 Alternative linear actuators
Even if the initial "dead space" above the ram piston was reduced significantly by redesigning 
the experimental rig the "dead space" produced as the device operates is still significant at 
251 ml for a 20 ml tube. Whilst the pneumatic drive had helped develop the piston driven 
device, pneumatic power for this application has a further drawback, lack of precise control. 
Pneumatic drive is ideally suited to "point to point" operations and this was demonstrated by 
the ease with which simple physical stops could be adjusted on the rig to give precise end 
points of operation e.g. stop at the end of the tube-forming run. However, acceleration and 
velocity are harder to control since this is determined by a number of factors including input 
pressure and exhaust bleed rate. Fine-tuning of these aspects of performance was required 
for future progress.
The compressible nature of air inherently leads to a "spring/' movement and not steady 
movement required to produce perfect alginate gel tubes. Electrically and hydraulically 
powered linear actuators were therefore considered as alternatives.
After advice from Nigel Smith at Hoerbiger-Origa, it was apparent that if a higher level of 
control was required, then an electrically driven system was the only way forward (Smith, 
2002).
A2.2.1 Modular electric linear drive systems
Modular electric linear drive systems similar in performance to the pneumatic drive system 
are manufactured by a number of companies. Hoerbiger-Origa electric linear drives were 
the most similar in dimensions (and therefore would be an easy fitment to the test rig) in 
that their product are based on their rodless cylinder system that we had previously used. 
Options included electric screw drive which is suitable for high force applications and low 
speed work (our requirement of approximately 1 cmsec1 is considered slow by linear drive 
manufacturers) and electric toothed belt drive which is suitable for applications requiring 
accurate positioning and high speed. Thus the screw drive version was potentially the best 
option for the application. However, the whole area of drives is considered at length in 
Chapter 5 and Chapter 6 as it was also a major influence on the reproducibility of the 
subsequent fluid driven versions of the tube forming device.
A2.3 Conclusions
Whilst the piston driven device was very capable of producing tubes of alginate, alginate plus 
live cells or alginate plus glass beads, it had certain fundamental drawbacks if this technique 
of creating a tube within a barrel was to be used in a commercial setting where for example, 
hundreds of thousands of metres of tube for blood vessel creation would be required per
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annum. These include:
• Sterility issues
• Handling
• Overall size
• Cost
Sterility issue are mainly due to the mode of filling the device with a shot of alginate solution 
and then having to add the regulator element. During these steps the device is "open" to the 
environment and thus would need to be carried out in a sterile environment e.g. a biosafety 
cabinet. The length of the barrel (an absolute minimum of 25 cm for a vessel suitable for 
CABG surgery) and the fact that the barrel must be upright during these steps makes these 
operations very challenging. This is further complicated in that most patients will require at 
least three vessels of 25 cm in length (allowing for a small amount of unavoidable wastage). 
If vessel for peripheral vascular disease bypass is contemplated, individual vessels of the order 
of 1 meter will be required (i.e. capable of running the entire length of the leg). Peripheral 
vascular disease (PVD) is a common medical condition in which the arteries that carry blood 
to the legs or arms become narrowed or blocked due to atherosclerotic plaques. PVD affects 
approximately 5% of the population aged over 50 years. The most common symptom is 
extremely painful cramping in the leg and/or thigh especially on walking (claudication). For 
example, the US estimates that it has 8 million people with PVD, 62% are symptomatic and 
require medical management (Society of Cardiovascular and Interventional Radiologists, 
USA). Medical management includes life style advice, medication for symptomatic relief (e.g. 
Praxilene -  Merck), bypass graft surgery and amputation. Thus the blood vessel lengths 
required for PVD grafting would require extremely large custom-made sterile hoods for 
loading the piston driven device.
Handling of the hydrogel tubes is also difficult. Since the drive required to fabricate the tubes 
is expensive, each drive would be required to produce many tubes per unit time. This would 
require the glass barrel containing the hydrogel tube to be uncoupled from the drive and 
transferred into a suitable bioreactor circuit, which in turn would necessitate couplings at 
each end of the barrel if the barrel was to be retained as part of the flow circuit. This presents 
three major obstacles:
• The upper most part of the tube is not attached in any way to the barrel
•  The lower most part contains the parked regulator embedded in gelled alginate
• Sterility issues involved in making couplings
Alternatively, removing the tube from the barrel prior to inserting it in a bioreactors also has 
major obstacles:
• Sterility issues involved in removing, handling and coupling the tube
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•  High risk of damaging the fragile hydrogel tube either due to deforming the tube by 
external force or merely the weight of the tube itself
• Coupling difficulties associated with attaching a hydrogel to a fixed input and output 
connectors
•  Removal of the regulator and detachment of the piston (cut off) -  this adds another 
unit operation and thus increases costs.
In brief, economically handling a one metre long "free-standing" tube with a 200 pm thick 
wall composed of 99% water in sterile conditions represents a significant challenge!
The overall size of the device is also an issue, for example if a continuous 1 metre length of 
tube was required to produce a bypass graft suitable for peripheral vascular disease surgery, 
the minimum height of the overall device is over 2 m (1 m cylinder plus 1 m piston stroke). 
Even the minimum device height for a single coronary artery bypass graft (CABG) would be 
in the order of 50 cm. The above dimensions assumes that the device is reconfigured so that 
the tube forming barrel and the calcium chloride tube are arranged parallel to open another, 
both at the same height thus minimising the overall height, i.e. not one above the other as per 
the prototype rig.
Sterility issues aside, the dimensions of the device and the size of the "hoods" required to 
service them would require a factory of enormous proportion just to serve a small geographical 
area. For example, today over 200 CABG operations are carried out in London each week, 
assuming that each vessel takes 10 weeks to grow and that each patient requires three 25 cm 
lengths, then 6000 cylinder devices of 50 cm in height would be required.
In summary, the approach to producing a tube within a cylinder is highly feasible; however 
driving the process with a piston is not a commercial option unless very short lengths of vessel 
are required e.g. arterio-venous shunts for long-term kidney dialysis patients (approximately 
10 cm in length). This issue and other disadvantages of using a piston within the tube forming 
barrel are discussed in Section 10.3, however, by recognising these shortfalls, it was possible 
to design and incorporate a far better drive methodology - fluid drive, into the next version 
of the device (see Chapter 5).
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